var images_info;if (!images_info) images_info =[]; images_info["63"]={"63001":{"type":"graphic_table","displayName":"Adverse effects antidepress","title":"Monitoring and addressing adverse responses to starting antidepressants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring and addressing adverse responses to starting antidepressants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Suicidality</td> <td class=\"subtitle1\">Akathisia*</td> <td class=\"subtitle1\">Manic switching<sup>&#182;</sup></td> <td class=\"subtitle1\">Discontinuation syndrome</td> <td class=\"subtitle1\">Serotonergic syndrome<sup>&#916;</sup></td> <td class=\"subtitle1\">Apathy</td> </tr> <tr> <td><strong>Symptoms</strong></td> <td>Thoughts or acts of self-harm</td> <td>Inner restlessness; sense of being \"driven\": pacing or movements usually bilateral, symmetrical, often specific muscle groups</td> <td>Silliness, giggling, angry outbursts, lack of sleep</td> <td>Fear, dizziness, lethargy, parasthesias, nausea, vivid dreams, insomnia, increased irritability or depression</td> <td>Confusion, restlessness, agitation, fever, hyperthermia, diaphoresis, hypertonia/clonus (usually symmetrical), tremor, shivering, hyper-reflexia</td> <td>Disinterest, confusion, lack of enjoyment in previously enjoyed activities; NOT depressed</td> </tr> <tr> <td><strong>Incidence</strong></td> <td>2 percent</td> <td>5-25 percent</td> <td>2-70 percent in bipolar depression, but 1-10 percent in unipolar depression (TCA &#62;SSRI)</td> <td>4-18 percent; shorter half-live antidepressants &#62;longer half-life agents</td> <td>Rare (&#60;1 percent)</td> <td>&nbsp;</td> </tr> <tr> <td><strong>When most commonly occurs</strong></td> <td>1-4 weeks</td> <td>2-6 weeks</td> <td>2-4 weeks, or within weeks of dose increases</td> <td>Within 1-7 days of stopping, decreasing antidepressant</td> <td>When multiple serotonergic medications are added or combined</td> <td>24-78 weeks</td> </tr> <tr> <td><strong>Response</strong></td> <td>Discontinue, monitor resolution of suicidality, consider alternative antidepressant</td> <td>Consider switch to alternative agent; if very positive response for depression, consider propanolol, or &#60;4 weeks augmentation with clonazapam</td> <td>Discontinue antidepressant; consider mood stablizers if impairing mania (vs milder hypomanic symptoms); after manic symptoms resolve, if prominent depression, consider alternative antidepressants, but titrate slowly and attempt low doses</td> <td>Resume antidepressant and titrate down slowly; consider switching/adding long half-life antidepressant (fluoxetine) to allow more gradual taper</td> <td>Hospital management of hyperthermia, benzodiazepines for seizures or muscle hyperactivity; serotonin antagonists such as cyproheptadine 4-8 mg up to four times a day</td> <td>Consider augmentation with additional antidepressant, but at low dose (eg, bupropion SR 100 mg every morning)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hansek L. A critical review of akathisia, and its possible association with suicidal behavior. Hum Psychopharm Clin Exp 2001; 16:495-505.<br />¶ Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004;158:773-780.<br />Δ Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.</div><div class=\"graphic_reference\">Reproduced with permission from: Rappaport, N, Bostic, JQ, Prince JB, Jellinek, M. Treating pediatric depression in primary care: Coping with the patients' blue mood and the FDA's black box. J Pediatr 2006; 148:567. Copyright &copy;2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 63001 Version 2.0</div></div></div>"},"63002":{"type":"graphic_table","displayName":"Monitoring in diabetes mellitus","title":"Monitoring in patients with diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring in patients with diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">History and physical examination</td> </tr> <tr> <td class=\"indent1\">Smoking cessation counseling</td> <td>Every visit</td> <td>For smokers only.</td> </tr> <tr> <td class=\"indent1\">Blood pressure</td> <td>Every visit</td> <td>Goal systolic pressure 125 to 130 mmHg.*</td> </tr> <tr> <td class=\"indent1\">Dilated eye examination</td> <td>Annually<sup>&#182;</sup></td> <td>Begin at onset of type 2 diabetes, three to five years after onset of type 1 diabetes. Examine more than annually if significant retinopathy.</td> </tr> <tr> <td class=\"indent1\">Foot examination</td> <td>Annually</td> <td>Every visit if peripheral vascular disease or neuropathy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dental examination</td> <td>Annually</td> <td>Periodontal disease is more severe but not necessarily more prevalent in patients with diabetes.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Laboratory studies</td> </tr> <tr> <td class=\"indent1\">Fasting serum lipid profile</td> <td>Initially, as indicated</td> <td>May obtain every five years if profile is low risk.</td> </tr> <tr> <td class=\"indent1\">A1C</td> <td>Every three to six months</td> <td>Goal &#8804;7% (may be lower or higher in selected patients).</td> </tr> <tr> <td class=\"indent1\">Urinary albumin-to-creatinine ratio</td> <td>Annually</td> <td>Begin three to five years after onset of type 1 diabetes; protein excretion and serum creatinine should also be monitored if persistent albuminuria is present.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Serum creatinine</td> <td>Initially, as indicated</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vaccinations</td> </tr> <tr> <td class=\"indent1\">Pneumococcus</td> <td>One time</td> <td>Patients over age 65 years need a second dose if vaccine was received &#8805;5 years previously and age was &#60;65 years at time of vaccination.</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>Annually</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatitis B</td> <td>Three-dose series</td> <td>Administer to unvaccinated adults who are ages 19 to 59 years. For older patients, administer based upon risk of acquiring hepatitis B and likelihood of an adequate immune response to vaccination.</td> </tr> <tr> <td><strong>Education, self management review</strong></td> <td>Annually</td> <td>More often at onset of diabetes and when there is a change in regimen.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin.<br />* When manual ausculatory method is used to measure blood pressure.<br />&para; Less frequent screening (every two to three years) may be appropriate for some patients.</div><div id=\"graphicVersion\">Graphic 63002 Version 11.0</div></div></div>"},"63004":{"type":"graphic_figure","displayName":"Unequal crossing over","title":"Molecular mechanism of unequal crossing over","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molecular mechanism of unequal crossing over</div><div class=\"cntnt\"><img style=\"width:429px; height:336px;\" src=\"images/HEME/63004_Unequal_crossing_over.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A common mechanism of interstitial deletions is unequal crossing over in meiosis I. When highly homologous repeats (&quot;Repeat&quot;) flank a DNA segment (&quot;Gene&quot;), two non-sister chromatids may recombine at an incorrect location due to inappropriate alignment. Thus, one of the chromatids (labeled &quot;A&quot;) acquires a duplication of the intervening sequence, while the corresponding segment is deleted on the other chromatid and only one repeat remains (labeled &quot;B&quot;).</div><div id=\"graphicVersion\">Graphic 63004 Version 1.0</div></div></div>"},"63005":{"type":"graphic_picture","displayName":"Lap hernia still A","title":"Lap hernia still A","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Lap hernia still A</div><div class=\"cntnt\"><img style=\"width:526px; height:272px;\" src=\"images/SURG/63005_Lap_hernia_still_A.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63005 Version 3.0</div></div></div>"},"63006":{"type":"graphic_figure","displayName":"Multiple sclerosis PI","title":"Multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:526px; height:648px;\" src=\"images/PI/63006_Multiple-sclerosis-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In multiple sclerosis, the immune system attacks nerve cells in the brain and spinal cord. These nerve cells work kind of like electrical wires. They carry electrical signals and are wrapped in insulation that helps the electrical signal move quickly down the nerve. This &quot;insulation&quot; is made of a material called myelin. Multiple sclerosis damages this myelin, so the nerve cells cannot carry signals very well.</div><div id=\"graphicVersion\">Graphic 63006 Version 2.0</div></div></div>"},"63007":{"type":"graphic_table","displayName":"Features of chronic GVHD","title":"Diagnostic and distinctive clinical manifestations of chronic graft-versus-host disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic and distinctive clinical manifestations of chronic graft-versus-host disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ or site</td> <td class=\"subtitle1\">Diagnostic (sufficient to establish the diagnosis of chronic GVHD)</td> <td class=\"subtitle1\">Distinctive (seen in chronic GVHD, but insufficient alone to establish a diagnosis of chronic GVHD)</td> </tr> <tr class=\"divider_bottom\"> <td>Skin</td> <td> <ul> <li>Poikiloderma </li> <li>Lichen planus-like features </li> <li>Sclerotic features </li> <li>Morphea-like features </li> <li>Lichen sclerosus-like features </li> </ul> </td> <td> <ul> <li>Depigmentation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Nails</td> <td>&nbsp;</td> <td> <ul> <li>Dystrophy </li> <li>Longitudinal ridging, splitting, or brittle features </li> <li>Onycholysis </li> <li>Pterygium unguis </li> <li>Nail loss (usually symmetric; affects most nails)* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Scalp and body hair</td> <td>&nbsp;</td> <td> <ul> <li>New onset of scarring or nonscarring scalp alopecia (after recovery from chemoradiotherapy) </li> <li>Scaling, papulosquamous lesions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mouth</td> <td> <ul> <li>Lichen-type features </li> <li>Hyperkeratotic plaques </li> <li>Restriction of mouth opening from sclerosis </li> </ul> </td> <td> <ul> <li>Xerostomia </li> <li>Mucocele </li> <li>Mucosal atrophy </li> <li>Pseudomembranes* </li> <li>Ulcers* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Eyes</td> <td>&nbsp;</td> <td> <ul> <li>New onset dry, gritty, or painful eyes<sup>&#916;</sup> </li> <li>Cicatricial conjunctivitis </li> <li>Keratoconjunctivitis sicca<sup>&#916;</sup> </li> <li>Confluent areas of punctate keratopathy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Genitalia</td> <td> <ul> <li>Lichen planus-like features </li> <li>Vaginal scarring or stenosis </li> </ul> </td> <td> <ul> <li>Erosions* </li> <li>Fissures* </li> <li>Ulcers* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>GI tract</td> <td> <ul> <li>Esophageal web </li> <li>Strictures or stenosis in the upper to mid third of the esophagus* </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Lung</td> <td> <ul> <li>Bronchiolitis obliterans diagnosed with lung biopsy </li> </ul> </td> <td> <ul> <li>Bronchiolitis obliterans diagnosed with PFTs and radiology<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>Muscles, fascia, joints</td> <td> <ul> <li>Fasciitis </li> <li>Joint stiffness or contractures secondary to sclerosis </li> </ul> </td> <td> <ul> <li>Myositis or polymyositis<sup>&#916;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnosis of chronic GVHD requires the presence of at least one diagnostic clinical sign of chronic GVHD or the presence of at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests in the same or another organ. Furthermore, other possible diagnoses for clinical symptoms must be excluded. No time limit is set for the diagnosis of chronic GVHD.</div><div class=\"graphic_footnotes\">GVHD: graft-versus-host disease; PFTs: pulmonary function tests.<br />* In all cases, infection, drug effects, malignancy, or other causes must be excluded.<br />&Delta; Diagnosis of chronic GVHD requires biopsy or radiology confirmation (or Schirmer test for eyes).</div><div class=\"graphic_reference\">Original figure modified for this publication. Filipovitch AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 1. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005; 11:945. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63007 Version 5.0</div></div></div>"},"63008":{"type":"graphic_picture","displayName":"Rosacea in dark skin","title":"Papulopustular rosacea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Papulopustular rosacea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63008_Rosacea_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory papules are present on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63008 Version 3.0</div></div></div>"},"63009":{"type":"graphic_picture","displayName":"Incontinentia pigmenti 4","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63009_Incontpigmenti4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Marble cake\" hyperpigmentation in a female infant with incontinentia pigmenti.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63009 Version 4.0</div></div></div>"},"63010":{"type":"graphic_picture","displayName":"Androgenetic alopecia","title":"Androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/DERM/63010_Androgenetic_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This man developed gradual thinning of hair on the vertex and frontoparietal areas of the scalp. Bitemporal recession is evident.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 63010 Version 6.0</div></div></div>"},"63011":{"type":"graphic_picture","displayName":"ILS histology","title":"Histology of intralobar pulmonary sequestration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of intralobar pulmonary sequestration</div><div class=\"cntnt\"><img style=\"width:263px; height:387px;\" src=\"images/PEDS/63011_ILS_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic examination of an intralobar pulmonary sequestration (ILS) demonstrates large, dilated airways containing numerous muciphages. The parenchyma shows small foci of lymphocytic infiltrates and is structurally abnormal, with thickened airspace walls and poorly subdivided airspaces.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD and Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 63011 Version 3.0</div></div></div>"},"63013":{"type":"graphic_figure","displayName":"Risk of breast cancer with ERT","title":"Breast cancer risk and hormone replacement therapy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Breast cancer risk and hormone replacement therapy</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/ENDO/63013_Risk_of_breast_cancer_wit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RR of breast cancer according to the duration of use within categories of time since the last use of hormone replacement therapy. The RR of breast cancer in this analysis of data from 51 epidemiologic studies was highest among women who were current or recent (within five years) users of ERT and had the longest duration of use compared&nbsp;with never users. The RR of developing cancer was 1.35 for women who were current ERT users and had taken hormones for five years or longer.</div><div class=\"graphic_footnotes\">ERT: estrogen replacement therapy; RR: relative risk.<br />* Relative to never-users, stratified by study, age at diagnosis, time since menopause, body-mass index, parity, and the age a woman was when her first child was born.<br />\"Last use &lt;5 years before diagnosis\" includes current users.</div><div class=\"graphic_reference\">Reproduced with permission from Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 1997; 350:1047. Copyright © The Lancet, Ltd. 1997.</div><div id=\"graphicVersion\">Graphic 63013 Version 3.0</div></div></div>"},"63014":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CT V","title":"Bronchogenic cyst adjacent to aortic arch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchogenic cyst adjacent to aortic arch</div><div class=\"cntnt\"><img style=\"width:360px; height:502px;\" src=\"images/PULM/63014_Med_bronchogen_cyst_CT_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a cystic mass in close apposition to the distal aortic arch.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63014 Version 3.0</div></div></div>"},"63015":{"type":"graphic_diagnosticimage","displayName":"RUL RML atelectasis-III","title":"Lateral chest radiograph reveals combined atelectasis of the right upper and right middle lobes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral chest radiograph reveals combined atelectasis of the right upper and right middle lobes</div><div class=\"cntnt\"><img style=\"width:321px; height:432px;\" src=\"images/PULM/63015_RUL_RML_atelectasis-III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wedge-shaped opacity (arrow) descends from the upper lung toward the cardiac silhouette. The right major fissure is deviated anteriorly. The retrosternal lucency is accounted for by hyperexpansion of the left upper lobe (asterisk).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63015 Version 3.0</div></div></div>"},"63018":{"type":"graphic_diagnosticimage","displayName":"CPAM with pleural effusion","title":"Fetus with congenital pulmonary airway malformation with pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Fetus with congenital pulmonary airway malformation with pleural effusion</div><div class=\"cntnt\"><img style=\"width:758px; height:237px;\" src=\"images/OBGYN/63018_Hydropspleffusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CPAM at 23 weeks of gestation with small pleural effusion.<br />(A) Ultrasound image demonstrates a small left pleural effusion (arrow)&nbsp;adjacent to an echogenic mass.<br />(B) Coronal T2w MRI confirms the presence of a small pleural effusion (arrow)&nbsp;adjacent to a left lower lobe heterogeneous high T2w signal mass.<br />(C) The effusion (arrow)&nbsp;continued to increase and by 28 weeks of gestation required pleural drainage.</div><div class=\"graphic_footnotes\">CPAM: congenital pulmonary airway malformation; T2w: T2-weighted (pulse); MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 63018 Version 4.0</div></div></div>"},"63020":{"type":"graphic_table","displayName":"Incidence prostate CA pre PSA","title":"Incidence of prostate cancer (adjusted for age)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of prostate cancer (adjusted for age)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Location</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Rates per 100,000 men</td>\n\n\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Increase, percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td class=\"subtitle2\">1968-72</td>\n\n\n      <td class=\"subtitle2\">1973-77&nbsp;</td>\n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>New York State</td>\n\n\n      <td>29.4</td>\n\n\n      <td>39.9</td>\n\n\n      <td>36</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"sublist1_start\">Detroit</td>\n\n\n      \n\n\n      \n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1 sublist1\">White men&nbsp;</td>\n\n\n      <td class=\"sublist_other\">36.1</td>\n\n\n      <td class=\"sublist_other\">41.4</td>\n\n\n      <td class=\"sublist_other\">15</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1 sublist1\">Black men</td>\n\n\n      <td class=\"sublist_other\">67.1</td>\n\n\n      <td class=\"sublist_other\">73.2</td>\n\n\n      <td class=\"sublist_other\">9</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"sublist1_start\">San Francisco Bay Area</td>\n\n\n      \n\n\n      \n\n\n      \n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1 sublist1\">White men&nbsp;</td>\n\n\n      <td class=\"sublist_other\">44.6</td>\n\n\n      <td class=\"sublist_other\">47.4</td>\n\n\n      <td class=\"sublist_other\">5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1 sublist1\">Black men</td>\n\n\n      <td class=\"sublist_other\">77.0</td>\n\n\n      <td class=\"sublist_other\">92.2</td>\n\n\n      <td class=\"sublist_other\">20</td>\n\n\n    </tr>\n\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46551&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Incidence_prostate_CA_pre_P.htm</title></head></div><div class=\"graphic_lgnd\">The age-adjusted incidence of prostate cancer between 1968 to 1972 and 1973 to 1977. There was a rising incidence of prostate cancer long before the widespread introduction of PSA-based screening practices.</div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen.</div><div class=\"graphic_reference\">Data from Flanders WD. Review: prostate cancer epidemiology.&nbsp;Prostate 1984; 5:621.</div><div id=\"graphicVersion\">Graphic 63020 Version 2.0</div></div></div>"},"63021":{"type":"graphic_table","displayName":"Low-potassium food PI","title":"Foods with low levels of potassium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods with low levels of potassium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Grains</strong></td> <td>Foods prepared with white flour (eg, pasta, bread), white rice</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Beverages</strong></td> <td>Non-dairy creamer, fruit punch, drink mixes (eg, Kool-Aid), tea (&#60;2 cups or 16 ounces per day), coffee (&#60;1 cup or 8 ounces per day)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sweets</strong></td> <td>Angel or yellow cake, pies without chocolate or high-potassium fruit, cookies without nuts or chocolate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fruits</strong></td> <td>Apples (1), apple juice, applesauce, apricots (canned), blackberries, blueberries, cherries, cranberries, fruit cocktail (drained), grapes, grape juice, grapefruit (&#189;), mandarin oranges, peaches (&#189; fresh or &#189; cup canned), pears (1 small fresh or &#189; cup canned), pineapple and juice, plums (1 whole), raspberries, strawberries, tangerine (1 whole), watermelon (1 cup), lemons</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vegetables</strong></td> <td>Alfalfa sprouts, asparagus (6 spears), green or wax beans, cabbage (cooked), carrots (cooked), cauliflower, celery (1 stalk), corn (&#189; fresh ear or &#189; cup), cucumber, eggplant, kale, iceberg lettuce, mushrooms (fresh), okra, onions, parsley, green peas, green peppers, radish, rhubarb, water chestnuts (canned, drained), watercress, spinach (raw, 1 cup), squash (yellow), zucchini, scallions, turnips, turnip greens</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Proteins</strong></td> <td>Chicken, turkey (3 ounces), tuna, eggs, baloney, shrimp (all 1 ounce),&nbsp;unsalted peanut butter (1 tablespoon)</td> </tr> <tr> <td><strong>Dairy products</strong></td> <td>Cheddar or swiss cheese (1 ounce), cottage cheese (&#189; cup)</td> </tr> <tr> <td><strong>Nuts, seeds, and legumes</strong></td> <td>&nbsp;Macadamia nuts, pecans, cashews, walnuts, almonds, peanuts, sesame seeds, sunflower or pumpkin seeds, chia seeds, flax seeds (all 1 ounce)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Unless noted, one serving is ½ cup (4 ounces). These foods have a low level of potassium (less than 200 mg potassium per serving on average). Be sure to measure the portion sizes of each food and calculate the total amount in each meal to maintain your low-potassium diet (eg, average of 2000 mg potassium per day).</div><div id=\"graphicVersion\">Graphic 63021 Version 5.0</div></div></div>"},"63023":{"type":"graphic_picture","displayName":"Mechanical triggering","title":"Mechanical triggering with flexor tenosynovitis (trigger finger)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanical triggering with flexor tenosynovitis (trigger finger)</div><div class=\"cntnt\"><img style=\"width:369px; height:275px;\" src=\"images/RHEUM/63023_Mechanical_triggering.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hands are placed in the palms-up position and the patient is asked to actively flex and extend the fingers. Alternatively, if active triggering is not present, the examiner places his fingers on the proximal interphalangeal (PIP) joint as the finger is actively flexed and extended, noting the presence of loss of smooth motion or a clicking sensation.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 63023 Version 5.0</div></div></div>"},"63025":{"type":"graphic_picture","displayName":"Urticaria pigmentosa","title":"Urticaria pigmentosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria pigmentosa</div><div class=\"cntnt\"><img style=\"width:256px; height:400px;\" src=\"images/RHEUM/63025_Urticaria_pigmentosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticaria pigmentosa lesions in an adult patient with cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Soter AN. J Invest Derm 1991; 96(3):S32. Copyright &copy; 1991 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 63025 Version 4.0</div></div></div>"},"63026":{"type":"graphic_diagnosticimage","displayName":"Severe aortic plaque","title":"Severe aortic plaque","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe aortic plaque</div><div class=\"cntnt\"><img style=\"width:400px; height:460px;\" src=\"images/SURG/63026_Severe_aortic_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe aortic plaque (arrow) visualized by gastrointestinal endoscopic ultrasound (EUS) probe.</div><div class=\"graphic_reference\">Courtesy of Dr. Zamir Brelvi, Division of Gastroenterology, New Jersey Medical School, Newark, NJ.</div><div id=\"graphicVersion\">Graphic 63026 Version 2.0</div></div></div>"},"63027":{"type":"graphic_figure","displayName":"Structure of the complement component 1 (C1) complex","title":"Structure of the complement component 1 (C1) complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the complement component 1 (C1) complex</div><div class=\"cntnt\"><img style=\"width:351px; height:255px;\" src=\"images/ALLRG/63027_C1_compl_complex_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A model of the C1 complex showing the intertwining of C1s-C1r-C1r-C1s in the C1q subcomponent. This structure permits the catalytic domains of C1s to contact the catalytic domains of C1r. The Fc portion of immunoglobulin G (IgG) and immunoglobulin M (IgM) engages the globular head of C1.</div><div class=\"graphic_reference\">Adapted from: Liszewski MK, Atkinson JP. The complement system. In: Immunology Scope Monograph, Schwart BD (Ed), Upjohn, Kalamazoo 1992.</div><div id=\"graphicVersion\">Graphic 63027 Version 6.0</div></div></div>"},"63030":{"type":"graphic_figure","displayName":"Changes calcium sensitivity","title":"Effects of interventions on the calcium sensitivity of the contractile apparatus","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Effects of interventions on the calcium sensitivity of the contractile apparatus</div><div class=\"cntnt\"><img style=\"width:467px; height:362px;\" src=\"images/CARD/63030_Changes_calcium_sensitivity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A summarizes different interventions and their effects on myofilament calcium sensitivity. Panel B show the effects of these interventions on the intracellular calcium transient. Note that drugs that decrease myofilament calcium sensitivity increase the amplitude of the calcium transient relative to drugs that do not change or increase myofilament calcium sensitivity. Panel C shows the effects of these agents on the force (F<sub>max</sub>) versus calcium concentration ([Ca<sup>2+</sup>]<sub>o</sub>) relationship of skinned or hyperpermeabilized fibers. The interventions that increase myofilament sensitivity to calcium have the potential to cause or exacerbate diastolic dysfunction; conversely, agents which decrease myofilament sensitivity to calcium have a potential lusitropic effect.</div><div id=\"graphicVersion\">Graphic 63030 Version 1.0</div></div></div>"},"63033":{"type":"graphic_table","displayName":"Abnormal vital signs","title":"Thresholds for defining abnormal vital signs in a potential pediatric organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thresholds for defining abnormal vital signs in a potential pediatric organ donor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormal vital signs</td> <td class=\"subtitle1\">RR (breaths/minute)</td> <td class=\"subtitle1\">Pulse (beats/minute)</td> <td class=\"subtitle1\">SBP (mmHg)</td> </tr> <tr> <td>Neonate</td> <td>&#62;40</td> <td>&#62;160</td> <td>&#60;60</td> </tr> <tr> <td>Infant</td> <td>&#62;40</td> <td>&#62;160</td> <td>&#60;70</td> </tr> <tr> <td>Toddler</td> <td>&#62;30</td> <td>&#62;140</td> <td>&#60;75</td> </tr> <tr> <td>School age</td> <td>&#62;25</td> <td>&#62;120</td> <td>&#60;85</td> </tr> <tr> <td>Adolescent</td> <td>&#62;20</td> <td>&#62;110</td> <td>&#60;90</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RR: respiratory rate; SBP: systolic blood pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Nakagawa, TA. Pediatric donor management guidelines. NATCO, The Organization for Transplant Professionals, 2008. p.2. Copyright ©2008 NATCO.</div><div id=\"graphicVersion\">Graphic 63033 Version 3.0</div></div></div>"},"63034":{"type":"graphic_table","displayName":"Manning criteria for IBS","title":"Manning criteria for the diagnosis of irritable bowel syndrome*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manning criteria for the diagnosis of irritable bowel syndrome*</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Pain relieved with defecation</td>\n   </tr>\n   <tr>\n   <td>More frequent stools at the onset of pain</td>\n   </tr>\n   <tr>\n   <td>Looser stools at the onset of pain</td>\n   </tr>\n   <tr>\n   <td>Visible abdominal distention</td>\n   </tr>\n   <tr>\n   <td>Passage of mucus</td>\n   </tr>\n   <tr>\n   <td>Sensation of incomplete evacuation</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* The likelihood of irritable bowel syndrome is proportional to the number of Manning criteria that are present.</div><div id=\"graphicVersion\">Graphic 63034 Version 1.0</div></div></div>"},"63036":{"type":"graphic_figure","displayName":"Femoral hernia","title":"Femoral hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral hernia</div><div class=\"cntnt\"><img style=\"width:409px; height:317px;\" src=\"images/PEDS/63036_Femoral_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this sagittal section, a femoral hernia protrudes through the femoral ring posterior to the inguinal canal.</div><div class=\"graphic_reference\">Adapted from O Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p. 230.</div><div id=\"graphicVersion\">Graphic 63036 Version 1.0</div></div></div>"},"63040":{"type":"graphic_picture","displayName":"Facial features hyper IgE","title":"Typical facial features in a patient with hyperimmunoglobulin E syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical facial features in a patient with hyperimmunoglobulin E syndrome</div><div class=\"cntnt\"><img style=\"width:214px; height:295px;\" src=\"images/ALLRG/63040_Facial_features_hyper_IgE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical facial features in a patient with the hyperimmunoglobulin E syndrome showing broad nose, prominent lower lip, and eczematoid skin with doughy consistency.</div><div id=\"graphicVersion\">Graphic 63040 Version 4.0</div></div></div>"},"63042":{"type":"graphic_picture","displayName":"MacConkey agar","title":"MacConkey agar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MacConkey agar</div><div class=\"cntnt\"><img style=\"width:364px; height:240px;\" src=\"images/ID/63042_MacConkey_agar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Because of the abundant normal flora present in stool, detection of enteric pathogens requires culture on selective and differential media. MacConkey agar inhibits the growth of gram-positive bacteria and differentiates between gram-negative bacteria that ferment lactose (pink to red colonies on this medium) and those that do not (colorless). Neither <EM>Salmonella </EM>nor <EM>Shigella </EM>can ferment lactose on this medium.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 63042 Version 4.0</div></div></div>"},"63045":{"type":"graphic_table","displayName":"Components of second and third trimester ultrasound examinations","title":"Components of second and third trimester ultrasound examinations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of second and third trimester ultrasound examinations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Presence or absence of fetal cardiac activity,&nbsp;fetal heart&nbsp;rate and rhythm</td> </tr> <tr> <td>Fetal number</td> </tr> <tr> <td>Fetal presentation</td> </tr> <tr> <td>Assessment of amniotic fluid volume</td> </tr> <tr> <td>Placental appearance and location</td> </tr> <tr> <td>Umbilical cord vessel number and placental insertion site, if technically possible</td> </tr> <tr> <td>Fetal biometry (biparietal diameter, head circumference, femoral length, abdominal circumference)</td> </tr> <tr> <td>Evaluation of the uterus, cervix, and adnexa when clinically appropriate</td> </tr> <tr> <td>Fetal anatomic survey*</td> </tr> <tr> <td>Presence or absence of fetal movement</td> </tr> <tr> <td>Evaluation of each fetus of a multiple gestation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Biometry can be used to estimate gestational age (if not previously determined), fetal weight, and fetal growth (by comparing two or more examinations over an appropriate time interval).</div><div class=\"graphic_footnotes\">* Fetal anatomic survey can include the following assessments: head (intact cranium, cavum septi pellucidi, midline falx, thalami, cerebral ventricles, cerebellum, cisterna magna, choroid plexus); face (orbits, mouth, upper lip intact); neck (absence of masses); chest/heart (shape/size of chest and lungs, cardiac activity present, four-chamber view of heart, aortic and pulmonary outflow tracts, diaphragmatic hernia); abdomen (stomach in normal position, bowel not dilated, both kidneys present, cord insertion site, bladder); skeletal (spine, masses, arms and hands, legs and feet); genitalia.</div><div class=\"graphic_reference\">Data adapted from:<br /><ol>&#xD;&#xA;    <li>ISUOG: practice guideline for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol 2011; 37:116.</li>&#xD;&#xA;    <li>Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. Obstet Gynecol 2014; 123:1070.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 63045 Version 7.0</div></div></div>"},"63047":{"type":"graphic_table","displayName":"Risk of preterm birth with selected infections","title":"Risk of preterm birth with selected infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of preterm birth with selected infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infection</td> <td class=\"subtitle1\">Odds ratio<br /> (95% CI)</td> </tr> <tr> <td>Bacterial vaginosis before 16 weeks</td> <td class=\"centered\">7.55 (1.8-31.7)</td> </tr> <tr> <td><em>N. gonorrhoae</em></td> <td class=\"centered\">5.31 (1.57-17.9)</td> </tr> <tr> <td>Asymptomatic bacteriuria</td> <td class=\"centered\">2.08 (1.45-3.03)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><em>Chlamydia trachomatis</em></td> </tr> <tr> <td class=\"sublist1\">at 24 weeks</td> <td class=\"sublist_other_centered\">2.2 (1.03-4.78)</td> </tr> <tr> <td class=\"sublist1\">at 28 weeks</td> <td class=\"sublist_other_centered\">0.95 (0.36-2.47)</td> </tr> <tr> <td><em>Trichomonas vaginalis</em></td> <td class=\"centered\">1.3 (1.1-1.4)</td> </tr> <tr> <td><em>U. urealyticum</em></td> <td class=\"centered\">1.0 (0.8-1.2)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data&nbsp;from: Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. Am J Obstet Gynecol 2004; 190:1493.</div><div id=\"graphicVersion\">Graphic 63047 Version 5.0</div></div></div>"},"63052":{"type":"graphic_figure","displayName":"HPLC alpha chain variants","title":"Alpha chain hemoglobin variants on HPLC","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Alpha chain hemoglobin variants on HPLC</div><div class=\"cntnt\"><img style=\"width:564px; height:488px;\" src=\"images/HEME/63052_HPLC_alpha_chain_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cation exchange HPLC pattern of some alpha chain variants. HbA, A2, A<sub>1C</sub>, F, S, and C are highlighted.</div><div class=\"graphic_footnotes\">HPLC: high performance liquid chromatography.</div><div id=\"graphicVersion\">Graphic 63052 Version 3.0</div></div></div>"},"63053":{"type":"graphic_figure","displayName":"Sling and swathe","title":"Sling and swathe with U slab for immobilization of a humeral fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sling and swathe with U slab for immobilization of a humeral fracture</div><div class=\"cntnt\"><img style=\"width:320px; height:526px;\" src=\"images/EM/63053_Uslabsplint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bae DS. Humeral Shaft and Proximal Humerus, Shoulder Dislocation. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn jM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63053 Version 12.0</div></div></div>"},"63054":{"type":"graphic_table","displayName":"Guidelines for surgery in asymptomatic PHPT","title":"Guidelines for surgery in asymptomatic PHPT: A comparison of current guidelines with the previous one*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for surgery in asymptomatic PHPT: A comparison of current guidelines with the previous one*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measurement<sup>&#182;</sup></td> <td class=\"subtitle1\">2008</td> <td class=\"subtitle1\">2014</td> </tr> <tr class=\"divider_bottom\"> <td>Serum calcium (&#62;upper limit of normal)</td> <td>1.0 mg/dL (0.25 mmol/L)</td> <td>1.0 mg/dL (0.25 mmol/L)</td> </tr> <tr class=\"divider_bottom\"> <td>Skeletal</td> <td> <ol class=\"numbers_to_nine\"> <li>BMD by DXA: T-score &#60;&ndash;2.5 at any site<sup>&#182;</sup> </li> <li>Previous fragility fracture<sup>&#916;</sup> </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>BMD by DXA: T-score &#60;&ndash;2.5 at lumbar spine, total hip, femoral neck, or distal 1/3 radius<sup>&#182;</sup> </li> <li>Vertebral fracture by radiograph, CT, MRI, or VFA </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Renal</td> <td> <ol class=\"numbers_to_nine\"> <li>eGFR &#60;60 mL/min </li> <li>24-hour urine for calcium not recommended </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Creatinine clearance &#60;60 mL/min </li> <li>24-hour urine for calcium &#62;400 mg/day (&#62;10 mmol/day) and increased stone risk by biochemical stone risk analysis<sup>&#9674;</sup> </li> <li>Presence of nephrolithiasis or nephrocalcinosis by radiograph, ultrasound, or CT </li> </ol> </td> </tr> <tr> <td>Age (years)</td> <td>&#60;50</td> <td>&#60;50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients need to meet only one of these criteria to be advised to have parathyroid surgery. They do not have to meet more than one.</div><div class=\"graphic_footnotes\">PHPT: primary hyperparathyroidism; BMD: bone mineral density; DXA: dual-energy x-ray absorptiometry; CT: computed tomography; MRI: magnetic resonance imaging; VFA: vertebral fracture assessment; eGFR: estimated glomerular filtration rate; ISCD: International Society for Clinical Densitometry.<br />* Surgery is also indicated in patients for whom medical surveillance is neither desired nor possible and in patients opting for surgery, in the absence of meeting any guidelines, as long as there are no medical contraindications.<br />¶ Consistent with the position established by the ISCD, the use of Z-scores instead of T-scores is recommended in evaluating BMD in premenopausal women and men younger than 50 years<SUP>[1]</SUP>.<br />Δ The history of a fragility fracture at any site would define someone as having a complication of PHPT, and thus, the individual would be automatically considered to be a surgical candidate.<br /><FONT class=lozenge>◊</FONT> Most clinicians will first obtain a 24-hour urine for calcium excretion. If marked hypercalciuria is present (&gt;400 mg/day [&gt;10 mmol/day]), further evidence of calcium-containing stone risk should be sought by a urinary biochemical stone risk profile, available through most commercial laboratories. In the presence of abnormal findings indicating increased calcium-containing stone risk and marked hypercalciuria, a guideline for surgery is met.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lewiecki EM, Baim S, Langman CB, Bilezikian JP. The official positions of the International Society for Clinical Densitometry: perceptions and commentary. J Clin Densitom 2009; 12:267.</li>&#xD;&#xA;</ol>&#xD;&#xA;Republished with permission of The Endocrine Society, from: Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3561. Copyright &copy; 2014 The Endocrine Society; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 63054 Version 11.0</div></div></div>"},"63058":{"type":"graphic_figure","displayName":"Doppler estimation of RA RV gradient","title":"Doppler echocardiographic assessment of tricuspid regurgitation and the estimation of the gradient between right ventricle and right atrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler echocardiographic assessment of tricuspid regurgitation and the estimation of the gradient between right ventricle and right atrium</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/CARD/63058_Calculation_RA_RV_gradient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the presence of tricuspid regurgitation a continuous wave Doppler can be passed from the apex to base across the tricuspid valve in the apical four chamber view (panel A) and the Doppler shift caused by the tricuspid regurgitation jet (TR) displayed (panel B). In this example, the peak velocity of the TR jet is 3 m/sec, which, by the Bernoulli equation, represents a 36 mmHg gradient (= 4 x 3 x 3) between right ventricle (RV) and right atrium (RA). If the RA pressure is known or can be estimated, the sum of RA pressure and the RA to RV gradient is equal to the peak pulmonary artery systolic pressure (assuming no pulmonary stenosis).</div><div id=\"graphicVersion\">Graphic 63058 Version 6.0</div></div></div>"},"63059":{"type":"graphic_picture","displayName":"Thin smear in relapsing fever","title":"Thin smear in relapsing fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thin smear in relapsing fever</div><div class=\"cntnt\"><img style=\"width:288px; height:234px;\" src=\"images/ID/63059_ThinsmearinRelapsingfev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wright stain reveals the spirochete of relapsing fever. The concentration of spirochetes in the blood must be 10<SUP>5</SUP> or greater to be visible in a single high power microscopic field.</div><div class=\"graphic_reference\">Courtesy of Alan Barbour, MD.</div><div id=\"graphicVersion\">Graphic 63059 Version 4.0</div></div></div>"},"63060":{"type":"graphic_picture","displayName":"Anti GBM disease IF","title":"Immunofluorescence microscopy showing linear IgG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence microscopy showing linear IgG</div><div class=\"cntnt\"><img style=\"width:395px; height:256px;\" src=\"images/NEPH/63060_Anti_GBM_disease_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy showing characteristic linear deposition of IgG in anti-GBM antibody disease.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; GBM: glomerular basement membrane.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63060 Version 3.0</div></div></div>"},"63061":{"type":"graphic_table","displayName":"Endothelial cell disorders","title":"Endothelial cell disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endothelial cell disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hereditary</td> </tr> <tr> <td class=\"indent1\">Hyperhomocysteinemia</td> </tr> <tr> <td class=\"indent1\">Fabry's disease</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator deficiency</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator inhibitor excess</td> </tr> <tr> <td class=\"indent1\">Protein S deficiency</td> </tr> <tr> <td class=\"indent1\">Activated Protein C resistance</td> </tr> <tr> <td class=\"indent1\">Nitric oxide synthase deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"indent1\">Trauma: mechanical, biochemical, toxin, infectious</td> </tr> <tr> <td class=\"indent1\">Atherosclerosis</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Dyslipidemia</td> </tr> <tr> <td class=\"subtitle1_single\">Immune-mediated</td> </tr> <tr> <td class=\"indent1\">Collagen vascular diseases</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td class=\"indent1\">Behcets disease</td> </tr> <tr> <td class=\"indent1\">Heparin-mediated antibodies</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"indent1\">Transplant vasculopathy</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63061 Version 5.0</div></div></div>"},"63062":{"type":"graphic_algorithm","displayName":"Management plan by BMI","title":"Child weight assessment algorithm","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Child weight assessment algorithm</div><div class=\"cntnt\"><img style=\"width:580px; height:486px;\" src=\"images/PEDS/63062_Management_plan_BMI_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm reflects the author's approach to management of childhood overweight and obesity in a primary care setting.</div><div class=\"graphic_footnotes\">BMI: body mass index; ALT: alanine aminotransferase; HbA1c: hemoglobin A1c.<br />* May be performed by nurse.<br />&para; Laboratory screening may be appropriate for selected patients in the overweight range (BMI &ge;85th-95th percentiles), such as those with a family history of dyslipidemia or multiple other risk factors (refer to UpToDate topics on clinical evaluation of children with obesity or dyslipidemia).<br />&Delta; Some providers also measure a fasting insulin level, for the purposes of counseling, rather than for screening.</div><div class=\"graphic_reference\">Courtesy of Dr. William Klish.</div><div id=\"graphicVersion\">Graphic 63062 Version 5.0</div></div></div>"},"63063":{"type":"graphic_figure","displayName":"Subumbilical incision in obese","title":"Subumbilical incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subumbilical incision</div><div class=\"cntnt\"><img style=\"width:326px; height:410px;\" src=\"images/SURG/63063_Subumbilical_incision_in_ob.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subumbilical incision is made after retraction of panniculus.</div><div id=\"graphicVersion\">Graphic 63063 Version 2.0</div></div></div>"},"63064":{"type":"graphic_picture","displayName":"Follicular mixed NHL","title":"Follicular lymphoma grade 2 (follicular mixed lymphoma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma grade 2 (follicular mixed lymphoma)</div><div class=\"cntnt\"><img style=\"width:289px; height:309px;\" src=\"images/HEME/63064_Follicular_mixed_NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is an intimate admixture of small cleaved cells (centrocytes) and large non-cleaved cells (centroblasts).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63064 Version 2.0</div></div></div>"},"63065":{"type":"graphic_figure","displayName":"Posterior cervical line C1 C3","title":"Posterior cervical line drawn between the anterior aspects of the C1 and C3 spinous processes","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Posterior cervical line drawn between the anterior aspects of the C1 and C3 spinous processes</div><div class=\"cntnt\"><img style=\"width:540px; height:584px;\" src=\"images/PEDS/63065_PostcervlineC1C3edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Posterior cervical line of Swischuk. Line is drawn from the cortex of the spinous process of C1 to the cortex of the spinous process of C3. Relationship of the line to cortex of the spinous process of C2 is noted. If the line is situated more than 2.0 mm anterior to the cortex of the spinous process of C2, underlying cervical pathology should be present. This line should be used only with anterior displacement of C2 on C3.<br> (B) Pseudosubluxation of C2 on C3 with normal posterior cervical line in a 2-year-old child. Note apparent widening of prevertebral soft tissue.<br> (C) Abnormal posterior cervical line with an underlying hangman's fracture. Actual offset is 4 mm.</div><div class=\"graphic_reference\">Reproduced with permission from: Woodward GA. Neck trauma. In: Fleisher GR, Ludwig S. Textbook of Pediatric Emergency Medicine, 6th edition, Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63065 Version 14.0</div></div></div>"},"63066":{"type":"graphic_diagnosticimage","displayName":"Long axis pulmonary artery","title":"Pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery</div><div class=\"cntnt\"><img style=\"width:259px; height:268px;\" src=\"images/CARD/63066_Long_axis_pulmonary_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right pulmonary artery (RPA) can be seen in the precordial long axis view as it crosses under the transverse aorta (Ao), superior to the left atrium (LA).</div><div id=\"graphicVersion\">Graphic 63066 Version 2.0</div></div></div>"},"63067":{"type":"graphic_waveform","displayName":"Prominent v waves in mitral regurgitation","title":"Prominent 'v' waves in acute mitral valve insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prominent 'v' waves in acute mitral valve insufficiency</div><div class=\"cntnt\"><img style=\"width:408px; height:304px;\" src=\"images/PULM/63067_Swan_Ganz_PAWP_tracing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous electrocardiographic and pulmonary artery occlusion (wedge) pressure tracings from a patient with acute mitral regurgitation. The pulmonary artery occlusion pressure is elevated; mitral regurgitation results in a large 'v' wave followed by a steep 'y' descent.</div><div class=\"graphic_reference\">Redrawn from Daily EK, Schroeder JS, Hemodynamic Waveforms: Exercises in Interpretation and Analysis, St. Louis, CV Mosby, 1983, p. 139.</div><div id=\"graphicVersion\">Graphic 63067 Version 3.0</div></div></div>"},"63069":{"type":"graphic_figure","displayName":"Type III AC joint injury","title":"Type III acromioclavicular joint injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Type III acromioclavicular joint injury</div><div class=\"cntnt\"><img style=\"width:428px; height:325px;\" src=\"images/EM/63069_Type_III_AC_joint_sprain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing depicts a Type&nbsp;III acromioclavicular (AC) joint injury. Both the AC ligament and the coracoclavicular ligament are completely disrupted. The clavicle is displaced superiorly with such injuries.</div><div id=\"graphicVersion\">Graphic 63069 Version 4.0</div></div></div>"},"63073":{"type":"graphic_diagnosticimage","displayName":"Coronal axial MRI Sturge-Weber","title":"Sturge-Weber syndrome coronal and axial MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sturge-Weber syndrome coronal and axial MRI</div><div class=\"cntnt\"><img style=\"width:402px; height:216px;\" src=\"images/PEDS/63073_Coronal_axial_MRI_Sturge-We.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal and axial brain MRI of a child with Sturge-Weber syndrome showing the extent of atrophy resulting from a large left hemisphere meningeal capillary-venous malformation (angioma). The left hemisphere is indicated by a white arrow in both images.</div><div class=\"graphic_reference\">Courtesy of John Bodensteiner, MD.</div><div id=\"graphicVersion\">Graphic 63073 Version 4.0</div></div></div>"},"63074":{"type":"graphic_figure","displayName":"Generation of the QRS complex","title":"Generation of the QRS complex","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Generation of the QRS complex</div><div class=\"cntnt\"><img style=\"width:480px; height:214px;\" src=\"images/CARD/63074_Generation_of_the_QRS_compl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventricular depolarization can be divided into two major phases, each represented by a vector. Panel A: The first phase (arrow 1) denotes depolarization of the ventricular septum, beginning on the left side and spreading to the right. This process is represented by a small &quot;septal&quot; r wave in the anterior-posterior lead V1 and a small septal q wave in the left-right lead V6. Panel B: Simultaneous depolarization of the left and right ventricles (LV and RV) constitutes the second phase. This second vector (arrow 2) is oriented to the left and posteriorly, reflecting the electrical predominance of the LV. The net effect is an S wave in lead V1 and an R wave in lead V6.</div><div id=\"graphicVersion\">Graphic 63074 Version 1.0</div></div></div>"},"63076":{"type":"graphic_figure","displayName":"Lead-induced side effects","title":"Summary of lowest lead levels for key lead-induced health effects in adults","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">Summary of lowest lead levels for key lead-induced health effects in adults</div><div class=\"cntnt\"><img style=\"width:705px; height:676px;\" src=\"images/PC/63076_Lead_induced_side_effects.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PbB: blood lead concentration; ALA: aminolevulinic acid; EP: erythrocyte protoporphyrin; GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Adapted from: ATSDR, US Department of Health and Human Services. Toxicological Profile for Lead, 1990.</div><div id=\"graphicVersion\">Graphic 63076 Version 4.0</div></div></div>"},"63077":{"type":"graphic_table","displayName":"Antihypertensive drugs for infants","title":"Recommended doses for selected agents to treat hypertensive infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses for selected agents to treat hypertensive infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Dose range</td> <td class=\"subtitle1\">Interval</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td rowspan=\"4\">ACE inhibitors</td> <td rowspan=\"2\">Captopril</td> <td rowspan=\"2\">Oral</td> <td> <p>&#60;3 months: 0.01 to 0.5 mg/kg/dose</p> Max 2 mg/kg/day</td> <td rowspan=\"2\">Three to four times per day</td> <td rowspan=\"4\"> <ol> <li>First dose may cause rapid drop in BP, especially if receiving diuretics </li> <li>In infants already receiving a diuretic, start at the lowest recommended dose </li> <li>Monitor serum creatinine and potassium </li> <li>Intravenous enalaprilat NOT recommended - see text </li> <li>Only captopril and enalapril are US Food &#38; Drug Administration approved in infancy </li> <li>ACE inhibitors should not be used in infants who are less than 44 weeks postconceptual age </li> </ol> </td> </tr> <tr> <td> <p>&#62;3 months: 0.15 to 0.3 mg/kg/dose</p> Max 6 mg/kg/day</td> </tr> <tr> <td>Enalapril</td> <td>Oral</td> <td>0.08 to 0.6 mg/kg/day</td> <td>Once or twice daily</td> </tr> <tr> <td>Lisinopril</td> <td>Oral</td> <td>0.07 to 0.6 mg/kg/day</td> <td>Once daily</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Alpha and beta antagonists</td> <td rowspan=\"3\">Labetalol</td> <td>Oral</td> <td> <p>0.5 to 1 mg/kg/dose</p> Max 10 mg/kg/day</td> <td>Two or three times daily</td> <td rowspan=\"3\">Acute decompensated heart failure, bronchopulmonary dysplasia relative contraindications</td> </tr> <tr> <td>IV bolus</td> <td>0.2 to 1 mg/kg/dose</td> <td>Administer every four to six hours</td> </tr> <tr> <td>IV infusion</td> <td>0.25 to 3 mg/kg/hr</td> <td>Continuous infusion</td> </tr> <tr> <td>Carvedilol</td> <td>Oral</td> <td>0.1 mg/kg/dose up to 0.5 mg/kg/dose</td> <td>Twice per day</td> <td>May be useful in chronic heart failure</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Beta antagonists</td> <td>Esmolol</td> <td>IV infusion</td> <td>100 to 500 mcg/kg/min</td> <td>Continuous infusion</td> <td>Very short-acting; constant infusion necessary. May be useful for management of acute hypertension after repair of aortic coarctation.</td> </tr> <tr> <td>Propranolol</td> <td>Oral</td> <td> <p>0.5 to 1 mg/kg/dose</p> Max 8 to 10 mg/kg/day</td> <td>Three to four times per day</td> <td>Monitor heart rate; avoid in bronchopulmonary dysplasia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Calcium channel blockers</td> <td>Amlodipine</td> <td>Oral</td> <td> <p>0.05 to 0.3 mg/kg/dose</p> Max 0.6 mg/kg/day</td> <td>Once per day</td> <td>May cause mild reflex tachycardia. Some infants may benefit by dividing dose twice per day. Full effect of dose adjustment may require one week or more.</td> </tr> <tr> <td>Isradipine</td> <td>Oral</td> <td> <p>0.05 to 0.15 mg/kg/dose</p> Max 0.8 mg/kg/day</td> <td>Four times per day</td> <td rowspan=\"2\">May cause mild reflex tachycardia</td> </tr> <tr> <td>Nicardipine</td> <td>IV infusion</td> <td>0.5 to 4 mcg/kg/min</td> <td>Continuous infusion</td> </tr> <tr class=\"divider_top\"> <td>Central alpha-agonist</td> <td>Clonidine</td> <td>Oral</td> <td> <p>5 to 10 mcg/kg/day</p> Max 25 mcg/kg/day</td> <td>Divided two to four times daily</td> <td>May cause mild sedation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Diuretics</td> <td>Chlorothiazide</td> <td>Oral</td> <td>5 to 15 mg/kg/dose</td> <td>Twice per day</td> <td rowspan=\"3\">Monitor electrolytes</td> </tr> <tr> <td>Hydrochlorothiazide</td> <td>Oral</td> <td>1 to 3 mg/kg/day</td> <td>Once daily or as two divided doses per day</td> </tr> <tr> <td>Spironolactone</td> <td>Oral</td> <td>0.5 to 1.5 mg/kg/dose</td> <td>Twice per day</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Vasodilators</td> <td rowspan=\"2\">Hydralazine</td> <td>Oral</td> <td> <p>0.25 to 1 mg/kg/dose</p> Max 7.5 mg/kg/day</td> <td>Three to four times per day</td> <td rowspan=\"2\">Tachycardia and fluid retention are common side effects</td> </tr> <tr> <td>IV bolus</td> <td>0.15 to 0.6 mg/kg/dose</td> <td>Q four hours</td> </tr> <tr> <td>Minoxidil</td> <td>Oral</td> <td>0.1 to 0.2 mg/kg/dose</td> <td>Two to three times per day</td> <td>Tachycardia and fluid retention common side effects; prolonged use causes hypertrichosis; pericardial effusion may occur</td> </tr> <tr> <td>Nitroprusside</td> <td>IV infusion</td> <td>0.5 to 10 mcg/kg/min</td> <td>Continuous infusion</td> <td>Thiocyanate toxicity can occur with prolonged (&#62;72 h) use or in renal failure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE inhibitor: angiotensin converting enzyme inhibitor; BP: blood pressure.</div><div class=\"graphic_reference\">Adapted from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 63077 Version 6.0</div></div></div>"},"63078":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 0","title":"Sacroiliitis grade 0","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 0</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/63078_Sacroiliitis_grade_0.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sacroiliac joints are normal and are graded as grade 0.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, PLA Hospital, China.</div><div id=\"graphicVersion\">Graphic 63078 Version 2.0</div></div></div>"},"63079":{"type":"graphic_table","displayName":"Carcinoid symptoms","title":"Carcinoid symptoms and their putative mediators","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carcinoid symptoms and their putative mediators</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ</td> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Frequency (%)</td> <td class=\"subtitle1\">Putative mediator</td> </tr> <tr> <td rowspan=\"4\">Skin</td> <td>Flushing</td> <td>85</td> <td>Kinins, histamine, kallikreins, other</td> </tr> <tr> <td>Telangiectasia</td> <td>25</td> <td>&nbsp;</td> </tr> <tr> <td>Cyanosis</td> <td>18</td> <td>&nbsp;</td> </tr> <tr> <td>Pellagra</td> <td>7</td> <td>Excess tryptophan metabolism</td> </tr> <tr class=\"divider_top\"> <td>Gastrointestinal tract</td> <td>Diarrhea and cramping</td> <td>75 to 85</td> <td>Serotonin</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\" rowspan=\"3\">Heart</td> <td class=\"sublist1_start\" colspan=\"2\">Valvular lesions</td> <td class=\"sublist1_start\" rowspan=\"3\">Serotonin</td> </tr> <tr> <td class=\"sublist1\">Right heart</td> <td class=\"sublist_other\">40</td> </tr> <tr> <td class=\"sublist1\">Left heart</td> <td class=\"sublist_other\">13</td> </tr> <tr class=\"divider_top\"> <td>Respiratory tract</td> <td>Bronchoconstriction</td> <td>19</td> <td>Unknown</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63079 Version 9.0</div></div></div>"},"63080":{"type":"graphic_figure","displayName":"Inguinal region","title":"Inguinal region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inguinal region</div><div class=\"cntnt\"><img style=\"width:416px; height:440px;\" src=\"images/PC/63080_Sports_hernias.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63080 Version 3.0</div></div></div>"},"63083":{"type":"graphic_table","displayName":"Use of SCOOP system I","title":"Patient management tips for the SCOOP transtracheal oxygen system - I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient management tips for the SCOOP transtracheal oxygen system - I</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Goal</td> <td class=\"subtitle1\">Management strategy</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">I</td> <td>Patient selection</td> <td>Select patients who are enthusiastic and desire to be active. The patient must be willing to assume responsibility for the catheter or have assistance from a significant other.</td> </tr> <tr> <td>Patient orientation</td> <td>Reinforce verbal instructions by showing a DVD and giving the patient a booklet and article to review. Give the patient the phone number of another transtracheal patient to call to ask questions or ask the transtracheal patient to place the call.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hoffman LA, Wesmiller SW.Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.</div><div id=\"graphicVersion\">Graphic 63083 Version 4.0</div></div></div>"},"63085":{"type":"graphic_figure","displayName":"Trigeminal nerve distribution","title":"Distribution of the trigeminal nerve (cranial nerve V)","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Distribution of the trigeminal nerve (cranial nerve V)</div><div class=\"cntnt\"><img style=\"width:614px; height:792px;\" src=\"images/NEURO/63085_Trigeminal_nerve_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The orientation drawing shows the trigeminal ganglion and its sensory and motor roots in situ.<br />(A) Lateral view showing distribution of the three divisions of the trigeminal nerve (CN V1, the ophthalmic nerve; CN V2, the maxillary nerve; and CN V3, the mandibular nerve) to the skin of the face and scalp. All three divisions are sensory.<br />(B) Lateral view. Each division supplies the skin and subcutaneous tissue and sends a branch to the dura mater. Each division provides sensory fibers that pass through an autonomic ganglion and delivers the postsynaptic parasympathetic fibers from that ganglion: CN V1 for the ciliary ganglion, CN V2 for the pterygopalatine ganglion, and CN V3 for the submandibular and otic ganglia. CN V3 is also motor to four pairs of muscles: temporal, masseter, and the two pterygoid muscles.<br />(C) \"Open book\" illustration of the innervation of the anterior wall of the nasal cavity. Passing from the pterygopalatine ganglion, the nasopalatine nerve passes through the sphenopalatine foramen; the greater and lesser palatine nerves pass through the canals of the same name, and the pharyngeal nerve passes through the pharyngeal canal.</div><div class=\"graphic_footnotes\">CN: cranial nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, 4th Ed, Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63085 Version 5.0</div></div></div>"},"63087":{"type":"graphic_table","displayName":"VFD localization asso sx","title":"Localizing retrochiasmal visual field defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Localizing retrochiasmal visual field defects</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\t\t<tr>\r\n\t\t\t\t\t\t<td class=\"subtitle1\">Defect</td>\r\n\t\t\t\t\t\t<td class=\"subtitle1\">Localization</td>\r\n\t\t\t\t\t\t<td class=\"subtitle1\">Associated symptoms, signs</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Homonymous sectoranopia</td>\r\n\t\t\t\t\t\t<td>Lateral geniculate body</td>\r\n\t\t\t\t\t\t<td>Optic atrophy, hemianesthesia, hemiparesis</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Homonymous pie-in-the-sky</td>\r\n\t\t\t\t\t\t<td>Anterior temporal lobe</td>\r\n\t\t\t\t\t\t<td>Receptive aphasia (dominant hemisphere)</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Homonymous quadrantanopia</td>\r\n\t\t\t\t\t\t<td>Posterior optic radiations, visual cortex</td>\r\n\t\t\t\t\t\t<td>Hemisensory loss, depending on lateralization: hemineglect Gerstmann's syndrome</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Homonymous paracentral scotomas</td>\r\n\t\t\t\t\t\t<td>Posterior primary visual cortex</td>\r\n\t\t\t\t\t\t<td>Isolated symptom</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Macular-sparing homonymous hemianopia</td>\r\n\t\t\t\t\t\t<td>Primary visual cortex (sparing posterior portion)</td>\r\n\t\t\t\t\t\t<td>Isolated if occipital lobe</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Temporal crescent only</td>\r\n\t\t\t\t\t\t<td>Far anterior primary visual cortex</td>\r\n\t\t\t\t\t\t<td>Often isolated symptom</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Temporal crescent-sparing homonymous hemianopia</td>\r\n\t\t\t\t\t\t<td>Primary visual cortex (sparing far anterior portion)</td>\r\n\t\t\t\t\t\t<td>Isolated symptom</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t<td>Bilateral homonymous hemianopia</td>\r\n\t\t\t\t\t\t<td>Bilateral posterior optic radiations or primary visual cortex</td>\r\n\t\t\t\t\t\t<td>Anton's syndrome</td>\r\n\t\t\t\t\t</tr>\r\n\t\t\t\t</table></div><div id=\"graphicVersion\">Graphic 63087 Version 1.0</div></div></div>"},"63089":{"type":"graphic_diagnosticimage","displayName":"APBU with stone","title":"Anomalous pancreaticobiliary union with biliary cyst and obstructing stone","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Anomalous pancreaticobiliary union with biliary cyst and obstructing stone</div><div class=\"cntnt\"><img style=\"width:465px; height:361px;\" src=\"images/PEDS/63089_APBU_with_stone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Endoscopic retrograde cholangiopancreatography (ERCP) shows obstructing stone. B) After sphincterotomy, a balloon is inserted through the papilla and inflated upstream of the stone. C) Contrast injected into the duct demonstrates successful removal of the stone and resolution of the obstruction.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 63089 Version 3.0</div></div></div>"},"63092":{"type":"graphic_movie","displayName":"Short axis coronary artery TOF","title":"Parasternal short axis view of coronary artery in tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis view of coronary artery in tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/63092_ShortaxiscoroartTOF.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:488px; height:357px;\" src=\"images/PEDS/63092_ShortaxiscoroarteryTOF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video clip in the parasternal short axis window of a patient with tetralogy of Fallot (TOF) shows the left anterior descending (LAD) arising from the right coronary artery (RCA). This vessel courses anterior to the right ventricular outflow tract (RVOT), just proximal to the pulmonary valve.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 63092 Version 3.0</div></div></div>"},"63093":{"type":"graphic_figure","displayName":"Extensor hood injury of finger","title":"Extensor hood injury of finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensor hood injury of finger</div><div class=\"cntnt\"><img style=\"width:317px; height:598px;\" src=\"images/EM/63093_Extensor_hood_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Posterior view of normal dorsal extensor expansion. The extensor expansion near the proximal interphalangeal joint splits into three parts; a central part, which is inserted into the base of the middle phalanx, and two lateral parts, which converge to be inserted into the base of the distal phalanx. B) Mallet or baseball finger. The insertion of the extensor expansion into the base of the distal phalanx is ruptured; sometimes a flake of bone on the base of the phalanx is pulled off. C) Boutonni&#232;re deformity. The insertion of the extensor expansion into the base of the middle phalanx is ruptured. The arrows indicate the direction of the pull of the muscles and the deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott, Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63093 Version 2.0</div></div></div>"},"63094":{"type":"graphic_figure","displayName":"Brain pituitary anatomy PI","title":"Pituitary gland","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Pituitary gland</div><div class=\"cntnt\"><img style=\"width:527px; height:458px;\" src=\"images/PI/63094_Brain_pituitary_anat_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pituitary is a small gland in the middle of the head, just below the brain. This gland releases several hormones that control the thyroid gland, adrenal glands, and reproductive organs.</div><div id=\"graphicVersion\">Graphic 63094 Version 4.0</div></div></div>"},"63096":{"type":"graphic_waveform","displayName":"Advanced case 8 with answer","title":"Hyperkalemia in renal failure","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hyperkalemia in renal failure</div><div class=\"cntnt\"><img style=\"width:540px; height:332px;\" src=\"images/CARD/63096_Advancedcase8withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing peaked T waves (most apparent in V2 to V5) characteristic of hyperkalemia. Note the concomitant findings of QTc prolongation (QT = 0.44 seconds at heart rate of 75 bpm) due to elongation of ST segment (eg, V<SUB innerHtml>2 </SUB>), consistent with hypocalcemia; and left ventricular hypertrophy by voltage criteria, along with left atrial abnormality, consistent with chronic systemic hypertension. This constellation of findings strongly suggests that the hypercalcemia is due to chronic renal failure. </div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 63096 Version 3.0</div></div></div>"},"63097":{"type":"graphic_picture","displayName":"L H Reed Sternberg cells","title":"\"Lymphocytic and histiocytic\" Reed-Sternberg cells in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">&quot;Lymphocytic and histiocytic&quot; Reed-Sternberg cells in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:414px; height:384px;\" src=\"images/HEME/63097_L_H_Reed_Sternberg_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of a lymph node from a patient with nodular lymphocyte predominant Hodgkin lymphoma showing three L&amp;H Hodgkin/Reed-Sternberg cells (arrows) with highly iregular polypoid nuclear contours, resembling popped corn. These cells are seen in a background of small lymphocytes.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle). Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63097 Version 2.0</div></div></div>"},"63098":{"type":"graphic_figure","displayName":"Key sensory points","title":"Dermatomal distribution","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Dermatomal distribution</div><div class=\"cntnt\"><img style=\"width:451px; height:585px;\" src=\"images/PC/63098_Key_sensory_points.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Neurological Classification of Spinal Cord Injury. American Spinal Cord Injury Association.</div><div id=\"graphicVersion\">Graphic 63098 Version 1.0</div></div></div>"},"63100":{"type":"graphic_table","displayName":"Vasoactive receptor activity","title":"Vasoactive medication receptor activity and clinical effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vasoactive medication receptor activity and clinical effects</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Drug\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">\r\n  \r\n   Receptor activity\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Predominant clinical effects\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Alpha-1\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Beta-1\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Beta-2\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   Dopaminergic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Phenylephrine</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>SVR &#8593; &#8593;, CO  &#8596;/&#8593;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Norepinephrine</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>SVR &#8593; &#8593;, CO  &#8596;/&#8593;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Epinephrine</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>CO &#8593; &#8593;, SVR &#8595; (low dose) SVR/&#8593; (higher dose)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\" colspan=\"6\" rowspan=\"1\">\r\n  \r\n   Dopamine (mcg/kg/min)*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   0.5 to 2.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   0\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   +\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   0\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   CO\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   5. to 10.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   +\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   0\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   CO &#8593;, SVR &#8593;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   10. to 20.\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   0\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   ++\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"sublist_other\">\r\n  \r\n   SVR &#8593; &#8593;\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Dobutamine</td>\r\n  \r\n   <td>0/+</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>++</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>CO &#8593;, SVR &#8595;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Isoproterenol</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>+++</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>CO &#8593;, SVR &#8595;</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=69800&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Vasoactive_receptor_activit.htm</title></head></div><div class=\"graphic_footnotes\">+++: Very strong effect; ++: Moderate effect; +: Weak effect; 0: No effect.<br> * Doses between 2. and 5. mcg/kg/min have variable effects.</div><div id=\"graphicVersion\">Graphic 63100 Version 1.0</div></div></div>"},"63101":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced thumb metacarpal fracture","title":"Nondisplaced thumb metacarpal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced thumb metacarpal fracture</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/EM/63101_First_metacarpal_fx_type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this radiograph, a nondisplaced fracture of the&nbsp;thumb metacarpal distal to the carpal metacarpal joint is seen. This is a nondisplaced type III fracture of the first metacarpal.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 63101 Version 3.0</div></div></div>"},"63102":{"type":"graphic_figure","displayName":"Uterosacral ligaments","title":"Uterosacral ligaments and endopelvic fascia","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Uterosacral ligaments and endopelvic fascia</div><div class=\"cntnt\"><img style=\"width:481px; height:365px;\" src=\"images/OBGYN/63102_Uterosacral_ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervix measures approximately 2.5 cm in height. Anteriorly (A) the cervix is separated from the bladder by the endopelvic fascia (arrow). Posteriorly (B) the cervix lies below the uterosacral ligaments and is covered with peritoneum, which reflects off the posterior vagina (cul-de-sac).</div><div class=\"graphic_reference\">Reproduced with permission from: Baggish, MS, Valle, RF, Guedj, H. Hysteroscopy: Visual Perspectives of Uterine Anatomy, Physiology and Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63102 Version 2.0</div></div></div>"},"63103":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for percutaneous procedures","title":"Antimicrobial prophylaxis for percutaneous procedures in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for percutaneous procedures in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Potential organisms encountered</td> <td class=\"subtitle1\">Routine prophylaxis recommended</td> <td class=\"subtitle1\">First-choice antibiotic</td> <td class=\"subtitle1\">Common antibiotic choices</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Angiography, angioplasty, thrombolysis, arterial closure device placement, stent placement</td> <td><em>Staphylococcus aureus</em>, <em>S. epidermidis</em></td> <td>No</td> <td>None</td> <td>Cefazolin (2 g IV if &#60;120 kg, 3 g IV if &#8805;120 kg IV) (if high-risk stent infection). If penicillin-allergic, can use vancomycin (15 mg/kg IV; max 2 g) or clindamycin (900 mg IV).</td> <td>Procedure classification: clean</td> </tr> <tr class=\"divider_bottom\"> <td>Endograft placement</td> <td><em>S. aureus</em>, <em>S. epidermidis</em></td> <td>Yes</td> <td>Cefazolin (2 g IV if &#60;120 kg, 3 g IV if &#8805;120 kg IV)</td> <td>If penicillin-allergic, can use vancomycin or clindamycin</td> <td>Procedure classification: clean</td> </tr> <tr class=\"divider_bottom\"> <td>Superficial venous insufficiency treatment</td> <td><em>S. aureus</em>, <em>S. epidermidis</em></td> <td>No</td> <td>None</td> <td>None</td> <td>Procedure classification: clean</td> </tr> <tr class=\"divider_bottom\"> <td>IVC filter placement</td> <td><em>S. aureus</em>, <em>S. epidermidis</em></td> <td>No</td> <td>None</td> <td>None</td> <td>Procedure classification: clean</td> </tr> <tr> <td>Tunneled central venous access</td> <td><em>S. aureus</em>, <em>S. epidermidis</em></td> <td>No consensus</td> <td>None</td> <td>Cefazolin (2 g IV if &#60;120 kg, 3 g IV if &#8805;120 kg IV) (eg, immunocompromised patients before chemotherapy; history of catheter infection). If penicillin-allergic, can use vancomycin (15 mg/kg IV; max 2 g) or clindamycin (900 mg IV).</td> <td>Procedure classification: clean (nontunneled catheter: no prophylaxis)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: intravenous; IVC: inferior vena cava.</div><div class=\"graphic_reference\">Reproduced from: Venkatesan AM, Kundu S, Sacks D, et al. Practice guideline for adult antibiotic prophylaxis during vascular and interventional radiology procedures. J Vasc Interv Radiol 2010; 21:1611. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63103 Version 9.0</div></div></div>"},"63104":{"type":"graphic_table","displayName":"Adenovirus serotypes","title":"Adenovirus serotypes and associated diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adenovirus serotypes and associated diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subgroup</td> <td class=\"subtitle1\">Serotypes</td> <td class=\"subtitle1\">Clinical syndromes</td> </tr> <tr> <td>A</td> <td>31</td> <td>Infantile gastroenteritis*</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">B</td> <td>3, 7, 21</td> <td>Upper respiratory disease, pneumonia, pharyngoconjunctival fever</td> </tr> <tr> <td>11, 34, 35</td> <td>Hemorrhagic cystitis, interstitial nephritis</td> </tr> <tr> <td>14</td> <td>Pneumonia</td> </tr> <tr class=\"divider_top\"> <td>C</td> <td>1, 2, 5</td> <td>Upper respiratory disease, pneumonia, hepatitis</td> </tr> <tr class=\"divider_top\"> <td>D</td> <td>8, 19, 37</td> <td>Epidemic keratoconjunctivitis</td> </tr> <tr class=\"divider_top\"> <td>E</td> <td>4</td> <td>Upper respiratory disease, pneumonia</td> </tr> <tr class=\"divider_top\"> <td>F</td> <td>40, 41</td> <td>Infantile gastroenteritis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Remaining serotypes are infrequently isolated or not clearly associated with disease.</div><div class=\"graphic_footnotes\">* Association with gastroenteritis not as firmly established as with types 40 and 41.</div><div id=\"graphicVersion\">Graphic 63104 Version 4.0</div></div></div>"},"63105":{"type":"graphic_picture","displayName":"Budding of yeast phase","title":"<EM>Blastomyces dermatitidis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Blastomyces dermatitidis</EM></div><div class=\"cntnt\"><img style=\"width:364px; height:252px;\" src=\"images/ID/63105_Budding_of_yeast_phase.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of yeast phase of <EM>Blastomyces dermatitidis</EM> in tissue shows a thick cell with reproduction via a single large broad-based bud.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 63105 Version 3.0</div></div></div>"},"63107":{"type":"graphic_movie","displayName":"Echo four chamber severe MR","title":"Echocardiogram apical four chamber with mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram apical four chamber with mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/63107_4chcmrsvconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:259px; height:214px;\" src=\"images/CARD/63107_4chcmrsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram with color flow Doppler shows severe mitral regurgitation with a broad &quot;jet&quot; that reaches the back of the left atrium. The left atrium and ventricle are also enlarged.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 63107 Version 3.0</div></div></div>"},"63110":{"type":"graphic_table","displayName":"Clonidine and related imidazoline poisoning - Rapid overview","title":"Clonidine and related imidazoline poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clonidine and related imidazoline poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, in the United States, call a certified poison control center at&nbsp;1-800-222-1222. Elsewhere, click <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" spellcheck=\"true\">here</a>&nbsp; to </span><span style=\"color: #ff0000;\">access the World Health Organization's list of international poison centers</span><span style=\"color: #ff0000;\">.</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Symptoms usually appear within 1 hour of oral ingestion of pills or liquids</td> </tr> <tr> <td>Delayed symptoms may be seen after clonidine transdermal patch exposure</td> </tr> <tr> <td>May mimic opioid intoxication</td> </tr> <tr> <td>Common findings: lethargy, coma, bradycardia, hypotension, respiratory depression, apnea, small pupils</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Initial evaluation: fingerstick blood glucose (if any alteration in mental status), 12-lead ECG, serum salicylate and acetaminophen levels (if suicidal attempt), pregnancy test (in women of childbearing age)</td> </tr> <tr> <td>Symptomatic patients: arterial or venous pH and pCO<sub>2</sub>, serum electrolytes, BUN, creatinine, and chest radiograph if serious and persistent respiratory depression or coma</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Remove any transdermal clonidine patches</td> </tr> <tr> <td>Support airway and breathing</td> </tr> <tr> <td class=\"sublist1_start\">Respiratory depression or mental status depression</td> </tr> <tr> <td class=\"sublist1\">Naloxone, 0.1 mg/kg IV (maximum single dose 2 mg); may repeat every 1 to 2 minutes up to 10 mg total dose in children and opioid na&#239;ve adults; for opioid dependent patients, give an initial dose of 0.05 mg IV&nbsp;if spontaneously breathing and 1 mg IV&nbsp;if apneic.</td> </tr> <tr> <td class=\"sublist1_start\">Symptomatic bradycardia</td> </tr> <tr> <td class=\"sublist1\">1st line: atropine, 0.02 mg/kg IV (minimum dose: 0.1 mg, maximum single dose:&nbsp;0.5 mg), repeat&nbsp;after 3 to&nbsp;5 minutes to maximum total dose of&nbsp;0.04 mg/kg or 3 mg in adults</td> </tr> <tr> <td class=\"sublist1\">2nd line: dopamine, initiate IV infusion at 5 to 10 micrograms/kg per minute, titrate to response; maximum dose 20 micrograms/kg per minute</td> </tr> <tr> <td class=\"sublist1_start\">Hypotension</td> </tr> <tr> <td class=\"sublist1\">1st line: crystalloid, IV&nbsp;normal saline or Ringer's lactate 20 mL/kg (maximum 1 L), up to 60 to 100 mL/kg (3 to 5 L) total volume</td> </tr> <tr> <td class=\"sublist1\">2nd line: dopamine, initiate IV infusion at 5 to 10 micrograms/kg per minute, titrate to response; maximum dose 20 micrograms/kg per minute</td> </tr> <tr> <td>Do not treat asymptomatic hypertension</td> </tr> <tr> <td>Administer activated charcoal (AC), 1 gram/kg (maximum dose, 50 grams) to alert patients who present within 1 hour of ingestion unless contraindicated</td> </tr> <tr> <td>Administer AC 1 gram/kg (maximum dose, 50 grams) followed by nasogastric whole bowel irrigation at 500 mL to 1 L of polyethylene glycol (PEG) per hour in alert patients who have ingested a clonidine transdermal patch, unless contraindicated</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63110 Version 16.0</div></div></div>"},"63111":{"type":"graphic_figure","displayName":"Midface motion examination","title":"Examination for abnormal midface motion","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Examination for abnormal midface motion</div><div class=\"cntnt\"><img style=\"width:454px; height:355px;\" src=\"images/EM/63111_Midface_motion_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To assess for abnormal midface&nbsp;instability, grasp the superior anterior teeth (or alveolar ridge if teeth are absent) between the thumb and index finger and attempt to move the maxilla anteriorly and posteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63111 Version 2.0</div></div></div>"},"63114":{"type":"graphic_picture","displayName":"Duodenal ulcer endoscopy","title":"Duodenal ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal ulcer</div><div class=\"cntnt\"><img style=\"width:394px; height:441px;\" src=\"images/GAST/63114_Duodenal_ulcer_endoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duodenal ulcer with a small amount of fresh blood oozing from the edge.</div><div class=\"graphic_reference\">Courtesy of Nimish Vakil, MD.</div><div id=\"graphicVersion\">Graphic 63114 Version 4.0</div></div></div>"},"63117":{"type":"graphic_picture","displayName":"Cutting zipper mechanism","title":"Cutting the zipper mechanism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutting the zipper mechanism</div><div class=\"cntnt\"><img style=\"width:396px; height:270px;\" src=\"images/PEDS/63117_Cutting_zipper_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The zipper mechanism consists of two faceplates connected with a median bar. The technique most often recommended for release of entrapment within the zipper mechanism involves cutting the median bar, which allows the zipper to fall apart, releasing the entrapped skin. The median bar may be cut with wire cutters, bone cutters, or a mini hacksaw.</div><div id=\"graphicVersion\">Graphic 63117 Version 2.0</div></div></div>"},"63118":{"type":"graphic_figure","displayName":"Lisinopril reduces mortality in patients with diabetes after MI","title":"Lisinopril reduces mortality in patients with diabetes after acute MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lisinopril reduces mortality in patients with diabetes after acute MI</div><div class=\"cntnt\"><img style=\"width:431px; height:240px;\" src=\"images/CARD/63118_Lisinopril_post_MI_diabetes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The GISSI-3 trial enrolled 18,131 patients of whom 2790 were diabetics. Treatment with lisinopril was associated with a significant 29.8 percent reduction in the six-week mortality among diabetics after myocardial infarction (MI), translating into 37 lives saved per 1000 patients. Lisinopril was less effective in nondiabetics; there was only a 5 percent reduction in mortality or three lives saved per 1000 patients.</div><div class=\"graphic_reference\">Data from Zuanetti G, Latini R, Maggioni AP, et al, for the GISSI-3 Investigators. Circulation 1997; 96:4239.</div><div id=\"graphicVersion\">Graphic 63118 Version 3.0</div></div></div>"},"63119":{"type":"graphic_figure","displayName":"Precordial chest leads","title":"Precordial chest leads V1 to V6","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Precordial chest leads V1 to V6</div><div class=\"cntnt\"><img style=\"width:484px; height:306px;\" src=\"images/CARD/63119_Precordial_chest_leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Similar to the unipolar leads, the reference electrode is zero potential while the exploring electrode is attached to various locations of the anterior chest. An impulse directed toward the exploring electrode generates a positive or upright deflection.</div><div id=\"graphicVersion\">Graphic 63119 Version 1.0</div></div></div>"},"63120":{"type":"graphic_algorithm","displayName":"Approach to the child with blurry vision","title":"Approach to the child with blurry vision","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Approach to the child with blurry vision</div><div class=\"cntnt\"><img style=\"width:463px; height:236px;\" src=\"images/EM/63120_Appr_child_blurry_vision.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FB: foreign body.</div><div id=\"graphicVersion\">Graphic 63120 Version 1.0</div></div></div>"},"63122":{"type":"graphic_algorithm","displayName":"Approach to acute optic neuropathy","title":"Approach to patient with acute optic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Approach to patient with acute optic neuropathy</div><div class=\"cntnt\"><img style=\"width:578px; height:602px;\" src=\"images/NEURO/63122_Optic_neuropathy_approach.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRP: C-reactive protein; CSF: cerebrospinal fluid; DM: diabetes mellitus; ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; HTN: hypertension; LP: lumbar puncture; MRI: magnetic resonance imaging; NAION: nonarteritic ischemic optic neuropathy.</div><div id=\"graphicVersion\">Graphic 63122 Version 4.0</div></div></div>"},"63126":{"type":"graphic_figure","displayName":"Causes of falls","title":"The multifactorial and interacting causes of falls","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">The multifactorial and interacting causes of falls</div><div class=\"cntnt\"><img style=\"width:522px; height:382px;\" src=\"images/PC/63126_Causes_of_falls.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ADL: activities of daily living.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubenstein, LZ, Josephson, KR. Falls and their prevention in elderly people: What does the evidence show? Med Clin North America 2006; 90:807. Copyright &copy; 2006 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 63126 Version 3.0</div></div></div>"},"63127":{"type":"graphic_table","displayName":"DSM-IV-TR BPD","title":"DSM-IV-TR diagnostic criteria for borderline personality disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR diagnostic criteria for borderline personality disorder</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td>A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following:</td>\n  </tr>\n  <tr>\n    <td><strong>1.</strong> Frantic efforts to avoid real or imagined abandonment</td>\n  </tr>\n  <tr>\n    <td><strong>2.</strong> A pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation</td>\n  </tr>\n  <tr>\n    <td><strong>3.</strong> Identity disturbance: markedly and persistently unstable self-image or sense of self</td>\n  </tr>\n  <tr>\n    <td><strong>4.</strong> Impulsivity in at least two areas that are potentially self-damaging (eg, spending, sex, substance abuse, reckless driving, binge eating)</td>\n  </tr>\n  <tr>\n    <td><strong>5.</strong> Recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior</td>\n  </tr>\n  <tr>\n    <td><strong>6.</strong> Affective instability/marked reactivity of mood</td>\n  </tr>\n  <tr>\n    <td><strong>7.</strong> Chronic feelings of emptiness</td>\n  </tr>\n  <tr>\n    <td><strong>8.</strong> Inappropriate, intense anger or difficulty controlling anger</td>\n  </tr>\n  <tr>\n    <td><strong>9.</strong> Transient, stress-related paranoid ideation or severe dissociative symptoms</td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">22.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/31/2010--Requested permission (JD). 6/2/2010--Permission granted; figures to Terrence, invoice to Jo (JD). The total fee of $&amp;quot;230.00&amp;quot;was originally charged to Dx_criteria_Personality_Dis DSM-IV-TR_BPD</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=62112&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>DSM-IV-TR_BPD.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright © 2000 American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 63127 Version 9.0</div></div></div>"},"63129":{"type":"graphic_picture","displayName":"Elliptocytes","title":"Elliptical red cells in hereditary elliptocytosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elliptical red cells in hereditary elliptocytosis</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/HEME/63129_Elliptocytes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear from a patient with hereditary elliptocytosis shows multiple elliptocytes.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 63129 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"63130":{"type":"graphic_diagnosticimage","displayName":"Bronch atresia bronchogram","title":"Bronchial atresia in infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchial atresia in infant</div><div class=\"cntnt\"><img style=\"width:360px; height:392px;\" src=\"images/PULM/63130_Bronch_atresia_bronchogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Bronchogram performed with oily Dionosil shows an absent superior division of the left upper lobe bronchus, with the lingular and left lower lobe bronchi displaced caudad.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63130 Version 2.0</div></div></div>"},"63131":{"type":"graphic_figure","displayName":"Pelvic packing","title":"Pelvic packing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic packing</div><div class=\"cntnt\"><img style=\"width:408px; height:606px;\" src=\"images/SURG/63131_Pelvic_packing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pelvic packing is performed through a 6-8 cm midline incision made from the pubic symphysis cephalad and the midline fascia is divided.<br> (B) The pelvic hematoma often dissects the preperitoneal and paravesical space toward the presacral region, thereby facilitating packing. If this has not occuured, blunt digital dissection is performed to open the preperitoneal space.<br> (C) Three standard surgical laparotomy pads are placed on each side of the bladder deep within the preperitoneal space. If a suprapubic tube is placed, it should exit through a separate stab incision, cephalad to the incision either in the midline or slightly off midline. The midline fascia is closed with a running suture and the skin is reapproximated with staples.</div><div id=\"graphicVersion\">Graphic 63131 Version 3.0</div></div></div>"},"63132":{"type":"graphic_waveform","displayName":"ECG - Myocarditis","title":"Electrocardiogram in a 17-year-old female with myocarditis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram in a 17-year-old female with myocarditis</div><div class=\"cntnt\"><img style=\"width:586px; height:313px;\" src=\"images/PEDS/63132_ECG_myocarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram demonstrating decreased QRS voltage with ST segment and T wave abnormalities in a 17-year-old female with myocarditis.</div><div id=\"graphicVersion\">Graphic 63132 Version 2.0</div></div></div>"},"63133":{"type":"graphic_figure","displayName":"Complete fracture reduction A","title":"Complete fracture reduction: Reestablish length","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Complete fracture reduction: Reestablish length</div><div class=\"cntnt\"><img style=\"width:526px; height:256px;\" src=\"images/EM/63133_CompletefxreductionA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels A and B) Use of the thumb to push the distal fragment hyperdorsiflexed 90 degrees (black arrow) until length is reestablished. Counteraction is applied in the opposite direction (white arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Schoenecker JG, Bae DS. Fractures of the Distal Radius and Ulna. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins.&nbsp;<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 63133 Version 14.0</div></div></div>"},"63134":{"type":"graphic_picture","displayName":"Morgan lens flow","title":"Morgan® lens flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morgan&#174; lens flow</div><div class=\"cntnt\"><img style=\"width:396px; height:185px;\" src=\"images/EM/63134_Morgan_lens_flow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prolonged irrigation is often necessary for alkali burns. Immediate ophthalmologic consultation is mandatory for all significant eye exposures.</div><div class=\"graphic_reference\">Reproduced with permission from: MorTan, Inc. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 63134 Version 3.0</div></div></div>"},"63135":{"type":"graphic_picture","displayName":"AIP phlebitis Light HP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/63135_AIP_phlebitis_Light_HP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a pancreas biopsy in a patient with autoimmune pancreatitis. Obliterative phlebitis is present focally (arrow).</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 63135 Version 1.0</div></div></div>"},"63136":{"type":"graphic_table","displayName":"Physical signs in miliary TB","title":"Physical signs in patients with miliary tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical signs in patients with miliary tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Sign</td>\n\n      <td class=\"subtitle1\">Maartens, 1990</td>\n\n      <td class=\"subtitle1\">Kim, 1990</td>\n\n      <td class=\"subtitle1\">Gelb, 1973</td>\n\n      <td class=\"subtitle1\">Munt, 1971</td>\n\n      <td class=\"subtitle1\">Proudfoot, 1969</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fever</td>\n\n      <td>96*</td>\n\n      <td>90</td>\n\n      <td>85</td>\n\n      <td>84</td>\n\n      <td>82</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary (rales, rhonchi, rubs,&nbsp;signs of effusion)</td>\n\n      <td>72</td>\n\n      <td>50</td>\n\n      <td>51</td>\n\n      <td>46</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Hepatomegaly</td>\n\n      <td>52</td>\n\n      <td>16</td>\n\n      <td>31</td>\n\n      <td>36</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Splenomegaly</td>\n\n      <td>15</td>\n\n      <td>13</td>\n\n      <td>11</td>\n\n      <td>13</td>\n\n      <td>10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neurologic (altered mental status, meningismus)</td>\n\n      <td>20</td>\n\n      <td>32</td>\n\n      <td>15</td>\n\n      <td>26</td>\n\n      <td>10</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Ascites</td>\n\n      <td>&nbsp;</td>\n\n      <td>8</td>\n\n      <td>4</td>\n\n      <td>&nbsp;</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jaundice</td>\n\n      <td>&nbsp;</td>\n\n      <td>5</td>\n\n      <td>9</td>\n\n      <td>&nbsp;</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dermatologic</td>\n\n      <td>4</td>\n\n      <td>8</td>\n\n      <td>&nbsp;</td>\n\n      <td>5</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Positive PPD</td>\n\n      <td>42</td>\n\n      <td>28</td>\n\n      <td>&nbsp;</td>\n\n      <td>53</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=32232&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Physical_signs_in_miliary_T.htm</title></head></div><div class=\"graphic_footnotes\">PPD: purified protein derivative.<br />* All numbers are percentages.</div><div id=\"graphicVersion\">Graphic 63136 Version 2.0</div></div></div>"},"63137":{"type":"graphic_table","displayName":"Nondegenerative causes of radiculopathy","title":"Nondegenerative causes of radiculopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nondegenerative causes of radiculopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diabetes mellitus</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis with nerve root infarction</td> </tr> <tr> <td class=\"subtitle1_single\">Nerve root avulsion</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious or granulomatous</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Histiocytosis X</td> </tr> <tr> <td>Sarcoid</td> </tr> <tr> <td class=\"subtitle1_single\">Infiltration</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Carcinomatous meningitis</td> </tr> <tr> <td class=\"subtitle1_single\">Acute demyelination</td> </tr> <tr> <td>Early Guillain-Barr&#233; syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63137 Version 4.0</div></div></div>"},"63138":{"type":"graphic_picture","displayName":"Light microscopy teratoma","title":"Teratoma","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Teratoma</div><div class=\"cntnt\"><img style=\"width:551px; height:342px;\" src=\"images/ONC/63138_Light_microscopy_teratoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This mixed germ cell tumor contained teratoma and yolk sac tumor. Panel A: squamous epithelium, skin adenexal tissue (adjacent to squamous epithelium), and enteric-type epithelium are present. Panel B: cartilage (top) and yolk sac tumor (bottom) are present.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 63138 Version 1.0</div></div></div>"},"63139":{"type":"graphic_figure","displayName":"Shoulder anat posterior PI","title":"Posterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Posterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:544px; height:456px;\" src=\"images/PI/63139_Shoulder_anat_posterior_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63139 Version 2.0</div></div></div>"},"63141":{"type":"graphic_figure","displayName":"Normal ear anatomy","title":"Normal ear anatomy","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Normal ear anatomy</div><div class=\"cntnt\"><img style=\"width:544px; height:505px;\" src=\"images/EM/63141_Normal_ear_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the normal structures of the outer, middle, and inner ear.</div><div id=\"graphicVersion\">Graphic 63141 Version 3.0</div></div></div>"},"63142":{"type":"graphic_picture","displayName":"Sweet syndrome II","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:320px; height:318px;\" src=\"images/DERM/63142_Sweets_syndrome_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema nodosum-like lesions of the lower extremities in a patient with Sweet syndrome.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 63142 Version 3.0</div></div></div>"},"63143":{"type":"graphic_figure","displayName":"Completed axillary dissection","title":"Completed axillary dissection","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Completed axillary dissection</div><div class=\"cntnt\"><img style=\"width:482px; height:425px;\" src=\"images/SURG/63143_Axillary-dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Completed axillary lymph node dissection.</div><div class=\"graphic_reference\">Modified with permission from: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63143 Version 3.0</div></div></div>"},"63145":{"type":"graphic_picture","displayName":"Diphtheria cutaneous lesion 2","title":"A diphtheria skin lesion on the leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A diphtheria skin lesion on the leg</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/63145_Diphth_cutan_lesion_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention Public Health Image Library. Available at:http://phil.cdc.gov/phil/home.asp./u003c/div/u003e/u003cdiv id/u003d\"graphicVersion\">Graphic 63145 Version 2.0</div></div></div>"},"63149":{"type":"graphic_algorithm","displayName":"Diagnosis anxiety disorder","title":"Algorithm for diagnosis of anxiety disorders","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of anxiety disorders</div><div class=\"cntnt\"><img style=\"width:620px; height:389px;\" src=\"images/PC/63149_Diagnosis_anxiety_disorder.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19:56. Copyright &copy;2005 Sage Publications, Ltd.</div><div id=\"graphicVersion\">Graphic 63149 Version 3.0</div></div></div>"},"63150":{"type":"graphic_picture","displayName":"Periductal mastitis piercing","title":"Nipple ring infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nipple ring infection</div><div class=\"cntnt\"><img style=\"width:396px; height:391px;\" src=\"images/PC/63150_Nipple_ring_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nipple rings can cause problems with recurrent infections.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 63150 Version 3.0</div></div></div>"},"63151":{"type":"graphic_table","displayName":"Complications of cough","title":"Complications of cough","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of cough</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cardiovascular</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arterial hypotension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Loss of consciousness</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rupture of subconjunctival, nasal and anal veins</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dislodgement/malfunctioning of intravascular catheters</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bradyarrhythmias, tachyarrhythmias</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Neurologic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cough syncope</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Headache</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebral air embolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>CSF rhinorrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute cervical radiculopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malfunctioning ventriculoatrial shunts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Seizures</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Stroke due to vertebral artery dissection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Gastrointestinal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Gastroesophageal reflux events</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hydrothorax in peritoneal dialysis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malfunction of gastrostomy button</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Splenic rupture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Inguinal hernia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Genitourinary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Urinary incontinence</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Inversion of bladder through urethra</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Musculoskeletal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>From asymptomatic elevations of serum creatine\nphosphokinase to rupture of rectus abdominis muscles</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rib fractures</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Respiratory</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary interstitial emphysema, with potential risk\nof pneumatosis intestinalis, pneumomediastinum, pneumoperitoneum,\npneumoretroperitoneum, pneumothorax, subcutaneous emphysema</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laryngeal trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tracheobronchial trauma (eg, bronchitis, bronchial\nrupture)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Exacerbation of asthma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intercostal lung herniation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Miscellaneous</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Petechiae and purpura</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Disruption of surgical wounds </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Constitutional symptoms </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lifestyle changes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Self-consciousness, hoarseness, dizziness</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Fear of serious disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Decrease in quality of life</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Irwin, RS, Boulet, LP, Cloutier, MM, et al. Managing a cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114(suppl 2):133S.</div><div id=\"graphicVersion\">Graphic 63151 Version 1.0</div></div></div>"},"63153":{"type":"graphic_diagnosticimage","displayName":"Rheumatoid pleural disease CT scan","title":"Rheumatoid pleural disease CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid pleural disease CT scan</div><div class=\"cntnt\"><img style=\"width:324px; height:321px;\" src=\"images/PULM/63153_Rheumatic_pleural_dz_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography demonstrates extensive thickening of the visceral pleura in a patient with rheumatoid arthritis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63153 Version 5.0</div></div></div>"},"63157":{"type":"graphic_table","displayName":"Complications EP study","title":"Complications of invasive cardiac electrophysiology studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of invasive cardiac electrophysiology studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Associated with percutaneous catheterization of veins and arteries</td> </tr> <tr> <td>Pain</td> </tr> <tr> <td>Adverse drug reaction</td> </tr> <tr> <td>Infection/abscess at the catheterization site, sepsis</td> </tr> <tr> <td>Excessive bleeding, hematoma formation</td> </tr> <tr> <td>Thrombophlebitis</td> </tr> <tr> <td>Pulmonary thromboembolism</td> </tr> <tr> <td>Arterial damage, aortic dissection</td> </tr> <tr> <td>Systemic thromboembolism</td> </tr> <tr> <td>Transient ischemic attack/stroke</td> </tr> <tr> <td class=\"subtitle1_single\">Associated with intracardiac catheters and programmed cardiac stimulation</td> </tr> <tr> <td>Cardiac chamber or coronary sinus perforation</td> </tr> <tr> <td>Hemopericardium, cardiac tamponade</td> </tr> <tr> <td>Atrial fibrillation</td> </tr> <tr> <td>Ventricular tachycardia/ventricular fibrillation</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Right or left bundle branch block</td> </tr> <tr> <td class=\"subtitle1_single\">Associated with transcatheter ablation</td> </tr> <tr> <td>Complete heart block</td> </tr> <tr> <td>Thromboembolism</td> </tr> <tr> <td>Vascular access problems&nbsp;(bleeding, infection, hematoma, vascular injury)</td> </tr> <tr> <td>Cardiac trauma (myocardial perforation, tamponade, valvular damage)</td> </tr> <tr> <td>Coronary artery thrombosis/myocardial infarction</td> </tr> <tr> <td>Cardiac arrhythmias</td> </tr> <tr> <td>Pericarditis</td> </tr> <tr> <td>Pulmonary vein stenosis</td> </tr> <tr> <td>Phrenic nerve paralysis</td> </tr> <tr> <td>Radiation skin burns</td> </tr> <tr> <td>Possible late malignancy</td> </tr> <tr> <td>Atrioesophageal fistula</td> </tr> <tr> <td class=\"subtitle1_single\">Death resulting from one of the above complications</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63157 Version 4.0</div></div></div>"},"63158":{"type":"graphic_diagnosticimage","displayName":"Gastric duplication cyst","title":"Fetal gastric duplication cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal gastric duplication cyst</div><div class=\"cntnt\"><img style=\"width:396px; height:323px;\" src=\"images/OBGYN/63158_Gastric_duplication_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of the abdomen shows an echogenic mass pressing on the stomach.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 63158 Version 2.0</div></div></div>"},"63159":{"type":"graphic_picture","displayName":"CRPS child hand","title":"Complex regional pain syndrome of the hand","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Complex regional pain syndrome of the hand</div><div class=\"cntnt\"><img style=\"width:468px; height:315px;\" src=\"images/PEDS/63159_CRPS_child_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David D Sherry, MD.</div><div id=\"graphicVersion\">Graphic 63159 Version 2.0</div></div></div>"},"63160":{"type":"graphic_figure","displayName":"Technique of Syme amputation","title":"Technique of Syme amputation","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Technique of Syme amputation</div><div class=\"cntnt\"><img style=\"width:462px; height:683px;\" src=\"images/SURG/63160_Syme-amputation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63160 Version 2.0</div></div></div>"},"63165":{"type":"graphic_picture","displayName":"Debrunner kyphometer","title":"Debrunner kyphometer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Debrunner kyphometer</div><div class=\"cntnt\"><img style=\"width:286px; height:432px;\" src=\"images/PC/63165_Debrunner_kyphometer.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kado DM, Christianson L, Palermo L, et al. Comparing a supine radiologic versus standing clinical measurement of kyphosis in older women: the Fracture Intervention Trial. Spine 2006; 31:463. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63165 Version 9.0</div></div></div>"},"63166":{"type":"graphic_figure","displayName":"CO2 dissociation curves","title":"CO2 dissociation curves","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CO2 dissociation curves</div><div class=\"cntnt\"><img style=\"width:323px; height:501px;\" src=\"images/PULM/63166_CO2dissociationcurves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top figure (A) shows the CO<sub>2</sub> dissociation curves for blood of different O<sub>2</sub> saturations. Note that oxygenated blood carries less CO<sub>2 </sub>for the same PCO<sub>2</sub>. The bottom figure (B) shows the \"physiological\" curve between arterial (a) and mixed venous (v) blood.</div><div class=\"graphic_reference\">Data from: West JB (Ed), Respiratory Physiology, 5th ed, Williams &amp;Wilkins, Baltimore, MD 1995.</div><div id=\"graphicVersion\">Graphic 63166 Version 2.0</div></div></div>"},"63167":{"type":"graphic_picture","displayName":"Mixed lymphoepithelial thymoma","title":"Mixed lymphoepithelial thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed lymphoepithelial thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PULM/63167_Mixed_lymphoepithelial_thym.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epithelial cells form pseudo-rosettes that can be confused with carcinoid tumor. The presence of a mixture of lymphocytes and epithelial cells favors a thymoma. (Hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 63167 Version 1.0</div></div></div>"},"63169":{"type":"graphic_picture","displayName":"Laerdal trachlight","title":"Laerdal trachlight","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Laerdal trachlight</div><div class=\"cntnt\"><img style=\"width:540px; height:397px;\" src=\"images/EM/63169_Laerdal_trachlight_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From top to bottom: Rigid internal stylet, lightwand, Trachlight handle and assembled device with a cuffed endotracheal tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy MF, Hung OR. Lighted stylet intubation. In: Walls RM, Murphy MF (eds). Manual of Emergency Airway Management, 3rd edition. Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63169 Version 5.0</div></div></div>"},"63170":{"type":"graphic_picture","displayName":"Pemphigus vulgaris large erosions","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63170_Pemph_vulgaris_large_eros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions on the trunk skin of this patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63170 Version 4.0</div></div></div>"},"63172":{"type":"graphic_figure","displayName":"Energy expenditure and weight","title":"Changes in energy expenditure minimize changes in weight","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Changes in energy expenditure minimize changes in weight</div><div class=\"cntnt\"><img style=\"width:451px; height:289px;\" src=\"images/PC/63172_Energyexpenditureandweig.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Observed minus predicted energy expenditure in subjects studied during food-induced weight gain and diet-induced weight loss. Changes in weight were associated with parallel changes in total energy expenditure, thereby making further alterations in weight more difficult.</div><div class=\"graphic_reference\">Data from: Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.</div><div id=\"graphicVersion\">Graphic 63172 Version 3.0</div></div></div>"},"63173":{"type":"graphic_figure","displayName":"Course acute dengue infection","title":"Acute dengue virus infection","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Acute dengue virus infection</div><div class=\"cntnt\"><img style=\"width:484px; height:384px;\" src=\"images/ID/63173_Course_acute_dengue_infecti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypothetical schema of events in acute dengue virus infection. The kinetics and general location of viral replication are diagrammed in relation to the presence of detectable viremia, general symptoms (fever, myalgias, headache, rash), and the period of risk for plasma leakage, shock, severe thrombocytopenia, and bleeding in dengue hemorrhagic fever (DHF). Nonspecific immune responses include the production of interferons (IFN) and natural killer (NK) cell activity. The kinetics of dengue virus-specific T lymphocyte activation and the production of dengue virus-specific antibodies occur later and are of lesser magnitude in primary infections (first exposure to dengue viruses) than in secondary infections (later infection with a second dengue virus serotype).</div><div id=\"graphicVersion\">Graphic 63173 Version 1.0</div></div></div>"},"63175":{"type":"graphic_table","displayName":"Changes in urinary electrolytes with persistent vomiting","title":"Variability in urinary electrolyte excretion and pH according to time after onset of vomiting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Variability in urinary electrolyte excretion and pH according to time after onset of vomiting</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Time</td>\n\n\n      <td class=\"subtitle1\">[Na+]</td>\n\n\n      <td class=\"subtitle1\">[K+]</td>\n\n\n      <td class=\"subtitle1\">[Cl-]</td>\n\n\n      <td class=\"subtitle1\">[HCO3-]</td>\n\n\n      <td class=\"subtitle1\">pH</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Days 1 to 3</td>\n\n\n      <td>&#8593;</td>\n\n\n      <td>&#8593;</td>\n\n\n      <td>&#8595;</td>\n\n\n      <td>&#8593;</td>\n\n\n      <td>&#62;6.5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Late*</td>\n\n\n      <td>&#8595;</td>\n\n\n      <td>&#8595;</td>\n\n\n      <td>&#8595;</td>\n\n\n      <td>&#8595;</td>\n\n\n      <td>&#60;5.5</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40006&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Urine_electrolytes_vomiting.htm</title></head></div><div class=\"graphic_footnotes\">* The late phase is dependent upon volume and chloride depletion being severe enough to allow all of the filtered bicarbonate to be reabsorbed. Some patients ingest enough NaCl so that the filtered bicarbonate concentration remains above reabsorptive capacity, leading to persistent urinary changes similar to that in the early phase.</div><div id=\"graphicVersion\">Graphic 63175 Version 2.0</div></div></div>"},"63176":{"type":"graphic_waveform","displayName":"ECG Monomorphic VT tutorial","title":"Single lead electrocardiogram (ECG) showing monomorphic ventricular tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing monomorphic ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:488px; height:150px;\" src=\"images/CARD/63176_MonomorphicVTtutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three or more successive ventricular beats are defined as ventricular tachycardia (VT). This VT is monomorphic since all of the QRS complexes have an identical appearance. Although the P waves are not distinct, they can be seen altering the QRS complex and ST-T waves in an irregular fashion, indicating the absence of a relationship between the P waves and the QRS complexes (ie, AV dissociation is present).</div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div id=\"graphicVersion\">Graphic 63176 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"63177":{"type":"graphic_picture","displayName":"Endosc esophageal papilloma","title":"Esophageal papilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal papilloma</div><div class=\"cntnt\"><img style=\"width:288px; height:267px;\" src=\"images/GAST/63177_Endosc_esophageal_papilloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of an esophageal papilloma appearing as an isolated, wart-like exophytic projection.</div><div class=\"graphic_reference\">Courtesy of Daniel Wild, MD, and Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 63177 Version 2.0</div></div></div>"},"63178":{"type":"graphic_picture","displayName":"Los Angeles grade D esophagitis","title":"Los Angeles grade D esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Los Angeles grade D esophagitis</div><div class=\"cntnt\"><img style=\"width:300px; height:284px;\" src=\"images/GAST/63178_LA_grade_D_esophagitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Los Angeles grade D esophagitis: One or more mucosal breaks bridging the tops of mucosal folds involving more than 75 percent of the circumference of the lumen.</div><div id=\"graphicVersion\">Graphic 63178 Version 3.0</div></div></div>"},"63179":{"type":"graphic_figure","displayName":"Single balloon enteroscopy technique","title":"Single balloon enteroscopy technique","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Single balloon enteroscopy technique</div><div class=\"cntnt\"><img style=\"width:501px; height:696px;\" src=\"images/GAST/63179_Single-balloon-enteroscopy-technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) With the balloon at the tip of the overtube inflated to anchor the small bowel, the enteroscope is advanced as deeply into the small bowel as possible (except for the initial insertion, when the enteroscope is advanced with the overtube balloon deflated).<br />(B) Once forward motion is no longer possible, the tip of the enteroscope is agulated to create a \"hook\" that will help anchor the enteroscope. Once the small bowel is anchored by the tip of the enteroscope, the overtube balloon is deflated.<br />(C) The overtube is advanced to the end of the enteroscope.<br />(D) The overtube balloon is inflated to anchor the small bowel.<br />(E) Both the enteroscope and the overtube are gently withdrawn to pleat the small bowel onto the overtube. The enteroscope is then advanced as in (A), and the process is repeated until forward progress with the enteroscope is no longer possible or the area of interest within the small bowel is reached.</div><div id=\"graphicVersion\">Graphic 63179 Version 2.0</div></div></div>"},"63180":{"type":"graphic_picture","displayName":"Cross section ARPKD kidney","title":"Cross-section of kidney from a patient with autosomal recessive polycystic kidney disease (ARPKD)","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Cross-section of kidney from a patient with autosomal recessive polycystic kidney disease (ARPKD)</div><div class=\"cntnt\"><img style=\"width:454px; height:301px;\" src=\"images/PEDS/63180_Cross_section_ARPKD_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-section of a kidney from a patient with ARPKD demonstrates the cortical extension of fusiform or cylindrical spaces, which correspond to the dilated collecting tubules that radiate from the medulla to the cortex.</div><div id=\"graphicVersion\">Graphic 63180 Version 2.0</div></div></div>"},"63181":{"type":"graphic_figure","displayName":"Right atrial enlargement","title":"Right atrial enlargement","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Right atrial enlargement</div><div class=\"cntnt\"><img style=\"width:490px; height:209px;\" src=\"images/CARD/63181_Right_atrial_enlargement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows the normal pattern of atrial activation as it would appear on lead II of the electrocardiogram: activation of the right atrium (RA) occurs first, followed by left atrial (LA) activation. The right panel shows the pattern in a patient with right atrial enlargement: delayed activation of the right atrium, due to dilatation, hypertrophy, scarring, or a conduction abnormality, results in simultaneous activation of the right and left atria. The synchronous electrical activity has an additive effect upon the surface ECG, resulting in a relatively narrow P wave which is of increased amplitude (P pulmonale). The amplitude of the P wave may become significantly increased in the presence of right atrial hypertrophy; it also becomes peaked due to the increase in amount of depolarized tissue.</div><div id=\"graphicVersion\">Graphic 63181 Version 1.0</div></div></div>"},"63182":{"type":"graphic_figure","displayName":"Prevention of dog ear deformity","title":"Prevention of dog ear deformity","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Prevention of dog ear deformity</div><div class=\"cntnt\"><img style=\"width:464px; height:397px;\" src=\"images/SURG/63182_Dog-ear-deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The obese or large breasted patient will often have redundant tissue, which can result in an unsightly and uncomfortable \"dog-ear\" deformity at the axillary end of the incision. A \"Y\" shaped incision can be used to excise excess skin and avoid this deformity. Instead of suturing the full length of the wound, the medial one-half to two-thirds of the wound is first sutured using a subcuticular suturing technique. The lateral tip of the incision is then approximated to the midline of the closure, excess skin is removed, and the final wound will be \"Y\" or \"fish-tail\" shaped with two \"arms\" facing towards the lateral side of the wound.</div><div id=\"graphicVersion\">Graphic 63182 Version 2.0</div></div></div>"},"63183":{"type":"graphic_figure","displayName":"Letter cancellation test","title":"Letter cancellation test","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Letter cancellation test</div><div class=\"cntnt\"><img style=\"width:531px; height:500px;\" src=\"images/NEURO/63183_Letter-cancellation-test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&#160; Letter Cancellation Test is used to evaluate the presence, pattern,&#160;and severity of visual scanning deficits. In this example, the patient correctly crossed out all instances of&#160;the letter A.</div><div id=\"graphicVersion\">Graphic 63183 Version 1.0</div></div></div>"},"63184":{"type":"graphic_picture","displayName":"Appendiceal mucocele Endosc","title":"Appendiceal mucocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appendiceal mucocele</div><div class=\"cntnt\"><img style=\"width:320px; height:319px;\" src=\"images/GAST/63184_Appendiceal_mucocele_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glossy, rounded, protruding mass arising from appendiceal orifice, consistent with mucocele.</div><div class=\"graphic_reference\">Courtesy of Louis-Michel Wong Kee Song, MD, FRCP and Norman E Marcon, MD.</div><div id=\"graphicVersion\">Graphic 63184 Version 1.0</div></div></div>"},"63186":{"type":"graphic_table","displayName":"Characteristics streptococcal toxic shock","title":"Clinical characteristics of the toxic shock-like syndrome caused by group A streptococci","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of the toxic shock-like syndrome caused by group A streptococci</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Age group affected</td> <td>All ages; predominantly adults</td> </tr> <tr> <td>Sex most often affected</td> <td>No predilection</td> </tr> <tr> <td>Portal of entry</td> <td>Variable, generally skin or soft tissue (also vagina and respiratory tract)</td> </tr> <tr> <td>Clinical features</td> <td>Fever; hypotension; altered mental status, coma; signs of soft tissue infection that usually progresses to necrotizing fasciitis or myositis; active varicella with secondary infection; multiorgan dysfunction, often with acute respiratory distress syndrome</td> </tr> <tr> <td>Bacteremia</td> <td>Often present (about 60 percent)</td> </tr> <tr> <td class=\"sublist1_start\">Causative organism</td> <td class=\"sublist_other_start\">Group A<em> Streptococcus</em></td> </tr> <tr> <td class=\"sublist1\">M serotype</td> <td class=\"sublist_other\">Variable; 1, 3, 12, and 28 most common</td> </tr> <tr> <td class=\"sublist1\">Type of pyrogenic exotoxin</td> <td class=\"sublist_other\">A, B, C, SSA, MF</td> </tr> <tr> <td>Case fatality rate</td> <td>30 to 60 percent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63186 Version 3.0</div></div></div>"},"63190":{"type":"graphic_picture","displayName":"Features of juvenile dermatomyositis","title":"Features of juvenile dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Features of juvenile dermatomyositis</div><div class=\"cntnt\"><img style=\"width:456px; height:501px;\" src=\"images/PEDS/63190_Physical_findings_JDM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Perivascular and perifascicular inflammatory infiltrates with necrotic fibres, perifascicular atrophy, and regeneration in a muscle biopsy.<br />(B) Magnetic resonance imaging (MRI) is a sensitive indicator of myositis. Inflamed areas appear bright on short-tau inversion recovery-weighted images (arrows).<br />(C) Capillaries are most often abnormal when viewed at the nailfold. Typical changes of dilatation with adjacent drop out (arrow) is seen.<br />(D) Approximately 30% of JDM patients have dystrophic calcinosis.<br />(E) Cutaneous ulceration with central necrosis, crust, and surrounding erythema at the elbow of a 10-year-old boy with severe JDM.<br />(F) Lipoatrophy of the forearm (arrow) in a boy with JDM.</div><div class=\"graphic_footnotes\">JDM: juvenile dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371:2201. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright ©2008 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 63190 Version 7.0</div></div></div>"},"63192":{"type":"graphic_figure","displayName":"GFR and arteriolar resistance","title":"Arteriolar resistance and GFR","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriolar resistance and GFR</div><div class=\"cntnt\"><img style=\"width:398px; height:222px;\" src=\"images/NEPH/63192_GFR_and_arteriolar_resistan.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between arteriolar resistance, glomerular filtration rate (GFR), and renal plasma flow (RPF). (a) If flow is constant, constriction of a vessel results in a rise in pressure proximally (P1) and a fall distally (P2). (b) Constriction of the afferent arteriole reduces Pgc and GFR. (c) Constriction of the efferent arteriole, on the other hand, tends to increase Pgc and, in some cases, GFR (depending in part on the effect on RPF). Since constriction of either arteriole also raises renal vascular resistance, RPF will fall in both (b) and (c). Arteriolar vasodilation has the opposite effects.</div><div id=\"graphicVersion\">Graphic 63192 Version 2.0</div></div></div>"},"63193":{"type":"graphic_table","displayName":"Calcium channel blocker poisoning - Rapid overview","title":"Calcium channel blocker poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calcium channel blocker poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td>Hypotension and bradycardia are prominent</td> </tr> <tr> <td>Electrocardiogram may show PR prolongation or any bradydysrhythmia</td> </tr> <tr> <td>Patients with a significant calcium channel blocker (CCB) ingestion can deteriorate rapidly</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Assays for CCBs are not routinely available</td> </tr> <tr> <td>Diagnosis depends on the history and clinical presentation</td> </tr> <tr> <td>Differential diagnosis for unexplained bradycardia includes toxicity from medications including CCBs, beta-blockers, clonidine, and digoxin</td> </tr> <tr> <td>Structural cardiac disease and active myocardial ischemia must be excluded</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Assess and stabilize airway, breathing, and circulation</td> </tr> <tr> <td class=\"subtitle2_single\">For patients with severe calcium channel blocker (CCB) poisoning (eg, profound hypotension refractory to crystalloid boluses and atropine), give ALL of the following: calcium salts, glucagon, high dose insulin and dextrose, vasopressor, and lipid emulsion therapy</td> </tr> <tr> <td class=\"indent1\">For patients with mild CCB poisoning, give the following treatments in succession based upon patient response (see topic text for details): IV crystalloid, atropine, calcium salts, glucagon, high dose insulin and dextrose, vasopressor, and lipid emulsion therapy</td> </tr> <tr> <td class=\"subtitle2_single\">Initiate treatment for hypotension and bradycardia, if present:</td> </tr> <tr> <td class=\"indent1\">Intravenous crystalloid (hypotension): isotonic saline 500 to 1000 mL boluses</td> </tr> <tr> <td class=\"indent1\">Atropine (bradycardia): 1 mg IV; may repeat for 3 total doses</td> </tr> <tr> <td class=\"subtitle2_single\">Intravenous calcium (hypotension and/or bradycardia)</td> </tr> <tr> <td class=\"sublist2_start\">Bolus therapy:</td> </tr> <tr> <td class=\"sublist2\">Calcium chloride - 10 to 20 mL of 10 percent solution (via central venous access if possible)</td> </tr> <tr> <td class=\"sublist2\">Calcium gluconate - 30 to 60 mL of 10 percent solution</td> </tr> <tr> <td class=\"indent1\">Continuous infusion of 0.5 meq calcium/kg per hour</td> </tr> <tr> <td class=\"indent1\">Monitor serum calcium and ECG for evidence of hypercalcemia</td> </tr> <tr> <td class=\"subtitle2_single\">Glucagon (bradycardia)</td> </tr> <tr> <td class=\"sublist2_start\">Bolus therapy:</td> </tr> <tr> <td class=\"sublist2\">1-5 mg IV push, may repeat up to 15 mg total</td> </tr> <tr> <td class=\"sublist2_start\">Continuous infusion:</td> </tr> <tr> <td class=\"sublist2\">Determine bolus amount needed to obtain response; give this \"response dose\" every hour as continuous infusion</td> </tr> <tr> <td class=\"subtitle2_single\">Vasopressor support (hypotension)</td> </tr> <tr> <td class=\"indent1\">Norepinephrine: begin 2 mcg/minute IV, titrate rapidly to systolic blood pressure 100 mmHg</td> </tr> <tr> <td class=\"subtitle2_single\">Hyperinsulinemia with euglycemia (hypotension)</td> </tr> <tr> <td class=\"sublist2_start\">Bolus therapy:</td> </tr> <tr> <td class=\"sublist2\">Regular insulin 1 Unit/kg IV</td> </tr> <tr> <td class=\"sublist2\">Dextrose 25-50 grams IV; repeat for hypoglycemia; give potassium for hypokalemia</td> </tr> <tr> <td class=\"sublist2_start\">Maintenance infusions:</td> </tr> <tr> <td class=\"sublist2\">Regular insulin: start infusion at 0.5 Units/kg per hour IV; titrate upwards until hypotension corrected or maximum dose of 2 Units/kg per hour reached</td> </tr> <tr> <td class=\"sublist2\">Dextrose 0.5 grams/kg per hour; titrate to euglycemia</td> </tr> <tr> <td class=\"subtitle2_single\">Gastrointestinal decontamination</td> </tr> <tr> <td class=\"indent1\">Activated charcoal: 1 gram/kg up to 50 grams</td> </tr> <tr> <td class=\"indent1\">Whole bowel irrigation: 2 L/hour by mouth; for extended-release preparations only</td> </tr> <tr> <td class=\"subtitle2_single\">Consider the following therapies if the above measures fail:</td> </tr> <tr> <td class=\"indent1\">Transvenous cardiac pacing</td> </tr> <tr> <td class=\"indent1\">Intraaortic balloon pump</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary bypass</td> </tr> <tr> <td class=\"indent1\">Extracorporeal membrane oxygenation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63193 Version 11.0</div></div></div>"},"63194":{"type":"graphic_figure","displayName":"Drainage procedures used with vagotomy ","title":"Drainage procedures used with vagotomy ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drainage procedures used with vagotomy </div><div class=\"cntnt\"><img style=\"width:402px; height:404px;\" src=\"images/GAST/63194_Drainage_procedures_vagotom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A number of drainage procedures are possible with truncal vagotomy. A gastrojejunostomy is best suited for patients in whom access to the pyloroduodenal area is not technically feasible. The Heineke-Mikulicz pyloroplasty (transverse closure of a longitudinal gastroduodenotomy) is frequently used after oversewing a bleeding duodenal ulcer. The Finney and Jaboulay gastroduodenostomies are used when the duodenal bulb is deformed from scarring.</div><div class=\"graphic_reference\">Reproduced with permission from: Matthews JB, Silen W. Operations for peptic ulcer disease and early postoperative complications. In: Gastrointestinal Disease, Sleisenger MH, Fordtran JS (Eds), WB Saunders, Philadelphia 1993. p.713. Copyright &copy; 1993 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 63194 Version 3.0</div></div></div>"},"63196":{"type":"graphic_table","displayName":"Saline load test","title":"Saline load test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Saline load test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Test performance</td> </tr> <tr> <td colspan=\"2\">Place a No. 16 French nasogastric sump tube into the stomach</td> </tr> <tr> <td colspan=\"2\">Position the tip 65 cm from the nares</td> </tr> <tr> <td colspan=\"2\">Empty the stomach</td> </tr> <tr> <td colspan=\"2\">Place patient right side down</td> </tr> <tr> <td colspan=\"2\">Infuse 750 mL of isotonic (0.9%) saline into the tube over 3 to 5 minutes</td> </tr> <tr> <td colspan=\"2\">After 30 min, aspirate and measure gastric residual volume</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Interpretation of gastric residual volume:</td> </tr> <tr> <td>&#62;400 mL:</td> <td>Definite gastric outlet obstruction</td> </tr> <tr> <td>300 to 400 mL:</td> <td>Probable gastric outlet obstruction</td> </tr> <tr> <td>200 to 300 mL:</td> <td>Indeterminate</td> </tr> <tr> <td>&#60;200 mL:</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Adapted from: Graham DY. In: Gastrointestinal Disease, 5th ed, Sleisenger M, Fordtran J (Eds), WB Saunders, Philadelphia 1993. p.698.</div><div id=\"graphicVersion\">Graphic 63196 Version 6.0</div></div></div>"},"63200":{"type":"graphic_figure","displayName":"Midgut formation","title":"Midgut formation","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Midgut formation</div><div class=\"cntnt\"><img style=\"width:582px; height:590px;\" src=\"images/PEDS/63200_Midgut_formation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left side views (A and B) of the counterclockwise 180&#176; rotation of the midgut loop as it is withdrawn into the abdominal cavity. C) The descent of the cecum takes place later.</div><div class=\"graphic_reference\">Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63200 Version 1.0</div></div></div>"},"63201":{"type":"graphic_figure","displayName":"Tongue protrusion","title":"Tongue protrusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tongue protrusion</div><div class=\"cntnt\"><img style=\"width:424px; height:335px;\" src=\"images/PEDS/63201_Tongue_protrusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Protrusion of the tongue beyond the mandibular alveolus facilitates latching on during breastfeeding.</div><div class=\"graphic_reference\">Courtesy of Tess E Isaacson.</div><div id=\"graphicVersion\">Graphic 63201 Version 2.0</div></div></div>"},"63202":{"type":"graphic_picture","displayName":"Unilateral 4th nerve palsy","title":"Congenital superior oblique palsy of the left eye","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Congenital superior oblique palsy of the left eye</div><div class=\"cntnt\"><img style=\"width:520px; height:362px;\" src=\"images/PEDS/63202_Unilateral_4th_nerve_palsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A typical abnormal head position is shown. The head is tilted to the right, away from the side of the palsied muscle. The chin is tilted downward slightly. In this head posture, the child fuses and avoids diplopia.<br />(B) There is a small left hypertropia (upward deviation)&nbsp;in primary gaze when the head is nearly straightened; this is the first step in the \"three-step test\".<br />(C) The left hypertropia is worse in gaze to the right; this is the second step in the \"three-step test\". <br />(D) A large left hypertropia is seen on forced (by the mother's hand) left head tilt; this is the third step in the \"three-step test\".</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright ©2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63202 Version 6.0</div></div></div>"},"63203":{"type":"graphic_diagnosticimage","displayName":"Breast MRI documenting response to neoadjuvant chemotherapy","title":"Breast MRI documenting response to neoadjuvant chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Breast MRI documenting response to neoadjuvant chemotherapy</div><div class=\"cntnt\"><img style=\"width:514px; height:484px;\" src=\"images/SURG/63203_Br_MRI_neoadj_chemo_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI can be used to document the response to neoadjuvant chemotherapy. This series illustrates the response to chemotherapy in a patient with a palpable right breast mass and nipple inversion. Mammography and ultrasound confirmed a large irregular mass and biopsy showed invasive lobular carcinoma. The patient was treated with neoadjuvant chemotherapy. MRI prior to therapy showed a large irregular mass extending from the nipple and involving the upper and central breast (A). Post-treatment MRI showed a partial response and scattered foci suggestive of residual disease (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 63203 Version 7.0</div></div></div>"},"63205":{"type":"graphic_waveform","displayName":"Sinus node reentry tutorial","title":"Sinus node reentry","html":"<div class=\"graphic normal\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Sinus node reentry</div><div class=\"cntnt\"><img style=\"width:461px; height:100px;\" src=\"images/CARD/63205_Sinus_node_reentry_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus node re-entry is due to continuous activity or re-entry within the sinus node or the sinoatrial junction. This arrhythmia has a sudden onset and offset with a rate that is usually 100 to 160 beats per minute. A P wave proceeds each QRS complex and has a morphology identical to the sinus P wave. The PR interval is also similar to that of sinus rhythm. Thus, it is only the abrupt onset and offset that distinguishes this arrhythmia from sinus tachycardia.</div><div id=\"graphicVersion\">Graphic 63205 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"63206":{"type":"graphic_figure","displayName":"Ileocolic anastomosis - Transection of ileum and colon","title":"Ileocolic anastomosis - Transection of ileum and colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocolic anastomosis - Transection of ileum and colon</div><div class=\"cntnt\"><img style=\"width:377px; height:370px;\" src=\"images/SURG/63206_Ileocolic-anast--transection-ileum-colon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63206 Version 1.0</div></div></div>"},"63207":{"type":"graphic_diagnosticimage","displayName":"Early stress fracture (Torg type I) of the fifth metatarsal","title":"Early stress fracture (Torg type I) of the fifth metatarsal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early stress fracture (Torg type I) of the fifth metatarsal</div><div class=\"cntnt\"><img style=\"width:341px; height:540px;\" src=\"images/EM/63207_Early_stress_fx_fifth_metat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oblique view of this radiograph shows an early stress fracture (Torg type I) of the fifth metatarsal diaphysis. Note the narrow fracture line (arrow) and the thickened cortex adjacent to the fracture on the lateral edge of the bone. It is difficult to determine on an oblique view whether this fracture lies in the typical location of a stress fracture (ie, distal to the intermetatarsal joint) or more proximally, where acute fractures typically occur.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 63207 Version 6.0</div></div></div>"},"63211":{"type":"graphic_diagnosticimage","displayName":"Diffuse panbronchiolitis CT","title":"Diffuse panbronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse panbronchiolitis</div><div class=\"cntnt\"><img style=\"width:340px; height:259px;\" src=\"images/PULM/63211_Diffuse_panbronchiolitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT scan in a patient with diffuse panbronchiolitis shows diffuse centrilobular nodular opacities. Some of these opacities are connected to branching structures (tree in bud appearance).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 63211 Version 2.0</div></div></div>"},"63214":{"type":"graphic_diagnosticimage","displayName":"CT spigelian hernia","title":"Spigelian hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spigelian hernia</div><div class=\"cntnt\"><img style=\"width:400px; height:327px;\" src=\"images/SURG/63214_CT_spigelian_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Herniation of fat through a defect in the aponeurosis between the left rectus abdominis (arrow) and the aponeurosis of the left transversus abdominis and internal oblique muscles. The lateral margin of the hernia sac is the external oblique muscle and fascia (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63214 Version 3.0</div></div></div>"},"63215":{"type":"graphic_figure","displayName":"Age specific RMSF","title":"Age-specific incidence of Rocky Mountain spotted fever (RMSF)* and case-fatality ratio, by age group - United States, 1990-1998•","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Age-specific incidence of Rocky Mountain spotted fever (RMSF)* and case-fatality ratio, by age group - United States, 1990-1998&#8226;</div><div class=\"cntnt\"><img style=\"width:544px; height:316px;\" src=\"images/ID/63215_Age_specific_RMSF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Per million population. <br> &#8226; Incidence rates were calculated using data from the National Electronic Telecommunications System for Surveillance and from 1990 - 1998 U.S. Bureau of the Census data. Case-fatality ratios were calculated from the laboratory-confirmed cases of RMSF reported to CDC through RMSF case report forms.</div><div class=\"graphic_reference\">Consequences of Delayed Diagnosis of Rocky Mountain Spotted Fever in Children - West Virginia, Michigan, Tennessee, and Oklahoma, May - July 2000. MMWR Morb Mortal Wkly Rep 2000; 49(39):885. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4839a2.htm.</div><div id=\"graphicVersion\">Graphic 63215 Version 1.0</div></div></div>"},"63219":{"type":"graphic_picture","displayName":"Nonurachal adenocarcinoma","title":"Nonurachal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nonurachal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:398px;\" src=\"images/ONC/63219_Nonurachal_adenocarcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of surgically resected cystectomy specimen with adenocarcinoma of the posterior wall and dome of the bladder.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 63219 Version 1.0</div></div></div>"},"63220":{"type":"graphic_table","displayName":"History and limp etiology in children","title":"Historical features associated with specific causes of limp in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Historical features associated with specific causes of limp in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Historical features</td> <td class=\"subtitle1\">Causes of limp</td> </tr> <tr> <td>Fever, weight loss, anorexia</td> <td>Malignancy, osteomyelitis, septic arthritis, chronic rheumatoid disease</td> </tr> <tr> <td>History of trauma (trivial to major)</td> <td>Fracture, contusion, slipped capital femoral epiphysis, osteochondritis dessicans</td> </tr> <tr> <td>Activity increases pain</td> <td>Stress fracture, benign hypermobility syndrome, overuse syndromes, compartment syndrome</td> </tr> <tr> <td>Activity decreases pain</td> <td>Juvenile idiopathic arthritis, complex regional pain syndrome</td> </tr> <tr> <td>Recent viral illness or antibiotic use</td> <td>Immune complex mediated diseases such as transient synovitis, Henoch-Sch&#246;nlein purpura, serum sickness</td> </tr> <tr> <td>Cyclic pattern, noctural</td> <td>Osteoid osteoma, malignant bone tumor</td> </tr> <tr> <td>Morning stiffness</td> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td>New or increased sport activity</td> <td>Stress fractures, overuse syndromes, Osgood-Schlatter disease, chrondomalacia</td> </tr> <tr> <td>Intramuscular injection vaccinations</td> <td>Sterile abscess, muscle inflammation</td> </tr> <tr> <td>New or poorly fitting shoes</td> <td>Pressure necrosis</td> </tr> <tr> <td>Psychosocial problems</td> <td>Child abuse, complex regional pain syndrome (eg, reflex sympathetic dystrophy), conversion reaction</td> </tr> <tr> <td>Family history of connective tissue disorders</td> <td>Systemic lupus erythematosus, sarcoid, juvenile idiopathic arthritis</td> </tr> <tr> <td>Migratory arthralgia</td> <td>Acute rheumatic fever, gonococcal arthritis</td> </tr> <tr> <td>Back pain</td> <td>Discitis, meningitis, vertebral osteomyelitis</td> </tr> <tr> <td>Endocrinopathies</td> <td>Slipped capital femoral epiphysis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Phillips WA. Orthop Clin North Am 1987; 18:489; and Kost S. Limp. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henertig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.415.</div><div id=\"graphicVersion\">Graphic 63220 Version 4.0</div></div></div>"},"63221":{"type":"graphic_table","displayName":"Pruritus systemic therapy","title":"Systemic therapies for pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic therapies for pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication*</td> <td class=\"subtitle1\">Dose range<sup>&#182;</sup></td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antihistamines</strong></td> <td>Variable depending on medication</td> <td>No direct effect on pruritus except in urticaria; sedating antihistamines may be useful through their soporific effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidepressants</td> </tr> <tr> <td class=\"indent1\">SNRIs</td> <td>Mirtazapine 7.5 to 15 mg at night</td> <td>Useful in nocturnal pruritus, may cause increased weight and appetite</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">SSRIs</td> <td>Paroxetine 10 to 40 mg per day</td> <td>Consider in psychiatric patients with pruritus and paraneoplastic pruritus</td> </tr> <tr> <td>Fluvoxamine 25 to 150 mg per day</td> <td>Consider in psychiatric patients with pruritus and paraneoplastic pruritus</td> </tr> <tr class=\"divider_bottom\"> <td>Sertraline 75 to 100 mg per day</td> <td>Useful in cholestatic pruritus</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#181;-opioid receptor antagonists</strong></td> <td>Naltrexone 25 to 50 mg per day</td> <td>Useful in patients with cholestatic and CKD-associated pruritus; may cause nausea, vomiting and drowsiness; reverses analgesia and may precipitate acute withdrawal in patients receiving opioid analgesics</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#954;-opioid receptor agonist/&#181;-opioid receptor antagonist</strong></td> <td>Butorphanol 1 to 4 mg intranasally per day</td> <td>Useful in nocturnal and intractable pruritus; may cause nausea and vomiting as well as drowsiness; may precipitate acute withdrawal in patients receiving opioid analgesics; some potential for abuse due to concomitant weak &#181;-opioid receptor agonist activity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Selective &#954;-opioid receptor agonist</strong></td> <td>Nalfurafine 2.5 to 5 micrograms per day</td> <td>Useful in CKD-associated pruritus; may cause insomnia; approved in Japan only</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Anticonvulsants</strong></td> <td>Gabapentin 100 to 3600 mg per day</td> <td class=\"divider_bottom\" rowspan=\"2\">Applies to both: useful in neuropathic pruritus, may cause drowsiness and weight gain; usually given in two to three divided daily doses; dose alteration for renal insufficiency may be needed</td> </tr> <tr class=\"divider_bottom\"> <td>Pregabalin 150 to 300 mg per day</td> </tr> <tr> <td><strong>Substance P antagonist</strong></td> <td>Aprepitant 80 mg per day</td> <td>Beneficial in pruritus associated with the S&#233;zary syndrome; expensive</td> </tr> <tr> <td><strong>&nbsp;Thalidomid</strong>e</td> <td>100 mg at night</td> <td>&nbsp;Primarily used for prurigo nodularis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; SNRI: selective neuroepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.<br />* Immunosuppressive agents such as cyclosporine, azathioprine, and mycophenolate mofetil may be beneficial for pruritus in severe atopic dermatitis.<br />¶ All doses are for adult patients, oral administration, unless noted otherwise.</div><div class=\"graphic_reference\">From: Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010; 11:1673. Copyright &copy; 2010 Informa Healthcare. Adapted with permission of Informa Healthcare.</div><div id=\"graphicVersion\">Graphic 63221 Version 5.0</div></div></div>"},"63222":{"type":"graphic_table","displayName":"Cisplatin and etoposide for relapsed germ cell tumors","title":"Cisplatin and etoposide for relapsed germ cell tumors<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin and etoposide for relapsed germ cell tumors<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>20 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 250 mL normal saline (NS) and administer over one hour. Do not administer with aluminum needles or intravenous sets.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV per day</td> <td>Dilute with 500 mL NS (concentration less than 0.4 mg/mL) and administer over one hour.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Induction of diuresis using intravenous NS minimizes the risk of cisplatin nephrotoxicity. At least 2000 mL of NS should be administered at a rate of 100 to 125 mL per hour throughout the five days of treatment and continued for at least two hours after the last dose of cisplatin. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Aprepitant can be given orally (125 mg on day 1, 80 mg on days 2 and 3) with ondansetron, prochlorperazine, and dexamethasone daily. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Both cisplatin and etoposide are irritants. Cisplatin can cause significant tissue damage; avoid extravasation.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not indicated. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Treatment in the setting of baseline renal dysfunction (creatinine &#62;3.0 mg/dL or GFR &#60;50 mL/min) requires a balanced discussion of the goals of treatment and the risks of administering cisplatin.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor vital signs during etoposide infusion. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity; monitor for hearing loss prior to each dose of cisplatin; audiometry as clinical indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Each cycle should begin on schedule regardless of the degree of myelosuppression.<sup>[1]</sup> If febrile neutropenia or thrombocytopenic bleeding occurs, a dose reduction of 25% for etoposide should be used for subsequent cycles. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>It is recommended that subsequent doses of cisplatin be withheld until the serum creatinine is less than 3.0 mg/dL. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; GFR: glomerular filtration rate; CBC: complete blood count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Loehrer PJ, et al. J Clin Oncol 1995; 13:470.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 63222 Version 16.0</div></div></div>"},"63223":{"type":"graphic_table","displayName":"Paramedic thrombolysis examination checklist","title":"Paramedic thrombolysis examination checklist","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paramedic thrombolysis examination checklist</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"centered\" colspan=\"5\"> <p>Wilkes County Emergency Medical Service</p> <p>Advanced level practical skills examination</p> <strong>Thrombolytic therapy</strong></td> </tr> <tr class=\"divider_top\"> <td colspan=\"5\">Date:</td> </tr> <tr> <td colspan=\"5\">Candidate name:</td> </tr> <tr> <td colspan=\"5\">Examiner signature:</td> </tr> <tr> <td colspan=\"5\">Level:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- EMT-P</td> </tr> <tr> <td class=\"subtitle1\">Automatic failure = critical critera</td> <td class=\"subtitle1\" colspan=\"4\">Cumulative failure = 2</td> </tr> <tr> <td class=\"subtitle2_left\">Exam series:&nbsp;&nbsp;&nbsp;- A&nbsp;&nbsp;&nbsp;- B&nbsp;&nbsp;&nbsp;- C&nbsp;&nbsp;&nbsp;- D</td> <td class=\"subtitle2_left\">Time start:<br /> &nbsp;<br /> &nbsp;</td> <td class=\"subtitle2_left\">Time finish:<br /> &nbsp;<br /> &nbsp;</td> <td class=\"subtitle2_left\">Yes</td> <td class=\"subtitle2_left\">No</td> </tr> <tr> <td colspan=\"3\">Takes appropriate precautions for personal protection [may verbalize]</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Assures that all steps on chest pain/suspected cardiac event protocol have been completed</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Assures patient has two (2) patent IV lines or has twin catheter that is functional</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Correctly interprets 12-lead ECG and transmits [may verbalize] to ED for physician review</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Performs history and assessment of acute MI signs and symptoms</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Repeats 12-lead ECG and correctly interprets 12-lead ECG</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Performs neurological assessment for thrombolytics</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Completes thrombolytic therapy screening form</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Performs [may verbalize] rectal exam using hemoccult slide and developer</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Contacts medical control and provides patient information and requests permission for thrombolytic therapy</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Ensures that all needed adjunctive medications and therapies have been administered <em>(according to WCEMS protocols)</em></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Administers enoxaparin (Lovenox) with correct dosage and route according to age and weight</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Properly reconstitutes tenecteplase (TNKase) for administration</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Administers the correct weight-based dose of TNKase over 5 seconds</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Verbalizes need for frequent assessment of patient clinical status</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Verbalizes need to contact medical control for patient report and transmission of repeat 12-lead ECG to ED for review</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"3\">Verbalizes need to document&nbsp;patient information&nbsp;with 12-lead ECG tracings and screening form</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">At the completion of test submit this form to the examination representative</td> </tr> <tr> <td colspan=\"5\"><strong>Critical criteria</strong> <em>(document rationale for critical criteria on reverse side of this form)</em> <ul> <li>Failure to assure two patent IV lines or&nbsp;one twin catheter </li> <li>Failure to perform a neurological assessment </li> <li>Failure to complete thrombolytic screening form </li> <li>Failure to&nbsp;provide all needed adjunctive medications and therapies </li> <li>Administers incorrect dose and or uses incorrect route of enoxaparin </li> <li>Administers incorrect weight based dose of TNKase </li> <li>Failure to verbalize need to reassess patient after enoxaparin/TNKase administration </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"5\"><em>OFFICIAL USE ONLY - DO NOT WRITE IN THIS BOX</em></td> </tr> <tr> <td colspan=\"3\">Candidate result:</td> <td>Pass</td> <td>Fail</td> </tr> <tr> <td colspan=\"3\">Failure due to:</td> <td>Critical criteria</td> <td>Cumulative</td> </tr> <tr> <td colspan=\"5\">Representative:</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"5\"></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Henderson McGinnis, MD.</div><div id=\"graphicVersion\">Graphic 63223 Version 1.0</div></div></div>"},"63226":{"type":"graphic_figure","displayName":"Healthy and COPD flow volume loops","title":"Rest and peak exercise flow volume (FV) responses in a healthy, average fit adult plotted within a maximal FV curve","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Rest and peak exercise flow volume (FV) responses in a healthy, average fit adult plotted within a maximal FV curve</div><div class=\"cntnt\"><img style=\"width:507px; height:369px;\" src=\"images/PULM/63226_Healthy_and_COPD_flow_vol_l.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD. Chest 2000; 117:42 S. Copyright &#169; 2000 American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 63226 Version 2.0</div></div></div>"},"63227":{"type":"graphic_diagnosticimage","displayName":"NSCLC brain met CT","title":"Brain metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain metastasis</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/63227_NSCLC_brain_met_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head CT showing one of multiple ring enhancing lesions in the brain of a 45-year-old male presenting with headaches. Biopsies of a right upper lobe mass and subcarinal adenopathy showed adenocarcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 63227 Version 3.0</div></div></div>"},"63229":{"type":"graphic_figure","displayName":"Anatomy of the ischiorectal fossa","title":"Anatomy of the ischiorectal fossa","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Anatomy of the ischiorectal fossa</div><div class=\"cntnt\"><img style=\"width:555px; height:375px;\" src=\"images/SURG/63229_ARF_isch_fossa_anat_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an illustration of the anatomy of the anus and rectum that includes the ischiorectal fossa. The left and right ischiorectal fossae communicate posteriorly.</div><div id=\"graphicVersion\">Graphic 63229 Version 5.0</div></div></div>"},"63230":{"type":"graphic_picture","displayName":"Erythrodermic sarcoidosis - flank","title":"Erythrodermic sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythrodermic sarcoidosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/63230_Erythrodermic_sarcoid_flank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythrodermic sarcoidosis. This patient has large, confluent, geometric erythematous plaques covering most of the body.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63230 Version 3.0</div></div></div>"},"63231":{"type":"graphic_diagnosticimage","displayName":"2D TTE Subcostal 4-chamber view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal four-chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal four-chamber view</div><div class=\"cntnt\"><img style=\"width:356px; height:306px;\" src=\"images/CARD/63231_Subcostal_4_chamber_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the transducer in the subcostal position, a four-chamber view can be obtained. In this view, the lateral border of the left ventricle (LV) is delimited by the midlateral wall as opposed to the inferolateral wall on the apical four-chamber view. The apex of the left ventricle is rarely seen in this view and the right ventricle (RV) is usually smaller than the left.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 63231 Version 3.0</div></div></div>"},"63233":{"type":"graphic_diagnosticimage","displayName":"Retropharyngeal abscess plain radiograph","title":"Retropharyngeal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retropharyngeal abscess</div><div class=\"cntnt\"><img style=\"width:289px; height:432px;\" src=\"images/PEDS/63233_Retropharyngealabscesspla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral neck radiograph demonstrating widening of the retropharyngeal space and reversal of the normal cervical spine curvature. The retropharyngeal space normally measures one-half the width of the adjacent vertebral body and is considered widened if it is greater than a full vertebral body at C2 or 3 when the spine is properly extended in an infant or child younger than 5 years of age. The epiglottis and subglottic area in this radiograph are normal.</div><div class=\"graphic_reference\">Courtesy of Joe Black, Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 63233 Version 4.0</div></div></div>"},"63234":{"type":"graphic_picture","displayName":"Scarlatiniform rash","title":"Scarlatiniform rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scarlatiniform rash</div><div class=\"cntnt\"><img style=\"width:400px; height:462px;\" src=\"images/PEDS/63234_Scarlet_fever_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine papules, &quot;sandpaper-like&quot; rash on trunk of child with scarlet fever.</div><div class=\"graphic_reference\">Reproduced with permission from: George A. Datto, III, MD.</div><div id=\"graphicVersion\">Graphic 63234 Version 2.0</div></div></div>"},"63235":{"type":"graphic_table","displayName":"Diff diagnosis Meniere disease","title":"Differential diagnosis for Meniere disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for Meniere disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Central nervous system</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acoustic neuroma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple sclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vascular loop compression of eighth nerve</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Basilar/vertebral artery insufficiency</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arnold-Chiari malformation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebellar tumors</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transient ischemic attacks</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Peripheral vestibular system</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Benign positional vertigo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Syphilitic endolymphatic hydrops</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Post-concussive hydrops</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Post-infectious hydrops (history of sudden sensorineural hearing loss, chronic otitis media, or labyrinthitis)</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Autoimmune inner ear disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Perilymphatic fistula</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Otosclerosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Migraine induced vertigo</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Other</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diabetes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Thyroid disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cogan's syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63235 Version 3.0</div></div></div>"},"63237":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CXR III","title":"Cystic hygroma in adult presenting as left apical mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in adult presenting as left apical mass</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/63237_Cystic_hygroma_CXR_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a left apical mass.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63237 Version 2.0</div></div></div>"},"63238":{"type":"graphic_picture","displayName":"Impetigo in HIV","title":"Impetigo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impetigo</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/ID/63238_Impetigo_in_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Staphylococcus aureus caused this large plaque on the upper lip and cheek.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 63238 Version 6.0</div></div></div>"},"63242":{"type":"graphic_picture","displayName":"Retinal ischemia in Behçet's syndrome","title":"Retinal ischemia in Behçet's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal ischemia in Behçet's syndrome</div><div class=\"cntnt\"><img style=\"width:351px; height:259px;\" src=\"images/RHEUM/63242_Retinal_ischemia_in_Behcets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph shows advanced retinal ischemia and optic nerve pallor in a patient with&nbsp;Behçet's syndrome and several previous attacks of severe vasoocclusive disease.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 63242 Version 4.0</div></div></div>"},"63245":{"type":"graphic_picture","displayName":"Hepatic VOD Light","title":"Sinusoidal obstruction syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinusoidal obstruction syndrome</div><div class=\"cntnt\"><img style=\"width:367px; height:252px;\" src=\"images/HEME/63245_Hepatic_VOD_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of sinusoidal obstruction syndrome in which venular occlusion has led to widespread zonal liver disruption and centrilobular hemorrhagic necrosis.</div><div class=\"graphic_reference\">Reproduced by permission from: Negrin RS, Blume KG. Bone marrow and peripheral blood progenitor cell transplantation. In: Leukemia, 6th ed, Henderson ES, Lister TA, Greaves ME (Eds), WB Saunders, Philadelphia, 1996. p.389.</div><div id=\"graphicVersion\">Graphic 63245 Version 2.0</div></div></div>"},"63246":{"type":"graphic_figure","displayName":"Transpl survival CML by stage","title":"Survival after allogeneic transplant in chronic myelogenous leukemia","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Survival after allogeneic transplant in chronic myelogenous leukemia</div><div class=\"cntnt\"><img style=\"width:463px; height:342px;\" src=\"images/HEME/63246_Transpl_survival_CML_by_sta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph shows the probability of survival versus years after allogeneic hematopoietic cell transplantation in patients with chronic myelogenous leukemia (CML) in chronic phase (red), accelerated phase (blue), and blast crisis (green). The difference in survival between patients in chronic phase and blast crisis was statistically significant (p &lt; 0.004).</div><div class=\"graphic_reference\">Data from Biggs, JC, et al. Blood 1992, 80:1352.</div><div id=\"graphicVersion\">Graphic 63246 Version 1.0</div></div></div>"},"63247":{"type":"graphic_figure","displayName":"CHI genetics and diazoxide responsiveness","title":"Diazoxide responsiveness in different types of congenital hyperinsulinemia of infancy","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Diazoxide responsiveness in different types of&nbsp;congenital hyperinsulinemia of&nbsp;infancy</div><div class=\"cntnt\"><img style=\"width:529px; height:347px;\" src=\"images/PEDS/63247_PHHI_genetics_resp_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Responsiveness to diazoxide treatment among 288 patients with congenital hyperinsulinemia of infancy (CHI). Diazoxide responsiveness varies depending on the genetic defect.</div><div class=\"graphic_reference\">Data from: Flanagan SE, Kapoor RR, and Hussain K. Genetics of congenital hyperinsulinemic hypoglycemia. Seminars in Pediatric Surgery 2011; 20:13.</div><div id=\"graphicVersion\">Graphic 63247 Version 4.0</div></div></div>"},"63248":{"type":"graphic_table","displayName":"Microbiology CAP","title":"Microbial etiology of community-acquired pneumonia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbial etiology of community-acquired pneumonia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">United States<sup>[1]</sup></td> <td class=\"subtitle1\">&nbsp;United Kingdom<sup>[2]</sup></td> <td class=\"subtitle1\">Spain<sup>[3]</sup></td> <td class=\"subtitle1\">Sweden<sup>[4]</sup></td> <td class=\"subtitle1\">Asia<sup>[5]</sup></td> </tr> <tr> <td>Total patients evaluated</td> <td>2259</td> <td>323</td> <td>3524</td> <td>184</td> <td>955</td> </tr> <tr> <td>Patients in whom a pathogen was identified</td> <td>853 (37.8)</td> <td>280 (86.7)</td> <td>1463 (41.5)</td> <td>124 (67.4)<sup>&#182;</sup></td> <td>428 (44.8)</td> </tr> <tr class=\"divider_bottom\"> <td>Patients in whom no pathogen was identified</td> <td>1406 (62.2)</td> <td>43 (13.3)</td> <td>2061 (58.5)</td> <td>60 (32.6)</td> <td>527 (55.2)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Pathogen<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"><strong>Bacteria</strong></td> </tr> <tr> <td class=\"sublist2\"><em>Streptococcus pneumoniae</em></td> <td class=\"sublist_other\">115 (5.1)</td> <td class=\"sublist_other\">115 (35.6)</td> <td class=\"sublist_other\">613 (17.4)</td> <td class=\"sublist_other\">70 (38)</td> <td class=\"sublist_other\">114 (11.9)</td> </tr> <tr> <td class=\"sublist2\"><em>Klebsiella pneumoniae</em></td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">13 (4.0)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">60 (6.3)</td> </tr> <tr> <td class=\"sublist2\"><em>Haemophilus influenzae</em></td> <td class=\"sublist_other\">13 (0.6)</td> <td class=\"sublist_other\">130 (40.2)</td> <td class=\"sublist_other\">70 (2)</td> <td class=\"sublist_other\">9 (4.9)</td> <td class=\"sublist_other\">59 (6.2)</td> </tr> <tr> <td class=\"sublist2\"><em>Pseudomonas aeruginosa</em></td> <td class=\"sublist_other\">8 (0.3)</td> <td class=\"sublist_other\">9 (2.8)</td> <td class=\"sublist_other\">50 (1.4)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">26 (2.7)</td> </tr> <tr> <td class=\"sublist2\"><em>Staphylococcus aureus</em></td> <td class=\"sublist_other\">37 (1.6)</td> <td class=\"sublist_other\">33 (10.2)</td> <td class=\"sublist_other\">25 (0.7)</td> <td class=\"sublist_other\">4 (2.2)</td> <td class=\"sublist_other\">19 (2)</td> </tr> <tr> <td class=\"sublist2\"><em>Mycobacterium tuberculosis</em></td> <td class=\"sublist_other\">8 (0.3)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">2 (1.1)</td> <td class=\"sublist_other\">13 (1.4)</td> </tr> <tr> <td class=\"sublist2\"><em>Moraxella catarrhalis</em></td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">44 (13.6)</td> <td class=\"sublist_other\">5 (0.1)</td> <td class=\"sublist_other\">7 (3.8)</td> <td class=\"sublist_other\">12 (1.3)</td> </tr> <tr> <td class=\"sublist2\"><em>Mycoplasma pneumoniae</em></td> <td class=\"sublist_other\">43 (1.9)</td> <td class=\"sublist_other\">6 (1.9)</td> <td class=\"sublist_other\">65 (1.8)<sup>&#9674;</sup></td> <td class=\"sublist_other\">15 (8.2)<sup>&#9674;</sup></td> <td class=\"sublist_other\">61/556 (11)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\"><em>Chlamydia pneumoniae</em></td> <td class=\"sublist_other\">9 (0.4)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">50 (1.4)<sup>&#9674;</sup></td> <td class=\"sublist_other\">0<sup>&#9674;</sup></td> <td class=\"sublist_other\">55/411 (13.4)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\"><em>Chlamydia psittaci</em></td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">2 (0.6)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\"><em>Legionella pneumophila</em></td> <td class=\"sublist_other\">32 (1.4)</td> <td class=\"sublist_other\">3 (0.9)</td> <td class=\"sublist_other\">118 (3.3)<sup>&#9674;</sup></td> <td class=\"sublist_other\">3 (1.6)</td> <td class=\"sublist_other\">7/648 (1.1)</td> </tr> <tr> <td class=\"sublist2\">Non-pneumophila <em>Legionella</em> spp</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">3 (0.9)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\"><em>Coxiella burnetii</em></td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">30 (0.8)<sup>&#9674;</sup></td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> </tr> <tr> <td class=\"sublist2\">Gram-negative enteric bacilli</td> <td class=\"sublist_other\">31 (1.4)</td> <td class=\"sublist_other\">37 (11.5)</td> <td class=\"sublist_other\">27 (0.8)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> </tr> <tr> <td class=\"sublist2\"><em>Acinetobacter baumannii</em></td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">3 (0.9)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> </tr> <tr> <td class=\"indent1\"><strong>Viruses</strong></td> <td><strong>&nbsp;</strong></td> <td>&nbsp;</td> <td><strong>&nbsp;</strong></td> <td><strong>&nbsp;</strong></td> <td><strong>&#167;</strong></td> </tr> <tr> <td class=\"sublist2\">Respiratory viruses<sup>&#165;</sup></td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">148 (4.2)<sup>&#9674;</sup></td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Influenza viruses</td> <td class=\"sublist_other\">132 (5.8)</td> <td class=\"sublist_other\">23 (7.1)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">14 (7.6)<sup>&#9674;</sup></td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Rhinovirus</td> <td class=\"sublist_other\">194 (8.6)</td> <td class=\"sublist_other\">41 (12.7)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">12 (6.5)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Respiratory syncytial virus</td> <td class=\"sublist_other\">68 (3.0)</td> <td class=\"sublist_other\">4 (1.2)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">7 (3.8)<sup>&#9674;</sup></td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Parainfluenza viruses</td> <td class=\"sublist_other\">67 (3.0)</td> <td class=\"sublist_other\">11 (3.4)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">7 (3.8)<sup>&#9674;</sup></td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Coronaviruses</td> <td class=\"sublist_other\">53 (2.3)</td> <td class=\"sublist_other\">&nbsp;9 (2.8)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">4 (2.2)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Human metapneumovirus</td> <td class=\"sublist_other\">88 (3.9)</td> <td class=\"sublist_other\">&nbsp;3 (0.9)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">4 (2.2)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Adenovirus</td> <td class=\"sublist_other\">32 (1.4)</td> <td class=\"sublist_other\">&nbsp;7 (2.2)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">3 (1.6)<sup>&#9674;</sup></td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Other pathogen</strong></td> <td>36 (1.6)</td> <td>&nbsp;</td> <td>54 (1.5)</td> <td>5 (2.7)</td> <td>77 (8)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Polymicrobial (&#62;1 pathogen identified)</strong></td> <td>115 (5.1)</td> <td>&#135;</td> <td>208 (5.9)<sup>&#9674;</sup></td> <td>46 (25)<sup>&#9674;</sup></td> <td>60 (6.3)<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diagnostic methods</strong></td> <td>Cultures (blood, endotracheal aspirates, quantitative BAL fluid specimens, pleural fluid), PCR from nasopharyngeal and oropharyngeal swabs (for adenovirus; <em>C. pneumoniae</em>; coronaviruses 229E, HKU1, NL63, and OC43; human metapneumovirus; rhinovirus; influenza A and B; <em>M. pneumoniae</em>; parainfluenza viruses 1-3; respiratory syncytial virus), real-time PCR from sputum (for <em>L. pneumophila</em>), PCR from pleural fluid (for Enterobacteriaceae, <em>H. influenzae</em>, <em>Pseudomonas</em>, <em>S. aureus</em>, <em>S. anginosus</em>, <em>S. mitis</em>, <em>S. pneumoniae</em>, <em>S. pyogenes</em>), urinary antigen testing (for <em>L. pneumophila</em> and <em>S. pneumoniae</em>), serologic testing (for adenovirus, human metapneumovirus, influenza A and B, parainfluenza viruses, respiratory syncytial virus)</td> <td>Fast multiplex real-time PCR of lower respiratory tract specimens (for <em>S. pneumoniae</em>, <em>H. influenzae</em>, <em>M. catarrhalis</em>, <em>S. aureus</em>, <em>E. coli</em>, <em>K. pneumoniae</em>, <em>P. aeruginosa, A. baumannii, M. pneumoniae, C. pneumoniae, C. psittaci, L. pneumophila</em>, non-pneumophila <em>Legionella</em> spp, influenza A, influenza B, RSV, parainfluenza viruses 1-3, adenovirus, human coronaviruses [229E, HKU1, NL63, and OC43], human metapneumovirus, rhinovirus)<sup>&#134;</sup></td> <td>Cultures (sputum, blood, transthoracic needle aspirate, transbronchial aspirates, BAL fluid, protected specimen brush respiratory samples, pleural fluid), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, <em>L. pneumophila</em>, <em>C. burnetti</em>, influenza A and B, parainfluenza viruses 1-3, respiratory syncytial virus, adenovirus), urinary antigen testing (for <em>S. pneumoniae</em> or <em>L. pneumophila</em>), immunofluorescence assay plus virus isolation or reverse transcriptase PCR for influenza A and B, parainfluenza viruses 1-3, respiratory syncytial virus, adenovirus</td> <td>Cultures (sputum, blood, nasopharyngeal secretions), real-time PCR on sputum (for <em>S. pneumoniae</em>, <em>H. influenzae</em>, <em>M. catarrhalis</em>), PCR from nasopharyngeal secretions (for <em>M. pneumoniae</em>), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, influenza A and B, parainfluenza viruses 1-3, respiratory syncytial virus, adenovirus), urinary antigen testing (for <em>S. pneumoniae</em>, <em>L. pneumophila</em>), virus isolation and real-time PCR (for influenza A and B, parainfluenza viruses 1-3, respiratory syncytial virus, adenovirus, human metapneumovirus, rhinovirus) on nasopharyngeal secretions</td> <td>Cultures (sputum, blood, BAL fluid, pleural fluid, transthoracic needle aspiration), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>), urinary antigen testing (for <em>L. pneumophila</em>)</td> </tr> <tr> <td><strong>Site of care</strong></td> <td>Inpatient</td> <td>Inpatient</td> <td>1302 inpatient, 161 outpatient</td> <td>Inpatient</td> <td>593 inpatient, 362 outpatient</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BAL: bronchoalveolar lavage; PCR: polymerase chain reaction.<br />* Results are reported as number of patients (percent).<br />¶ A pathogen was identified in 85 percent of the 38 patients who had all of the diagnostic studies performed, as described in \"Diagnostic methods.\"<br />Δ Results are reported as the number of patients with a given pathogen, followed by the percentage of patients in whom the pathogen was identified out of all of the patients in the study. For example, in the first column,<EM>&nbsp;S. pneumonia</EM>e&nbsp;was detected in 115 of 2259 patients in the study (5.1 percent). Among the 853 patients in whom a pathogen was identified,<EM>&nbsp;S. pneumonia</EM>e&nbsp;was detected in 13.5 percent.<br /><FONT class=lozenge>◊</FONT> Pathogens detected by serologic methods may represent recent infection rather than active infection.<br />§ Viral etiology was not evaluated.<br />¥ Influenza viruses A or B, parainfluenza viruses 1-3, respiratory syncytial virus, adenovirus.<br />‡ Some patients had &gt;1 pathogen identified, but the total number was not reported.<br />† Lower respiratory tract cultures were also sent from patients included in this study, but they are not&nbsp;shown in this table because complete data (ie, total number of patients in whom a pathogen was detected by either molecular methods or by culture) were not reported in the study.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373:415.</LI>&#xD;&#xA;<LI>Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016; 62:817.</LI>&#xD;&#xA;<LI>Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340.</LI>&#xD;&#xA;<LI>Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.</LI>&#xD;&#xA;<LI>Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31:107.</LI></OL></div><div id=\"graphicVersion\">Graphic 63248 Version 18.0</div></div></div>"},"63250":{"type":"graphic_picture","displayName":"Black thyroid syndrome","title":"Black thyroid syndrome","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Black thyroid syndrome</div><div class=\"cntnt\"><img style=\"width:531px; height:378px;\" src=\"images/ENDO/63250_Black_thyroid_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Gross thyroid specimen with diffuse black discoloration from tetracycline use.<br />(B) LM image showing black pigment deposition in the thyroid colloid.<br />(C) Higher magnification of LM demonstrating black material within the colloid and the surrounding follicular cells.<br />(D) Electron microscopy image showing black pigment within cellular lysosomes.</div><div class=\"graphic_footnotes\">LM: light microscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Yusim A, Ghofrani M, Ocal IT, Roman S. Black thyroid syndrome. Thyroid 2006; 16:811. Copyright ©2006 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 63250 Version 3.0</div></div></div>"},"63251":{"type":"graphic_figure","displayName":"Metabolic syndrome age","title":"Prevalence of NCEP ATP III metabolic syndrome among subjects in the NHANES III survey, by age","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Prevalence of NCEP ATP III metabolic syndrome among subjects in the NHANES III survey, by age</div><div class=\"cntnt\"><img style=\"width:468px; height:299px;\" src=\"images/ENDO/63251_Metabolic_syndrome_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356.</div><div id=\"graphicVersion\">Graphic 63251 Version 2.0</div></div></div>"},"63252":{"type":"graphic_picture","displayName":"Menetriers disease Gross","title":"Ménétrier's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M&#233;n&#233;trier's disease</div><div class=\"cntnt\"><img style=\"width:367px; height:230px;\" src=\"images/GAST/63252_Menetriers_disease_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen from an adult with M&#233;n&#233;trier's disease. The body of the stomach is covered by thick knobby folds with a coarsely granular surface, the result of irregular pit hyperplasia.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63252 Version 4.0</div></div></div>"},"63253":{"type":"graphic_waveform","displayName":"Basic case 13 with answer","title":"Evolving anterior myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Evolving anterior myocardial infarction</div><div class=\"cntnt\"><img style=\"width:518px; height:267px;\" src=\"images/CARD/63253_Basic_case_13_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram shows findings typical of an evolving ST-elevation/Q-wave anterior MI: loss of R waves in leads V1 to V3, ST segment elevations in V2 to V4, and T wave inversions in leads I, aVL, and V2 to V5. Prominent precordial voltage suggests underlying left ventricular hypertrophy. Sinus bradycardia (55 beats/min) is present due to therapy with a beta blocker.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 63253 Version 3.0</div></div></div>"},"63254":{"type":"graphic_diagnosticimage","displayName":"Partially calcified primary TB","title":"Partially calcified primary tuberculous complex in a three-year-old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partially calcified primary tuberculous complex in a three-year-old</div><div class=\"cntnt\"><img style=\"width:375px; height:396px;\" src=\"images/ID/63254_Part_calcified_primary_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a partially calcified primary tuberculous complex in a three-year-old girl. There is right-sided hilar adenopathy with some atelectasis along the horizontal fissure.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 63254 Version 3.0</div></div></div>"},"63257":{"type":"graphic_diagnosticimage","displayName":"RAO LV angiogram tetralogy","title":"Left ventricular angiogram in tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular angiogram in tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:341px; height:304px;\" src=\"images/CARD/63257_RAO_LV_angiogram_tetralogy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A left venticular (LV) angiogram with the camera in a right anterior oblique projection in tetralogy of Fallot does not permit good visualization of the ventricular septal defect (VSD); however, the left to right flow across the VSD does allow excellent visualization of the hypertrophied infundibulum (INF) and the severe subpulmonary obstruction (*).</div><div class=\"graphic_footnotes\">MPA: main pulmonary artery.</div><div class=\"graphic_reference\">Photo courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 63257 Version 2.0</div></div></div>"},"63258":{"type":"graphic_waveform","displayName":"Ventricular couplet tutorial","title":"Ventricular couplet","html":"<div class=\"graphic normal\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Ventricular couplet</div><div class=\"cntnt\"><img style=\"width:497px; height:98px;\" src=\"images/CARD/63258_Ventricular_couplet_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two ventricular premature beats (VPBs) occur following three normal QRS complexes. This is a unifocal couplet since both VPBs have the same morphology.</div><div id=\"graphicVersion\">Graphic 63258 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"63259":{"type":"graphic_picture","displayName":"Bonfils fiberoptic stylets","title":"Bonfils fiberoptic stylets","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bonfils fiberoptic stylets</div><div class=\"cntnt\"><img style=\"width:504px; height:284px;\" src=\"images/EM/63259_Bonfils_fiberoptic_stylts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image courtesy of KARL STORZ Endoskope, Germany.</div><div id=\"graphicVersion\">Graphic 63259 Version 3.0</div></div></div>"},"63260":{"type":"graphic_picture","displayName":"Examination of wrist extension","title":"Examination of wrist extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of wrist extension</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/EM/63260_Wrist_extension_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain with resisted wrist extension with the elbow in full extension is characteristic of lateral epicondylitis.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 63260 Version 2.0</div></div></div>"},"63265":{"type":"graphic_table","displayName":"Inotropic agents HF","title":"Inotropic agents in heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inotropic agents in heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>Digitalis</strong></td> </tr> <tr> <td class=\"indent1\">Digoxin&nbsp;(predominantly oral; intravenous form available)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>Phosphodiesterase inhibitors</strong></td> </tr> <tr> <td class=\"indent1\">Milrinone (intravenous)</td> </tr> <tr> <td class=\"indent1\">Enoximone* (intravenous)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>Calcium-sensitizing agents</strong></td> </tr> <tr> <td class=\"indent1\">Levosimendan* (intravenous)</td> </tr> <tr> <td class=\"indent1\">Pimobendan* (oral)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>Beta-receptor agonists</strong></td> </tr> <tr> <td class=\"indent1\">High-dose dopamine (intravenous)</td> </tr> <tr> <td class=\"indent1\">Dobutamine (intravenous)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The administration route approved for treatment of selected patients with heart failure with reduced ejection fraction is shown.</div><div class=\"graphic_footnotes\">* Not approved by the US Food and Drug Administration. Available in countries outside the United States.</div><div id=\"graphicVersion\">Graphic 63265 Version 5.0</div></div></div>"},"63266":{"type":"graphic_table","displayName":"Recurrence risk NTDs","title":"Recurrence risk of neural tube malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recurrence risk of neural tube malformations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Affected relatives</td>\n<td class=\"subtitle1\">Risk of anencephaly and spina bifida (percent)</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\" colspan=\"2\">No siblings</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neither parent</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td class=\"indent1\">One parent</td>\n<td>4.5</td>\n</tr>\n<tr>\n<td class=\"indent1\">Both parents</td>\n<td>30</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">One sibling</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neither parent</td>\n<td>4</td>\n</tr>\n<tr>\n<td class=\"indent1\">One parent</td>\n<td>12</td>\n</tr>\n<tr>\n<td class=\"indent1\">Both parents</td>\n<td>38</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">Two siblings</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neither parent</td>\n<td>10</td>\n</tr>\n<tr>\n<td class=\"indent1\">One parent</td>\n<td>20</td>\n</tr>\n<tr>\n<td class=\"indent1\">Both parents</td>\n<td>43</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">One sibling and one second-degree relative</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neither parent</td>\n<td>7</td>\n</tr>\n<tr>\n<td class=\"indent1\">One parent</td>\n<td>18</td>\n</tr>\n<tr>\n<td class=\"indent1\">Both parents</td>\n<td>42</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"subtitle2_left\">One sibling and one third-degree relative</td>\n</tr>\n<tr>\n<td class=\"indent1\">Neither parent</td>\n<td>5.5</td>\n</tr>\n<tr>\n<td class=\"indent1\">One parent</td>\n<td>16</td>\n</tr>\n<tr>\n<td class=\"indent1\">Both parents</td>\n<td>42</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=44267&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Recurrence_risk_NTDs.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Nussbaum RL, McInnes RR, Willard HF. Genetics of disorders with complex inheritance. In: Thompson and Thompson Genetics in Medicine, 6th ed, WB Saunders, Philadelphia 2001. p. 289. Copyright © 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 63266 Version 2.0</div></div></div>"},"63267":{"type":"graphic_table","displayName":"Metab conseq bowel segment","title":"Primary indications and metabolic consequences for use of bowel segments<sup>[1-17]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary indications and metabolic consequences for use of bowel segments<sup>[1-17]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Bowel segment</td> <td class=\"subtitle1\">Primary indication</td> <td class=\"subtitle1\">Metabolic consequences</td> <td class=\"subtitle1\">Clinical symptoms</td> </tr> <tr> <td>Gastric</td> <td> <p>Children requiring diversion (exstrophy, pelvic radiation)</p> <p>Renal insufficiency</p> </td> <td>Metabolic alkalosis (&#8595; K, &#8595; Cl, hypergastrinemia)</td> <td> <p>Hematuria-dysuria syndrome</p> <p>Dehydration, lethargy, seizures, respiratory distress</p> </td> </tr> <tr> <td>Jejunum</td> <td> <p>Pelvic radiation</p> <p>Deficient ureteral length</p> <p>Compromised viability of other small or large bowel</p> </td> <td>Metabolic acidosis (&#8595; Na, &#8595; Cl, &#8593; K, azotemia)</td> <td>Dehydration, nausea/vomiting, weakness, lethargy, seizures</td> </tr> <tr> <td>Ileum or ileal-colic reservoirs</td> <td> <p>Malignancies requiring removal of the bladder</p> <p>Severe hemorrhagic cystitis</p> <p>Incontinence</p> </td> <td>Metabolic acidosis (&#8593; Cl, &#8595; bicarbonate, azotemia)</td> <td> <p>Fatigue, anorexia, weight loss, diarrhea, polydipsia</p> <p>B<sub>12</sub> and fat-soluble vitamin deficiency</p> <p>Diarrhea, urinary calculi, cholelithiasis</p> </td> </tr> <tr> <td>Colon (ureterosigmoidostomy)</td> <td> <p>Children requiring diversion (exstrophy, pelvic radiation)</p> <p>No other bowel segment alternative</p> </td> <td>Metabolic acidosis (&#8593; Cl, &#8595; bicarbonate, azotemia)</td> <td> <p>Fatigue, anorexia, weight loss, diarrhea, polydipsia</p> <p>Pyelonephritis</p> <p>Adenocarcinoma at anastomotic site</p> </td> </tr> <tr> <td>Transverse colon conduit</td> <td> <p>Malignancies requiring removal of the bladder</p> <p>Small bowel not practical</p> </td> <td>Metabolic acidosis (&#8593; Cl, &#8595; bicarbonate, azotemia)</td> <td> <p>Fatigue, anorexia, weight loss, diarrhea, polydipsia</p> <p>Pyelonephritis</p> <p>Adenocarcinoma at anastomotic site</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">K: potassium; Cl: chloride; ↓: decreased; ↑: increased.</div><div class=\"graphic_reference\">1. Adams, MC, Mitchell, ME, Rink, RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol 1988; 140:1152.<br> 2. Kaveggia, FF, Thompson, JS, Schafer, EC, et al. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990; 150:2389.<br> 3. McDougal, WS, Koch, MO. Accurate determination of renal function in patients with intestinal urinary diversions. J Urol 1986; 135:1175.<br> 4. Koch, MO, McDougal, WS, Flora, MD. Urease and the acidosis of urinary intestinal diversion. J Urol 1991; 146:458.<br> 5. Koch, MO, McDougal, WS, Thompson, CO. Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study with rats. J Urol 1991; 146:1390.<br> 6. Klein, EA, Montie, JE, Montague, DK, et al. Jejunal conduit urinary diversion. J Urol 1986; 135:244.<br> 7. Plawker, MW, Rabinowitz, SS, Etwaru, DJ, Glassberg, KI. Hypergastrinemia, dysuria-hematuria and metabolic alkalosis: complications associated with gastrocystoplasty. J Urol 1995; 154:546.<br> 8. Nguyen, DH, Bain, MA, Salmonson, KL, et al. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993; 150:707.<br> 9. Gosalbez, R Jr, Woodard, JR, Broecker, BH, Warshaw, B. Metabolic complications of the use of stomach for urinary reconstruction. J Urol 1993; 150:710.<br> 10. Filipsson, S, Hulten, L, Lindstedt, G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978; 13:529.<br> 11. Thompson, WG, Wrathell, E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977; 20:461.<br> 12. Koch, MO, McDougal, WS. Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments. J Urol 1985; 134:165.<br> 13. Boyd, SD, Schiff, WM, Skinner, DG, et al. Prospective study of metabolic abnormalities in patient with continent Kock pouch urinary diversion. Urology 1989; 33:85.<br> 14. Koch, MO, Gurevitch, E, Hill, DE, McDougal, WS. Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. J Urol 1990; 143:1275.<br> 15. Mills, R. D., Studer, U. E.: Metabolic consequences of continent urinary diversion. J Urol 1999; 161:1057.<br> 16. Stampfer, DS, McDougal, WS, McGovern, FJ. The use of in bowel urology. Metabolic and nutritional complications. Urol Clin North Am 1997; 24:715.<br> 17. McDougal, WS, Stampfer, DS, Kirley, S, et al. Intestinal ammonium transport by ammonium and hydrogen exchange. J Am Coll Surg 1995; 181:241.</div><div id=\"graphicVersion\">Graphic 63267 Version 2.0</div></div></div>"},"63268":{"type":"graphic_picture","displayName":"Acute otitis media","title":"Acute otitis media","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Acute otitis media</div><div class=\"cntnt\"><img style=\"width:564px; height:244px;\" src=\"images/PEDS/63268_Acuteotitismediaedit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of the white, bulging tympanic membrane seen in acute otitis media. Panel A demonstrates a bulging tympanic membrane with minimal erythema. Panel B&nbsp;demonstrates tympanic membrane bulging, marked erythema along the handle of the malleus, and an air-fluid level in the anterosuperior portion of the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Alejandro Hoberman, MD.</div><div id=\"graphicVersion\">Graphic 63268 Version 5.0</div></div></div>"},"63270":{"type":"graphic_picture","displayName":"Proboscoid hernia","title":"Proboscoid hernia warranting early repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proboscoid hernia warranting early repair</div><div class=\"cntnt\"><img style=\"width:367px; height:432px;\" src=\"images/PEDS/63270_Proboscoid_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary L Brandt, MD.</div><div id=\"graphicVersion\">Graphic 63270 Version 2.0</div></div></div>"},"63272":{"type":"graphic_picture","displayName":"Chronic paronychia 2","title":"Chronic paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic paronychia</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/DERM/63272_Chronic_paronychia_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the swelling of the proximal nail fold, the loss of the cuticle, and the dystrophy of the nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63272 Version 1.0</div></div></div>"},"63273":{"type":"graphic_table","displayName":"Compliance with medical consult","title":"Factors that influence or improve compliance with consultant recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that influence or improve compliance with consultant recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Prompt response (within 24 hours)</td> </tr> <tr> <td>Limit number of recommendations (&#8804;5)</td> </tr> <tr> <td>Identify crucial or critical recommendations (versus routine)</td> </tr> <tr> <td>Focus on central issues</td> </tr> <tr> <td>Make specific, relevant recommendations</td> </tr> <tr> <td>Use definitive language</td> </tr> <tr> <td>Specify drug dosage, route, frequency, duration</td> </tr> <tr> <td>Frequent follow-up, including progress notes</td> </tr> <tr> <td>Direct verbal contact</td> </tr> <tr> <td>Therapeutic (versus diagnostic) recommendations</td> </tr> <tr> <td>Severity of illness</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63273 Version 2.0</div></div></div>"},"63276":{"type":"graphic_diagnosticimage","displayName":"M mode aorta dilated CM","title":"M-mode of aortic root and valve in dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode of aortic root and valve in dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:383px; height:329px;\" src=\"images/CARD/63276_M_mode_aorta_dilated_CM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram from a normal subject (panel A) and a patient with dilated cardiomyopathy and low stroke volume (panel B) are shown. Note the difference in the cyclic anterior motion of the aortic root; the patient with low stroke volume has nearly flat root motion (panel B). Additionally, the aortic valve (Ao) has lost its &quot;square wave&quot; opening and now drifts closed as soon as it reaches its peak excursion. The valve appears more vivid in the low stroke volume patient partially because it moves less and more slowly, making it a better target for ultrasound. Also present is left atrial (LA) and right ventricular (RV) enlargement. The arrows point to reflected signals from a flow directed catheter in the patient's right ventricle outflow tract.</div><div id=\"graphicVersion\">Graphic 63276 Version 2.0</div></div></div>"},"63277":{"type":"graphic_diagnosticimage","displayName":"Mediastinal goiter MRI I","title":"Mediastinal goiter displacing the trachea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal goiter displacing the trachea</div><div class=\"cntnt\"><img style=\"width:360px; height:243px;\" src=\"images/PULM/63277_Mediastinal_goiter_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted section shows a soft tissue mass due to mediastinal goiter (arrow) displacing the trachea (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63277 Version 3.0</div></div></div>"},"63279":{"type":"graphic_table","displayName":"Diff HBV genotypes B and C","title":"Clinical and virological differences between genotype B and C","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and virological differences between genotype B and C</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp;</td>\r\n                    <td class=\"subtitle1\">Genotype C</td>\r\n                    <td class=\"subtitle1\">Genotype B</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prevalence of HBeAg </td>\r\n                    <td>High </td>\r\n                    <td>Low</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Spontaneous HBeAg seroconversion</td>\r\n                    <td>Late </td>\r\n                    <td>Early</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Histological activity </td>\r\n                    <td>High </td>\r\n                    <td>Low</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Rate of progression to cirrhosis</td>\r\n                    <td>High </td>\r\n                    <td>Low</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Risk of HCC </td>\r\n                    <td rowspan=\"2\">High </td>\r\n                    <td>Low (Japan, China)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Variable (Taiwan)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Frequency of PC variant (G1896A)</td>\r\n                    <td>Low</td>\r\n                    <td>High</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Frequency of CP variant (A1762T, G1764A)</td>\r\n                    <td>High</td>\r\n                    <td>Low</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Response to IFN</td>\r\n                    <td rowspan=\"2\">Low</td>\r\n                    <td>High</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>(Similar in 1 study on PEG-IFN)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\" colspan=\"3\">Response to nucleotide(side) analogues</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1\">On treatment </td>\r\n                    <td class=\"sublist_other\">Similar</td>\r\n                    <td class=\"sublist_other\">Similar</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Courtesy of Anna SF Lok, MD and Chi-Jen Chu, MD.</div><div id=\"graphicVersion\">Graphic 63279 Version 2.0</div></div></div>"},"63280":{"type":"graphic_table","displayName":"Empiric intravenous antibiotic therapy for animal bites","title":"Empiric intravenous antibiotic therapy for animal bites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric intravenous antibiotic therapy for animal bites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\">Children</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Options for empiric gram-negative and anaerobic coverage include:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:</td> </tr> <tr> <td class=\"indent2\">Ampicillin-sulbactam 3 g IV every six hours</td> <td>50 mg/kg per dose (based on ampicillin component) every six hours*</td> </tr> <tr> <td class=\"indent2\">Piperacillin-tazobactam&nbsp;3.375 g IV every&nbsp;six hours</td> <td>100 mg/kg per dose (based on piperacillin component) every eight hours*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>A third-generation cephalosporin such as ceftriaxone 1 to 2&nbsp;g IV every 24 hours</p> <p class=\"indent1\"><strong>PLUS</strong></p> Metronidazole 500 mg IV every eight hours</td> <td> <p>A third-generation cephalosporin such as ceftriaxone 100 mg/kg&nbsp;IV&nbsp;daily, given in one to two divided doses*</p> <p class=\"indent1\"><strong>PLUS</strong></p> Metronidazole 10 mg/kg IV per dose every eight hours*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative empiric regimens include:</td> </tr> <tr> <td class=\"indent1\"> <p>A fluoroquinolone (eg, ciprofloxacin 400 mg IV every 12 hours,&nbsp;levofloxacin 500 mg IV daily, or moxifloxacin 400 mg IV daily) </p> <p><strong>PLUS</strong></p> <p>Metronidazole 500 mg IV every eight hours</p> </td> <td> <p>Use fluoroquinolones with caution in children &#60;18 years of age; if unable to tolerate other choices: </p> <p>A fluoroquinolone (ciprofloxacin 20 mg/kg IV per dose twice daily or levofloxacin 10 mg/kg IV per dose twice daily if &#60;5 years old or once daily if &#8805;5 years)</p> <p><strong>PLUS</strong></p> <p><strong></strong>Metronidazole 10 mg/kg IV per dose&nbsp;every eight hours</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Monotherapy with a carbapenem<sup>&#182;</sup>, such as one of the following:</td> </tr> <tr> <td class=\"indent2\">Imipenem-cilastatin 500 mg every six hours</td> <td>25 mg/kg per dose every six hours (maximum 500 mg per dose)</td> </tr> <tr> <td class=\"indent2\">Meropenem 1 g every eight hours</td> <td>20 mg/kg per dose every eight hours (maximum 1 g per dose)</td> </tr> <tr> <td class=\"indent2\">Ertapenem 1 g daily</td> <td> <p>Children &#8804;12 years old: 15 mg/kg per dose every 12 hours&nbsp;(maximum 500 mg per dose)</p> <p>Children &#62;12 years old: Refer to adult dosing</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.&nbsp;Additional coverage for certain gram-positive pathogens may also be warranted, eg, if the patient has risk factors for colonization with community-acquired methicillin-resistant <EM>Staphylococcus aureus </EM>(MRSA). Refer to topic reviews of soft tissue infections due to dog and cat bites and MRSA treatment for recommendations.</div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Maximum pediatric dose: See adult dose.<br />¶ Carbapenems should not be routinely used in patients with a history of hypersensitivity to beta-lactams; skin testing and graded challenge may be useful for assessment of immediate-type hypersensitivity reactions. For recommendations, refer to UpToDate review of carbapenems use in penicillin-allergic patients.</div><div class=\"graphic_reference\">References:<br /><br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics (AAP). Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed., Kimberlin DW, Brady MT, Jackson MA, Long SA,&nbsp;(Eds), American Academy of Pediatrics, Elk Grove Village, IL&nbsp;2015.</LI>&#xD;&#xA;<LI>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</LI></OL></div><div id=\"graphicVersion\">Graphic 63280 Version 8.0</div></div></div>"},"63284":{"type":"graphic_table","displayName":"Cholinesterase inhibitors","title":"Cholinesterase inhibitors used for treatment of dementia: Dose and administration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cholinesterase inhibitors used for treatment of dementia: Dose and administration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"27.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Formulations</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Maintenance dose</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Donepezil</td> <td>Tablet or oral disintegrating tablet</td> <td>5 mg orally, once daily</td> <td>10 mg daily (increased after 4 to 6 weeks)*</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Galantamine</td> <td>Immediate-release tablet or solution</td> <td>4 mg orally, twice daily</td> <td>12 mg twice daily (increased in monthly intervals by 4 mg twice-daily increments)</td> <td>Give with meals. Maximum 8 mg twice daily with moderate renal or liver impairment. Do not use with severe renal or liver impairment.</td> </tr> <tr class=\"divider_bottom\"> <td>Extended-release capsule</td> <td>8 mg orally, once daily</td> <td>24 mg once daily (increased in monthly intervals by 8 mg once-daily increments)</td> <td>Maximum 12 mg once daily with moderate renal or liver impairment. Do not use with severe renal or liver impairment.</td> </tr> <tr> <td rowspan=\"2\">Rivastigmine</td> <td>Capsule</td> <td>1.5 mg orally, twice daily</td> <td>6 mg twice daily (increased in 2- to 4-week intervals by 1.5 mg twice-daily increments)</td> <td>Give with meals. Slow and cautious titration with renal or liver impairment or low body weight.</td> </tr> <tr> <td>Transdermal patch</td> <td>4.6 mg/24 hours</td> <td>9.5 to 13.3 mg/24 hours (increased in monthly intervals by 4.6 mg increments)</td> <td>Can cause rash; rotate sites. Fewer side effects than capsule. Maximum dose 4.6 mg/24 hours with mild to moderate liver impairment or low body weight. Do not use with severe liver impairment.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">*A 23 mg noncrushable tablet of donepezil is available, but evidence does not support a clinically important advantage to the higher dose and it is associated with increased side effects.</div><div id=\"graphicVersion\">Graphic 63284 Version 2.0</div></div></div>"},"63285":{"type":"graphic_diagnosticimage","displayName":"Complex atherosclerotic plaque in the thoracic aorta","title":"Complex atherosclerotic plaque in the thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex atherosclerotic plaque in the thoracic aorta</div><div class=\"cntnt\"><img style=\"width:312px; height:584px;\" src=\"images/SURG/63285_Atherosclerotic_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex atherosclerotic plaque in the thoracic aorta visualized by 2D TEE.<br> (A) Ulcerated plaque in the aortic arch.<br> (B) Plaque with a mobile component representing superimposed thrombus (arrow) in the descending thoracic aorta.</div><div class=\"graphic_reference\">Courtesy of Dr. Muhamed Saric.</div><div id=\"graphicVersion\">Graphic 63285 Version 4.0</div></div></div>"},"63286":{"type":"graphic_figure","displayName":"Lateral view of the internal carotid artery","title":"Lateral view of the internal carotid artery","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Lateral view of the internal carotid artery</div><div class=\"cntnt\"><img style=\"width:590px; height:651px;\" src=\"images/SURG/63286_LV_internal_carotid_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of a schematic drawing of the carotid arteries, vertebral arteries, and intracranial vessels and their relationships in the neck and brain.</div><div class=\"graphic_reference\">Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63286 Version 1.0</div></div></div>"},"63287":{"type":"graphic_figure","displayName":"Meningococcus map","title":"Areas with frequent epidemics of meningococcal meningitis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Areas with frequent epidemics of meningococcal meningitis</div><div class=\"cntnt\"><img style=\"width:550px; height:425px;\" src=\"images/ID/63287_Meningococcus_map_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disease data source: World Health Organization. International Travel and Health. Geneva, Switzerland: 2012.</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 63287 Version 5.0</div></div></div>"},"63288":{"type":"graphic_figure","displayName":"Rubber band ligation","title":"Rubber band ligation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rubber band ligation</div><div class=\"cntnt\"><img style=\"width:430px; height:563px;\" src=\"images/SURG/63288_Rubber_band_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panels&nbsp;A through E depict the technique of applying the rubber band to treat internal hemorrhoids.<br />(A) shows the forceps grasping the hemorrhoid. Note the band on the drum of the ligator.<br />(B) is a lateral view of the forceps grasping the hemorrhoid.<br />(C) shows the retraction of the forceps and the hemorrhoid into the drum of the ligator.<br />(D) shows the hemorrhoid pulled through the drum and the rubber band applied at the base of the hemorrhoid. Gentle traction is applied on the hemorrhoid by the forceps to secure it while the band is released from the ligator.<br />(E) depicts the banded, swollen hemorrhoid.</div><div id=\"graphicVersion\">Graphic 63288 Version 5.0</div></div></div>"},"63289":{"type":"graphic_picture","displayName":"Vulvar necrotiz fasciitis","title":"Vulvar necrotizing fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar necrotizing fasciitis</div><div class=\"cntnt\"><img style=\"width:322px; height:432px;\" src=\"images/OBGYN/63289_Vulvar_necrotiz_fasciitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative photograph of necrotizing fasciitis of the vulva. The catheter notes the location of the urethra. Note the extent of the dissection.</div><div class=\"graphic_reference\">Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &#169;2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63289 Version 1.0</div></div></div>"},"63290":{"type":"graphic_table","displayName":"Methods of genetic testing","title":"Methods of genetic testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods of genetic testing</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n DNA-based\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Direct DNA Testing\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Looks for known mutation that causes a condition; requires that the indicated mutation can be identified by testing.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Linkage Testing\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n When the conditions for direct DNA testing are not met, linkage testing can infer the presence of a mutation through the study of several family members to identify DNA markers that are co-inherited with the gene of interest.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Methylation Studies\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Analyzes the attachment of methyl groups to the DNA molecule of genes in disorders in which methylation patterns influence disease.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Protein Trunction Test (PTT)\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Identifies shortened protein product when the mutation that acts by this method, resulting in reduced or absent protein function.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Uniparental Disomy (UPD)\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Detection of two copies of the same chromosome pair from one parent and none from the other parent that can result in genetic disease.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n X Inactivation Studies\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n In general, one of the pair of X-chromosomes is randomly inactivated in each cell and does not reactivate.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n When in certain condition, X-inactivation is non-random, it can be measured and carrier status of women with a history of these disorders can be predicted on this basis.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Cytogenetic\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Fluorescence In Situ Hybridization (FISH)\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Viewing of a fluorescence-labeled chromosomal probe introduced into the cell nucleus where it attaches to its match within the cell; used to test for missing or additional chromosome material.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1_single\">\r\n \r\n Biochemical\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Analyte\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Quantitative analysis of a substance in the body when increased or decreased amounts may be indicative of a genetic disorder.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Enzyme Assay\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n An enzyme assay that quantifies enzyme activity in order to assess genetic disease or carrier status of a specific disease related to this reaction.\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">\r\n \r\n Protein Analysis\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">\r\n \r\n Analysis of protein structure looking for alteration that may result in a disease state.\r\n \r\n </td>\r\n \r\n </tr>\r\n\r\n <tr>\r\n \r\n <td class=\"subtitle2_single\">Array Genomic Hybridization (aGH)</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td class=\"indent1\">Quantitative analysis of labeled total genomic DNA to a microarray (DNA chip) to detect submicroscopic deletions and duplications.</td>\r\n \r\n </tr>\r\n\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">12/4/2000-emailed au for more information. Looks like she already requested permission. Au says not taken directly from GeneTests and that Dr. Pagon will be request permission, decided to go with &amp;quot;adapted from&amp;quot;  and see if anything happens with the au permission. \r\n12/5/2000-perm granted from Dr. Pagon.</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59832&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Methods_of_genetic_testing.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from GeneTests.</div><div id=\"graphicVersion\">Graphic 63290 Version 2.0</div></div></div>"},"63291":{"type":"graphic_table","displayName":"Complications of arterial catheters","title":"Complications of arterial catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of arterial catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">All sites</td> </tr> <tr> <td>Pain and swelling</td> </tr> <tr> <td>Thrombosis</td> </tr> <tr> <td>Embolization</td> </tr> <tr> <td>Hematoma</td> </tr> <tr> <td>Limb ischemia</td> </tr> <tr> <td>Pseudoaneurysm</td> </tr> <tr> <td>Diagnostic blood loss</td> </tr> <tr> <td>Arteriovenous fistula</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td class=\"subtitle1_single\">Radial artery</td> </tr> <tr> <td>Cerebral embolization</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td class=\"subtitle1_single\">Femoral artery</td> </tr> <tr> <td>Retroperitoneal hematoma</td> </tr> <tr> <td class=\"subtitle1_single\">Axillary artery</td> </tr> <tr> <td>Cerebral embolization</td> </tr> <tr> <td>Brachial plexopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Brachial artery</td> </tr> <tr> <td>Cerebral embolization</td> </tr> <tr> <td>Median nerve damage</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63291 Version 4.0</div></div></div>"},"63293":{"type":"graphic_picture","displayName":"Nocturnal nasal NPPV","title":"Nocturnal nasal NPPV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nocturnal nasal NPPV</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/PULM/63293_Nocturnal_nasal_NPPV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient is being fitted for a transparent custom acrylic nasal interface for nocturnal nasal NPPV.</div><div class=\"graphic_reference\">Courtesy of John R Bach, MD.</div><div id=\"graphicVersion\">Graphic 63293 Version 2.0</div></div></div>"},"63294":{"type":"graphic_table","displayName":"T lymphocyte ratios in disease","title":"CD4:CD8 T lymphocyte ratios in diseases presenting with lymphocytic alveolitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CD4:CD8 T lymphocyte ratios in diseases presenting with lymphocytic alveolitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">CD4 : CD8 raised</td></tr>\n\t\t\t\t\t\t<tr><td>Sarcoidosis</td></tr>\n\t\t\t\t\t\t<tr><td>Berylliosis</td></tr>\n\t\t\t\t\t\t<tr><td>Asbestosis</td></tr>\n\t\t\t\t\t\t<tr><td>Crohn's disease</td></tr>\n\t\t\t\t\t\t<tr><td>Rheumatoid arthritis</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">CD4 : CD8 normal</td></tr>\n\t\t\t\t\t\t<tr><td>Tuberculosis</td></tr>\n\t\t\t\t\t\t<tr><td>Lymphangioleiomyomatosis</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">CD4 : CD8 lowered</td></tr>\n\t\t\t\t\t\t<tr><td>Hypersensitivity pneumonitis</td></tr>\n\t\t\t\t\t\t<tr><td>Silicosis</td></tr>\n\t\t\t\t\t\t<tr><td>Drug induced</td></tr>\n\t\t\t\t\t\t<tr><td>BOOP</td></tr>\n\t\t\t\t\t\t<tr><td>HIV infection</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Poulter LW, Rossi GA, Bjermer L, et al, Eur Respir Rev 1992; 2:75.</div><div id=\"graphicVersion\">Graphic 63294 Version 2.0</div></div></div>"},"63296":{"type":"graphic_table","displayName":"Initial prenatal labs","title":"Initial prenatal laboratory examination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial prenatal laboratory examination</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Blood type and antibody screen</td>\n</tr>\n<tr>\n<td>Rhesus type</td>\n</tr>\n<tr>\n<td>Hematocrit or hemoglobin</td>\n</tr>\n<tr>\n<td>PAP smear</td>\n</tr>\n<tr>\n<td>Rubella status (immune or nonimmune)</td>\n</tr>\n<tr>\n<td>Syphilis screen</td>\n</tr>\n<tr>\n<td>Urinary infection screen</td>\n</tr>\n<tr>\n<td>Hepatitis B surface antigen</td>\n</tr>\n<tr>\n<td>HIV counseling and testing</td>\n</tr>\n<tr>\n<td>Chlamydia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63296 Version 1.0</div></div></div>"},"63297":{"type":"graphic_table","displayName":"Diversions vs conduits","title":"Comparison of complications in continent diversions versus ileal conduits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of complications in continent diversions versus ileal conduits</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of diversion</td> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">Series</td> <td class=\"subtitle1\">No. of patients</td> <td class=\"subtitle1\">Time from surgery</td> <td class=\"subtitle1\">Complications in percent</td> </tr> <tr> <td rowspan=\"3\">Ileal conduit</td> <td>2000</td> <td>Parekh et al. </td> <td>81</td> <td>19</td> <td>22</td> </tr> <tr> <td>1998</td> <td>Gburek et al. </td> <td>66</td> <td>20</td> <td>18</td> </tr> <tr> <td>2003</td> <td>Studer et al. </td> <td>131</td> <td>98</td> <td>66</td> </tr> <tr> <td rowspan=\"8\">Continent diversion</td> <td>2000</td> <td>Parekh et al. </td> <td>117</td> <td>20</td> <td>12</td> </tr> <tr> <td>1998</td> <td>Gburek et al. </td> <td>66</td> <td>17</td> <td>18</td> </tr> <tr> <td>1999</td> <td>Shimogaki et al.</td> <td>8</td> <td>59.9</td> <td>0</td> </tr> <tr> <td>2000</td> <td>Mills et al.</td> <td>15</td> <td>19</td> <td>13</td> </tr> <tr> <td>1999</td> <td>Ali-el-dein et al.</td> <td>60</td> <td>20.2</td> <td>13</td> </tr> <tr> <td>1999</td> <td>Hautmann et al. </td> <td>363</td> <td>57</td> <td>15.4-23.4*</td> </tr> <tr> <td>2000</td> <td>Steven et al. </td> <td>166</td> <td>32</td> <td>23.5-37.4*</td> </tr> <tr> <td>1997</td> <td>Studer et al. </td> <td>200</td> <td>30-134</td> <td>12-22*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Early (within 90 days)&nbsp;versus late (&gt;90 days) complications.</div><div id=\"graphicVersion\">Graphic 63297 Version 2.0</div></div></div>"},"63298":{"type":"graphic_figure","displayName":"WHO analgesic ladder","title":"World Health Organization (WHO) analgesic ladder","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) analgesic ladder</div><div class=\"cntnt\"><img style=\"width:472px; height:516px;\" src=\"images/ONC/63298_WHOanalgesicladder.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug.</div><div id=\"graphicVersion\">Graphic 63298 Version 3.0</div></div></div>"},"63299":{"type":"graphic_table","displayName":"Dehydration vs septic shock","title":"Comparison of clinical signs of dehydration and septic shock in the severely malnourished child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of clinical signs of dehydration and septic shock in the severely malnourished child</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical sign</td> <td class=\"subtitle1\">Some dehydration</td> <td class=\"subtitle1\">Severe dehydration</td> <td class=\"subtitle1\">Incipient septic shock</td> <td class=\"subtitle1\">Developed septic shock</td> </tr> <tr> <td>Watery diarrhea</td> <td>Yes</td> <td>Yes</td> <td>Yes or no*</td> <td>Yes or no*</td> </tr> <tr> <td>Thirst</td> <td>Drinks eagerly<sup>&#182;</sup></td> <td>Drinks poorly</td> <td>No*</td> <td>No*</td> </tr> <tr> <td>Mental state&nbsp;</td> <td>Restless, irritable<sup>&#182;</sup>&nbsp;</td> <td>Lethargic, comatose&nbsp;</td> <td>Apathetic*&nbsp;</td> <td>Lethargic&nbsp;</td> </tr> <tr> <td>Hypothermia</td> <td>No</td> <td>No</td> <td>Yes* or no</td> <td>Yes* or no</td> </tr> <tr> <td>Weak or absent radial pulse</td> <td>No<sup>&#182;</sup></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Cold hands and feet</td> <td>No<sup>&#182;</sup></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Sunken eyes&nbsp;</td> <td>Yes<sup>&#182;</sup><sup>&#916;</sup>&nbsp;</td> <td>Yes<sup>&#182;</sup><sup>&#916;</sup>&nbsp;</td> <td>No*&nbsp;</td> <td>No*&nbsp;</td> </tr> <tr> <td>Urine flow</td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Hypoglycemia</td> <td>Sometimes</td> <td>Sometimes</td> <td>Sometimes</td> <td>Sometimes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Signs that may be useful in diagnosing septic shock.<br />&para; Signs that may be useful in diagnosing dehydration.<br />&Delta; If confirmed as recent by the mother.</div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 63299 Version 6.0</div></div></div>"},"63300":{"type":"graphic_picture","displayName":"Neonatal HSV lung","title":"Lung pathology in disseminated neonatal herpes simplex virus (HSV) infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung pathology in disseminated neonatal herpes simplex virus (HSV) infection</div><div class=\"cntnt\"><img style=\"width:334px; height:503px;\" src=\"images/PEDS/63300_Neonatal_HSV_lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic slide (magnification 40X) of lung tissue from a neonate who died of disseminated HSV, showing pneumonitis and lung inclusion cells (arrows)&nbsp;characteristic of herpes virus infection.</div><div class=\"graphic_reference\">Courtesy of Edwina Popek, DO, Department of Pathology, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 63300 Version 2.0</div></div></div>"},"63301":{"type":"graphic_figure","displayName":"Ligaments of the wrist","title":"Ligaments of the wrist","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Ligaments of the wrist</div><div class=\"cntnt\"><img style=\"width:532px; height:498px;\" src=\"images/PEDS/63301_Wrist_ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows the volar surface of the wrist.</div><div id=\"graphicVersion\">Graphic 63301 Version 4.0</div></div></div>"},"63302":{"type":"graphic_diagnosticimage","displayName":"Miliary tuberculosis CXR","title":"Chest radiograph of miliary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of miliary tuberculosis</div><div class=\"cntnt\"><img style=\"width:554px; height:306px;\" src=\"images/ID/63302_Miliary_tuberculosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A full posterior-anterior radiograph of the chest shows diffuse involvement (left). The right panel is magnified, illustrating the reticulonodular pattern of miliary tuberculosis.</div><div class=\"graphic_reference\">Courtesy of Jo-Anne Shepard, MD, Massachusetts General Hospital, Boston.</div><div id=\"graphicVersion\">Graphic 63302 Version 3.0</div></div></div>"},"63304":{"type":"graphic_picture","displayName":"Velamentous cord insertion with bilobed placenta","title":"Velamentous cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Velamentous cord</div><div class=\"cntnt\"><img style=\"width:430px; height:651px;\" src=\"images/OBGYN/63304_Velamentous_cord2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Velamentous umbilical cord insertion of a bilobed placenta.</div><div class=\"graphic_reference\">Courtesy of the Pathology Department at The Valley Hospital in Ridgewood, New Jersey.</div><div id=\"graphicVersion\">Graphic 63304 Version 2.0</div></div></div>"},"63306":{"type":"graphic_figure","displayName":"Autosomal dominant--pedigree","title":"Example of an autosomal dominant pedigree showing complete penetrance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of an autosomal dominant pedigree showing complete penetrance</div><div class=\"cntnt\"><img style=\"width:337px; height:253px;\" src=\"images/PC/63306_Autosomal_dominant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autosomal dominant trait. Features of autosomal dominant inheritance seen here include: affected individual in each generation;&nbsp;lack of gender bias; approximately 50% affection rate among siblings of affected subjects.</div><div id=\"graphicVersion\">Graphic 63306 Version 5.0</div></div></div>"},"63307":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor I CT","title":"Fibrous tumor of the pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura</div><div class=\"cntnt\"><img style=\"width:380px; height:270px;\" src=\"images/PULM/63307_Fibrous_pleural_tumor_I_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT shows a large posterior thoracic mass enhancing heterogeneously after intravenous contrast material. The cardiomediastinal structures, including the descending aorta, are shifted to the right, and the left hilus is displaced anteriorly, indicating that this mass is intrapleural rather than intraparenchymal.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63307 Version 4.0</div></div></div>"},"63308":{"type":"graphic_table","displayName":"Estimating energy expenditure","title":"Revised World Health Organization equations for estimating energy expenditure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised World Health Organization equations for estimating energy expenditure</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Step 1: Estimate basal metabolic rate</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\">Men 18 to 30 years = (0.0630 x actual weight in kg + 2.8957) x 240 kcal/day</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\">Men 31 to 60 years = (0.0484 x actual weight in kg + 3.6534) x 240 kcal/day</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\">Women 18 to 30 years = (0.0621 x actual weight in kg + 2.0357) x 240 kcal/day</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\">Women 31 to 60 years = (0.0342 x actual weight in kg + 3.5377) x 240 kcal/day</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Step 2: Determine activity factor</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Activity level</td>\n\n      <td class=\"subtitle2_single\">Activity factor</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Low (sedentary)</td>\n\n      <td>1.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Intermediate (some regular exercise)</td>\n\n      <td>1.5</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">High (regular activity or demanding job)</td>\n\n      <td>1.7</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Step 3: Estimate total energy expenditure</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td rowspan=\"1\" colspan=\"2\">Total energy expenditure = Basal metabolic rate x activity factor</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63308 Version 1.0</div></div></div>"},"63310":{"type":"graphic_diagnosticimage","displayName":"Tubal recanalization b","title":"Pelvic fluoroscopic image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic fluoroscopic image</div><div class=\"cntnt\"><img style=\"width:392px; height:403px;\" src=\"images/OBGYN/63310_Tubal_recanalization_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pelvic fluoroscopic image during fallopian tube recanalization shows a guidewire and microcatheter passed through the left fallopian tube.</div><div id=\"graphicVersion\">Graphic 63310 Version 2.0</div></div></div>"},"63311":{"type":"graphic_picture","displayName":"Neuroendocrine low power","title":"Large cell neuroendocrine carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large cell neuroendocrine carcinoma</div><div class=\"cntnt\"><img style=\"width:390px; height:260px;\" src=\"images/PULM/63311_Neuroendocrine_low-power.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph showing tumor nests with an organoid appearance characteristic of a neuroendocrine neoplasm. There is an abundant necrosis (N) associated with many of the tumor cell nests.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 63311 Version 4.0</div></div></div>"},"63312":{"type":"graphic_picture","displayName":"Lupus pernio - nose","title":"Lupus pernio in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus pernio in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/63312_Lupus_pernio_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous to violaceous plaque is present on the nose of this patient with cutaneous sarcoidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63312 Version 3.0</div></div></div>"},"63313":{"type":"graphic_picture","displayName":"Hypopigmented sarcoidosis - close view","title":"Hypopigmented sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypopigmented sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63313_Hypopig_sarcoid_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented sarcoidosis. Discrete, hypopigmented macules with central papules are present. The lesions resemble the configuration of a fried egg.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63313 Version 4.0</div></div></div>"},"63314":{"type":"graphic_picture","displayName":"Impetigo of the face","title":"Impetigo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impetigo</div><div class=\"cntnt\"><img style=\"width:360px; height:327px;\" src=\"images/ID/63314_Impetigo_face_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Honey-crusted\" plaques on the face of a child with impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63314 Version 2.0</div></div></div>"},"63315":{"type":"graphic_figure","displayName":"Chronic respiratory acidosis","title":"Compensation to chronic respiratory acidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compensation to chronic respiratory acidosis</div><div class=\"cntnt\"><img style=\"width:252px; height:274px;\" src=\"images/NEPH/63315_Chrnc_resprtry_acidosis_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">95% significance bands for plasma pH and H<SUP>+</SUP> and HCO<SUB>3</SUB><SUP>–</SUP> concentrations in chronic hypercapnia. Because of the compensatory rise in the plasma HCO<SUB>3</SUB><SUP>–</SUP> concentration, there is much less change in H<SUP>+</SUP> concentration and pH than in acute hypercapnia.</div><div class=\"graphic_reference\">Schwartz WB, Brackett NC Jr, Cohen JJ. J Clin Invest 1965; 44:291. By copyright permission of the American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 63315 Version 4.0</div></div></div>"},"63319":{"type":"graphic_picture","displayName":"Skin biopsy NSF Light I","title":"Low power light micrograph of a skin biopsy from a patient with nephrogenic systemic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low power light micrograph of a skin biopsy from a patient with nephrogenic systemic fibrosis</div><div class=\"cntnt\"><img style=\"width:442px; height:346px;\" src=\"images/NEPH/63319_Skin_biopsy_NSF_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A low magnification image of a skin biopsy from a patient with nephrogenic systemic fibrosis shows subcutaneous septa that are widely expanded by collagen deposits (arrow). The asterisk highlights an area of normal septal thickness, and S indicates the skin surface.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 63319 Version 3.0</div></div></div>"},"63320":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of a normal fetal chest","title":"Prenatal ultrasound image of a normal fetal chest at 28 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of a normal fetal chest at 28 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:514px; height:248px;\" src=\"images/OBGYN/63320_US_normal_fetal_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal (A) and axial (B) images of the chest demonstrate homogeneous echogenic lung parenchyma, slightly echogenic compared to the liver.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 63320 Version 2.0</div></div></div>"},"63321":{"type":"graphic_diagnosticimage","displayName":"Benign breast cysts","title":"Benign breast cysts","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Benign breast cysts</div><div class=\"cntnt\"><img style=\"width:501px; height:286px;\" src=\"images/PC/63321_Benign_breast_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple well defined ovoid nodules seen on CC mammogram (Panel A). Simple cyst is seen on ultrasound (Panel B), confirming benign nature of the mammographic nodule.</div><div class=\"graphic_footnotes\">CC: craniocaudal.</div><div id=\"graphicVersion\">Graphic 63321 Version 2.0</div></div></div>"},"63323":{"type":"graphic_picture","displayName":"Gastric neuroendocrine carcinoma","title":"Gastric neuroendocrine carcinoma (Grade 2)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric neuroendocrine carcinoma (Grade 2)*</div><div class=\"cntnt\"><img style=\"width:411px; height:252px;\" src=\"images/GAST/63323_Gastric_carcinoid_poorly_di.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a gastric carcinoid reveals sheets of poorly differentiated tumors cells with areas of necrosis (arrow).</div><div class=\"graphic_footnotes\">* All neuroendocrine tumors of the GI tract, including gastric carcinoids, are graded as grade 1, 2, or 3 (large cell or small cell type neuroendocrine carcinoma) based on the mitotic count and/or the Ki67 proliferation index.</div><div class=\"graphic_reference\">From Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63323 Version 3.0</div></div></div>"},"63325":{"type":"graphic_figure","displayName":"Towel clamp on myoma","title":"Towel clamp on myoma during myomectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Towel clamp on myoma during myomectomy</div><div class=\"cntnt\"><img style=\"width:446px; height:382px;\" src=\"images/OBGYN/63325_Towel_clamp_on_myoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Towel clamp placed on myoma for traction to aid in dissection.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 63325 Version 2.0</div></div></div>"},"63326":{"type":"graphic_table","displayName":"Features of idiopathic interstitial pneumonias","title":"Distinguishing features of the idiopathic interstitial pneumonias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features of the idiopathic interstitial pneumonias</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">&nbsp; </td>\r\n                    <td class=\"subtitle1\">AIP </td>\r\n                    <td class=\"subtitle1\">DIP </td>\r\n                    <td class=\"subtitle1\">UIP </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prodrome</td>\r\n                    <td>Abrupt (1 to 2 weeks)</td>\r\n                    <td>Subacute (weeks to months)</td>\r\n                    <td>Chronic (&#62;12 months)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chest radiography</td>\r\n                    <td>Diffuse, bilateral air-space opacification</td>\r\n                    <td>Ground-glass opacity in lower lung zones</td>\r\n                    <td>\r\n                    <p>Bilateral reticular opacities</p>\r\n                    <p>Honeycombing</p>\r\n                    <p>Lower zone predominance</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>HRCT features</td>\r\n                    <td>\r\n                    <p>Bilateral, symmetric areas of ground-glass opacity</p>\r\n                    <p>Bilateral air space consolidation</p>\r\n                    </td>\r\n                    <td>Diffuse ground-glass opacity in middle and lower lungzones</td>\r\n                    <td>\r\n                    <p>Intralobular interstitial opacities</p>\r\n                    <p>Irregular interlobular septal thickening</p>\r\n                    <p>Traction bronchiectasis and honeycombing</p>\r\n                    <p>Lower zone predominance</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Histopathologic features</td>\r\n                    <td>Diffuse, uniform organizing diffuse alveolar damage (hyaline membranes)</td>\r\n                    <td>Diffuse, uniform intraalveolar macrophage accumulation</td>\r\n                    <td>Variegated, patchy, subpleural interstitial fibrosisand honeycombing</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Treatment</td>\r\n                    <td>\r\n                    <p>Mechanical ventilation</p>\r\n                    <p>Glucocorticoid responsiveness unknown</p>\r\n                    </td>\r\n                    <td>Glucocorticoid responsive</td>\r\n                    <td>Poor response to glucocorticoids or cytotoxic agents</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prognosis</td>\r\n                    <td>60 percent mortality in &#60;6 months</td>\r\n                    <td>5 percent mortality in 5 years</td>\r\n                    <td>50 to 70 percent mortality in 5 years</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">AIP: acute interstitial pneumonia; UIP: usualinterstitial pneumonia; DIP: desquamative interstitial pneumonia; HRCT: high resolution CT scan.</div><div id=\"graphicVersion\">Graphic 63326 Version 2.0</div></div></div>"},"63327":{"type":"graphic_picture","displayName":"Myocardial sarcoidosis","title":"Myocardial sarcoidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myocardial sarcoidosis</div><div class=\"cntnt\"><img style=\"width:304px; height:234px;\" src=\"images/PULM/63327_Myocardial_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph demonstrating granulomatous inflammation within the myocardial wall.</div><div class=\"graphic_reference\">Courtesy of Om P Sharma, MD.</div><div id=\"graphicVersion\">Graphic 63327 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial byopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/CARD/80914_Normal_myocardium_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy from a normal endomyocardial biopsy.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80914 Version 1.0</div></div></div>"},"63328":{"type":"graphic_figure","displayName":"V-Y advancement for anal fissures","title":"V-Y advancement for anal fissures","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">V-Y advancement for anal fissures</div><div class=\"cntnt\"><img style=\"width:542px; height:255px;\" src=\"images/SURG/63328_V-Y-advancement-for-anal-fissures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of pictures show the incision for creating a V-Y advancement flap for coverage of a chronic anal fissure.</div><div class=\"graphic_reference\">Chambers W, Sajal R, Dixon A. V-Y advancement flap as first-line treatment for all chronic anal fissures. Int J Colorectal Dis 2010; 25:645.</div><div id=\"graphicVersion\">Graphic 63328 Version 7.0</div></div></div>"},"63329":{"type":"graphic_picture","displayName":"Histologic images of healed plaque rupture","title":"Histologic images of healed plaque rupture","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Histologic images of healed plaque rupture</div><div class=\"cntnt\"><img style=\"width:560px; height:425px;\" src=\"images/CARD/63329_Hist_image_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cross-sectional histologic image of healed plaque rupture. (Movat, magnification x40). Necrotic core (NC) is covered by thick fibrous cap.<br> (B) Magnified image (x200) of the inset in panel A. Type III collagen is overlying the rupture site (yellow arrow).<br> (C) Sirius red staining corresponding to panel B under the polarized light, the NC is identified as a black area contained within the type III collagen layer (green under polarized light) of the fibrous cap.<br> (D) Healed plaque rupture with severe luminal narrowing (Movat, magnification x40).<br> (E, F) Sirius red stained sections corresponding to panel D under the normal (E) and polarized light (F), respectively.<br> (G, H, I) Magnified image (x200) of the insets in panel D. There are multiple layered NCs, which ruptured at various times prior to the eventual multi-layered appearance, which indicate that repeated episodes of plaque rupture had occurred.</div><div class=\"graphic_footnotes\">NC: necrotic core.</div><div class=\"graphic_reference\">Courtesy of Drs. Renu Virmani, Frank Kolodgie, and Fumiyuki Otsuka.</div><div id=\"graphicVersion\">Graphic 63329 Version 2.0</div></div></div>"},"63330":{"type":"graphic_figure","displayName":"Periph blood Tregs","title":"Detection of human T regulatory cells in peripheral blood","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Detection of human T regulatory cells in peripheral blood</div><div class=\"cntnt\"><img style=\"width:234px; height:466px;\" src=\"images/ALLRG/63330_Periph_blood_Tregs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal expression of CD4+ CD25+ CD127dim regulatory T (Treg) cells in peripheral blood. Foxp3 staining in the CD25+ CD127dim CD4+ cells is shown.</div><div id=\"graphicVersion\">Graphic 63330 Version 2.0</div></div></div>"},"63333":{"type":"graphic_table","displayName":"TNM staging HCC","title":"TNM staging for hepatocellular cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging for hepatocellular cancer</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Primary tumor (T)\n   </td>\n   </tr>\n   <tr>\n   <td>TX</td>\n   <td  colspan=\"3\">\n   Primary tumor cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>T0</td>\n   <td  colspan=\"3\">\n   No evidence of primary tumor\n   </td>\n   </tr>\n   <tr>\n   <td>T1</td>\n   <td  colspan=\"3\">\n   Solitary tumor without vascular invasion\n   </td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td  colspan=\"3\">\n   Solitary tumor with vascular invasion or multiple tumors none more than 5 cm\n   </td>\n   </tr>\n   <tr>\n   <td>T3a</td>\n   <td  colspan=\"3\">\n   Multiple tumors more than 5 cm\n   </td>\n   </tr>\n   <tr>\n   <td>T3b</td>\n   <td  colspan=\"3\">\n   Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein\n   </td>\n   </tr>\n   <tr>\n   <td>T4</td>\n   <td  colspan=\"3\">\n   Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Regional lymph nodes (N)\n   </td>\n   </tr>\n   <tr>\n   <td>NX</td>\n   <td  colspan=\"3\">\n   Regional lymph nodes cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>N0</td>\n   <td  colspan=\"3\">\n   No regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>N1</td>\n   <td  colspan=\"3\">\n   Regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Distant metastasis (M)\n   </td>\n   </tr>\n   <tr>\n   <td>M0</td>\n   <td  colspan=\"3\">\n   No distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>M1</td>\n   <td  colspan=\"3\">\n   Distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Fibrosis score (F)*\n   </td>\n   </tr>\n   <tr>\n   <td>F0</td>\n   <td  colspan=\"3\">\n   Fibrosis score 0-4 (none to moderate fibrosis)\n   </td>\n   </tr>\n   <tr>\n   <td>F1</td>\n   <td  colspan=\"3\">\n   Fibrosis score 5-6 (severe fibrosis or cirrhosis)\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Anatomic stage/prognostic groups\n   </td>\n   </tr>\n   <tr>\n   <td>Stage I</td>\n   <td>T1</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage II</td>\n   <td>T2</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIIA</td>\n   <td>T3a</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIIB</td>\n   <td>T3b</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIIC</td>\n   <td>T4</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IVA</td>\n   <td>Any T</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IVB</td>\n   <td>Any T</td>\n   <td>Any N</td>\n   <td>M1</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48424&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>TNM_staging_HCC.htm</title></head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* The fibrosis score as defined by Ishak is recommended because of its prognostic value in overall survival. This scoring system uses a 0-6 scale.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 63333 Version 11.0</div></div></div>"},"63334":{"type":"graphic_diagnosticimage","displayName":"Avascular necrosis hip MRI","title":"Magnetic resonance image: Avascular necrosis of the hip (Legg-Calvé-Perthes disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image: Avascular necrosis of the hip (Legg-Calvé-Perthes disease)</div><div class=\"cntnt\"><img style=\"width:358px; height:286px;\" src=\"images/PEDS/63334_AvascularnecrosishipMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted coronal MR of the pelvis demonstrates lack of signal in the left capital femoral epiphysis compared with the right (arrow). Fragmentation is present. Note that the overlying synovial cartilage is maintained, as is the joint space.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 63334 Version 4.0</div></div></div>"},"63336":{"type":"graphic_table","displayName":"Median survival advanced cancer","title":"Median survivals from studies that include untreated patients with advanced cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Median survivals from studies that include untreated patients with advanced cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor histology</td> <td class=\"subtitle1\">Disease stage</td> <td class=\"subtitle1\">Median survival*</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>Colorectal adenocarcinoma</td> <td>IV</td> <td>5 to 6 months</td> <td>Scheithauer 1993</td> </tr> <tr> <td>Gastric adenocarcinoma</td> <td>IV</td> <td>5 months</td> <td>Glimelius 1997</td> </tr> <tr> <td>Head and neck squamous cell carcinoma</td> <td>IV/recurrent</td> <td>4 months</td> <td>Kowalski 2000</td> </tr> <tr> <td rowspan=\"4\">Non-small cell lung cancer</td> <td rowspan=\"3\">IIIb/IV</td> <td>4.1 months</td> <td>Roszkowski 2000</td> </tr> <tr> <td>5.3 months</td> <td>Attali 1987</td> </tr> <tr> <td>5.9 months</td> <td>Cellerino 1991</td> </tr> <tr> <td>\"Advanced disease\"</td> <td>2.5 months</td> <td>Meta-analysis, BMJ 1995</td> </tr> <tr> <td>Hepatocellular carcinoma</td> <td>Unresectable</td> <td>4.2 to 8 months</td> <td>Llovet 2008, Cheng 2009</td> </tr> <tr> <td rowspan=\"2\">Pancreatic adenocarcinoma</td> <td>IV</td> <td>7 months</td> <td>Huguier 2001</td> </tr> <tr> <td>IV, following failure of front-line gemcitabine chemotherapy (locally advanced inoperable or metastatic)</td> <td>2.3 months</td> <td>Pelzer 2011</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Values pertain to the subset of untreated patients.</div><div id=\"graphicVersion\">Graphic 63336 Version 4.0</div></div></div>"},"63338":{"type":"graphic_table","displayName":"Risk factors BP VSP rx","title":"Risk factors for adverse consequences of high blood pressure (BP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for adverse consequences of high blood pressure (BP)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle2_left\">Systolic BP &#8805;160 mmHg or diastolic BP &#8805;100 mmHg</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Diabetes mellitus</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Established CV disease including any history of:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Ischemic stroke, cerebral hemorrhage, or transient ischemic attack</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Myocardial infarction, angina, coronary revascularization, or heart failure </td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Peripheral artery disease</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Retinal hemorrhages or exudates and papilledema</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Established or subclinical renal disease including:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Microalbuminuria or proteinuria (&#62;30 mg/24 h)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Serum creatinine in men &#62;1.5 mg/dL, women &#62;1.4 mg/dL</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Calculated or estimated glomerular filtration rate &#60;60 mL/min/1.73 m<sup>2</sup></td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Subclinical organ damage previously documented by:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">ECG or echocardiogram revealing left ventricular hypertrophy</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Carotid ultrasound study revealing wall thickening or plaque</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\">Three or more of the following CV risk factors:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Age (men &#62;55 y, women &#62;65 y)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Cigarette smoking</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist2_start\">Dyslipidemia as measured by:</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist2\">Total cholesterol &#62;190 mg/dL or</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist2\">Low-density lipoprotein cholesterol &#62;130 mg/dL or</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist2\">High-density lipoprotein cholesterol (men &#60;40 mg/dL; women &#60;46 mg/dL) or</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"sublist2\">Triglyceride &#62;150 mg/dL</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Fasting plasma glucose &#62;100 mg/dL</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Family history of premature CV disease (first-degree male relative age &#60;55 y or first-degree female relative &#60;65 y)</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\">Abdominal obesity male waist circumference &#62;40 in; female &#62;35 in (in persons of East Asian ancestry: male waist circumference &#62;35 in and for women &#62;31 in)</td>\n\t  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/28/2010--Requested permission (JD). 6/10/2010--Quote received and accepted, awaiting formal invoice; figure to Terrence (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26562&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Risk_factors_BP_VSP_rx.htm</title></head></div><div class=\"graphic_footnotes\">CV: cardiovascular.</div><div class=\"graphic_reference\">Reproduced with permission from: Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596. Copyright © 2010 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 63338 Version 7.0</div></div></div>"},"63340":{"type":"graphic_figure","displayName":"Normal conduction system","title":"Normal conduction system","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Normal conduction system</div><div class=\"cntnt\"><img style=\"width:534px; height:550px;\" src=\"images/CARD/63340_Normal_conduction_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the normal intraventricular conduction system (His-Purkinje system). The Bundle of His divides into the left bundle branch and right bundle branch. The left bundle branch divides into anterior, posterior, and, in some cases, median fascicles. RA, RV, LA, and LV refer to the right and left atria and ventricles.</div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div id=\"graphicVersion\">Graphic 63340 Version 5.0</div></div></div>"},"63341":{"type":"graphic_figure","displayName":"ARF fistulotomy seton","title":"Superficial anal fistula tract with seton","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Superficial anal fistula tract with seton</div><div class=\"cntnt\"><img style=\"width:542px; height:294px;\" src=\"images/SURG/63341_ARF fistulotomy seton.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration shows a probe inserted from the secondary external opening into the primary internal opening of the fistula tract. A seton was inserted in the tract and secured to itself. The lateral view shows the relationship of the seton to the internal and external sphincter muscles.</div><div id=\"graphicVersion\">Graphic 63341 Version 3.0</div></div></div>"},"63343":{"type":"graphic_picture","displayName":"Barretts esophagus CPC Endosc","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:252px; height:264px;\" src=\"images/GAST/63343_Barretts_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distal esophagus showing multiple extensions of salmon-colored mucosa above the esophagogastric junction.</div><div class=\"graphic_reference\">Courtesy of Steven D. Freedman, MD, PhD and Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 63343 Version 2.0</div></div></div>"},"63344":{"type":"graphic_figure","displayName":"Freedom primary endpoint","title":"Survival plot showing freedom from primary endpoint (combined treatment failure, retransplantation, or death) following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Survival plot showing freedom from primary endpoint (combined treatment failure, retransplantation, or death) following liver transplantation</div><div class=\"cntnt\"><img style=\"width:523px; height:408px;\" src=\"images/GAST/63344_Freedom_primary_endpoint.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Includes 1 patient lost to follow-up.<br>• Includes 2 patients lost to follow-up.</div><div class=\"graphic_reference\">Reproduced with permission from: O'Grady, JG, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360:1119. Copyright ©2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 63344 Version 2.0</div></div></div>"},"63348":{"type":"graphic_table","displayName":"Surgery for chronic LBP (excluding spinal stenosis)","title":"Surgery for chronic low back pain (excluding spinal stenosis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Surgery for chronic low back pain (excluding spinal stenosis)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Net benefit*</td> <td class=\"subtitle1\">Graded recommendation<sup>&#182;</sup></td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Interbody fusion</td> <td>Nonspecific low back pain or degenerative disc disease with presumed discogenic low back pain</td> <td>Moderate versus standard physical therapy supplemented by other nonsurgical therapies, no benefit versus intensive rehabilitation</td> <td>Suggested (for highly selected patient population) <strong>(2B)</strong></td> <td>Inconsistency between trials may be related to use of different comparator interventions.</td> </tr> <tr> <td>Artificial disc replacement</td> <td>Nonspecific low back pain or degenerative disc disease with presumed discogenic low back pain</td> <td>No evidence</td> <td>Suggest not performing <strong>(2C)</strong></td> <td>One trial found Charite artificial disc noninferior to fusion and one trial found Prodisc-L artificial disc superior to fusion.</td> </tr> <tr> <td>Standard open discectomy or microdiscectomy</td> <td>Lumbar disc prolapse with radiculopathy</td> <td>Moderate</td> <td>Suggested <strong>(2B)</strong></td> <td> <p>In largest trial, 40 to 55% crossover in both arms; on-treatment analysis consistent with other trials.</p> <p>Benefits associated with surgery attenuated with longer-term follow-up.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5 to 10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1 to 2 points on the Roland Morris Disability Questionnaire (RDQ), 10 to 20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2 to 0.5. Moderate benefit defined as 10 to 20 points on a VAS for pain, 2 to 5 points on the RDQ, 10 to 20 points on the ODI, or a SMD of 0.5 to 0.8. Large benefit defined as &gt;20 points on a 100-point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.<br />¶&nbsp;Grading:<br /><STRONG>1A</STRONG> - Strong recommendation. High quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.<br /><STRONG>1B</STRONG> - Strong recommendation. Moderate quality evidence. Strong recommendation, likely to apply to most patients.<br /><STRONG>1C</STRONG> - Strong recommendation. Low quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.<br /><STRONG>2A</STRONG> - Weak recommendation. High quality evidence. Weak recommendation; best action may differ depending on circumstances or patients or societal values.<br /><STRONG>2B</STRONG> - Weak recommendation. Moderate quality evidence. Weak recommendation; alternative approaches likely to be better for some patients under some circumstances.<br /><STRONG>2C</STRONG> - Weak recommendation. Low quality evidence. Very weak recommendation; other alternatives may be equally reasonable.</div><div id=\"graphicVersion\">Graphic 63348 Version 2.0</div></div></div>"},"63353":{"type":"graphic_diagnosticimage","displayName":"Filiform polyps in UC BE","title":"Filiform polyps in chronic ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Filiform polyps in chronic ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:314px; height:324px;\" src=\"images/GAST/63353_Filiform_polyps_in_UC_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema shows fine linear polyps arising from the colon wall (arrows). These polyps are typically seen in chronic ulcerative colitis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 63353 Version 2.0</div></div></div>"},"63356":{"type":"graphic_diagnosticimage","displayName":"Specific E2 antigen in PBC","title":"E2 antigen in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">E2 antigen in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:351px; height:271px;\" src=\"images/GAST/63356_Specific_E2_antigen_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confocal micrographs of bile ducts from a patient with primary biliary cholangitis (PBC) (panels A and C) and primary sclerosing cholangitis (PSC, panels B and D). The sections are stained with a mouse monoclonal antibody directed against the E2 antigen of human pyruvate dehydrogenase. Panel A: The PBC bile duct epithelial cells demonstrate intense homogeneous luminal staining (arrow). Only one of eight mouse monoclonal antibodies reacted with the luminal antigen in the PBC bile duct cell. This suggests that the reaction was with protein that had some antigenic similarity to pyruvate dehydrogenase but was different from it. Panel B: The PSC bile duct shows only granular staining similar to that of normal mitochondrial staining in the cytoplasm. Panel C: The PBC bile duct section was examined using Lutz color intensity banding. Red staining, which is the second highest intensity to white, is found at the luminal surface and is different from the blue and green staining of mitochondria. Panel D: In the PSC bile duct, staining is restricted to low intensity green and blue and demonstrates only the normal staining of mitochondria.</div><div class=\"graphic_reference\">Reprinted with permission from: Van de Water J, Turchany J, Leung PS, et al. J Clin Invest 1993; 91:2656.</div><div id=\"graphicVersion\">Graphic 63356 Version 4.0</div></div></div>"},"63357":{"type":"graphic_table","displayName":"Renal dosing of antituberculous agents","title":"Dosing of antituberculous agents for adult patients with reduced renal function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing&nbsp;of antituberculous agents&nbsp;for adult patients with reduced renal function</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug </td> <td class=\"subtitle1\">Change in frequency? </td> <td class=\"subtitle1\">Recommended dose and frequency for patients with CrCl &#60;30 mL/min or for patients receiving intermittent hemodialysis </td> </tr> <tr> <td>Isoniazid</td> <td>No change</td> <td>300 mg PO once daily, or 900 mg PO three times per week</td> </tr> <tr> <td>Rifampin</td> <td>No change</td> <td>600 mg PO once daily, or 600 mg PO three times per week</td> </tr> <tr> <td>Pyrazinamide</td> <td>Yes</td> <td>25 to 35 mg/kg (IBW) per dose PO three times per week (NOT daily); max 2.5 g per dose.</td> </tr> <tr> <td>Ethambutol</td> <td>Yes</td> <td>20&nbsp;to 25 mg/kg (IBW) per dose PO three times per week (NOT daily); max 1.6 g per dose</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Standard doses are given unless there is intolerance.<br />On the day of hemodialysis, medications should be administered after hemodialysis.<br />Monitoring of serum drug concentrations should be considered to ensure adequate drug absorption without excessive accumulation and to assist in avoiding toxicity.</div><div class=\"graphic_footnotes\">CrCl: creatinine clearance by Cockcroft-Gault equation (refer to the UpToDate&nbsp;calculator on&nbsp;creatinine clearance estimate by Cockcroft-Gault equation); PO: by mouth; IBW: ideal body weight.</div><div class=\"graphic_reference\">Data from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016.</div><div id=\"graphicVersion\">Graphic 63357 Version 7.0</div></div></div>"},"63358":{"type":"graphic_diagnosticimage","displayName":"MRI cerebellar hemangioblastoma","title":"Cerebellar hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cerebellar hemangioma</div><div class=\"cntnt\"><img style=\"width:446px; height:229px;\" src=\"images/ONC/63358_MRI_cerebellar_hemangioblas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gadolinium-enhanced T1-weighted images of a cystic hemangioblastoma in the right cerebellum.<br> (Left panel) Axial image.<br> (Right panel) Coronal image.</div><div class=\"graphic_reference\">Courtesy of Eric T Wong, MD.</div><div id=\"graphicVersion\">Graphic 63358 Version 4.0</div></div></div>"},"63359":{"type":"graphic_figure","displayName":"24-hour fluid diary PI","title":"24-hour voiding and fluid diary","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">24-hour voiding and fluid diary</div><div class=\"cntnt\"><img style=\"width:555px; height:556px;\" src=\"images/PI/63359_24hourfluiddiaryPIedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You can use this diary to record how much your child drinks and/or urinates for a 24-hour period.</div><div id=\"graphicVersion\">Graphic 63359 Version 11.0</div></div></div>"},"63360":{"type":"graphic_diagnosticimage","displayName":"Biliary atresia type 1","title":"Biliary atresia type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliary atresia type 1</div><div class=\"cntnt\"><img style=\"width:351px; height:360px;\" src=\"images/PEDS/63360_Biliary_atresia_type_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biliary atresia type 1. No visualization of biliary tree. Opacification of normal pancreatic duct.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 63360 Version 10.0</div></div></div>"},"63361":{"type":"graphic_picture","displayName":"Marking the erythema associated with a hand infection","title":"Marking the erythema associated with a hand infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marking the erythema associated with a hand infection</div><div class=\"cntnt\"><img style=\"width:336px; height:504px;\" src=\"images/SURG/63361_Skin_necrosis_MRSA_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This demonstrates erythema following a catfish sting. The area of erythema has been marked to allow assessment of the patient's response to antibiotic therapy.</div><div id=\"graphicVersion\">Graphic 63361 Version 1.0</div></div></div>"},"63362":{"type":"graphic_picture","displayName":"Hypertrophic lesion due to HSV-2 in an HIV-infected woman","title":"Hypertrophic lesion due to HSV-2 in an HIV-infected woman","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hypertrophic lesion due to HSV-2 in an HIV-infected woman</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/63362_Hypertr_lesion_HSV2_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Boothby M, Radcliffe K. An unusual vulval lesion in an HIV-infected woman. Int J STD AIDS 2007; 18:218. Copyright &#169; 2007 The Royal Society of Medicine Press. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63362 Version 1.0</div></div></div>"},"63363":{"type":"graphic_picture","displayName":"Esoph adenocarcinoma Light","title":"Adenocarcinoma of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma of the esophagus</div><div class=\"cntnt\"><img style=\"width:371px; height:252px;\" src=\"images/GAST/63363_Esoph_adenocarcinoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrograph shows an adenocarcinoma that developed in a patient with Barrett's esophagus. There is marked distortion of the glandular architecture that makes it difficult to ascertain where one gland ends and another begins.</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association&#169;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 63363 Version 1.0</div></div></div>"},"63364":{"type":"graphic_diagnosticimage","displayName":"Parenchymal changes EUS","title":"Pancreatic parenchymal changes following pancreatic stent placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic parenchymal changes following pancreatic stent placement</div><div class=\"cntnt\"><img style=\"width:381px; height:233px;\" src=\"images/GAST/63364_Parenchymal_changes_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound shows hypoechoic parenchymal changes (P) surrounding the proximal end of a stricture following pancreatic duct stenting.</div><div class=\"graphic_reference\">Courtesy of Marc Catalano, MD.</div><div id=\"graphicVersion\">Graphic 63364 Version 3.0</div></div></div>"},"63366":{"type":"graphic_diagnosticimage","displayName":"Left upper lobe atelectasis B","title":"Resolving left upper lobe atelectasis in a child with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Resolving left upper lobe atelectasis in a child with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:577px; height:308px;\" src=\"images/PEDS/63366_Left_upper_lobe_atelectas1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up radiographs obtained four days later demonstrate partial reexpansion of the left upper lobe, with residual posterior segment and ligular atelectasis. The opacity on the lateral film represents \"plate-like\" atelectasis of the posterior left upper lobe.</div><div id=\"graphicVersion\">Graphic 63366 Version 3.0</div></div></div>"},"63367":{"type":"graphic_picture","displayName":"Rash - Henoch-Schonlein purpura (IgA vasculitis)","title":"Skin manifestations of Henoch-Schönlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin manifestations of Henoch-Schönlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:504px; height:352px;\" src=\"images/PEDS/63367_Rash_HSP_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the classic skin manifestations of Henoch-Schönlein purpura (IgA vasculitis), with clusters of typical ecchymoses, petechiae, and palpable lesions on the legs in a typical distribution (gravity/pressure-dependent areas).</div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Courtesy of Susan Kim, MD.</div><div id=\"graphicVersion\">Graphic 63367 Version 6.0</div></div></div>"},"63368":{"type":"graphic_table","displayName":"Suicide evaluation","title":"\"MALPRACTICE\" mnemonic for evaluation of suicidal child or adolescent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">&quot;MALPRACTICE&quot; mnemonic for evaluation of suicidal child or adolescent</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">M -Mental health</td>\n\n      <td>Does the patient have a psychiatric diagnosis?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Is he or she taking psychotropic medications?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Is there a family history of mental health illness?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">A -Attempts</td>\n\n      <td>When did the patient first consider suicide?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Has the patient tried to harm him- or herself before?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Did he or she receive medical attention for that attempt?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">L -Lethality</td>\n\n      <td>Did the patient want to die?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Does he or she still want to?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Does he or she have access to lethal means?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">P -Plans</td>\n\n      <td>Is the patient able to make plans for the future?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Will he or she graduate from school?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>What kind of job will he or she do?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1_left\">R -Risk-taking</td>\n\n      <td>Is the patient engaging in activities that may be disguised attempts at self-harm?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Is the patient engaging in unprotected sexual activity?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"4\" class=\"subtitle1_left\">A -Alcohol and drugs</td>\n\n      <td>Were substances involved in the current attempt?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>For how long have substances been used?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>What substances are being used?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>When was the last use?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_left\">C -Conflict</td>\n\n      <td>Is there an interpersonal conflict that precipitated this event?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">T -Trauma</td>\n\n      <td>Does the patient report having been physically or sexually abused?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Has the patient been a witness to violence?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Has the patient recently lost a loved one?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"4\" class=\"subtitle1_left\">I -Impulsivity</td>\n\n      <td>Was the act premeditated?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>How much planning went into the suicide attempt?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Was a suicide note written?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Did the patient tell anyone about his or her plans?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle1_left\">C -Community resources</td>\n\n      <td>Does the patient have a social support system?</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\" class=\"subtitle1_left\">E -Exposure</td>\n\n      <td>Have other family members or friends attempted or completed suicide?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Has the patient been exposed to suicide in the media?</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>Is this attempt part of a suicide epidemic?</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Press, BR, Khan, SA. Curr Opin Pediatr 1997; 9:237.</div><div id=\"graphicVersion\">Graphic 63368 Version 1.0</div></div></div>"},"63373":{"type":"graphic_picture","displayName":"Nail changes docetaxel","title":"Nail changes with docetaxel","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Nail changes with docetaxel</div><div class=\"cntnt\"><img style=\"width:524px; height:180px;\" src=\"images/ONC/63373_Nailchangesdocetaxel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These fingernail and toenail changes were noted&nbsp;eight weeks after the start of docetaxel chemotherapy in a 40-year-old breast cancer patient. Onycholysis, where separation of the nail plate starts distally, is an unusual side effect of taxanes. Other features are nail pigmentation, subungual hematoma, sterile abscesses, Beau's lines, and acute paronychia. Prompt recognition avoids unnecessary antibiotics and antifungals. Therapy can continue and using a frozen glove reduces the incidence of this side effect. The lesions heal slowly with regrowth of the nails after the taxane is discontinued.</div><div class=\"graphic_reference\">Courtesy of Dr. Elaine Sugden.</div><div id=\"graphicVersion\">Graphic 63373 Version 4.0</div></div></div>"},"63375":{"type":"graphic_picture","displayName":"Alternate site testing PI","title":"Other places to test your blood sugar","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Other places to test your blood sugar</div><div class=\"cntnt\"><img style=\"width:468px; height:350px;\" src=\"images/PI/63375_Alternate_site_testing_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows how you can test your blood sugar in places other than your fingertips. You might need to gently massage the skin to get a large enough drop of blood. Do not use other places if you think your blood sugar is low.</div><div id=\"graphicVersion\">Graphic 63375 Version 2.0</div></div></div>"},"63376":{"type":"graphic_diagnosticimage","displayName":"Battery esophageal stenosis","title":"Battery esophageal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Battery esophageal stenosis</div><div class=\"cntnt\"><img style=\"width:391px; height:442px;\" src=\"images/PEDS/63376_Battery_esophageal_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An esophagram one day after removal of a battery from this child's esophagus shows some subtle narrowing due to tissue damage from the battery. <br />(B) A barium swallow two weeks later shows worsening esophageal stenosis.</div><div class=\"graphic_reference\">Courtesy of Barbara Specter, MD.</div><div id=\"graphicVersion\">Graphic 63376 Version 3.0</div></div></div>"},"63377":{"type":"graphic_table","displayName":"Pseudodystonias","title":"Pseudodystonias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pseudodystonias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Atlanto-axial subluxation</td> </tr> <tr> <td>Syringomyelia</td> </tr> <tr> <td>Arnold-Chiari malformation</td> </tr> <tr> <td>Head tilt due to trochlear nerve palsy</td> </tr> <tr> <td>Vestibular torticollis</td> </tr> <tr> <td>Posterior fossa mass</td> </tr> <tr> <td>Soft tissue neck mass</td> </tr> <tr> <td>Congenital muscular torticollis</td> </tr> <tr> <td>Congenital Klippel-Feil syndrome</td> </tr> <tr> <td>Isaacs syndrome</td> </tr> <tr> <td>Sandiffer syndrome</td> </tr> <tr> <td>Satoyoshi syndrome</td> </tr> <tr> <td>Stiff-person syndrome</td> </tr> <tr> <td>Camptocormia</td> </tr> <tr> <td>Scoliosis</td> </tr> <tr> <td>Ventral hernia</td> </tr> <tr> <td>Trigger finger</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.</div><div id=\"graphicVersion\">Graphic 63377 Version 4.0</div></div></div>"},"63378":{"type":"graphic_picture","displayName":"Hypocellular marrow aspirate","title":"Bone marrow aspirate in aplastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate in aplastic anemia</div><div class=\"cntnt\"><img style=\"width:427px; height:285px;\" src=\"images/HEME/63378_Hypocellular_marrow_aspirat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power (10X) view of a bone marrow aspirate in a patient with aplastic anemia. The supporting stromal meshwork of the bone marrow spicule is outlined by the red arrows. However, hematopoietic cells are sparse, giving the pattern of an empty wicker basket.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 63378 Version 1.0</div></div></div>"},"63379":{"type":"graphic_picture","displayName":"Reed Sternberg cell","title":"Reed-Sternberg cells in Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reed-Sternberg cells in Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:443px; height:283px;\" src=\"images/HEME/63379_Reed_Sternberg_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Reed-Sternberg cell as seen in a bone marrow specimen. Right panel: Reed-Sternberg cells in a lymph node section. Note the characteristic clear area surrounding the nucleoli in the right panel (red arrows), giving an &quot;owl's eyes&quot; appearance to the nuclei. Shrinkage artifact causes these cells to separate from the adjacent tissue, leaving a clear area surrounding these cells (ie, lacunar cells, blue arrows).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63379 Version 1.0</div></div></div>"},"63380":{"type":"graphic_diagnosticimage","displayName":"Angio subclavian steal syndrome","title":"Arteriogram of the aortic vessels in subclavian steal ","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Arteriogram of the aortic vessels in subclavian steal </div><div class=\"cntnt\"><img style=\"width:555px; height:230px;\" src=\"images/CARD/63380_Angiosubclastealsyndedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Arteriography of the aortic arch vessels&nbsp;demonstrates a significant stenosis of the proximal&nbsp;innominate artery. <br />(B) Reversal of flow in the right vertebral artery.</div><div class=\"graphic_reference\">Courtesy of Peter Spittell, MD.</div><div id=\"graphicVersion\">Graphic 63380 Version 6.0</div></div></div>"},"63381":{"type":"graphic_table","displayName":"Laxatives for children","title":"Starting doses of laxatives for functional constipation in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Starting doses of laxatives for functional constipation in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"70%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\"><span style=\"color: #0000ff;\"></span>Osmotic and lubricant laxatives</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2\">Laxative</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Onset (hours)</td> </tr> <tr> <td colspan=\"2\"><strong>Polyethylene glycol 3350 powder (MiraLax, GlycoLax)</strong>*</td> <td class=\"centered\">24 to 96</td> </tr> <tr> <td class=\"indent1\">Children (weight-based dosing)</td> <td>0.4 to 0.8 g/kg per day<sup>&#182;&#916;</sup> in 2 to 8 ounces (60 to 240 mL) of noncarbonated beverage (maximum 17 g daily for starting dose)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Children (age-based dosing)</td> <td>&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Younger than 18 months</td> <td class=\"sublist_other\">0.5 to 1 teaspoon, once daily</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">18 months to 3 years</td> <td class=\"sublist_other\">2 to 3 teaspoons, once daily</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Older than 3 years</td> <td class=\"sublist_other\">2 to 4 teaspoons, once daily<sup>&#8226;</sup><sup>&#916;</sup></td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adults</td> <td>17 g of powder (1 heaping tablespoon) per day, in 8 ounces of water or other noncarbonated beverage</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><strong>Lactulose (70 percent solution)</strong></td> <td class=\"centered\">24 to 48</td> </tr> <tr> <td class=\"indent1\">Children</td> <td>1 mL/kg (up to adult dose), once or twice daily (maximum 60 mL daily)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Adults</td> <td>15 to 30 mL, once daily (maximum 60 mL/day)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><strong>Sorbitol (syrup, 70 percent solution)</strong></td> <td class=\"centered\">24 to 48</td> </tr> <tr> <td class=\"indent1\">1 to 11 years old</td> <td>1 mL/kg, once or twice daily (maximum 30 mL daily)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">12 years to adults</td> <td>15 to 30 mL, once or twice daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Mineral oil</strong></td> <td>Caution: Should not be used in individuals at risk for aspiration, including infants, neurologically impaired children, or patients with marked gastroesophageal reflux</td> <td class=\"centered\">6 to 8</td> </tr> <tr> <td class=\"indent1\">1 to 11 years old</td> <td>1 to 3 mL/kg, once daily (maximum 45 mL daily)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">12 years to adults</td> <td>15 to 45 mL, once daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Magnesium hydroxide (milk of magnesia)</strong></td> <td>&nbsp;</td> <td class=\"centered\">0.5 to 6</td> </tr> <tr> <td class=\"indent1\">1 to 11 years old</td> <td>1 to 3 mL/kg daily of 400 mg/5 mL solution (maximum 60 mL daily, in single or divided doses)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">12 years to adults</td> <td> <p>30 to 60 mL daily of 400 mg/5 mL solution (in single or divided doses)</p> 15 to 30 mL daily of 800 mg/5 mL solution (in single or divided doses)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Stimulant laxatives</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2\">Laxative</td> <td class=\"subtitle2\">Dose</td> <td class=\"subtitle2\">Onset (hours)</td> </tr> <tr> <td colspan=\"2\"><strong>Senna (syrup, 8.8 mg sennosides/5 mL; or tablets 8.6 mg sennosides/tab)</strong></td> <td class=\"centered\">6 to 12</td> </tr> <tr> <td class=\"indent1\">1 to 2 years old</td> <td>1.25 to 2.5 mL, once or twice daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">2 to 6 years old</td> <td>2.5 to 3.75 mL, once or twice daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">6 to 12 years old</td> <td>5 to 7.5 mL (or 1 to 2 tabs), once or twice daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">12 years and older</td> <td>5 to 15 mL (or 1 to 3 tabs), once or twice daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><strong>Bisacodyl (5 mg tablets, or <strong>10 mg suppositories</strong>)</strong></td> <td class=\"centered\"> <p>0.25 to 1 (rectal)</p> 6 to 10 (oral)</td> </tr> <tr> <td class=\"indent1\">2 to 12 years old</td> <td>1 to 2 tablets (<strong>or </strong>1/2 to 1 suppository), once daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">12 years to adult</td> <td>1 to 3 tablets (<strong>or</strong> 1 suppository), once daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"2\"><strong>Glycerin (glycerol) suppositories</strong><sup>&#9674;</sup></td> <td class=\"centered\">0.25 to 0.5</td> </tr> <tr> <td class=\"indent1\">Children 2 to 5 years</td> <td>1 pediatric suppository, once daily</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Children 6 years to adult</td> <td>1 adult suppository, once daily</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines <strong>initial</strong> doses for each laxative medication; the dose should then be increased or decreased as needed to produce regular soft stools. Refer to the text of the UpToDate topic on chronic constipation in children for guidelines about dose titration. All of the doses are for oral administration except bisacodyl and glycerin suppositories.</div><div class=\"graphic_footnotes\">* Polyethylene glycol (PEG) 3350 is also known as PEG without electrolytes and macrogol. We suggest mixing polyethylene glycol powder in palatable beverages such as fruit juices, sports drinks, or milk, which may mask gritty texture. Trade names shown are for over-the-counter products available in the United States and some other countries.<br />¶&nbsp;Doses of 1 to 1.5 g/kg/day may be used for fecal disimpaction, for up to 6 consecutive days.<br />Δ After dose titration, maintenance doses of PEG 3350 may be as high as 1.5 g/kg per day (maximum approximately 34 g daily) for some patients.<SUP>[1]</SUP>&nbsp;<br />◊ Glycerin suppositories should not be used frequently because infants may become behaviorally conditioned to depend upon rectal stimulation to initiate stooling. In addition, glycerin may irritate the anus or rectal mucosa, causing symptoms to become chronic.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. J Pediatr 2001; 139:428.</LI></OL>Adapted from: Tabbers MM, Dilorenzo C, Berger MY, et al. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258.</div><div id=\"graphicVersion\">Graphic 63381 Version 9.0</div></div></div>"},"63383":{"type":"graphic_picture","displayName":"Gottron papules","title":"Gottron's papules in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gottron's papules in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63383_Gottron_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous, scaly papules are present overlying the joints on the dorsal hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63383 Version 4.0</div></div></div>"},"63384":{"type":"graphic_picture","displayName":"Estrogen receptor immunohistochemical staining in breast cancer","title":"Estrogen receptor stain in breast cancer","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Estrogen receptor stain in breast cancer</div><div class=\"cntnt\"><img style=\"width:515px; height:414px;\" src=\"images/ONC/63384_Estro_recept_st_br_ca_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Strongly ER positive invasive cancer. Tumor cells exhibit variable intensity of staining in &gt;90 percent of the cells.<br> (B) Tumor cells stained for ER show no ER activity. Normal breast ducts, shown at right have variable positivity indicating that the assay can be interpreted.<br> (C) Breast cancer with variable ER activity in invasive tumor cells. Although many areas are negative, some are strongly positive and the proportion of positive cells is greater than 1 percent. No intrinsic normal elements (ducts) are seen, but they were also positive in this case.<br> (D) Illustrates intrinsic controls. Slide shows DCIS at the lower left and normal ducts at the upper right. The DCIS is strongly ER positive.</div><div class=\"graphic_footnotes\">ER: estrogen receptor; DCIS: ductal carcinoma in situ.</div><div id=\"graphicVersion\">Graphic 63384 Version 4.0</div></div></div>"},"63387":{"type":"graphic_table","displayName":"Low sodium diet B","title":"Low-sodium diet (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low-sodium diet (continued)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Foods to choose\n   </td>\n   <td  class=\"subtitle1\">\n   Foods to avoid\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Breads:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Whole-grain breads, English muffins, bagels\n   </td>\n   <td>Biscuits, prepared mixes (pancake, muffin, cornbread)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Cereals:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Cooked hot cereals (not instant), such as oatmeal, cream of wheat, rice, or farina; puffed wheat; puffed rice; shredded wheat\n   </td>\n   <td>Instant hot cereals, many boxed cold cereals</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Crackers and snack foods:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   All unsalted crackers and snack foods, unsalted peanut butter, unsalted nuts or seeds\n   </td>\n   <td>Salted crackers and snack items (chips, pretzels, popcorn), regular peanut butter, prepared dips/spreads, salted nuts or seeds</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Pasta, rice, and potatoes:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Any type of pasta; potatoes; white or brown rice\n   </td>\n   <td>Macaroni and cheese mix; rice, noodle, or spaghetti mixes; canned spaghetti; frozen lasagna; instant potatoes; seasoned potato mixes</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Dried beans and peas:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Any dried beans or peas without seasoning\n   </td>\n   <td>Beans or peas prepared with ham, bacon, salt pork, or bacon grease; all canned beans</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Meats and alternatives:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Fresh or frozen beef, poultry, and fish; low-sodium canned tuna and salmon; eggs\n   </td>\n   <td>Salted, smoked, canned, spiced, and cured meat, poultry, or fish; bacon; ham; sausage; lunch meats; hot dogs; breaded frozen meat, fish, or poultry; frozen dinners; pizza</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Fruits and vegetables:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Any fresh, frozen, or canned fruit, any fresh or frozen vegetables without sauce, canned vegetables without salt, low-salt tomato sauce/paste\n   </td>\n   <td>Regular canned vegetables and vegetable juices, regular tomato sauce and tomato paste, olives, pickles, relishes, sauerkraut, frozen vegetables in butter or sauces, crystallized and glazed fruit, maraschino cherries, fruit dried with sodium sulfite</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Dairy products:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Milk, cream, sour cream, non-dairy creamer, yogurt, low-sodium cottage cheese, low-sodium cheese\n   </td>\n   <td>Buttermilk, Dutch processed chocolate milk, processed cheese slices and spreads, processed cheese, cottage cheese, aged or natural cheese</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Fats and oils:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Plant oils (olive, canola, corn, peanut), unsalted butter or margarine\n   </td>\n   <td>Prepared salad dressings, bacon, salt pork, fat back, salted butter or margarine</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Soups:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Salt-free soups and low-sodium bouillon cubes, unsalted broth, homemade soup without added salt\n   </td>\n   <td>Regular canned or prepared soups, stews, broths, or bouillon; packaged and frozen soups</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Desserts:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Gelatin, sherbet, pudding, ice cream, salt-free baked goods, sugar, honey, jam, jelly, marmalade, syrup\n   </td>\n   <td>Packaged baked goods</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Beverages:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Coffee, tea, soft drinks, fruit-flavored drinks, low-salt tomato juice, any fruit juice\n   </td>\n   <td>Softened water; carbonated beverages with sodium or salt added; regular tomato juice (V-8); ask about alcoholic beverages</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\" colspan=\"2\">\n   Condiments:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   Fresh and dried herbs; lemon juice; low-salt mustard, vinegar, Tabasco sauce; low- or no-salt ketchup; seasoning blends that do not contain salt\n   </td>\n   <td>Table salt, lite salt, bouillon cubes, meat extract, taco seasoning, Worcestershire sauce, tartar sauce, ketchup, chili sauce, cooking sherry and wine, onion salt, mustard, garlic salt, soy sauce, tamari, meat flavoring or tenderizer, steak and barbecue sauce, seasoned salt, monosodium glutamate (MSG), Dutch processed cocoa</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 63387 Version 1.0</div></div></div>"},"63388":{"type":"graphic_diagnosticimage","displayName":"CNS Listeria CT","title":"Computed tomography (CT) scan showing a brain lesion in a patient with listeriosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) scan showing a brain lesion in a patient with listeriosis</div><div class=\"cntnt\"><img style=\"width:252px; height:310px;\" src=\"images/ID/63388_CNS_Listeria_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in a 72-year-old, previously healthy man with acute left hemiplegia and fever. A hypolucent area is present in a temporoparietal distribution. Blood cultures grew <EM>Listeria monocytogenes</EM>.</div><div id=\"graphicVersion\">Graphic 63388 Version 4.0</div></div></div>"},"63389":{"type":"graphic_picture","displayName":"Athletes foot PI","title":"Acute tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute tinea pedis</div><div class=\"cntnt\"><img style=\"width:378px; height:268px;\" src=\"images/PI/63389_Athletes_foot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows tinea pedis (athlete's foot) on the toe.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 63389 Version 1.0</div></div></div>"},"63390":{"type":"graphic_picture","displayName":"Clubfoot infant","title":"Clubfoot in an infant with myelomeningocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clubfoot in an infant with myelomeningocele</div><div class=\"cntnt\"><img style=\"width:360px; height:534px;\" src=\"images/PEDS/63390_Clubfoot_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 63390 Version 2.0</div></div></div>"},"63391":{"type":"graphic_table","displayName":"Evaluation emotional neglect","title":"Assessment for inadequate provision of affection, nurturance, or love","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment for inadequate provision of affection, nurturance, or love</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ask:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>How does the parent describe the child and his or her feelings toward the child?</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>How does the parent show the child affection?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Is there something about the child that is difficult for the parent to accept? (eg, unwanted pregnancy)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>How satisfied is the parent with his or her role as a parent?</td>\n\n    </tr>\n\n    <tr>\n\n      <td>What is the child's perception of the parent's approach to him or her?</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Observe:</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Is there warmth, affection, and caring in the parent child interactions?</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Dubowitz, H, Giardino, A, Gustavson, E. Child neglect: guidance for pediatricians. Pediatr Rev 2000; 21:111.</div><div id=\"graphicVersion\">Graphic 63391 Version 1.0</div></div></div>"},"63392":{"type":"graphic_table","displayName":"Selected lysosomal storage disorders","title":"Selected lysosomal storage disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected lysosomal storage disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mucopolysaccharidoses (MPS)</td> </tr> <tr> <td>MPS I (Hurler, Hurler-Scheie, Scheie)</td> </tr> <tr> <td>MPS II (Hunter)</td> </tr> <tr> <td>MPS III (Sanfillippo)</td> </tr> <tr> <td>MPS IV (Morquio)</td> </tr> <tr> <td>MPS VI (Maroteaux-Lamy)</td> </tr> <tr> <td>MPS VII (Sly)</td> </tr> <tr> <td>MPS IX (Natowicz)</td> </tr> <tr> <td class=\"subtitle1_single\">Sphingolipidoses</td> </tr> <tr> <td>GM1 gangliosidosis</td> </tr> <tr> <td>GM2 gangliosidosis type 1 (Tay-Sachs)</td> </tr> <tr> <td>GM2 gangliosidosis type 2 (Sandhoff)</td> </tr> <tr> <td>Fabry disease</td> </tr> <tr> <td>Farber disease</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Niemann-Pick disease</td> </tr> <tr> <td>Krabbe disease</td> </tr> <tr> <td>Metachromatic leukodystrophy</td> </tr> <tr> <td class=\"subtitle1_single\">Oligosaccharidoses (glycoproteinoses)</td> </tr> <tr> <td>Galactosialidosis</td> </tr> <tr> <td>Fucosidosis types</td> </tr> <tr> <td>Mannosidosis</td> </tr> <tr> <td>Aspartylglucosaminuria</td> </tr> <tr> <td class=\"subtitle1_single\">Mucolipidosis</td> </tr> <tr> <td>Mucolipidosis type I (Sialidosis)</td> </tr> <tr> <td>Mucolipidosis type II (I-cell)*</td> </tr> <tr> <td>Mucolipidosis type III (pseudo-Hurler)*</td> </tr> <tr> <td>Mucolopidosis type IV (Sialolipidosis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These disorders are caused by the same enzyme deficiency (N-acetylglucosamyl phosphotransferase).</div><div id=\"graphicVersion\">Graphic 63392 Version 5.0</div></div></div>"},"63393":{"type":"graphic_diagnosticimage","displayName":"Tib-fib fracture","title":"Tib-fib fracture","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Tib-fib fracture</div><div class=\"cntnt\"><img style=\"width:460px; height:540px;\" src=\"images/SURG/63393_Tib_fib_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of a tib-fib fracture.</div><div id=\"graphicVersion\">Graphic 63393 Version 1.0</div></div></div>"},"63395":{"type":"graphic_table","displayName":"Ideal menstrual frequency poll","title":"Dutch women's view of ideal menstruation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dutch women's view of ideal menstruation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr><td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">&nbsp;</td><td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Age of women</td></tr><tr>\n\t<td class=\"subtitle2\">15-19 years</td><td class=\"subtitle2\">20-24 years</td><td class=\"subtitle2\">25-34 years</td>\n</tr>\n\n<tr><td class=\"subtitle3\" colspan=\"3\" rowspan=\"1\">Percent who prefer the specified menstrual frequency</td></tr><tr>\n\t<td>Once a month</td><td>26</td><td>33</td><td>29</td>\n</tr>\n<tr>\n\t<td>Once every 3 months</td><td>38</td><td>25</td><td>21</td>\n</tr>\n<tr>\n\t<td>Once every 6 months</td><td>8</td><td>7</td><td>4</td>\n</tr>\n<tr>\n\t<td>Once a year</td><td>4</td><td>3</td><td>7</td>\n</tr>\n<tr>\n\t<td>Never</td><td>22</td><td>25</td><td>26</td>\n</tr>\n\n\t</tbody></table></div><div class=\"graphic_footnotes\">OC: oral contraceptives.</div><div class=\"graphic_reference\">Adapted from Kaunitz, AM. Choosing to menstruate - or not. Contemporary OB/GYN 2001; 46:73. Copyright &#169; 2001 Medical Economics.</div><div id=\"graphicVersion\">Graphic 63395 Version 2.0</div></div></div>"},"63396":{"type":"graphic_figure","displayName":"Septate uterus and cervix","title":"Septate uterus: complete (septum to external os)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septate uterus: complete (septum to external os)</div><div class=\"cntnt\"><img style=\"width:353px; height:295px;\" src=\"images/OBGYN/63396_Septateuterusandcervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63396 Version 14.0</div></div></div>"},"63397":{"type":"graphic_figure","displayName":"IPSS risk class outcome in MDS","title":"International Prognostic Scoring System (IPSS) predicts clinical outcome in myelodysplastic syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">International Prognostic Scoring System (IPSS) predicts clinical outcome in myelodysplastic syndrome</div><div class=\"cntnt\"><img style=\"width:354px; height:492px;\" src=\"images/HEME/63397_IPSS_risk_class_outcome_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier curves of patient survival (top panel) and freedom from acute myeloid leukemia (AML) evolution (bottom panel) in patients with myelodysplastic syndrome (MDS) according to their classification by the International Prognostic Scoring System (IPSS) for MDS.</div><div class=\"graphic_reference\">Reprinted with permission from Greenberg, P, Cox, Le Beau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997: 89:2079.</div><div id=\"graphicVersion\">Graphic 63397 Version 2.0</div></div></div>"},"63398":{"type":"graphic_table","displayName":"Infectious causes of acute pharyngitis in children","title":"Infectious causes of acute pharyngitis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of acute pharyngitis in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Clinical clues</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em>, group A*<sup>&#182;</sup></td> <td>Tonsillopharyngitis and scarlet fever</td> <td>Acute onset, fever, headache, abdominal pain, tonsillopharyngeal erythema and exudate, tender anterior cervical lymph nodes</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em>, groups C and G<sup>&#182;</sup></td> <td>Tonsillopharyngitis and scarlatiniform rash</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Neisseria gonorrhoeae</em><sup>&#182;</sup></td> <td>Pharyngitis</td> <td>Oral-genital contact in sexually active adolescents</td> </tr> <tr> <td class=\"indent1\"><em>Fusobacterium necrophorum</em><sup>&#182;</sup></td> <td>Jugular vein suppurative thrombophlebitis (Lemierre syndrome)</td> <td>Primarily affects adolescents and young adults, high fever (&#62;39&#176;C [102.2&#176;F]), rigors respiratory symptoms, unilateral neck swelling or pain</td> </tr> <tr> <td class=\"indent1\"><em>Arcanobacterium haemolyticum</em><sup>&#182;</sup></td> <td>Pharyngitis and scarlatiniform rash</td> <td>More common in adolescents, rash occurs in approximately one-half</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium diphtheriae</em><sup>&#182;</sup></td> <td>Diphtheria</td> <td>Tightly adherent membrane in nose and throat, history of travel (particularly to former Soviet Union, Africa, or Asia), lack of immunizations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tularemia<sup>&#182;</sup></td> <td>Ulcerative-exudative pharyngitis</td> <td>Ingestion of poorly cooked wild animal meat or contaminated water</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Atypical bacteria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Mycoplasma pneumoniae</em></td> <td>Pneumonia, bronchitis, and pharyngitis</td> <td>Adolescents and adults</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Viruses that infect the pharynx directly</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (EBV)<sup>&#182;</sup></td> <td>Infectious mononucleosis</td> <td>Fever, severe pharyngitis, frequent exudates, anterior and posterior cervical lymphadenopathy, prominent constitutional symptoms</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus (CMV)</td> <td>Infectious mononucleosis</td> <td>Fever, mild or no pharyngitis, anterior and posterior cervical lymphadenopathy, prominent constitutional symptoms</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)<sup>&#182;</sup></td> <td>Primary HIV infection</td> <td>Mononucleosis-like syndrome with fever, weight loss, diffuse adenopathy, rash, splenomegaly, lymphopenia</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus types 1 and 2<sup>&#182;</sup></td> <td>Pharyngitis</td> <td>Exudative or nonexudative tonsillopharyngitis in sexually active adolescents, ulcerative lip lesion in 10 to 40 percent of cases</td> </tr> <tr> <td class=\"indent1\">Influenza A and B viruses<sup>&#182;</sup></td> <td>Influenza</td> <td>Fever, cough, pharyngitis, headache, myalgia, seasonal epidemics</td> </tr> <tr> <td class=\"indent1\">Enteroviruses (Coxsackie A)</td> <td>Herpangina and hand-foot-and-mouth disease</td> <td>Vesicles in posterior pharynx may be accompanied by lesions on hands and feet</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adenovirus</td> <td>Pharyngoconjunctival fever and acute respiratory disease</td> <td>Conjunctivitis, tonsillopharyngeal erythema and exudates</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Viruses that cause nasopharyngitis</td> </tr> <tr> <td class=\"indent1\">Rhinovirus</td> <td>Common cold</td> <td>Nasal symptoms predominate</td> </tr> <tr> <td class=\"indent1\">Coronavirus</td> <td>Common cold</td> <td>Nasal symptoms predominate</td> </tr> <tr> <td class=\"indent1\">Respiratory syncytial virus</td> <td>Bronchiolitis, common cold</td> <td>Nasal symptoms predominate, seasonal epidemics</td> </tr> <tr> <td class=\"indent1\">Parainfluenza</td> <td>Common cold, croup</td> <td>Stridor, hoarseness, prominent nasal symptoms</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most common cause requiring antimicrobial therapy.<br />&para; Identification is important for treatment or infection control purposes (refer to UpToDate content on acute pharyngitis in children for details).</div><div id=\"graphicVersion\">Graphic 63398 Version 9.0</div></div></div>"},"63399":{"type":"graphic_figure","displayName":"CDC stature for age boys 2 to 20 years","title":"Stature-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Stature-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:558px; height:669px;\" src=\"images/PEDS/63399_Stature_age_boys_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 63399 Version 5.0</div></div></div>"},"63401":{"type":"graphic_algorithm","displayName":"Acute pelvic pain in the premenarchal adolescent female","title":"Acute pelvic pain in the premenarchal adolescent female","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute pelvic pain in the premenarchal adolescent female</div><div class=\"cntnt\"><img style=\"width:352px; height:840px;\" src=\"images/EM/63401_Pelvic_pain_adol_premen_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RLQ: right lower quadrant; UTI: urinary tract infection; CVA: costovertebral angle.<br />*&nbsp;Refer to UpToDate topics&nbsp;on causes of abdominal pain in children and adolescents.</div><div id=\"graphicVersion\">Graphic 63401 Version 5.0</div></div></div>"},"63402":{"type":"graphic_figure","displayName":"Cross-reactivity of topical corticosteroids","title":"Coopman classification of cross-reactivity in allergic reactions to topical corticosteroids","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Coopman classification of cross-reactivity in allergic reactions to topical corticosteroids</div><div class=\"cntnt\"><img style=\"width:595px; height:779px;\" src=\"images/DERM/63402_Cross_reactivity_top_cort.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. Curr Opin Allergy Clin Immunol 2010; 10:273. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63402 Version 8.0</div></div></div>"},"63403":{"type":"graphic_picture","displayName":"Pterygium crossing visual axis","title":"Pterygium extending across visual axis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pterygium extending across visual axis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/63403_Pteryg_extend_visual_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63403 Version 5.0</div></div></div>"},"63404":{"type":"graphic_picture","displayName":"IPH portal tract fibrosis","title":"Idiopathic portal hypertension (IPH)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic portal hypertension (IPH)</div><div class=\"cntnt\"><img style=\"width:432px; height:303px;\" src=\"images/GAST/63404_IPH_portal_tract_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Masson's trichrome stain of a liver biopsy specimen in a patient with IPH showing portal tract fibrosis and mild chronic inflammation. There is no visible portal vein radicle. Some dilated aberrant vascular structures can be seen (black arrows) at the periphery of the portal tract. A relatively small bile duct (BD: blue arrow) and hepatic artery (HA: red arrow) are visible in the portal triad.</div><div class=\"graphic_reference\">Courtesy of Rosa Miquel, MD.</div><div id=\"graphicVersion\">Graphic 63404 Version 2.0</div></div></div>"},"63408":{"type":"graphic_picture","displayName":"Ganglioneuroblastoma","title":"Ganglioneuroblastoma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ganglioneuroblastoma</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/PEDS/63408_Ganglioneuroblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The neuroblasts, which generally have a more mature appearance, are clustered together in foci or nests surrounded by the Schwannian cells.</div><div class=\"graphic_reference\">Courtesy of MJ Hicks, MD.</div><div id=\"graphicVersion\">Graphic 63408 Version 1.0</div></div></div>"},"63409":{"type":"graphic_figure","displayName":"Location of foot and ankle pain","title":"Location of foot and ankle pain","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Location of foot and ankle pain</div><div class=\"cntnt\"><img style=\"width:582px; height:613px;\" src=\"images/PEDS/63409_Lctn_ft_ankl_pn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Posteromedial ankle and heel pain.<br />(B) Posterior ankle and heel pain.<br />(C) Anterolateral ankle, midfoot, and forefoot pain.<br />(D) Plantar foot pain.</div><div id=\"graphicVersion\">Graphic 63409 Version 5.0</div></div></div>"},"63410":{"type":"graphic_table","displayName":"Properties of hydroxyurea","title":"Clinical properties of hydroxyurea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical properties of hydroxyurea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic </td> <td class=\"subtitle1\">Hydroxyurea </td> </tr> <tr> <td>Drug class</td> <td>Antimetabolite</td> </tr> <tr> <td>Mechanism of action</td> <td>Not genotoxic, impairs DNA repair by inhibiting ribonucleotide reductase, increases HbF production</td> </tr> <tr> <td>Specificity</td> <td>Affects all cell lines</td> </tr> <tr> <td>Pharmacology</td> <td>Half-life&nbsp;4 hours; 40% renally excreted, 60% metabolized</td> </tr> <tr> <td>Starting dose</td> <td>15 to 20 mg/kg per day orally for routine treatment of MPNs or sickle cell disease; 50 to 100 mg/kg per day orally for treatment of hyperleukocytosis</td> </tr> <tr> <td>Onset of action</td> <td>3 to 5 days for routine treatment of MPNs; weeks, up to 6 months, for treatment of sickle cell disease; 1 to 2 days for hyperleukocytosis </td> </tr> <tr> <td>Side effects observed in &#62;10% of patients</td> <td>Neutropenia, anemia, oral ulcers, mild gastrointestinal upset, hyperpigmentation, rash, nail changes</td> </tr> <tr> <td>Side effects observed in &#8804;10% of patients</td> <td>Ankle ulcers, lichen planus-like lesions of the mouth and skin, nausea, diarrhea</td> </tr> <tr> <td>Rare side effects</td> <td>Fever, liver function test abnormalities</td> </tr> <tr> <td>Contraindications</td> <td>Severe bone marrow suppression (eg, neutropenia, thrombocytopenia); pregnancy, attempted conception, breast feeding</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on specific indications for additional details about administration, monitoring, and adverse effects.</div><div class=\"graphic_footnotes\">MPN: myeloproliferative neoplasm; HbF: fetal hemoglobin.</div><div id=\"graphicVersion\">Graphic 63410 Version 4.0</div></div></div>"},"63411":{"type":"graphic_diagnosticimage","displayName":"Sigmoid cancer in UC BE","title":"Sigmoid cancer developing in ulcerative colitis, as seen on barium enema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sigmoid cancer developing in ulcerative colitis, as seen on barium enema</div><div class=\"cntnt\"><img style=\"width:425px; height:288px;\" src=\"images/GAST/63411_Sigmoid_cancer_in_UC_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium enema study demonstrates a focal stricture in the sigmoid colon caused by an infiltrating cancer. The adjacent bowel is featureless and folds are absent, findings characteristic of chronic ulcerative colitis.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 63411 Version 3.0</div></div></div>"},"63412":{"type":"graphic_diagnosticimage","displayName":"Fibroid embolization 4b","title":"Left uterine angiogram","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Left uterine angiogram</div><div class=\"cntnt\"><img style=\"width:481px; height:492px;\" src=\"images/OBGYN/63412_Fibroid_embolization_4b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left uterine angiogram before uterine fibroid embolization demonstrates dilated branches of the left uterine artery supplying multiple hypervascular uterine fibroids (arrows) on the left.</div><div id=\"graphicVersion\">Graphic 63412 Version 2.0</div></div></div>"},"63413":{"type":"graphic_table","displayName":"Initial hx female chronic pelvic pain","title":"Initial history for women with chronic pelvic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial history for women with chronic pelvic pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Perform thorough review of systems and&nbsp;obtain past medical and surgical histories, with focus on past menstrual history, prior contraceptive use, and prior obstetrics and gynecologic history</td> </tr> <tr> <td class=\"sublist1_start\">Evaluate for history suggestive of diagnosis of:</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Endometriosis</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Pelvic inflammatory disease</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Gastrointestinal disease, especially irritable bowel syndrome</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Urinary disease, especially interstitial cystitis/painful bladder syndrome</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Musculoskeletal disease</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Psychiatric disease, with a focus on symptoms of depression and anxiety</li> </ul> </td> </tr> <tr> <td>&nbsp;Assess characteristics of the pain:</td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Associated findings </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Provocative and palliative factor </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Quality of pain </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Radiation of pain </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Setting in which pain occurs </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Temporal: timing when the pain occurs and events that precede or trigger pain</li> </ul> </td> </tr> <tr> <td>Obtain psychosocial history, with particular focus on:&nbsp;</td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Substance use or abuse, including alcohol, marijuana, and prescription medication</li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul id=\"_telerik_insertedList_id\"> <li>Patient safety: Does the patient have a current or past history of physical, sexual, or emotional abuse?</li> </ul> </td> </tr> <tr> <td>Ask about prior&nbsp;diagnostic tests or pain treatments</td> </tr> <tr> <td>Inquire about family history of relevant clinical conditions, such as chronic pain syndromes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Gambone, JC, Mittman, BS, Munro, MG, et al. Fertil Steril 2002; 78:961.</div><div id=\"graphicVersion\">Graphic 63413 Version 3.0</div></div></div>"},"63414":{"type":"graphic_diagnosticimage","displayName":"Sonogram abn ut bleeding2","title":"Long axis sonographic view of a patient with abnormal uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long axis sonographic view of a patient with abnormal uterine bleeding</div><div class=\"cntnt\"><img style=\"width:389px; height:261px;\" src=\"images/OBGYN/63414_Sonogram_abn_ut_bleeding2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endometrial echo is not well visualized and there is an area of acoustic shadowing in the posterior portion of the myometrium.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 63414 Version 3.0</div></div></div>"},"63417":{"type":"graphic_picture","displayName":"Moderate fluorosis","title":"Moderate fluorosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moderate fluorosis</div><div class=\"cntnt\"><img style=\"width:409px; height:250px;\" src=\"images/PEDS/63417_Moderate_fluorosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These incisors with moderate fluorosis have an opaque white appearance and a round lesion where hypomineralized enamel has been abraded from the surface during normal function.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright &copy; WB Saunders 2000.</div><div id=\"graphicVersion\">Graphic 63417 Version 3.0</div></div></div>"},"63418":{"type":"graphic_table","displayName":"Reducing absorption","title":"Steps to take to minimize lead absorption in your family","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steps to take to minimize lead absorption in your family</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Make sure that your children wash their hands and face before eating and sleeping.</td> </tr> <tr> <td>2. Prevent your children from eating things other than food (eg, dirt, paint).</td> </tr> <tr> <td>3. Make sure that all surfaces (floors, countertops, tabletops, etc) have been thoroughly cleaned with a detergent. This is especially important for toddlers since they crawl and lay on the floor and frequently put their hands in their mouths.</td> </tr> <tr> <td>4. If your home was built prior to 1977, it is extremely important to remove any flaking or peeling paint in the house, since older homes frequently were painted with lead-based paint. Hire a professional certified in lead paint abatement. Painting over lead-based paint, or applying wallpaper, are only temporary ways to control exposure, and are not acceptable means of control. Protective equipment and respirators must be worn in the removal of lead-based paint from walls and woodwork.</td> </tr> <tr> <td>5. Make sure that your children receive the recommended daily allowance of multivitamins with iron. They should have well-balanced diets that include a combination of fruits, vegetables, grains, protein, and dairy products.</td> </tr> <tr> <td>6. Do not use herbal or folk medicine (these may contain lead).</td> </tr> <tr> <td>7. If you are not sure if your pottery has a lead glaze, use it only for decoration.</td> </tr> <tr> <td>8. Store food in glass, plastic, or stainless steel containers, not in open cans.</td> </tr> <tr> <td>9. Use water from the cold tap for cooking and drinking. Let it run for several minutes before collecting for use.</td> </tr> <tr> <td>10. Be careful to keep materials for hobbies, such as those used for making ceramics or stained glass, away from children and areas where they spend time.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63418 Version 5.0</div></div></div>"},"63419":{"type":"graphic_picture","displayName":"Surgical treatment of pyogenic flexor tenosynovitis","title":"Surgical treatment of pyogenic flexor tenosynovitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of pyogenic flexor tenosynovitis</div><div class=\"cntnt\"><img style=\"width:384px; height:576px;\" src=\"images/SURG/63419_Surg_tx_pyog_flex_tenosyn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For patients with pyogenic flexor tenosynovitis that does not respond to antibiotics, surgical drainage with closed-sheath irrigation should be performed.</div><div id=\"graphicVersion\">Graphic 63419 Version 2.0</div></div></div>"},"63421":{"type":"graphic_picture","displayName":"Dermatophytid reaction","title":"Dermatophytid reaction (autoeczematization or id reaction due to dermatophyte infection)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatophytid reaction (autoeczematization or id reaction due to dermatophyte infection)</div><div class=\"cntnt\"><img style=\"width:387px; height:504px;\" src=\"images/DERM/63421_Dermatophytid_reaction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A widespread eczematous eruption primarily distributed on the face, neck, and ears developed in this child with tinea capitis. The terms autoeczematization and id reaction are also used to refer to this phenomenon.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 63421 Version 3.0</div></div></div>"},"63422":{"type":"graphic_picture","displayName":"Acanthosis nigricans on lips","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/63422_Acanthosis_nigricans_lips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous changes are present on the lips.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63422 Version 3.0</div></div></div>"},"63423":{"type":"graphic_picture","displayName":"Bullous V vulnificus","title":"Bullous lesions in <EM>Vibrio vulnificus </EM>infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous lesions in <EM>Vibrio vulnificus </EM>infection</div><div class=\"cntnt\"><img style=\"width:389px; height:262px;\" src=\"images/ID/63423_Bullous_V_vulnificus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distinctive bullous skin lesions are seen in approximately 75 percent of patients with <EM>V. vulnificus</EM> infection.</div><div class=\"graphic_reference\">Courtesy of Glenn Morris Jr, MD, MPH&amp;TM.</div><div id=\"graphicVersion\">Graphic 63423 Version 5.0</div></div></div>"},"63427":{"type":"graphic_figure","displayName":"Cervical conization PI","title":"Cervical conization","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Cervical conization</div><div class=\"cntnt\"><img style=\"width:545px; height:385px;\" src=\"images/PI/63427_Cone_biopsy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cervical conization is the surgical removal of a cone-shaped portion of cervix. This can be done in order to diagnose cervical cancer (called a \"cone biopsy\"),&nbsp;or in some cases to treat very early-stage&nbsp;cervical cancer by removing the cancerous area. <br />The procedure is performed through the vagina, usually in the operating room after the woman receives either general or regional anesthesia.</div><div id=\"graphicVersion\">Graphic 63427 Version 7.0</div></div></div>"},"63428":{"type":"graphic_picture","displayName":"Poorly diff squamous CA Light","title":"Non-keratinizing (poorly differentiated) squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-keratinizing (poorly differentiated) squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/ONC/63428_Poorly_diff_squamous_CA_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent nests of tumor cells lacking keratinization or intercellular bridges. There is a slight background lymphocytic infiltrate probably representing host response. The identification of this tumor as squamous carcinoma may require confirmatory immunostaining for cytokeratin, p63, or p40.</div><div class=\"graphic_reference\">Courtesy of Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 63428 Version 4.0</div></div></div>"},"63430":{"type":"graphic_table","displayName":"Typical local reactions to mosquito bites","title":"Typical (normal) reactions to mosquito bites: Stages of development with repeated bites with the same species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical (normal) reactions to mosquito bites: Stages of development with repeated bites with the same species</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Clinical findings</td> </tr> <tr> <td class=\"centered\">I</td> <td>No observable skin reaction (sensitization stage)</td> </tr> <tr> <td class=\"centered\">II</td> <td>Delayed skin reaction</td> </tr> <tr> <td class=\"centered\">III</td> <td>Immediate skin reaction followed by delayed skin reaction</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Immediate skin reaction only</td> </tr> <tr> <td class=\"centered\">V</td> <td>No reactivity (natural desensitization stage)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">1</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=91579&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 63430 Version 4.0</div></div></div>"},"63431":{"type":"graphic_diagnosticimage","displayName":"Cholangiogram following stone clearance","title":"Cholangiogram following stone clearance","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cholangiogram following stone clearance</div><div class=\"cntnt\"><img style=\"width:468px; height:466px;\" src=\"images/GAST/63431_Cholangiogr_stone_clear_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing a non-obstructed biliary system following clearance of a stone using intraductal lithotripsy.</div><div id=\"graphicVersion\">Graphic 63431 Version 2.0</div></div></div>"},"63432":{"type":"graphic_picture","displayName":"Postinfectious glomerulonephritis immunofluorescence microscopy","title":"Postinfectious glomerulonephritis immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Postinfectious glomerulonephritis immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:441px;\" src=\"images/NEPH/63432_Postinfectglomerimmmicro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence in bacterial infection-associated glomerulonephritis typically shows coarsely granular C3 positivity (starry sky pattern) in a global mesangial and glomerular capillary wall distribution.</div><div class=\"graphic_reference\">Provided by Samih H Nasr, MD.</div><div id=\"graphicVersion\">Graphic 63432 Version 2.0</div></div></div>"},"63433":{"type":"graphic_table","displayName":"Causes panc exocrine insuffic","title":"Causes of pancreatic exocrine insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pancreatic exocrine insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Chronic pancreatitis</td>\n</tr>\n<tr>\n<td>Cystic fibrosis</td>\n</tr>\n<tr>\n<td>Main pancreas duct obstruction (adenocarcinoma, intraductal papillary mucinous neoplasm, pancreas divisum, etc.)</td>\n</tr>\n<tr>\n<td>Pancreatic resection</td>\n</tr>\n<tr>\n<td>Gastric resection</td>\n</tr>\n<tr>\n<td>Short bowel syndrome</td>\n</tr>\n<tr>\n<td>Severe undernutrition</td>\n</tr>\n<tr>\n<td>Hereditary hemochromatosis</td>\n</tr>\n<tr>\n<td>Alpha 1 antitrypsin deficiency</td>\n</tr>\n<tr>\n<td>Shwachmann-Diamond-Oski syndrome</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 63433 Version 1.0</div></div></div>"},"63434":{"type":"graphic_table","displayName":"Causes of chronic wrist injury in children and adolescents","title":"Causes of chronic wrist injury in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic wrist injury in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Radiographic findings</td> <td class=\"subtitle1\">Associated activities</td> </tr> <tr> <td>Distal radius physis stress syndrome</td> <td>Radial</td> <td>Pain with dorsiflexion and axial loading</td> <td>Widening and irregularity of the physis; palmar spurring of metaphysis</td> <td>Gymnastics; rock climbing; weight lifting;</td> </tr> <tr> <td>Median neuropathy (Carpal tunnel syndrome)</td> <td>Radial</td> <td>Dysesthesia or paresthesias; positive Tinels or Phelan sign</td> <td>Carpal tunnel view to exclude osseous compression</td> <td>Racquet, stick, and club sports; cycling; rowing; skiing; keyboard typing</td> </tr> <tr> <td>Radial neuropathy (Wartenburg syndrome)</td> <td>Radial</td> <td>Pain and paresthesias over the dorsal thumb and dorsal radial hand</td> <td>Radiographs not necessary</td> <td>Activities that involve repeated supination and pronation</td> </tr> <tr> <td>Scaphoid impaction</td> <td>Radial</td> <td>Pain over the scapholunate ligament when wrist is dorsiflexed and axially loaded</td> <td>Normal or may demonstrate ossicle formation</td> <td>Gymnastics; weight lifting</td> </tr> <tr> <td>de Quervain tenosynovitis</td> <td>Radial</td> <td>Pain during pinch grasping or thumb and wrist movement</td> <td>Radiographs not necessary</td> <td>Racquet, stick, and club sports; fly fishing; repetitive thumb extension </td> </tr> <tr> <td>Dorsal ganglion </td> <td>Radial, dorsal</td> <td>Cystic swelling</td> <td>Radiographs not necessary</td> <td>&nbsp;</td> </tr> <tr> <td>Kienbock disease(Osteonecrosis of the lunate) </td> <td>Radial, dorsal</td> <td>Mild swelling, persistent pain, crepitation, stiffness and decreased range of motion</td> <td>AP radiographs demonstrate progressive changes</td> <td>Martial arts; volleyball</td> </tr> <tr> <td>Ulnar neuropathy (Guyon canal syndrome)</td> <td>Ulnar</td> <td>Weakness and paresthesias affecting the 4th and 5th digits</td> <td>Radiographs not necessary</td> <td>Racquet, stick, and club sports, cycling</td> </tr> <tr> <td>Ulnar impaction syndrome</td> <td>Ulnar</td> <td>Tenderness of ulnar snuff box; tenderness with ulnar deviation</td> <td>Positive ulnar variance, cyst formation or sclerosis of ulnar head or lunotriquetral interface</td> <td>Gymnastics (vaulting)</td> </tr> <tr> <td>Triangular fibrocartilage complex (TFCC) tears</td> <td>Ulnar, dorsal</td> <td>Point tenderness over the lateral wrist just distal to the ulnar styloid; pain with forced ulnar deviation or TFCC compression test</td> <td>Associated (but not diagnostic) findings: widening of DRUJ space, positive ulnar variance, fracture of ulnar styloid on AP; dislocation/subluxation on lateral</td> <td>Impact sports; racquet, stick, and club sports; gymnastics</td> </tr> <tr> <td>Distal radioulnar joint (DRUJ) injury</td> <td>Ulnar, dorsal</td> <td>Pain with supination and pronation; positive DRUJ compression or piano key tests</td> <td>Dislocation can be seen on plain radiographs; MRI may be necessary for instability</td> <td>Impact sports; racquet, stick, and club sports; gymnastics</td> </tr> <tr> <td>Extensor carpi ulnaris (ECU) tendonitis</td> <td>Ulnar, dorsal</td> <td>Tenderness over ECU tendon in ulnar groove exacerbated by wrist extension against resistance</td> <td>Radiographs not necessary</td> <td>Rowing; racquet, stick, and club sports</td> </tr> <tr> <td>ECU subluxation</td> <td>Ulnar, dorsal</td> <td>Pain and snapping with rotation of forearm; can be observed with ulnar deviation in full supination</td> <td>Radiographs not necessary</td> <td>Racquet, stick, and club sports</td> </tr> <tr> <td>Hamate hook fracture</td> <td>Ulnar, palmar</td> <td>Pain with sports but not daily activities; point tenderness over the hook of the hamate</td> <td>Fracture best seen on 45&#176; supination oblique or carpal tunnel view or with computed tomography</td> <td>Racquet, stick, and club sports</td> </tr> <tr> <td>Flexor tendonitis (flexor carpi radialis [FCR], fexor carpi ulnaris [FCU])</td> <td>Palmar</td> <td>Tenderness over FCR or FCU</td> <td>Radiographs not necessary</td> <td>Racquet, stick, and club sports</td> </tr> <tr> <td>Hypothenar hammer syndrome</td> <td>Palmar</td> <td>Pain in palm, coldness of digits, abnormal modified Allen test</td> <td>Radiographs not necessary</td> <td>Impact sports; martial arts; volleyball; racquet, stick, and club sports</td> </tr> <tr> <td>Intersection syndrome</td> <td>Dorsal</td> <td>Tenderness 4 to 6 cm proximal to wrist joint; crepitus with active extension of the wrist</td> <td>Radiographs not necessary</td> <td>Rowing; weight training; racquet, stick, and club sports</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63434 Version 4.0</div></div></div>"},"63436":{"type":"graphic_table","displayName":"Disability definitions","title":"Disability definitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disability definitions</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Definitions of impairment\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"A loss, loss of use or derangement of any body part, organ system or organ function.\" AMA \"Guides\" Fifth edition<sup>[1]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"A significant deviation, loss, or loss of use of any body structure or body function in an individual with a health condition, disorder or disease.\" AMA \"Guides\" Sixth edition<sup>[2]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"Results from anatomical, physiological, or psychological abnormalities which can be shown by medically acceptable clinical and laboratory diagnostic techniques. A physical or mental impairment must be established by medical evidence consisting of signs, symptoms, and laboratory findings - not only by the individual's statement of symptoms.\" For an impairment to be considered \"severe\" by Social Security, it must only cause more than a mild limitation on the ability to function and work. The Social Security Administration (SSA)<sup>[3]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"[A]ny physiological disorder or condition, cosmetic disfigurement, or anatomical loss affecting one or more of the following body systems: neurological, musculoskeletal, special sense organs, respiratory (including speech organs), cardiovascular, reproductive, digestive, genitourinary, hemic and lymphatic, skin, and endocrine.\" The Americans with Disabilities Act<sup>[4]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"[A]ny mental or psychological disorder, such as mental retardation, organic brain syndrome, emotional or mental illness, and specific learning disabilities.\" Neither the statute nor the regulation lists all diseases or conditions that make up \"physical or mental impairments,\" because it would be impossible to provide a comprehensive list, given the variety and expanding number of possible impairments. For example, a person suffering from general \"stress\" because of job or personal life pressures would not be considered to have an impairment. However, if this person is diagnosed by a psychiatrist as having an identifiable stress disorder, she or he would have an impairment that may be a disability. The Americans with Disabilities Act<sup>[4]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"A problem in body function or structure such as a significant deviation or loss.\" \"Body functions are the physiological functions of body systems (including psychological functions). Body structures are anatomical parts of the body such as organs, limbs and their components.\" WHO's International Classification of Functioning, Disability and Health (ICF)<sup>[5]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Definitions of disability\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"An alteration of an individual's capacity to meet personal, social or occupational demands or statutory or regulatory requirements because of an impairment.\" AMA \"Guides\" Fifth edition<sup>[1]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"Activity limitations and/or participation restrictions in an individual with a health condition disorder or disease.\" AMA \"Guides\" Sixth edition<sup>[2]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; \"The inability to engage in any substantial, gainful activity (SGA) by reason of a medically determinable physical or mental impairment(s), which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months.\" The Social Security Administration (SSA)<sup>[3]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; A physical or mental impairment that substantially limits one or more major life activities; has a record of such an impairment; or is regarded as having such an impairment. The Americans with Disabilities Act<sup>[4]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2_start\">\n   &#8226; A restriction or lack (resulting from an impairment) of ability to perform an activity in the manner or within the range considered normal for a human being. The ICF identifies three components of disability:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   - Impairments - Problems in body function or structure\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   - Activity - Execution of a task or action\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   - Participation - Involvement in a life situation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   WHO's International Classification of Functioning, Disability and Health (ICF)<sup>[5]</sup>\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"indent1\">\n   &#8226; The IOM, in evaluating the definition of disability, notes that it is \"complex, with medical, functional, and vocational components.\" A complete and comprehensive assessment of all aspects of the definition would require a detailed clinical evaluation of the underlying medical cause(s) for the impairment; analysis of the expected duration of the impairment (prognosis); a comprehensive assessment of the work-related functional limitations attributable to the impairment, the individual's remaining functional capacity; a detailed vocational analysis of the individual's work history and acquired work skills, educational background, and age; and a thorough analysis of the individual's current vocational prospects<sup>[5]</sup>.\n   </td>\n   </tr>\n </table></div><div class=\"graphic_reference\">1. Cocchiarella, L, Anderson, GBJ. Guides to the Evaluation of Permanent Impairment, 5th Ed, American Medical Association 2001. p.565.<br>2. Rondinelli, R. Medical Editor AMA Guides to the Evaluation of Permanent Impairment, Sixth Ed, 2007.<br>3. SSA Pub. No. 64-039 ICN 468600 September 2008 Disability Evaluation Under Social Security (Blue Book-September 2008).<br>4. What is the ADA: Definition of Disability:www.adata.org/whatsada-definition.aspx.<br>5. World Health Organization. International Classification of Impairments, Disability and Health. Geneva, Switzerland 2001.</div><div id=\"graphicVersion\">Graphic 63436 Version 1.0</div></div></div>"},"63438":{"type":"graphic_picture","displayName":"Peripheral ulcerative keratitis","title":"Peripheral ulcerative keratitis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Peripheral ulcerative keratitis</div><div class=\"cntnt\"><img style=\"width:500px; height:373px;\" src=\"images/RHEUM/63438_Periph_ulcer_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral ulcerative keratitis (PUK) in a patient with&nbsp;rheumatoid arthritis who also has&nbsp;necrotizing scleritis posterior to the PUK.</div><div class=\"graphic_reference\">Courtesy of C Stephen Foster, MD.</div><div id=\"graphicVersion\">Graphic 63438 Version 2.0</div></div></div>"},"63439":{"type":"graphic_waveform","displayName":"Pulsus paradoxus mechanism","title":"Measurement and mechanism of pulsus paradoxus","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Measurement and mechanism of pulsus paradoxus</div><div class=\"cntnt\"><img style=\"width:475px; height:687px;\" src=\"images/CARD/63439_Pulsus_paradoxus_mech_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler echocardiogram in a patient with cardiac tamponade. Note the inspiratory increase of tricuspid flow velocities (A) and the expiratory increase of mitral (B) and aortic (C) flow velocities.</div><div class=\"graphic_reference\">Reproduced from: Hoit BD. Imaging the pericardium. Cardiol Clin 1990; 8:587. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63439 Version 6.0</div></div></div>"},"63441":{"type":"graphic_table","displayName":"Mercury levels in seafood","title":"Mercury levels in commercial fish and shellfish","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mercury levels in commercial fish and shellfish</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Mercury concentration (PPM) (mean)</td> <td class=\"subtitle1\">No. of samples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fish and shellfish with highest levels of mercury</td> </tr> <tr> <td class=\"indent1\">Mackerel King</td> <td>0.730</td> <td>213</td> </tr> <tr> <td class=\"indent1\">Shark</td> <td>0.988</td> <td>351</td> </tr> <tr> <td class=\"indent1\">Swordfish</td> <td>0.976</td> <td>618</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tilefish (Gulf of Mexico)</td> <td>1.450</td> <td>60</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fish and shellfish with lower levels of mercury<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Anchovies</td> <td>0.043</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Butterfish</td> <td>0.058</td> <td>89</td> </tr> <tr> <td class=\"indent1\">Catfish</td> <td>0.049</td> <td>23</td> </tr> <tr> <td class=\"indent1\">Clam*</td> <td>ND</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Cod</td> <td>0.095</td> <td>39</td> </tr> <tr> <td class=\"indent1\">Crab<sup>&#916;</sup></td> <td>0.060</td> <td>63</td> </tr> <tr> <td class=\"indent1\">Crawfish</td> <td>0.033</td> <td>44</td> </tr> <tr> <td class=\"indent1\">Croaker Atlantic (Atlantic)</td> <td>0.072</td> <td>35</td> </tr> <tr> <td class=\"indent1\">Flatfish*<sup>&#9674;</sup></td> <td>0.045</td> <td>23</td> </tr> <tr> <td class=\"indent1\">Haddock (Atlantic)</td> <td>0.031</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Hake</td> <td>0.014</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Herring</td> <td>0.044</td> <td>38</td> </tr> <tr> <td class=\"indent1\">Jacksmelt</td> <td>0.108</td> <td>16</td> </tr> <tr> <td class=\"indent1\">Lobster (spiny)</td> <td>0.09</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Mackerel Atlantic (N. Atlantic)</td> <td>0.050</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Mackerel Chub (Pacific)</td> <td>0.088</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Mullet</td> <td>0.046</td> <td>191</td> </tr> <tr> <td class=\"indent1\">Oyster</td> <td>0.013</td> <td>38</td> </tr> <tr> <td class=\"indent1\">Perch Ocean*</td> <td>ND</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Pollock</td> <td>0.041</td> <td>62</td> </tr> <tr> <td class=\"indent1\">Salmon (canned)*</td> <td>ND</td> <td>23</td> </tr> <tr> <td class=\"indent1\">Salmon (fresh/frozen)*</td> <td>0.014</td> <td>34</td> </tr> <tr> <td class=\"indent1\">Sardine</td> <td>0.016</td> <td>29</td> </tr> <tr> <td class=\"indent1\">Scallop</td> <td>0.050</td> <td>66</td> </tr> <tr> <td class=\"indent1\">Shad American</td> <td>0.065</td> <td>59</td> </tr> <tr> <td class=\"indent1\">Shrimp*</td> <td>ND</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Squid</td> <td>0.070</td> <td>200</td> </tr> <tr> <td class=\"indent1\">Tilapia*</td> <td>0.010</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Trout (freshwater)</td> <td>0.072</td> <td>34</td> </tr> <tr> <td class=\"indent1\">Tuna (canned, light)</td> <td>0.118</td> <td>347</td> </tr> <tr> <td class=\"indent1\">Whitefish</td> <td>0.069</td> <td>28</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Whiting</td> <td>ND</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mercury levels of other fish and shellfish<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Bass (saltwater, black, striped)<sup>&#167;</sup></td> <td>0.219</td> <td>47</td> </tr> <tr> <td class=\"indent1\">Bass Chilean</td> <td>0.386</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Bluefish</td> <td>0.337</td> <td>52</td> </tr> <tr> <td class=\"indent1\">Buffalofish</td> <td>0.19</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Carp</td> <td>0.14</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Croaker White (Pacific)</td> <td>0.287</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Grouper (all species)</td> <td>0.465</td> <td>43</td> </tr> <tr> <td class=\"indent1\">Halibut</td> <td>0.252</td> <td>46</td> </tr> <tr> <td class=\"indent1\">Lobster (Northern/American)</td> <td>0.310</td> <td>88</td> </tr> <tr> <td class=\"indent1\">Lobster (species unknown)</td> <td>0.169</td> <td>16</td> </tr> <tr> <td class=\"indent1\">Mackerel Spanish (Gulf of Mexico)</td> <td>0.454</td> <td>66</td> </tr> <tr> <td class=\"indent1\">Mackerel Spanish (S. Atlantic)</td> <td>0.182</td> <td>43</td> </tr> <tr> <td class=\"indent1\">Marlin*</td> <td>0.485</td> <td>16</td> </tr> <tr> <td class=\"indent1\">Monkfish</td> <td>0.180</td> <td>81</td> </tr> <tr> <td class=\"indent1\">Orange Roughy</td> <td>0.554</td> <td>49</td> </tr> <tr> <td class=\"indent1\">Perch (freshwater)</td> <td>0.14</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Sablefish</td> <td>0.220</td> <td>102</td> </tr> <tr> <td class=\"indent1\">Scorpionfish</td> <td>0.286</td> <td>78</td> </tr> <tr> <td class=\"indent1\">Sheepshead</td> <td>0.128</td> <td>59</td> </tr> <tr> <td class=\"indent1\">Skate</td> <td>0.137</td> <td>56</td> </tr> <tr> <td class=\"indent1\">Snapper</td> <td>0.189</td> <td>43</td> </tr> <tr> <td class=\"indent1\">Tilefish (Atlantic)</td> <td>0.144</td> <td>32</td> </tr> <tr> <td class=\"indent1\">Tuna (canned, Albacore)</td> <td>0.353</td> <td>399</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, all)</td> <td>0.383</td> <td>228</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, Albacore)</td> <td>0.357</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, Bigeye)</td> <td>0.639</td> <td>13</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, Skipjack)</td> <td>0.205</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, Yellowfin)</td> <td>0.325</td> <td>87</td> </tr> <tr> <td class=\"indent1\">Tuna (fresh/frozen, species unknown)</td> <td>0.414</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Weakfish (Sea Trout)</td> <td>0.256</td> <td>39</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Source of data: FDA 1990-2004, \"National Marine Fisheries Service Survey of Trace Elements in the Fishery Resource\" Report 1978, \"The Occurrence of Mercury in the Fishery Resources of the Gulf of Mexico\" Report 2000. Mercury was measured as Total Mercury except for species (*) when only Methylmercury was analyzed.</div><div class=\"graphic_footnotes\">ND: mercury concentration below detection level (Level of Detection (LOD) = 0.01 ppm).<br />&para; The following species have been removed from the tables: Bass (freshwater) - not commercial; Pickerel - not commercial.<br />&Delta; Includes: Blue, King, Snow.<br /><span class=\"lozenge\">&loz;</span> Includes: Flounder, Plaice, Sole.<br />&sect; Includes: Sea bass/Striped Bass/Rockfish.</div><div class=\"graphic_reference\">Data from: Mercury levels in commercial fish and Shellfish. US Food and Drug Administration. Available at http://www.fda.gov/Food/FoodSafety/Product-SpecificInformation/Seafood/FoodbornePathogensContaminants/Methylmercury/ucm115644.htm. Accessed 1/26/2010.</div><div id=\"graphicVersion\">Graphic 63441 Version 5.0</div></div></div>"},"63442":{"type":"graphic_diagnosticimage","displayName":"Contrast CT panc neck","title":"Contrast CT of tumor in pancreatic neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast CT of tumor in pancreatic neck</div><div class=\"cntnt\"><img style=\"width:279px; height:575px;\" src=\"images/ONC/63442_Contrast_CT_panc_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT axial images of a patient with a solid, ill-defined tumor in the neck of the pancreas (arrow in A). No vascular encasement is observed. However, multiple small hypodense lesions are seen throughout the liver parenchyma (arrows in B and C), which are highly suspicious for metastatic disease.</div><div class=\"graphic_reference\">Courtesy of Dr. Rocio Perez-Johnston.</div><div id=\"graphicVersion\">Graphic 63442 Version 2.0</div></div></div>"},"63443":{"type":"graphic_figure","displayName":"Anatomy of the triangular fibrocartilage complex ","title":"Anatomy of the triangular fibrocartilage complex","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Anatomy of the triangular fibrocartilage complex</div><div class=\"cntnt\"><img style=\"width:488px; height:419px;\" src=\"images/PEDS/63443_Anatomy_TFCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The triangular fibrocartilage complex is comprised of the triangular fibrocartilage, ulnar collateral ligament, dorsal and palmar radioulnar ligaments, ulnolunate and ulnotriquetral ligaments, and the extensor carpi ulnaris tendon sheath. This figure shows the dorsal surface of the wrist.</div><div id=\"graphicVersion\">Graphic 63443 Version 3.0</div></div></div>"},"63444":{"type":"graphic_figure","displayName":"Oswestry questionnaire","title":"Oswestry questionnaire","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Oswestry questionnaire</div><div class=\"cntnt\"><img style=\"width:597px; height:785px;\" src=\"images/PC/63444_Oswestry_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For each section of six statements the total score is 5; if the first statement is marked the score = 0; if the last statement is marked it = 5. Intervening statements are scored according to rank. If more than one box is marked in each section, take the highest score. If all 10 sections are completed the score is calculated as follows:<br> Example: if 16 (total scored) out of 50 (total possible score) x 100 = 32 percent.<br> If one section is missed (or not applicable) the score is calculated:<br> Example: 16 (total scored)/45 (total possible score) x 100 = 35.6 percent.<br> So the final score may be summarized as:<br> (total score/(5 x number of questions answered)) x 100 percent.<br> It is suggested rounding the percentage to a whole number for convenience.</div><div class=\"graphic_reference\">Reproduced with permission from: Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine 2000; 25:2940. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63444 Version 9.0</div></div></div>"},"63446":{"type":"graphic_figure","displayName":"Hulka clip sterilization","title":"Clip method of laparoscopic sterilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clip method of laparoscopic sterilization</div><div class=\"cntnt\"><img style=\"width:373px; height:324px;\" src=\"images/OBGYN/63446_Hulka_clip_sterilization.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 63446 Version 1.0</div></div></div>"},"63447":{"type":"graphic_diagnosticimage","displayName":"MRI myocardial viability","title":"Assessment of myocardial viability by cardiac magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Assessment of myocardial viability by cardiac magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:396px; height:335px;\" src=\"images/CARD/63447_MRI_mycrdl_vblty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis CMR images obtained after contrast administration are compared with corresponding short-axis 201-thallium (Tl) tomograms at rest and after redistribution (REDIST). Persistent enhancement (arrow) develops in the inferolateral wall, corresponding to severe irreversible 201TI defect in same region (arrowhead in REDIST image). The inferior wall also demonstrates substantial perfusion defect at rest but shows mild redistribution, indicating myocardial viability; CMR images in this area show lesser degree of enhancement than in area of irreversible injury.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">With permission from: Ramani K, Judd RM, Holly TA, et al. Circulation 1998; 98:2687.</div><div id=\"graphicVersion\">Graphic 63447 Version 6.0</div></div></div>"},"63448":{"type":"graphic_figure","displayName":"Creation of esophagojejunostomy","title":"Creation of esophagojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Creation of esophagojejunostomy</div><div class=\"cntnt\"><img style=\"width:514px; height:716px;\" src=\"images/SURG/63448_Esophagojejunostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To create the esophagojejunostomy, the anvil of a number 25 end-to-end anastomosis (EEA) stapling device is secured in the distal esophagus, and a retrocolic Roux-en-Y esophagojejunostomy is fashioned through the transverse mesocolon using a jejunal limb approximately 40 cm from the ligament of Treitz.</div><div id=\"graphicVersion\">Graphic 63448 Version 3.0</div></div></div>"},"63450":{"type":"graphic_picture","displayName":"How to stretch the backs of your legs PI","title":"How to stretch the backs of your legs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">How to stretch the backs of your legs</div><div class=\"cntnt\"><img style=\"width:234px; height:342px;\" src=\"images/PI/63450_Posterior_leg_stretch_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand facing the wall, feet together, about 2 feet from the wall. With your heels firmly on the floor and your shoulders, hips, and knees lined up straight, lean forward into the wall. This should stretch the backs of your legs. Hold this position for 10 to 30 seconds. Repeat 5 times each session, at least twice a day.</div><div id=\"graphicVersion\">Graphic 63450 Version 1.0</div></div></div>"},"63451":{"type":"graphic_figure","displayName":"T4 replacement and the heart","title":"T4 replacement increases cardiac contractility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T4 replacement increases cardiac contractility</div><div class=\"cntnt\"><img style=\"width:320px; height:428px;\" src=\"images/ENDO/63451_T4_replacement_heart.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of L-thyroxine replacement in patients with hypothyroidism on serum T4, TSH, and cardiac contractility as measured by the PEP as a function of LVET. Contractility increased (as demonstrated by a fall in PEP/LVET) in a dose-dependent fashion.</div><div class=\"graphic_footnotes\">T4: thyroxine; TSH: thyroid-stimulating hormone; PEP: pre-ejection period; LVET: left ventricular ejection time; L-thyroxine: levothyroxine.</div><div class=\"graphic_reference\">Adapted from: Crowley WF Jr, Ridgway EC, Bough EW, et al. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med 1977; 296:1.</div><div id=\"graphicVersion\">Graphic 63451 Version 5.0</div></div></div>"},"63453":{"type":"graphic_table","displayName":"CDC criteria for Lyme disease","title":"Centers for Disease Control and Prevention criteria for Lyme disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Centers for Disease Control and Prevention criteria for Lyme disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n  <tbody>\r\n    <tr>\r\n      <td>Presence of EM <strong>OR</strong></td>\r\n    </tr>\r\n    <tr>\r\n      <td>At least one late manifestation plus laboratory confirmation of infection.*</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"subtitle1_single\">The late manifestations include any of the following when an alternate explanation is not found:</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"subtitle2_single\">Musculoskeletal system</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"indent1\">Recurrent brief attacks of objective joint swelling in one or a few joints, <strong>sometimes</strong> followed by chronic arthritis in one or a few joints. Manifestations not considered as criteria for diagnosis include chronic progressive arthritis not preceded by brief attacks and chronic symmetrical polyarthritis. Additionally, arthralgias, myalgias, or fibromyalgia syndromes alone are <strong>not accepted</strong> as criteria for musculoskeletal involvement.</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"subtitle2_single\">Nervous system</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"indent1\">Lymphocytic meningitis, cranial neuritis, particularly facial palsy (may be bilateral), radiculoneuropathy or,\r\nrarely, encephalomyelitis alone or in combination. Encephalomyelitis must be confirmed by showing antibody production against B. burgdorferi\r\nin the cerebrospinal fluid (CSF), which is demonstrated by a higher titer of antibody in CSF than in serum. Headache, fatigue, paresthesias, or mild stiff neck alone are <strong>not accepted</strong> as criteria for neurologic involvement.</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"subtitle2_single\">Cardiovascular</td>\r\n    </tr>\r\n    <tr>\r\n      <td class=\"indent1\">Acute onset, high grade (2nd or 3rd degree) atrioventricular conduction defects that resolve in days to weeks and are sometime associated with myocarditis. Palpitations, bradycardia, bundle branch block, or myocarditis alone are not accepted as criteria for cardiovascular involvement.</td>\r\n    </tr>\r\n  </tbody>\r\n</table></div><div class=\"graphic_footnotes\">EM: erythema migrans.<br> * Isolation of Borrelia burgdorferi from a clinical specimen <strong>or</strong><br> Demonstration of diagnostic immunoglobulin M or immunoglobulin G antibodies to B. burgdorferi in serum or cerebrospinal fluid (CSF). A two-test approach using a sensitive enzyme immunoassay or immunofluorescence antibody followed by Western blot is recommended (CDC. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR 1995;44:590-1.).</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Recomm Rep 1997;46(RR-10):1.</div><div id=\"graphicVersion\">Graphic 63453 Version 4.0</div></div></div>"},"63455":{"type":"graphic_waveform","displayName":"Continuous wave Doppler AR","title":"Continuous wave Doppler across the aortic valve in a patient with aortic regurgitation (AR)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler across the aortic valve in a patient with aortic regurgitation (AR)</div><div class=\"cntnt\"><img style=\"width:299px; height:237px;\" src=\"images/CARD/63455_Continuous_wave_Doppler_AR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The severity of aortic regurgitation can be established by the continuous wave Doppler using the pressure half time (PHT), which is computed by placing a line (arrow) along the slope of velocity decay or deceleration time (A to B); in this patient, the PHT is 99 msec. Values of less than 200 msec identify severe aortic regurgitation. In addition, the density of the regurgitant diastolic signal is nearly equal to the systolic signal.</div><div id=\"graphicVersion\">Graphic 63455 Version 4.0</div></div></div>"},"63456":{"type":"graphic_picture","displayName":"Moderate FSGS Light","title":"Moderate FSGS","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moderate FSGS</div><div class=\"cntnt\"><img style=\"width:386px; height:290px;\" src=\"images/NEPH/63456_Moderate_FGS_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in focal segmental glomerulosclerosis shows a moderately large segmental area of sclerosis with capillary collapse on the upper left side of the glomerular tuft; the lower right segment is relatively normal. Focal deposition of hyaline material (arrow) is also seen.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63456 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"63457":{"type":"graphic_picture","displayName":"Panc intraepith neoplas","title":"Pancreatic intraepithelial neoplasia","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Pancreatic intraepithelial neoplasia</div><div class=\"cntnt\"><img style=\"width:571px; height:342px;\" src=\"images/ONC/63457_Panc_intraepith_neoplas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Normal interlobular duct. B) Pancreatic intraepithelial neoplasia (PanIN)-1A with non-papillary mucinous epithelium. C) PanIN-1B with papillary epithelium. D) PanIN-2 with moderate dysplasia, right, and normal ductal epithelium, left. E) PanIN-3 with severe dysplasia. Note that, under current classification systems, B, C, and D would now all be classified as low-grade PanIN; E would be called high-grade PanIN. Hematoxylin and eosin-stained sections.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 63457 Version 3.0</div></div></div>"},"63461":{"type":"graphic_picture","displayName":"Hypertrophic actinic keratosis","title":"Hypertrophic actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hypertrophic actinic keratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/63461_Hypertrophic_actinic_kerat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This hypertrophic actinic keratosis demonstrates a thick accumulation of keratin overlying an erythematous base.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63461 Version 4.0</div></div></div>"},"63462":{"type":"graphic_table","displayName":"Treatment of newly diagnosed Ph positive ALL","title":"Overview of the treatment for newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of the treatment for newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Induction therapy</td> </tr> <tr> <td>A BCR-ABL tyrosine kinase inhibitor (TKI) <strong>plus</strong> one of the following combination chemotherapy regimens: <ul> <li>Cancer and Leukemia Group B (CALGB study 8811 or 9111) ALL regimen<sup>[1,2]</sup> </li> <li>Hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) alternating with high-dose methotrexate and cytarabine<sup>[3]</sup> </li> <li>French GRAALL-2003 regimen<sup>[4]</sup> </li> <li>German GMALL protocols 06/99 and 7/03<sup>[5]</sup> </li> </ul> <br /> The combination of a TKI with or without a corticosteroid is capable of producing complete remissions in previously untreated Ph+ ALL with low toxicity<sup>[6]</sup>. This combination has not been directly compared with a TKI plus chemotherapy. If initial data are supported by subsequent studies, the combination of a TKI plus steroid may become an excellent option for patients, such as older adults, who are not able to tolerate combination chemotherapy.</td> </tr> <tr> <td class=\"subtitle1_single\">Consolidation</td> </tr> <tr> <td>Allogeneic hematopoietic cell transplantation in first complete remission is preferred. If the patient is not a candidate for transplantation, consolidation chemotherapy should be given that incorporates a BCR-ABL TKI.</td> </tr> <tr> <td class=\"subtitle1_single\">Maintenance</td> </tr> <tr> <td>A BCR-ABL TKI for two years after allogeneic hematopoietic cell transplantation or indefinitely if a transplantation is not performed</td> </tr> <tr> <td class=\"subtitle1_single\">Follow-up</td> </tr> <tr> <td>Serial bone marrow evaluation and minimal residual disease testing with BCR-ABL transcripts using real time quantitative polymerase chain reaction</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: The BCR-ABL TKI chosen should be consistent with the BCR-ABL tyrosine kinase used in the specific treatment protocol.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025. </li> <li>Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556. </li> <li>Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116:2070. </li> <li>Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911. </li> <li>Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108:1469. </li> <li>Fo&#224; R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118:6521. </li> </ol></div><div id=\"graphicVersion\">Graphic 63462 Version 1.0</div></div></div>"},"63463":{"type":"graphic_figure","displayName":"Adnexa at hysterectomy","title":"Removal or conservation of adnexa at hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Removal or conservation of adnexa at hysterectomy</div><div class=\"cntnt\"><img style=\"width:546px; height:329px;\" src=\"images/OBGYN/63463_Adnexa_at_hysterectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Placement of stapling device for ligation of utero-ovarian or infudibulopelvic ligaments.</div><div id=\"graphicVersion\">Graphic 63463 Version 1.0</div></div></div>"},"63464":{"type":"graphic_diagnosticimage","displayName":"Color Doppler TEE aortic rupture ","title":"Transesophageal echocardiogram with color Doppler of aortic rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram with color Doppler of aortic rupture</div><div class=\"cntnt\"><img style=\"width:385px; height:288px;\" src=\"images/CARD/63464_Aortic_rupture_color_TEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transesophageal echocardiogram with color Doppler flow mapping of aortic rupture showing similar blood flow velocities on both sides of the medial flap, and a mosaic of colors at the site of the disruption due to blood flow turbulence.</div><div class=\"graphic_reference\">Courtesy of P Vignon, MD and RM Lang, MD.</div><div id=\"graphicVersion\">Graphic 63464 Version 3.0</div></div></div>"},"63465":{"type":"graphic_table","displayName":"Pathogens in neutropenic fever","title":"Range of pathogens encountered in febrile neutropenic patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Range of pathogens encountered in febrile neutropenic patients</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Commonly cultured organisms</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-negative bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> </tr> <tr> <td class=\"indent1\"><em>Citrobacter</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Acinetobacter </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Stenotrophomonas maltophila</em></td> </tr> <tr> <td class=\"subtitle2_single\">Gram-positive bacteria</td> </tr> <tr> <td class=\"indent1\">Coagulase-negative staphylococci</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent1\"><em>Enterococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Viridans</em> group streptococci</td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pyogenes</em></td> </tr> <tr> <td class=\"subtitle2_single\">Other bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium difficile</em></td> </tr> <tr> <td class=\"indent1\">Anaerobes</td> </tr> <tr> <td class=\"indent1\">Mycobacteria</td> </tr> <tr> <td class=\"subtitle2_single\">Fungi</td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Candida</em> spp</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Less commonly cultured organisms</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-negative bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Proteus </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Serratia</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Neisseria meningitidis</em></td> </tr> <tr> <td class=\"indent1\"><em>Capnocytophaga canimorsus</em></td> </tr> <tr> <td class=\"indent1\"><em>Legionella</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Moraxella </em>spp</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-positive bacteria</td> </tr> <tr> <td class=\"indent1\"><em>Bacillus </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Listeria monocytogenes</em></td> </tr> <tr> <td class=\"indent1\"><em>Stomatococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium jeikeium</em></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Additional organisms</td> </tr> <tr> <td class=\"subtitle2_single\">Fungi</td> </tr> <tr> <td class=\"indent1\"><em>Cryptococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Histoplasma capsulatum</em></td> </tr> <tr> <td class=\"indent1\"><em>Coccidioides</em> spp</td> </tr> <tr> <td class=\"indent1\">Mucorales</td> </tr> <tr> <td class=\"indent1\"><em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>)</td> </tr> <tr> <td class=\"subtitle2_single\">Viruses</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus 1,2</td> </tr> <tr> <td class=\"indent1\">Varicella-zoster virus</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"indent1\">Human herpesvirus 6</td> </tr> <tr> <td class=\"indent1\">Enteroviruses</td> </tr> <tr> <td class=\"indent1\">Respiratory syncytial virus</td> </tr> <tr> <td class=\"indent1\">Influenza virus</td> </tr> <tr> <td class=\"indent1\">Parainfluenza virus</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\"><em>Babesia </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Plasmodium</em> spp (the cause of malaria)</td> </tr> <tr> <td class=\"indent1\"><em>Toxoplasma </em>spp</td> </tr> <tr> <td class=\"indent1\"><em>Strongyloides stercoralis</em></td> </tr> <tr> <td class=\"indent1\"><em>Nocardia</em> spp</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Commonly cultured gram-negative and gram-positive organisms adapted with permission from: Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56. Copyright &copy; 2011 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 63465 Version 18.0</div></div></div>"},"63468":{"type":"graphic_picture","displayName":"Cherry angioma2","title":"Cherry angioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cherry angioma</div><div class=\"cntnt\"><img style=\"width:360px; height:365px;\" src=\"images/OBGYN/63468_Cherry_angioma2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 63468 Version 1.0</div></div></div>"},"63470":{"type":"graphic_figure","displayName":"Thyroid nodules after radiation","title":"Thyroid nodules in irradiated patients","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Thyroid nodules in irradiated patients</div><div class=\"cntnt\"><img style=\"width:481px; height:290px;\" src=\"images/ENDO/63470_Thyroid_nodules_after_radia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Size distribution of 157 thyroid nodules in 47 patients with a history of radiation exposure; seven others had no nodules. Eleven nodules were 1.5 cm or larger, five of which were palpable.</div><div class=\"graphic_reference\">Data from: Schneider AB, Bekerman C, Leland J, et al. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation.&nbsp;J Clin Endocrinol Metab 1997; 82:4020.</div><div id=\"graphicVersion\">Graphic 63470 Version 2.0</div></div></div>"},"63471":{"type":"graphic_picture","displayName":"Histology Ewing sarcoma","title":"Histology of Ewing sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of Ewing sarcoma</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/ONC/63471_Histology_Ewings_sarcoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoxylin and eosin-stained section of a Ewing sarcoma, showing sheets of malignant-appearing round cells with clear cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Andrew L Rosenberg, MD.</div><div id=\"graphicVersion\">Graphic 63471 Version 3.0</div></div></div>"},"63472":{"type":"graphic_figure","displayName":"Surgical drainage of a breast abscess","title":"Surgical drainage of a breast abscess","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Surgical drainage of a breast abscess</div><div class=\"cntnt\"><img style=\"width:504px; height:196px;\" src=\"images/PC/63472_Non_lactational_abscess_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin compromise necessitates incision and drainage. Note pus can be drained adequately though a small skin incision.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 63472 Version 3.0</div></div></div>"},"63474":{"type":"graphic_figure","displayName":"Bile duct injury during laparoscopic cholecystectomy","title":"Bile duct injury during laparoscopic cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bile duct injury during laparoscopic cholecystectomy</div><div class=\"cntnt\"><img style=\"width:416px; height:418px;\" src=\"images/SURG/63474_Lap_chole_bile_duct_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The common bile duct is mistaken for the cystic duct and transected. A variable extent of the extrahepatic biliary tree is resected with the gallbladder. The right hepatic artery, in background, is also often injured.</div><div class=\"graphic_reference\">Redrawn with permission from: Branum, G, Schmidt, C, Baillie, J, et al. Management of major biliary complications after laparoscopic cholecystectomy. Ann Surg 1993; 217:532. Copyright &#169; 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63474 Version 2.0</div></div></div>"},"63475":{"type":"graphic_picture","displayName":"Aphthous ulcers","title":"Aphthous ulcers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aphthous ulcers</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63475_Aphthous_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Round, yellow-gray ulcers are present on the oral mucosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63475 Version 4.0</div></div></div>"},"63477":{"type":"graphic_movie","displayName":"Anterior wall MI four chamber echo 3","title":"Anterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior wall myocardial infarction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/63477_4chanmi3conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:275px; height:441px;\" src=\"images/CARD/63477_4chanmi3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows a large, extensive anterior wall infarction with a dilated left ventricle that is diffusely hypokinetic with regions of akinesis. The myocardium is thin and fails to thicken with systole. Additionally, there is right and left atrial enlargement.</div><div id=\"graphicVersion\">Graphic 63477 Version 2.0</div></div></div>"},"63479":{"type":"graphic_diagnosticimage","displayName":"Renal abscess US","title":"Renal abscess on ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal abscess on ultrasonography</div><div class=\"cntnt\"><img style=\"width:359px; height:282px;\" src=\"images/NEPH/63479_Renal_abscess_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonic examination of the kidney showing an abscess cavity (arrow). The internal echoes within the lesion can also be seen with a malignancy but not with a simple cyst.</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 63479 Version 2.0</div></div></div>"},"63480":{"type":"graphic_figure","displayName":"Aspects MCA variants","title":"ASPECTS study form and MCA variants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ASPECTS study form and MCA variants</div><div class=\"cntnt\"><img style=\"width:340px; height:560px;\" src=\"images/NEURO/63480_Aspects_MCA_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(A and B)</strong> Right hemisphere, observer variations: lower and upper ASPECTS slices show as shaded areas the minimal and maximal variations in size of the cortical areas of the MCA (M1-M6) chosen by six expert observers. Left hemisphere, ASPECTS study form: A = anterior circulation; P = posterior circulation; C = caudate head; L = lentiform nucleus; IC = internal capsule; I = insular ribbon; MCA = middle cerebral artery; M1 = anterior MCA cortex; M2 = MCA cortex lateral to insular ribbon; M3 = posterior MCA cortex; M4, M5, and M6 are anterior, lateral, and posterior MCA territories, respectively, approximately 2 cm superior to M1, M2, and M3, respectively, rostral to basal ganglia. <strong>(C and D)</strong> Cortical MCA area variations with change of baseline. In the right hemisphere, the baseline is parallel to the inferior OML; in the left hemisphere, the baseline is the superior OML. OML=orbitomeatal line. <strong>(E and F)</strong> Normal vascular variations in MCA size on the two ASPECTS slices. The right hemisphere shows the larger normal variations described by van der Zwan* (light shading). The left hemisphere of each shows the smaller, textbook&#8226;, variations (dark shading).</div><div class=\"graphic_reference\">References<br> * van der Zwan, A, Hillen, B, Tulleken, AF, et al. Variability of the territories or the major cerebral arteries. J Neurosurg 1992; 77:927.<br> &#8226; Osborn, AG. Neuroradiology, Mosby, St. Louis 1995.<br> Reproduced with permission from: Pexman, JH, Barber, PA, Hill, MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001; 22:1534. Copyright &#169; 2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 63480 Version 1.0</div></div></div>"},"63481":{"type":"graphic_diagnosticimage","displayName":"MRI left occipit lobe infar","title":"MRI left occipital lobe infarct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI left occipital lobe infarct</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/NEURO/63481_MRI_left_occipit_lobe_infar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial FLAIR MRI showing a left occipital lobe infarction.</div><div class=\"graphic_footnotes\">FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 63481 Version 3.0</div></div></div>"},"63482":{"type":"graphic_figure","displayName":"Heart rate and VO2","title":"Relation between heart rate and VO2 during exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relation between heart rate and VO2 during exercise</div><div class=\"cntnt\"><img style=\"width:412px; height:305px;\" src=\"images/CARD/63482_HeartrateandVO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between attained heart rate and oxygen uptake during exercise. One metabolic equivalent (MET) is defined as 3.5 mL O<SUB>2</SUB> uptake/kg per min. Mean values of approximately 10 METs (V<SUB>O2</SUB> 35 mL/kg per min) can be achieved by nonathletic, healthy, middle-aged men; this should occur at a heart rate of approximately 175 beats/min.</div><div id=\"graphicVersion\">Graphic 63482 Version 2.0</div></div></div>"},"63483":{"type":"graphic_diagnosticimage","displayName":"C1 fracture posterior neural arch","title":"C1 posterior neural arch fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C1 posterior neural arch fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:336px;\" src=\"images/EM/63483_C1_fx_post_neural_arch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posterior neural arch fracture of C1 results from compression of the posterior elements between the occiput and the spinous process of C2 during forced neck extension. A vertical fracture line through the posterior neural arch is seen on this lateral x-ray (white arrow).</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 63483 Version 3.0</div></div></div>"},"63484":{"type":"graphic_diagnosticimage","displayName":"Middle phalanx fracture with impaction","title":"Middle phalanx fracture with impaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle phalanx fracture with impaction</div><div class=\"cntnt\"><img style=\"width:247px; height:432px;\" src=\"images/EM/63484_Mid_phalanx_fx_prox_imp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior radiograph reveals significant impaction of the ulnar plateau at the articular base of the middle phalanx. Note the irregular contour and loss of joint space at the distal interphalangeal joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63484 Version 5.0</div></div></div>"},"63487":{"type":"graphic_diagnosticimage","displayName":"Convex probe image","title":"Endobronchial ultrasound (EBUS) convex probe image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) convex probe image</div><div class=\"cntnt\"><img style=\"width:320px; height:706px;\" src=\"images/PULM/63487_Convex_probe_image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography reveals enlargement of the mediastinal lymph node, #4R.<br />(B) The convex probe endobronchial ultrasound image in the Doppler mode demonstrates the relationship between lymph node #4R and the superior vena cava (SVC).<br />(C) Real-time transbronchial fine needles aspiration. The 22-gauge needle is shown within lymph node #4R.</div><div id=\"graphicVersion\">Graphic 63487 Version 4.0</div></div></div>"},"63489":{"type":"graphic_diagnosticimage","displayName":"Spiculated nodule CT","title":"Spiculated solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spiculated solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:364px; height:353px;\" src=\"images/PULM/63489_Spiculated_nodule_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiculated border in a malignant solitary pulmonary nodule located in the right middle lobe. Smoker with obvious centrilobular emphysema.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63489 Version 2.0</div></div></div>"},"63490":{"type":"graphic_waveform","displayName":"Electrocardiographic changes from tricyclic antidepressant ","title":"Electrocardiographic changes from tricyclic antidepressant overdose","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic changes from tricyclic antidepressant overdose</div><div class=\"cntnt\"><img style=\"width:526px; height:294px;\" src=\"images/PULM/63490_Tricyclic_ECG_changes_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS complex is prolonged with delayed right ventricular activation and intraventricular conduction delay, which results in rightward shift in the terminal 40 msec frontal plane QRS vector. In qualitative terms, this shift manifests as a deep, slurred S wave in leads I and AVL, and an R wave in lead AVR (blue arrows).</div><div id=\"graphicVersion\">Graphic 63490 Version 3.0</div></div></div>"},"63491":{"type":"graphic_table","displayName":"Prev midline cath infection","title":"Prevention of infection with midline catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with midline catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Replacement and relocation of catheter</td> </tr> <tr> <td>Per manufacturing guidelines, may need to be replaced every 28 to 30 days (earlier if any complication).</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td> </tr> <tr> <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled, or inspection of the site is necessary. Replace dressings more frequently in diaphoretic patients.</td> </tr> <tr> <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.</td> </tr> <tr> <td>Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation*</strong> for replacement of tubing used for intermittent infusions.</td> </tr> <tr> <td>Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td> </tr> <tr> <td class=\"subtitle1_single\">Hang time for parenteral fluids</td> </tr> <tr> <td>Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.</td> </tr> <tr> <td>Complete infusion of blood or blood products within four hours of hanging the blood.</td> </tr> <tr> <td><strong>No recommendation*</strong> for nonlipid-containing parenteral nutrition fluids.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 63491 Version 3.0</div></div></div>"},"63495":{"type":"graphic_picture","displayName":"Capacitive coupling in electrosurgery","title":"Capacitive coupling in electrosurgery","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Capacitive coupling in electrosurgery</div><div class=\"cntnt\"><img style=\"width:504px; height:252px;\" src=\"images/OBGYN/63495_capacitive_coupling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capacitive coupling. Hybrid trocar sleeves are prone to induce capacitive coupling since the plastic locking anchor prevents the capacitive current from dissipating in the abdominal wall, resulting in electrical current passing through nearby structures such as bowel</div><div class=\"graphic_reference\">Reprinted from: www.encision.com/tech.html Copyright &#169;2006 Encision Inc.</div><div id=\"graphicVersion\">Graphic 63495 Version 2.0</div></div></div>"},"63497":{"type":"graphic_table","displayName":"Conditions associated with a high serum amylase","title":"Conditions associated with a high serum amylase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with a high serum amylase</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pancreatic disease</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Complications of pancreatitis (pseudocysts, abscess)</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Surgery</td> </tr> <tr> <td class=\"indent1\">Endoscopic retrograde cholangiopancreatography (ERCP)</td> </tr> <tr> <td class=\"indent1\">Ductal obstruction</td> </tr> <tr> <td class=\"indent1\">Pancreatic carcinoma</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Salivary disease</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Radiation</td> </tr> <tr> <td class=\"indent1\">Ductal obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disease</td> </tr> <tr> <td class=\"indent1\">Perforated or penetrating peptic ulcer</td> </tr> <tr> <td class=\"indent1\">Perforated bowel</td> </tr> <tr> <td class=\"indent1\">Obstructed bowel</td> </tr> <tr> <td class=\"indent1\">Mesenteric infarction</td> </tr> <tr> <td class=\"indent1\">Appendicitis</td> </tr> <tr> <td class=\"indent1\">Cholecystitis</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Severe gastroenteritis</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"subtitle1_single\">Gynecologic disease</td> </tr> <tr> <td class=\"indent1\">Ruptured ectopic pregnancy</td> </tr> <tr> <td class=\"indent1\">Ovarian or fallopian cysts</td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasms</td> </tr> <tr> <td class=\"indent1\">Solid tumors of the ovary, prostate, lung, esophagus, breast, and thymus</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">Macroamylasemia</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Acidosis (ketotic and nonketotic)</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Acquired immune deficiency syndrome (AIDS)</td> </tr> <tr> <td class=\"indent1\">Cerebral trauma</td> </tr> <tr> <td class=\"indent1\">Abdominal aortic aneurysm</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa, bulimia</td> </tr> <tr> <td class=\"indent1\">Postoperative</td> </tr> <tr> <td class=\"indent1\">Drug induced</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">Following double-balloon enteroscopy</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63497 Version 4.0</div></div></div>"},"63501":{"type":"graphic_figure","displayName":"Causes of hematuria","title":"Causes of hematuria","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Causes of hematuria</div><div class=\"cntnt\"><img style=\"width:551px; height:722px;\" src=\"images/NEPH/63501_Causes_of_hematuria_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Hematuria may not be attributed solely to alterations in coagulation or platelet function until competing causes have been ruled out.</div><div class=\"graphic_reference\">Courtesy of Michael Kurtz, MD.</div><div id=\"graphicVersion\">Graphic 63501 Version 7.0</div></div></div>"},"63502":{"type":"graphic_table","displayName":"Hypothermia treatment","title":"Preferred rewarming methods by stage of hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred rewarming methods by stage of hypothermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Rewarming methods*</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">All</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">&nbsp;</td> <td>Remove wet clothing</td> <td>Check ECG, continuously monitor cardiac rhythm</td> </tr> <tr> <td>Provide dry insulation</td> <td>Monitor core temperature</td> </tr> <tr> <td>Warm airway humidity</td> <td>Monitor circulation</td> </tr> <tr class=\"divider_bottom\"> <td>Warm IV (40-44&#176;C)<sup>&#182;</sup></td> <td>Warmed volume support</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mild (&#62;34&#176;C, 93&#176;F)</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Active external</td> <td>Watch for afterdrop</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moderate (30-34&#176;C, 86-93&#176;F)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\">Active external (forced air preferred)</td> <td>Watch for afterdrop</td> </tr> <tr class=\"divider_bottom\"> <td>Direct heating methods (eg, hot packs, heating pads) may cause burns</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Severe (&#60;30&#176;C, 86&#176;F) - or if methods above prove ineffective</td> </tr> <tr> <td class=\"indent1\">Circulation intact</td> <td>Left pleural lavage or forced air rewarming<sup>&#916;</sup></td> <td>As above, plus ensure warming is effective</td> </tr> <tr> <td class=\"indent1\">Circulation absent</td> <td>ECR rewarming</td> <td>Left pleural lavage (if ECR is unavailable)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ECR: extracorporeal.<br />* Many rewarming methods may be appropriate. The choice of methods should be based on provider experience, equipment availability, and individual patient needs.<br />¶ Warmed oral fluids may be given instead of warmed intravenous fluids to patients with mild hypothermia and normal mental status.<br />Δ When using forced air rewarming in a patient with severe hypothermia, the clinician should also provide aggressive fluid resuscitation with warmed intravenous normal saline and remain vigilant for core afterdrop and rewarming shock.</div><div id=\"graphicVersion\">Graphic 63502 Version 3.0</div></div></div>"},"63503":{"type":"graphic_picture","displayName":"SunMed introducer","title":"Sun-Med tracheal tube introducer (bougie)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sun-Med tracheal tube introducer (bougie)</div><div class=\"cntnt\"><img style=\"width:283px; height:454px;\" src=\"images/EM/63503_SunMed_bougie_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flexible endotracheal tube introducer (often referred to as a &quot;bougie&quot;) is an invaluable tool for difficult airway management. Once inserted into the trachea, the introducer serves as a conduit for an endotracheal tube, as shown in the picture.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun-Med. Copyright © 2008 Sun-Med.</div><div id=\"graphicVersion\">Graphic 63503 Version 4.0</div></div></div>"},"63504":{"type":"graphic_picture","displayName":"Prostate adenocarcinoma2 light","title":"Prostate cancer, Gleason pattern 4","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate cancer, Gleason pattern 4</div><div class=\"cntnt\"><img style=\"width:369px; height:278px;\" src=\"images/ONC/63504_Prostate_adenocarcinoma2_li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrograph of an hematoxylin- and eosin-stained section of the prostate gland containing prostate adenocarcinoma. This high-grade Gleason pattern 4 cancer is characterized by haphazardly infiltrating, poorly formed glands.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 63504 Version 3.0</div></div></div>"},"63505":{"type":"graphic_figure","displayName":"Exercise oxygen uptake","title":"Oxygen uptake, heart rate, and a-v O2 content difference at rest and during increasing levels of exercise","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Oxygen uptake, heart rate, and a-v O2 content difference at rest and during increasing levels of exercise</div><div class=\"cntnt\"><img style=\"width:500px; height:530px;\" src=\"images/CARD/63505_Exercise_oxygen_uptake.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With exercise and an increase in work load, there is an increase in oxygen (O2) uptake (upper panel), heart rate (HR) (middle panel), and a-v O2 difference (lower panel). Exercise training produced an increase in the maximal oxygen uptake (VO2 max) that can be achieved (upper panel) and a decrease in maximal HR occurring at any given work load (dashed blue line, middle panel).</div><div class=\"graphic_reference\">Data from Mitchell JH, Blomqvist, G. Maximal oxygen uptake. N Engl J Med 1971; 284:1018.</div><div id=\"graphicVersion\">Graphic 63505 Version 2.0</div></div></div>"},"63506":{"type":"graphic_table","displayName":"Etiology long term problems","title":"Environmental and occupational causes of health problems: latent or long-term effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Environmental and occupational causes of health problems: latent or long-term effects</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Latent or long-term effects</td>\n\n      <td class=\"subtitle1\">Agent</td>\n\n      <td class=\"subtitle1\">Potential exposures</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"3\" rowspan=\"1\">Chronic dyspnea</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Pulmonary fibrosis</td>\n\n      <td class=\"sublist_other\">Asbestos, silica, beryllium, coal, aluminum, nylon flock</td>\n\n      <td class=\"sublist_other\">Mining, insulation, pipefitting, sandblasting,\nquarrying, metal alloy work, aircraft or electrical parts nylon\nflocking industry</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Chronic bronchitis, emphysema</td>\n\n      <td class=\"sublist_other\">Cotton dust, cadmium coal dust, organic solvents,\ncigarettes</td>\n\n      <td class=\"sublist_other\">Textile industry, battery production, soldering,\nmining, solvent use</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lung cancer</td>\n\n      <td>Asbestos, arsenic, uranium, coke oven emission</td>\n\n      <td>Insulation, pipefitting, smelting, coke ovens, shipyard\nwork, nickel refining, uranium mining</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bladder cancer</td>\n\n      <td>&#946;-Naphthylamine, benzidine dyes</td>\n\n      <td>Dye industry, leather, rubber working, chemists</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Peripheral neuropathy</td>\n\n      <td>Lead, arsenic, n-hexane, methyl butylketone, acrylamide</td>\n\n      <td>Battery production, plumbing, smelting, painting,\nshoemaking, solvent use, insecticides</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Behavioral changes</td>\n\n      <td>Lead, carbon disulfide, manganese</td>\n\n      <td>Battery makers, smelting, viscose rayon industry,\ndegreasing, manufacture/repair of scientific instruments, dental\namalgam work, mining, ceramics</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Extrapyramidal syndrome</td>\n\n      <td>Carbon disulfide, manganese</td>\n\n      <td>Viscose rayon industry, steel production, battery\nproduction, foundry, mining</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aplastic anemia, leukemia</td>\n\n      <td>Benzene, ionizing radiation</td>\n\n      <td>Chemists, furniture refinishing, cleaning, degreasing,\nradiation work</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Goldman RH, Peters JM. JAMA 1981; 246:2831.</div><div id=\"graphicVersion\">Graphic 63506 Version 2.0</div></div></div>"},"63510":{"type":"graphic_movie","displayName":"Tongue atrophy and fasciculations in ALS","title":"Tongue atrophy and fasciculations in a patient with amyotrophic lateral sclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tongue atrophy and fasciculations in a patient with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/63510_alstnfscconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:243px;\" src=\"images/NEURO/63510_alstnfsc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is tongue atrophy and weakness. Tongue fasciculations and the characteristic &quot;can of worms&quot; appearance are evident. The patient has difficult protruding the tongue.</div><div class=\"graphic_reference\">Courtesy of Nestor Galvez-Jimenez, MD, FACP.</div><div id=\"graphicVersion\">Graphic 63510 Version 3.0</div></div></div>"},"63511":{"type":"graphic_picture","displayName":"HUS glomerular","title":"Light micrograph showing renal thrombotic microangiopathy with intracapillary glomerular thrombi","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing renal thrombotic microangiopathy with intracapillary glomerular thrombi</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/63511_HUS_Glomerular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing multiple intracapillary glomerular thrombi (arrows) typical of a thrombotic microangiopathy as can be seen in any of the forms of the hemolytic uremic syndrome.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63511 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"63514":{"type":"graphic_figure","displayName":"CRRT circuit","title":"Continuous renal replacement therapy circuit represented pumps and sites of entry of dialysate and predilution and postdilution substitution fluid","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Continuous renal replacement therapy circuit represented pumps and sites of entry of dialysate and predilution and postdilution substitution fluid</div><div class=\"cntnt\"><img style=\"width:750px; height:352px;\" src=\"images/NEPH/63514_CRRT_circuit.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Q<SUB>s</SUB> (pre): substitution fluid rate infused prefilter; Q<SUB>b</SUB>: blood flow rate; Q<SUB>d</SUB>: dialysate flow rate; Q<SUB>ef</SUB>: effluent flow rate (equivalent to Q<SUB>uf</SUB> in slow continuous ultrafiltration and continuous venovenous hemofiltration, Q<SUB>d</SUB> in continuous venovenous hemodialysis, and Q<SUB>uf</SUB> + Q<SUB>d</SUB> in continuous venovenous hemodiafiltration); Q<SUB>uf</SUB>: ultrafiltration rate; Q<SUB>s</SUB> (post): substitution fluid rate infused postfilter.</div><div class=\"graphic_reference\">Reproduced from: Macedo E, Mehta RL. Continuous dialysis therapies: Core curriculum 2016. Am J Kidney Dis 2016; 68:645. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63514 Version 3.0</div></div></div>"},"63515":{"type":"graphic_table","displayName":"Causes of ptosis","title":"Cardinal features of common underlying causes of ptosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardinal features of common underlying causes of ptosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Cause</td>\n<td class=\"subtitle1\">Levator function</td>\n<td class=\"subtitle1\">Eyelid crease margin</td>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Other clinical features</td>\n</tr>\n<tr>\n<td>Congenital abnormality of the levator muscle*</td>\n<td>Reduced</td>\n<td>Crease often absent</td>\n<td>Often unilateral</td>\n<td>Many patients also have amblyopia, strabismus</td>\n</tr>\n<tr>\n<td>Aponeurotic ptosis</td>\n<td>Normal</td>\n<td>Often increased</td>\n<td>Uni- or bilateral</td>\n<td>Isolated finding of ptosis</td>\n</tr>\n<tr>\n<td>Cranial nerve 3 palsy</td>\n<td>Reduced</td>\n<td>Normal</td>\n<td>Usually unilateral</td>\n<td>Impaired extraocular movement in ipsilateral eye. If ipsilateral pupil dilated, urgent evaluation for aneurysm is required.</td>\n</tr>\n<tr>\n<td>Horner's syndrome</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>Usually unilateral</td>\n<td>Ipsilateral miotic pupil</td>\n</tr>\n<tr>\n<td>Myasthenia</td>\n<td>Reduced</td>\n<td>Normal</td>\n<td>Uni- or bilateral</td>\n<td>Variable and fatigable. Diplopia and extraocular movement abnormalities often present.</td>\n</tr>\n<tr>\n<td>Muscle disease</td>\n<td>Reduced</td>\n<td>Normal</td>\n<td>Usually bilateral</td>\n<td>Orbicularis oculi, other extraocular or bulbar muscles may be affected</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Other, less common causes of congenital ptosis are discussed in text.</div><div id=\"graphicVersion\">Graphic 63515 Version 1.0</div></div></div>"},"63516":{"type":"graphic_figure","displayName":"VO2 and survival in HF","title":"Peak oxygen consumption and survival in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak oxygen consumption and survival in HF</div><div class=\"cntnt\"><img style=\"width:396px; height:231px;\" src=\"images/CARD/63516_VO2andsurvivalinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative survival in patients with heart failure according to maximal oxygen consumption (V<SUB>O2</SUB>) in mL/kg per min. Survival is markedly reduced in patients with a peak V<SUB>O2</SUB> below 10 mL/kg per min.</div><div class=\"graphic_reference\">Data from: Mancini DM, Eisen H, Kussmaul W, et al, Circulation 1991; 83:778.</div><div id=\"graphicVersion\">Graphic 63516 Version 2.0</div></div></div>"},"63517":{"type":"graphic_diagnosticimage","displayName":"Cervical wedge fracture","title":"Cervical anterior wedge fracture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cervical anterior wedge fracture</div><div class=\"cntnt\"><img style=\"width:504px; height:308px;\" src=\"images/EM/63517_Cervical_wedge_fx_lat2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 63517 Version 2.0</div></div></div>"},"63518":{"type":"graphic_algorithm","displayName":"Main airway management algorithm","title":"Main emergency airway management algorithm©","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Main emergency airway management algorithm&copy;</div><div class=\"cntnt\"><img style=\"width:572px; height:554px;\" src=\"images/EM/63518_Mainairwayalgoed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RSI: rapid sequence intubation.</div><div class=\"graphic_reference\">Reproduced with permission from: The Difficult Airway Course®: Emergency and Brown III CA, Walls RM. The Emergency Airway Algorithms. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia 2018. Copyright © 2018 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 63518 Version 12.0</div></div></div>"},"63519":{"type":"graphic_table","displayName":"AHA NASPE driving after VT VF","title":"AHA/NASPE guidelines for driving restriction following initiation of therapy for ventricular tachyarrhythmia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AHA/NASPE guidelines for driving restriction following initiation of therapy for ventricular tachyarrhythmia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of treatment and arrhythmia</td> <td class=\"subtitle1\">Noncommercial driving</td> <td class=\"subtitle1\">Commercial driving</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ICD or drugs for secondary prevention</td> </tr> <tr> <td class=\"indent1\">Sustained ventricular tachycardia (VT)</td> <td>Six months</td> <td>Indefinite</td> </tr> <tr> <td class=\"indent1\">Ventricular fibrillation</td> <td>Six months</td> <td>Indefinite</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ICD for primary prevention</td> </tr> <tr> <td class=\"indent1\">No symptomatic arrhythmia</td> <td> <p>At least one week post ICD implantation</p> <p>If appropriate ICD therapy received, especially with symptoms of cerebral hypoperfusion, should apply restrictions for treatment for secondary prevention</p> </td> <td>Indefinite</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Candidates for primary prevention</td> </tr> <tr> <td class=\"indent1\">Nonsustained VT with impaired consciousness</td> <td>Three months</td> <td>Six months unless ICD placed (see above)</td> </tr> <tr> <td class=\"indent1\">Nonsustained VT without impaired consciousness</td> <td>No restrictions (unless ICD placed; see above)</td> <td>No restrictions (unless ICD placed; see above)</td> </tr> <tr> <td class=\"indent1\">Idiopathic VT without impaired consciousness*</td> <td>Three months</td> <td>Six months unless ICD placed (see above)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.<br> * Idiopathic VT refers to VT occurring in patients with normal coronary arteries and normal ventricular function.</div><div class=\"graphic_reference\">Adapted from: Epstein, AE, Miles, WM, Benditt, DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147 and Epstein, AE, Baessler, CA, Curtis, AB, et al. Addendum to &quot;Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology&quot;: public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and Heart Rhythm Society. Circulation 2007; 115:1170.</div><div id=\"graphicVersion\">Graphic 63519 Version 4.0</div></div></div>"},"63521":{"type":"graphic_table","displayName":"Quantitative drug levels","title":"Quantitative drug levels that may direct therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quantitative drug levels that may direct therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Carboxyhemoglobin</td> </tr> <tr> <td>Methemoglobin</td> </tr> <tr> <td>Digoxin</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Theophylline</td> </tr> <tr> <td>Salicylate</td> </tr> <tr> <td>Paraquat</td> </tr> <tr> <td>Iron</td> </tr> <tr> <td>Methanol</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td class=\"sublist1_start\">Antiepileptic agents</td> </tr> <tr> <td class=\"sublist1\">Carbamazepine</td> </tr> <tr> <td class=\"sublist1\">Phenytoin</td> </tr> <tr> <td class=\"sublist1\">Valproic acid</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Lead</td> </tr> <tr> <td class=\"sublist1\">Mercury</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63521 Version 3.0</div></div></div>"},"63522":{"type":"graphic_table","displayName":"Characteristics of vasculitis","title":"Demographic characteristics of 807 patients with vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Demographic characteristics of 807 patients with vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease category</td> <td class=\"subtitle1\">Percent with disorder</td> <td class=\"subtitle1\">Mean age at disease onset</td> <td class=\"subtitle1\">Percent female</td> </tr> <tr> <td>Polyarteritis nodosa</td> <td>15</td> <td>48</td> <td>38</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> <td>3</td> <td>50</td> <td>37</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> <td>10</td> <td>45</td> <td>37</td> </tr> <tr> <td>Hypersensitivity vasculitis</td> <td>12</td> <td>47</td> <td>54</td> </tr> <tr> <td>Henoch-Schonlein purpura (IgA vasculitis)</td> <td>10</td> <td>17</td> <td>46</td> </tr> <tr> <td>Giant cell arteritis</td> <td>26</td> <td>69</td> <td>75</td> </tr> <tr> <td>Takayasu arteritis</td> <td>8</td> <td>26</td> <td>86</td> </tr> <tr> <td>Other vasculitis, type unspecified</td> <td>16</td> <td>44</td> <td>55</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Hunder GG, Arend WP, Bloch DA, et al. Arthritis Rheum 1990; 33:1065.</div><div id=\"graphicVersion\">Graphic 63522 Version 4.0</div></div></div>"},"63523":{"type":"graphic_figure","displayName":"Port placement for TAPP hernia repair","title":"Port placement for TAPP hernia repair","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Port placement for TAPP hernia repair</div><div class=\"cntnt\"><img style=\"width:486px; height:602px;\" src=\"images/SURG/63523_TAPP_ports.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63523 Version 3.0</div></div></div>"},"63526":{"type":"graphic_table","displayName":"Medications for spasticity","title":"Oral medications commonly used for spasticity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral medications commonly used for spasticity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">&nbsp;</td>\n\t\t\t\t\t<td class=\"subtitle1\">Starting dose</td>\n\t\t\t\t\t<td class=\"subtitle1\">Maximum dose</td>\n\t\t\t\t\t<td class=\"subtitle1\">Adverse effects</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Baclofen</td>\n\t\t\t\t\t<td>5 mg, three times daily</td>\n\t\t\t\t\t<td>80 mg daily, in divided doses</td>\n\t\t\t\t\t<td>Muscle weakness, sedation, dizziness, withdrawal syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Tizanidine</td>\n\t\t\t\t\t<td>2 mg daily</td>\n\t\t\t\t\t<td>36 mg daily in divided doses</td>\n\t\t\t\t\t<td>Sedation, weakness, dizziness, reversible elevation of transaminase</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diazepam</td>\n\t\t\t\t\t<td>2 mg twice daily or 5 mg at hs</td>\n\t\t\t\t\t<td>40 to 60 mg daily, in divided doses</td>\n\t\t\t\t\t<td>Sedation, cognitive impairment, dizziness, potential for dependence and withdrawal syndrome</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Dantrolene</td>\n\t\t\t\t\t<td>25 mg</td>\n\t\t\t\t\t<td>100 mg, four times daily</td>\n\t\t\t\t\t<td>Potentially irreversible hepatotoxicity requires regular monitoring, weakness, sedation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Clonidine</td>\n\t\t\t\t\t<td>0.05 mg, twice daily</td>\n\t\t\t\t\t<td>0.1 mg, four times daily</td>\n\t\t\t\t\t<td>Hypotension, bradycardia, dizziness, constipation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gabapentin</td>\n\t\t\t\t\t<td>100 mg three times daily</td>\n\t\t\t\t\t<td>3600 mg daily in divided doses</td>\n\t\t\t\t\t<td>Sedation, dizziness</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63526 Version 1.0</div></div></div>"},"63528":{"type":"graphic_figure","displayName":"Occiput anterior position","title":"Occiput anterior positions","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Occiput anterior positions</div><div class=\"cntnt\"><img style=\"width:540px; height:159px;\" src=\"images/OBGYN/63528_Occiput_anterior_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Right occiput anterior (ROA).<br />(B) Left occiput anterior (LOA)<br />(C) Occiput anterior (OA).</div><div class=\"graphic_footnotes\">* Posterior fontanel. This is the smaller of the two fontanels and is at the intersection of the three sutures: the sagittal suture and two lambdoid sutures.<br />** Anterior fontanel. This large fontanel is at the intersection of four sutures: the sagittal, frontal, and two coronal sutures.</div><div id=\"graphicVersion\">Graphic 63528 Version 3.0</div></div></div>"},"63529":{"type":"graphic_figure","displayName":"ICD low EF post MI MADIT II","title":"ICD improves survival in MADIT II","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">ICD improves survival in MADIT II</div><div class=\"cntnt\"><img style=\"width:454px; height:256px;\" src=\"images/CARD/63529_ICDlowEFpostMIMADITII.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of the probability of survival in the MADIT II trial in 1232 patients who had a myocardial infarction more than 30 days prior to enrollment (and more than three months if bypass surgery was performed) and an LVEF ≤30 percent. The patients were randomly assigned to a prophylactic ICD or conventional medical therapy. The study was prematurely terminated after an average follow-up of 20 months because the ICD significantly reduced all-cause mortality (14.2 versus 19.8 percent for conventional therapy, hazard ratio 0.65, 95% CI 0.51-0.93). The survival benefit was largely due to a reduction in sudden death.</div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction; ICD: implantable cardioverter-defibrillator.</div><div class=\"graphic_reference\">Data from: Moss AJ, Zareba W, Hall WJ, et al. N Engl J Med 2002; 346:877.</div><div id=\"graphicVersion\">Graphic 63529 Version 4.0</div></div></div>"},"63531":{"type":"graphic_diagnosticimage","displayName":"Hepatic hydrothorax PA","title":"Hepatic hydrothorax","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hydrothorax</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/PULM/63531_Hepatic_hydrothorax_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large right sided pleural effusion forming typical meniscoid arc (arrow) in patient with advanced liver cirrhosis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63531 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"63533":{"type":"graphic_picture","displayName":"Tubular amyloidosis","title":"Renal tubular amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Renal tubular amyloidosis</div><div class=\"cntnt\"><img style=\"width:501px; height:322px;\" src=\"images/NEPH/63533_Tubular_amyloidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amyloidosis with marked deposition in the tubular basement membranes on light microscopy (left panel, arrows). The amyloid deposits show green birefringence when viewed under polarized light with Congo red stain (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63533 Version 1.0</div></div></div>"},"63534":{"type":"graphic_figure","displayName":"Frequency of intracranial aneurysm rupture","title":"Graph showing risk of rupture of intracranial aneurysms among patients with and without history of prior subarachnoid hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing risk of rupture of intracranial aneurysms among patients with and without history of prior subarachnoid hemorrhage</div><div class=\"cntnt\"><img style=\"width:406px; height:458px;\" src=\"images/NEURO/63534_Probability_of_SAH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrospective analysis of the probability of subarachnoid hemorrhage (SAH) over time in patients with an unruptured intracranial aneurysm: 446 without (top panel) and 438 with (bottom panel) a history of SAH from a different aneurysm. The results are shown according to the size of the aneurysm. The risk is clearly related to the size of the aneurysm in patients with no prior history of SAH, with aneurysms &lt;10 mm in size having a very low incidence of rupture. Such a relationship was not apparent in those with a prior history of SAH; the values are not shown for aneurysms &ge;25 mm in this group because of the small number of patients.</div><div class=\"graphic_reference\">Data from: The International Study of Unruptured Intracranial Aneurysms Investigators, N Engl J Med 1998; 339:1725.</div><div id=\"graphicVersion\">Graphic 63534 Version 4.0</div></div></div>"},"63535":{"type":"graphic_figure","displayName":"External cephalic version forward somersault","title":"External cephalic version: Forward somersault","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External cephalic version: Forward somersault</div><div class=\"cntnt\"><img style=\"width:380px; height:526px;\" src=\"images/OBGYN/63535_External_cephalic_version2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetus is converted from breech to vertex presentation in (A) through (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Beckmann C, Ling FW, et al. Obstetrics and Gynecology, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63535 Version 5.0</div></div></div>"},"63537":{"type":"graphic_table","displayName":"Chemo met panc endocrine tum","title":"Selected trials of systemic chemotherapy for metastatic pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected trials of systemic chemotherapy for metastatic pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Number of patients*</td> <td class=\"subtitle1\">Tumor response rate, percent</td> <td class=\"subtitle1\">Median progression-free survival, months</td> <td class=\"subtitle1\">Median overall survival, months</td> <td class=\"subtitle1\">Author, year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Prospective studies</td> </tr> <tr> <td class=\"indent1\">Chlorozotocin</td> <td>33</td> <td>30<sup>&#182;</sup></td> <td>17</td> <td>18.0</td> <td rowspan=\"3\">Moertel C; 1992</td> </tr> <tr> <td class=\"indent1\">Fluorouracil + streptozocin</td> <td>33</td> <td>45<sup>&#182;</sup></td> <td>14</td> <td>16.8</td> </tr> <tr> <td class=\"indent1\">Doxorubicin + streptozocin</td> <td>36</td> <td>69<sup>&#182;</sup></td> <td>18</td> <td>26.4</td> </tr> <tr> <td class=\"indent1\">Dacarbazine (DTIC)</td> <td>50</td> <td>34</td> <td>NR</td> <td>19.3</td> <td>Ramanathan R; 2001</td> </tr> <tr> <td class=\"indent1\">Temozolomide + thalidomide</td> <td>11</td> <td>45</td> <td>NR</td> <td>NR</td> <td>Kulke M; 2006</td> </tr> <tr> <td class=\"indent1\">Temozolomide + bevacizumab</td> <td>15</td> <td>33</td> <td>14.3</td> <td>41.7</td> <td>Chan JA; 2012</td> </tr> <tr> <td class=\"indent1\">Temozolomide + everolimus</td> <td>40</td> <td>40</td> <td>15.4</td> <td>NR</td> <td>Chan JA; 2013</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Temozolomide + capecitabine</td> <td>11</td> <td>36</td> <td>&#62;20</td> <td>&#62;24.4</td> <td>Fine RL; 2014</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Retrospective series</td> </tr> <tr> <td class=\"indent1\">Steptozocin + doxorubicin + fluorouracil</td> <td>84<sup>&#916;</sup></td> <td>39</td> <td>18</td> <td>37</td> <td>Kouvaraki M; 2004</td> </tr> <tr> <td class=\"indent1\">Temozolomide (diverse regimens)</td> <td>53</td> <td>34</td> <td>13.6</td> <td>35.3</td> <td>Kulke M; 2009</td> </tr> <tr> <td class=\"indent1\">Streptozocin + fluorouracil</td> <td>96&nbsp;</td> <td>43</td> <td>19.4</td> <td>54.8</td> <td>Dilz LM; 2015</td> </tr> <tr> <td class=\"indent1\">Temozolomide (single agent)</td> <td>12</td> <td>8</td> <td>NR</td> <td>NR</td> <td>Ekeblad S; 2007</td> </tr> <tr> <td class=\"indent1\">Temozolomide + capecitabine</td> <td>30</td> <td>70</td> <td>18</td> <td>NR</td> <td>Strosberg J; 2011</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br />* Number of patients evaluable for efficacy endpoints.<br />¶ Combined biochemical and radiologic response rate.<br />Δ Includes patients with locally advanced disease.</div><div id=\"graphicVersion\">Graphic 63537 Version 10.0</div></div></div>"},"63538":{"type":"graphic_picture","displayName":"Alopecia areata severe","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:350px; height:330px;\" src=\"images/DERM/63538_Alopecia_areata_severe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread patchy hair loss is present in this patient with extensive alopecia areata involving the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63538 Version 2.0</div></div></div>"},"63539":{"type":"graphic_figure","displayName":"Cubitus varus deformity","title":"Cubitus varus deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cubitus varus deformity</div><div class=\"cntnt\"><img style=\"width:379px; height:499px;\" src=\"images/EM/63539_Cubitus_varus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Varus deformity of the elbow, also called cubitus varus, results in prominence of the elbow and decreased carrying angle (the forearm pointing towards the body when the arm is anatomic position). This abnormality is a complication of supracondylar fractures and lateral condyle elbow fractures.</div><div id=\"graphicVersion\">Graphic 63539 Version 2.0</div></div></div>"},"63540":{"type":"graphic_table","displayName":"Organophosphate and carbamate poisoning - Rapid overview","title":"Organophosphate and carbamate poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organophosphate and carbamate poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical syndromes</td> </tr> <tr> <td class=\"subtitle2_single\">Acute toxicity</td> </tr> <tr> <td class=\"indent1\">Generally manifests in minutes to hours</td> </tr> <tr> <td class=\"sublist2_start\">Evidence of cholinergic excess</td> </tr> <tr> <td class=\"sublist2\">SLUDGE = Salivation, Lacrimation, Urination, Defecation, Gastric Emptying</td> </tr> <tr> <td class=\"sublist2\">BBB = Bradycardia, Bronchorrhea, Bronchospasm</td> </tr> <tr> <td class=\"indent1\">Respiratory insufficiency can result from muscle weakness, decreased central drive, increased secretions, and bronchospasm</td> </tr> <tr> <td class=\"subtitle2_single\">Intermediate syndrome</td> </tr> <tr> <td class=\"indent1\">Occurs 24-96 hours after exposure</td> </tr> <tr> <td class=\"indent1\">Bulbar, respiratory, and proximal muscle weakness are prominent features</td> </tr> <tr> <td class=\"indent1\">Generally resolves in 1-3 weeks</td> </tr> <tr> <td class=\"subtitle2_single\">Organophosphorus Agent-Induced Delayed Peripheral Neuropathy (OPIDN)</td> </tr> <tr> <td class=\"indent1\">Usually occurs several weeks after exposure</td> </tr> <tr> <td class=\"indent1\">Primarily motor involvement</td> </tr> <tr> <td class=\"indent1\">May resolve spontaneously, but can result in permanent neurologic dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation of acute toxicity</td> </tr> <tr> <td class=\"sublist1_start\">Atropine challenge if diagnosis is in doubt (1 mg IV in adults, 0.01 to 0.02 mg/kg in children)</td> </tr> <tr> <td class=\"sublist1\">Absence of anticholinergic signs (tachycardia, mydriasis, decreased bowel sounds, dry skin) strongly suggests poisoning with organophosphate or carbamate</td> </tr> <tr> <td>Draw blood sample for measurement of RBC acetylcholinesterase activity to confirm diagnosis</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment of acute toxicity</td> </tr> <tr> <td>Deliver 100 percent oxygen via facemask; early intubation often required; avoid succinylcholine</td> </tr> <tr> <td><strong>Decontamination</strong> if ingestion within 1 hour give single dose activated charcoal, adult 50 g (1 g/kg in children) unless airway not protected or other contraindication. Aggressive dermal and ocular irrigation as needed. Bag/discard clothing.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Atropine</strong> 2 to 5 mg IV/IM/IO bolus (0.05 mg/kg IV in children)</td> </tr> <tr> <td class=\"sublist1\">Escalate (double) dose every 3-5 minutes until bronchial secretions and wheezing stop</td> </tr> <tr> <td class=\"sublist1\">TACHYCARDIA AND MYDRIASIS ARE NOT CONTRAINDICATIONS TO ATROPINE USE</td> </tr> <tr> <td class=\"sublist1\">Hundreds of milligrams may be needed over several days in severe poisonings</td> </tr> <tr> <td class=\"sublist1\">Inhaled ipratropium 0.5 mg with parenteral atropine may be helpful for bronchospasm; may repeat</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Pralidoxime</strong> (2-PAM) 2 g (25 mg/kg in children) IV over 30 minutes; may repeat after 30 minutes or give continuous infusion if severe</td> </tr> <tr> <td class=\"sublist1\">Continuous infusion at 8 mg/kg/hour in adults (10 mg/kg/hour in children)</td> </tr> <tr> <td class=\"sublist1\">If no IV access, give pralidoxime 600 mg IM (15 mg/kg in children &#60;40 kg). Rapidly repeat as needed to total of 1800 mg or 45 mg/kg in children.</td> </tr> <tr> <td class=\"sublist1\">Pralidoxime is given with atropine</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Benzodiazepine therapy</strong></td> </tr> <tr> <td class=\"sublist1\">Diazepam 10 mg IV (0.1 to 0.2 mg/kg in children), repeat as necessary if seizures occur. Do not give phenytoin.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63540 Version 11.0</div></div></div>"},"63541":{"type":"graphic_figure","displayName":"Antigen presentation","title":"Representation of T cell activation","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Representation of T cell activation</div><div class=\"cntnt\"><img style=\"width:482px; height:260px;\" src=\"images/ENDO/63541_Antigenpresentation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of initiation of the immunologic response to an antigen. The antigen binds to a groove in MHC class II molecules on antigen-presenting cells (such as macrophages). This binding allows the antigen to be presented to antigen receptors on autoreactive CD4 inducer or helper T cells, which, in type 1 diabetes mellitus, initiate autoimmune injury to the pancreatic beta cells. In addition, the respective binding of B7 proteins and LFA-3 on antigen-presenting cells to CD28 and CD2 on T cells are important <STRONG>costimulatory pathways</STRONG> that further increase T cell activation. Other molecules can also&nbsp;participate in the immune response, such as the binding of interleukin-2 to its receptor (IL-2R).</div><div class=\"graphic_footnotes\">MHC: major histocompatibility complex; LFA-3: lymphocyte functional antigen-3; IL-2R: interleukin-2 receptor.</div><div id=\"graphicVersion\">Graphic 63541 Version 5.0</div></div></div>"},"63544":{"type":"graphic_figure","displayName":"Flow volume loop airway lesions","title":"Schematic flow-volume loop configuration in a spectrum of airway lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic flow-volume loop configuration in a spectrum of airway lesions</div><div class=\"cntnt\"><img style=\"width:400px; height:234px;\" src=\"images/PULM/63544_Flow_volume_loop_airway_les.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal.<br />(B) Variable extrathoracic upper airway obstruction.<br />(C) Variable intrathoracic upper airway lesions.<br />(D) Fixed upper airway obstruction.<br />(E) Lower airways obstruction.</div><div id=\"graphicVersion\">Graphic 63544 Version 3.0</div></div></div>"},"63545":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR III","title":"Infected subcarinal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected subcarinal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/63545_Med_bronchogen_cyst_CXR_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a bronchogenic cyst after infection. Gas is visible projecting posterior to the right atrium.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63545 Version 3.0</div></div></div>"},"63547":{"type":"graphic_figure","displayName":"Sarcomere function","title":"Relationship between myocardial sarcomere length and tension","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Relationship between myocardial sarcomere length and tension</div><div class=\"cntnt\"><img style=\"width:562px; height:296px;\" src=\"images/CARD/63547_Sarcomerefunctionedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel (A) is a schematic of a sarcomere. The thin filaments (actin, shown in black) are attached at the Z band. The length of two actin filaments as they extend from the Z band is indicated by \"b.\" The length of a thick filament (myosin, shown in maroon) is denoted by \"a.\" Panels B and C show the correlation between sarcomere stretch and tension. Position number 1 shows extreme sarcomere stretch (as occurs in the volume-overloaded ventricle) where neither actin filament can interact with the myosin filament; as a result, tension development is zero. Points 2 and 3 demonstrate situations of maximum actin myosin overlap with maximal tension production.</div><div class=\"graphic_reference\">Reproduced with permission from: Braunwald E, Ross J Jr, Sonnenblick EH, Mechanisms of Contraction of the Normal and Failing Heart, 2d ed, Little, Brown, Boston, 1972. Copyright © 1972 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 63547 Version 8.0</div></div></div>"},"63551":{"type":"graphic_diagnosticimage","displayName":"MRI of tethered spinal cord and lipoma","title":"MRI of the lumbar spine showing a tethered cord and lipoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of the lumbar spine showing a tethered cord and lipoma</div><div class=\"cntnt\"><img style=\"width:207px; height:504px;\" src=\"images/PEDS/63551_Tethered_cord_and_lipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lumbar spine MRI with T1-weighted sagittal image demonstrating a tethered cord (arrow) and lipoma (asterisk) in a two-year-old girl.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 63551 Version 4.0</div></div></div>"},"63554":{"type":"graphic_diagnosticimage","displayName":"Pelvic rt field","title":"Pelvic radiation therapy field with vaginal marker","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pelvic radiation therapy field with vaginal marker</div><div class=\"cntnt\"><img style=\"width:332px; height:558px;\" src=\"images/OBGYN/63554_Pelvic_rt_field.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph (A) and computed tomography (CT) scan (B) demonstrating a radiopaque vaginal marker, placed to aid in localization of the vagina for treatment planning.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 63554 Version 2.0</div></div></div>"},"63556":{"type":"graphic_picture","displayName":"Infant with bullous mastocytosis","title":"Bullous eruption on the back of a child with diffuse cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous eruption on the back of a child with diffuse cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/ALLRG/63556_Infant_bullous_mastocyt_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63556 Version 2.0</div></div></div>"},"63557":{"type":"graphic_picture","displayName":"Photoallergic eruption 2","title":"Photoallergic eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photoallergic eruption</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63557_Photoallergic_eruption_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 45-year-old woman developed an acute, well-demarcated, erythematous plaque with vesicles after topical application of ketoprofen gel followed by sun exposure. The patient wore socks, which protected the foot from the sun, creating the line of demarcation that is visible in the image.</div><div class=\"graphic_reference\">Copyright © Eric Ehrsam, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 63557 Version 8.0</div></div></div>"},"63558":{"type":"graphic_table","displayName":"Metabolic actions insulin","title":"Metabolic actions of insulin on lipid and protein metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Metabolic actions of insulin on lipid and protein metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Glucose metabolism (see text)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Lipid metabolism</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Inhibition of lipolysis in fat; decreased plasma fatty acid concentrations</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Stimulation of fatty acid and triacylglycerol synthesis in fat and liver</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Increased lipoprotein lipase activity in fat; increased triglyceride uptake into fat</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Decreased fatty acid oxidation in muscle and liver</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Increased rate of formation of very-low-density lipoproteins in liver</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Protein metabolism</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Increased transport of some amino acids into muscle, adipose tissue, liver and other cells</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Increased rate of protein synthesis in muscle, adipose tissue, liver and other tissues</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Decreased proteolysis in muscle</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Decreased urea formation</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63558 Version 2.0</div></div></div>"},"63559":{"type":"graphic_algorithm","displayName":"Confirmation of the triggers of anaphylaxis","title":"Confirmation of the triggers of anaphylaxis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confirmation of the triggers of anaphylaxis</div><div class=\"cntnt\"><img style=\"width:261px; height:446px;\" src=\"images/ALLRG/63559_Anatriggerconfirmedt3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.<br />* Proceed with caution. Perform only if the cause is in doubt. Allergen challenge tests should only be conducted in well-equipped medical facilities staffed with clinicians and nurses who are trained in patient selection, in patient assessment on the day of challenge, and in prevention and treatment of anaphylaxis.</div><div id=\"graphicVersion\">Graphic 63559 Version 10.0</div></div></div>"},"63560":{"type":"graphic_figure","displayName":"Vertical skin incisions of the abdominal wall","title":"Vertical skin incisions of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Vertical skin incisions of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:481px; height:350px;\" src=\"images/SURG/63560_Longitudinal_incisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 63560 Version 4.0</div></div></div>"},"63561":{"type":"graphic_figure","displayName":"CV risk with HTN is lower in women than men","title":"Hypertensive cardiovascular risk is less in women than men","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Hypertensive cardiovascular risk is less in women than men</div><div class=\"cntnt\"><img style=\"width:594px; height:355px;\" src=\"images/NEPH/63561_Lower_CV_risk_in_HTV_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approximate 10 year risk of cardiovascular disease (CVD) per 100 patients according to severity of hypertension, the number of risk factors, age, and gender. The cardiovascular risk increases with the degree of hypertension, the number of risk factors and age and, when these three factors are equivalent, is substantially less in women.</div><div class=\"graphic_footnotes\">* Treatment is indicated in individuals with sustained average blood pressures above 170/100 even if they might have low absolute risk.</div><div class=\"graphic_reference\">Redrawn from: Jackson R, Barham P, Bills J, et al, BMJ 1993; 307:107.</div><div id=\"graphicVersion\">Graphic 63561 Version 2.0</div></div></div>"},"63562":{"type":"graphic_table","displayName":"Risk factors primary BSI","title":"Risk factors for catheter-associated primary bloodstream infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for catheter-associated primary bloodstream infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Peripheral intravascular catheters</td> </tr> <tr> <td>Lower extremities more than upper extremities</td> </tr> <tr> <td>Wrist more than hand</td> </tr> <tr> <td>Placement longer than three to four days</td> </tr> <tr> <td>Polyvinyl chloride and polyethylene more than Teflon</td> </tr> <tr> <td class=\"subtitle1_single\">Arterial catheters</td> </tr> <tr> <td>Colonization at catheter site</td> </tr> <tr> <td>Catheterization longer than four to six days</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary artery catheters</td> </tr> <tr> <td>Catheterization longer than three to five days</td> </tr> <tr> <td>Colonization of skin at insertion site</td> </tr> <tr> <td>Catheter insertion using submaximal barrier precautions</td> </tr> <tr> <td>Internal jugular more than subclavian</td> </tr> <tr> <td>Regular protective plastic sleeves more than shield sleeves</td> </tr> <tr> <td class=\"subtitle1_single\">Central venous catheters</td> </tr> <tr> <td>Internal jugular more than subclavian</td> </tr> <tr> <td>Repeated catheterization</td> </tr> <tr> <td>Presence of septic focus elsewhere</td> </tr> <tr> <td>Nontunneled more than tunneled</td> </tr> <tr> <td>Tunneled more than totally implantable device</td> </tr> <tr> <td>Catheter insertion using submaximal barrier precautions</td> </tr> <tr> <td>Lower risk with silver-chelated collagen cuff</td> </tr> <tr> <td>Lower risk with antibiotic or antiseptic impregnated short-term catheters</td> </tr> <tr> <td class=\"subtitle1_single\">Catheter-care factors</td> </tr> <tr> <td>Insertion circumstance:&nbsp;Emergency more than elective</td> </tr> <tr> <td>Skill of the inserter: General more than specialized</td> </tr> <tr> <td>Skin under dressing: Moist greater than dry</td> </tr> <tr> <td>Cutaneous antiseptics: 70% alcohol and 10% povidone iodine more</td> </tr> <tr> <td>Antibiotic-lock solutions: Lower risk in neutropenic patients with long-term catheters</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63562 Version 2.0</div></div></div>"},"63566":{"type":"graphic_table","displayName":"Pediatric hip pain history","title":"Important aspects of the history in the evaluation of a child with hip pain unrelated to acute trauma or fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in the evaluation of a child with hip pain unrelated to acute trauma or fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential clinical significance</td> </tr> <tr> <td><strong>Age</strong></td> <td>Typical age for: <ul> <li>Bacterial arthritis: 0 to 6 years </li> <li>Transient synovitis: 3 to 8 years </li> <li>SCFE: Early adolescence </li> <li>Idiopathic chondrolysis: 10 to 20 years </li> </ul> </td> </tr> <tr> <td><strong>Sex</strong></td> <td> <p>More common in males: Legg-Calv&#233;-Perthes disease, septic arthritis, transient synovitis, SCFE</p> More common in females: Idiopathic chondrolysis, chronic recurrent multifocal osteomyelitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pain</td> </tr> <tr> <td class=\"indent1\">Onset</td> <td> <p>Acute: Infectious, transient synovitis, acute trauma</p> Insidious: SCFE, Legg-Calv&#233;-Perthes disease, spondyloarthritis</td> </tr> <tr> <td class=\"indent1\">Severity</td> <td> <p>Refusal to bear weight: Septic arthritis, osteomyelitis (femur or pelvis), malignancy, trauma, transient synovitis; also may be due to discitis</p> Willing to bear weight with limp or antalgic gait: Transient synovitis, systemic JIA, SCFE, Legg-Calv&#233;-Perthes disease</td> </tr> <tr> <td class=\"indent1\">Location</td> <td> <p>Isolated hip pain (which may be localized to the thigh or knee): Septic arthritis, osteomyelitis, Legg-Calv&#233;-Perthes disease, SCFE</p> Pain in other joints (uncommon): Viral/postviral, JIA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Associated systemic symptoms</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>Infection, systemic JIA, IBD-associated arthritis, neoplasm</td> </tr> <tr> <td class=\"indent1\">Other constitutional (eg, fatigue, weight loss) or gastrointestinal symptoms</td> <td>Systemic JIA, IBD-associated arthritis, neoplasm</td> </tr> <tr> <td class=\"indent1\">Rash</td> <td>Systemic JIA, viral/postviral</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past medical history</td> </tr> <tr> <td class=\"indent1\">Previous episodes of hip pain</td> <td>Systemic JIA, transient synovitis, mechanical</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> <td>SCFE</td> </tr> <tr> <td class=\"indent1\">Endocrine disorder (hypothyroidism, growth hormone deficiency)</td> <td>SCFE</td> </tr> <tr> <td class=\"indent1\">Recent infection</td> <td>Postinfectious or reactive arthritis, septic arthritis (if bacterial), osteomyelitis (if bacterial)</td> </tr> <tr> <td class=\"indent1\">Recent antibiotics</td> <td>May alter the presentation of septic arthritis or osteomyelitis</td> </tr> <tr> <td class=\"indent1\">Tick exposure</td> <td>Lyme arthritis</td> </tr> <tr> <td><strong>Family history</strong></td> <td>Family history of inflammatory arthritis, psoriasis, IBD, or uveitis may be associated with JIA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Social history</td> </tr> <tr> <td class=\"indent1\">Sports participation, particularly endurance sports or dance</td> <td>Stress fracture, iliac apophysitis, snapping iliopsoas tendon, trochanteric bursitis; acetabular labral tear, femoroacetabular impingement</td> </tr> <tr> <td class=\"indent1\">Sexually active</td> <td>Infectious (eg, disseminated gonococcal) or reactive (<em>Chlamydia trachomatis</em>) arthritis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCFE: slipped capital femoral epiphysis; JIA: juvenile idiopathic arthritis; IBD: inflammatory bowel disease.</div><div id=\"graphicVersion\">Graphic 63566 Version 5.0</div></div></div>"},"63567":{"type":"graphic_figure","displayName":"McBurney incision 2","title":"McBurney incision 2","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">McBurney incision 2</div><div class=\"cntnt\"><img style=\"width:536px; height:283px;\" src=\"images/SURG/63567_McBurney_incision_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(C) Peritoneum and transversalis fascia incised. (D) Fibers of internal oblique reapproximated.</div><div id=\"graphicVersion\">Graphic 63567 Version 4.0</div></div></div>"},"63568":{"type":"graphic_waveform","displayName":"Advanced case 7","title":"Advanced case 7","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 7</div><div class=\"cntnt\"><img style=\"width:540px; height:264px;\" src=\"images/CARD/63568_Advanced_case_7.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63568 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"63569":{"type":"graphic_waveform","displayName":"Intermediate case 11 answer","title":"Hyperkalemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperkalemia</div><div class=\"cntnt\"><img style=\"width:337px; height:253px;\" src=\"images/CARD/63569_Intermediate_case_11_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral precordial leads showing peaked, narrow (tented) T waves and prolongation of the QRS complex (0.14 to 0.16 seconds) associated with moderate to severe hyperkalemia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 63569 Version 2.0</div></div></div>"},"63571":{"type":"graphic_diagnosticimage","displayName":"Finger flexor power Doppler","title":"Finger flexor power Doppler sonogram","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Finger flexor power Doppler sonogram</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/RHEUM/63571_Finger_flexor_power_Doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This power Doppler sonogram shows a longitudinal cut of a finger flexor tenosynovitis at the third proximal interphalangeal joint (PIP 3), showing signs of inflammation, including tendon contour irregularity, sheath widening, sheath thickening, surrounding anechoic fluid, and positive power Doppler signal (red and orange areas).</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 63571 Version 3.0</div></div></div>"},"63573":{"type":"graphic_waveform","displayName":"LV and aortic pressure - high fidelity","title":"LV and aortic pressure - high fidelity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LV and aortic pressure - high fidelity</div><div class=\"cntnt\"><img style=\"width:419px; height:312px;\" src=\"images/CARD/63573_LV_aort_press_high_fidelity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LV and aortic pressures from dual high fidelity transducer catheter during pullback across aortic valve. Note the matching of aortic pressures between central locations.</div><div id=\"graphicVersion\">Graphic 63573 Version 2.0</div></div></div>"},"63574":{"type":"graphic_picture","displayName":"Necrobiosis lipoidica 3","title":"Necrobiosis lipoidica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrobiosis lipoidica</div><div class=\"cntnt\"><img style=\"width:420px; height:365px;\" src=\"images/DERM/63574_Necrobiosis_lipoidica_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow-red or yellow-brown plaques with atrophy and telangiectasias are consistent with necrobiosis lipoidica.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63574 Version 2.0</div></div></div>"},"63575":{"type":"graphic_figure","displayName":"HDV virion","title":"HDV virion","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">HDV virion</div><div class=\"cntnt\"><img style=\"width:460px; height:336px;\" src=\"images/GAST/63575_HDV_virion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the hepatitis D virus virion. The HD virion comprises an RNA genome, a single HDV encoded antigen, and a lipoprotein envelope provided by HBV.</div><div id=\"graphicVersion\">Graphic 63575 Version 1.0</div></div></div>"},"63577":{"type":"graphic_table","displayName":"Differentiation of foot ulcers","title":"Differentiation of foot ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiation of foot ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Arterial ulcer*</td> <td class=\"subtitle1\">Venous ulcer</td> <td class=\"subtitle1\">Neuropathic ulcer*</td> </tr> <tr> <td>Location</td> <td>Over toe joints, malleoli (over the bony prominence), anterior shin, base of heel, pressure points</td> <td>Medial and lateral malleolar area above bony prominence, posterior calf, may be large, circumferential</td> <td>Plantar surface of foot over metatarsal heads, heel, pressure points</td> </tr> <tr> <td>Appearance</td> <td>Irregular margins, base dry and often pale or necrotic (brown/black fibrous tissue)</td> <td>Irregular margins, pink or red base that may be covered with yellow fibrinous tissue, exudate common (may be heavy); ulcers can be large, sometimes circumferential</td> <td>Punched out ulcer, usually superficial but sometimes deep, red base</td> </tr> <tr> <td>Ulcer within callus</td> <td>Rare</td> <td>No</td> <td>Calloused border, ulcer can be underlying a callus</td> </tr> <tr> <td>Foot temperature</td> <td>Warm or cool</td> <td>Warm</td> <td>Warm</td> </tr> <tr> <td>Pain</td> <td>Yes, may be severe</td> <td>Yes, usually mild but may be severe</td> <td>No</td> </tr> <tr> <td>Arterial pulses</td> <td>Absent</td> <td>Present</td> <td>Present or absent</td> </tr> <tr> <td>Sensation</td> <td>Variable</td> <td>Present</td> <td>Absent tactile, pain, temperature and vibratory sensations</td> </tr> <tr> <td>Foot deformities</td> <td>No</td> <td>No</td> <td>Often</td> </tr> <tr> <td>Skin changes</td> <td> <p>Shiny, taut, loss of hair</p> <p>Dependent rubor of leg and foot that becomes pale with leg elevation</p> </td> <td>Erythema, brown-blue hyperpigmentation can be spotty or diffuse: \"stasis\" changes; atrophie blanche (white sclerotic areas), edema; dry skin; varicose veins common; if lipodermatosclerosis is present, skin may be bound down; bilateral lower extremities often affected</td> <td>Waxy or shiny, loss of hair, may be taut; dry skin; may have non-pitting edema, especially on dorsal foot</td> </tr> <tr> <td>Reflexes</td> <td>Present</td> <td>Present</td> <td>Absent</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Ulcers on the foot and leg are most often due to arterial or venous disease, neuropathy, or more than one of these conditions. Although the most common causes of lower extremity ulcers are venous, arterial, and neuropathic, there are other causes (eg, vasculitis). Mixed ulcers are common (eg, arterial-venous, arterial-neuropathic), and characteristics will vary from single etiology ulcers. In particular, diabetic ulcers are often due to peripheral artery disease and neuropathic disease.<br />Duplex ultrasound is indicated in cases of ankle ulceration for detection of venous reflux. Deep venous insufficiency can lead to lateral or medial ulcer locations. In the absence of deep venous insufficiency, a lateral venous ulcer is most frequently associated with small saphenous vein reflux while medial ulcers are associated with greater saphenous vein reflux.</div><div class=\"graphic_footnotes\">* Diabetic foot ulcers are often due to both arterial disease (involving the microcirculation as well as large vessels) and neuropathic disease.</div><div class=\"graphic_reference\">Adapted from: Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31:S1.</div><div id=\"graphicVersion\">Graphic 63577 Version 4.0</div></div></div>"},"63578":{"type":"graphic_table","displayName":"High chol treat PI","title":"American Academy of Pediatrics recommendations on screening for and treatment of high cholesterol in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Academy of Pediatrics recommendations on screening for and treatment of high cholesterol in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">When to perform screening tests*?</td> </tr> <tr> <td>If family history of high cholesterol or early cardiovascular disease</td> </tr> <tr> <td>If family history unknown</td> </tr> <tr> <td>If child has risk factors (obesity, high blood pressure, medical illness that increases risk)</td> </tr> <tr> <td>Perform testing every 3 to 5 years beginning at age 2 years</td> </tr> <tr> <td class=\"subtitle1_single\">When to begin lifestyle changes (diet, exercise)?</td> </tr> <tr> <td>At 1 year of age, begin reduced-fat (2 percent) milk for children at risk due to obesity or family history of cardiovascular disease</td> </tr> <tr> <td>In children with elevated serum LDL-C, the recommended diet should have saturated fat &#60;7 percent, trans fat &#60;1 percent, dietary cholesterol &#60;200 mg/day, and fiber intake equal to child's age plus 5 g/day (up to 20 g/day at 15 years of age)</td> </tr> <tr> <td>Encourage physical activity to manage weight and treat high triglyceride levels and low HDL cholesterol levels</td> </tr> <tr> <td class=\"subtitle1_single\">When to consider medication for high cholesterol?</td> </tr> <tr> <td>Consider medication in children at least 8 years of age or older, if LDL &#8805;190 mg/dL or &#8805;160 mg/dL with positive family history or two additional risk factors or &#8805;130 mg/dL with type 1 diabetes mellitus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Screening tests usually include blood tests for total cholesterol, HDL (high density lipoprotein), LDL (low density lipoprotein), and triglycerides, drawn before the first meal of the day.</div><div class=\"graphic_reference\">Data from: Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198.</div><div id=\"graphicVersion\">Graphic 63578 Version 4.0</div></div></div>"},"63579":{"type":"graphic_picture","displayName":"Entropion","title":"Entropion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Entropion</div><div class=\"cntnt\"><img style=\"width:432px; height:284px;\" src=\"images/PC/63579_Entropion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inward turning of the lower eyelid with eyelashes rubbing against the ocular surface.</div><div id=\"graphicVersion\">Graphic 63579 Version 1.0</div></div></div>"},"63580":{"type":"graphic_table","displayName":"Associations with E nodosum","title":"Conditions associated with erythema nodosum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with erythema nodosum</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n<tr>\n<td>Idiopathic</td>\n</tr>\n<tr>\n<td>Familial</td>\n</tr>\n<tr>\n<td>Pregnancy (particularly second trimester)</td>\n</tr>\n\n<tr>\n<td class=\"sublist1_start\">Systemic diseases</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Inflammatory bowel disease</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Sarcoidosis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Malignancy</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Collagen vascular disease</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Sweet's syndrome</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Drugs</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Antibiotics (penicillin, sulfonamides)</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Birth control pills</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Omeprazole</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Immunizations</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Infections</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Streptococcal pharyngitis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Tuberculosis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Salmonella gastroenteritis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Cat scratch fever</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Leprosy</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Yersinia colitis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Psittacosis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Histoplasmosis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Blastomycosis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Coccidiomycosis</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">15.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=70187&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Associations_with_E_nodosum.htm</title></head></div><div id=\"graphicVersion\">Graphic 63580 Version 1.0</div></div></div>"},"63581":{"type":"graphic_form","displayName":"Subjective global assessment form","title":"Evaluation form for subjective global assessment","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Evaluation form for subjective global assessment</div><div class=\"cntnt\"><img style=\"width:595px; height:784px;\" src=\"images/GAST/63581_Subj_glob_assess_form_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(A) Well nourished</strong> _____.<br> <strong>(B) Mild/moderate undernutrition</strong> _____.<br> <strong>(C) Severe undernutrition</strong> _____.<br> The subjective global assessment (SGA) score is a subjective score. Each medical history and physical examination paramater is rated by the clinician as A (well-nourished), B (moderately malnourished), or C (severly malnourished). The ratings for each of the parameters are then used as a guide to determine the patient's subjecitve SGA score. For example, if a patient has more B or C ratings than A ratings, the patient is more likely to be malnourished.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced with permission from: Sacks GS, Dearman K, Replogle WH, et al. Use of subjective global assessment to identify nutrition-associated complications and death in geriatric long-term care facility residents. J Am Coll Nutr 2000; 19:570. Copyright © 2000 American College of Nutrition.</div><div id=\"graphicVersion\">Graphic 63581 Version 3.0</div></div></div>"},"63582":{"type":"graphic_picture","displayName":"Negative pressure wound dressing in situ","title":"Negative pressure wound dressing in situ","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Negative pressure wound dressing in situ</div><div class=\"cntnt\"><img style=\"width:546px; height:365px;\" src=\"images/SURG/63582_Vacuumassistedclosdress.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fischer JE, Evenson AR. Gastrointestinal-cutaneous fistulae. In: Mastery of Surgery, Fischer JE (Ed), Lippincott Williams &amp; Wilkins 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63582 Version 8.0</div></div></div>"},"63584":{"type":"graphic_table","displayName":"Risk factors fracture after transplant","title":"Risk factors for fracture after transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for fracture after transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pretransplant factors</td> </tr> <tr> <td class=\"sublist1_start\">Low bone mineral density related to underlying disease</td> </tr> <tr> <td class=\"sublist1\">Hepatic osteodystrophy</td> </tr> <tr> <td class=\"sublist1\">Osteoporosis of end-stage pulmonary disease</td> </tr> <tr> <td class=\"sublist1\">Renal osteodystrophy</td> </tr> <tr> <td class=\"sublist1\">Heart failure</td> </tr> <tr> <td class=\"sublist1\">Diabetes</td> </tr> <tr> <td>Pre-existing history of fracture</td> </tr> <tr> <td>Advanced age</td> </tr> <tr> <td class=\"sublist1_start\">Chronic illness</td> </tr> <tr> <td class=\"sublist1\">Poor nutrition</td> </tr> <tr> <td class=\"sublist1\">Vitamin D deficiency</td> </tr> <tr> <td class=\"sublist1\">Immobilization</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> <tr> <td>Hypogonadism</td> </tr> <tr> <td class=\"sublist1_start\">Medications</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids</td> </tr> <tr> <td class=\"sublist1_start\">Lifestyle factors</td> </tr> <tr> <td class=\"sublist1\">Smoking</td> </tr> <tr> <td class=\"sublist1\">Alcohol abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Posttransplant factors</td> </tr> <tr> <td class=\"sublist1_start\">Immunosuppressive regimens</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids</td> </tr> <tr> <td class=\"sublist1\">Calcineurin inhibitors (cyclosporine, tacrolimus)</td> </tr> <tr> <td class=\"sublist1_start\">Chronic illness</td> </tr> <tr> <td class=\"sublist1\">Poor nutrition</td> </tr> <tr> <td class=\"sublist1\">Vitamin D deficiency</td> </tr> <tr> <td class=\"sublist1\">Immobilization</td> </tr> <tr> <td>Hypogonadism</td> </tr> <tr> <td class=\"sublist1_start\">Lifestyle factors</td> </tr> <tr> <td class=\"sublist1\">Smoking</td> </tr> <tr> <td class=\"sublist1\">Alcohol abuse</td> </tr> <tr> <td class=\"sublist1\">Inactivity</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Maalouf NM and Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90:2456.</LI>&#xD;&#xA;<LI>Rakel A, Sheehy O, Rahme E, et al. Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study. J Bone Miner Res 2007; 22:1878.</LI></OL></div><div id=\"graphicVersion\">Graphic 63584 Version 3.0</div></div></div>"},"63586":{"type":"graphic_table","displayName":"R-CHOP21 regimen for non-Hodgkin lymphoma","title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP21) for non-Hodgkin lymphoma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP21) for non-Hodgkin lymphoma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Rituximab</strong></td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated<sup>[2]</sup>. For subsequent infusions, administer 20 percent of the total dose over the first 30 minutes and the remaining 80 percent over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &#8805;5000/microL.*</td> <td>Day 1</td> </tr> <tr> <td><strong>Cyclophosphamide</strong></td> <td>750 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS or D5W and administer over 30 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Doxorubicin</strong></td> <td>50 mg/m<sup>2</sup> IV</td> <td>Dilute in 50 mL NS or D5W and administer over three to five minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Vincristine</strong></td> <td>1.4 mg/m<sup>2</sup> IV (max dose 2 mg)</td> <td>Dilute in 50 mL NS or D5W and administer over 15 to 20 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Prednisone</strong></td> <td>100 mg orally</td> <td>Administer 30 minutes prior to chemotherapy on day 1, then every 24 hours on days 2 to 5.</td> <td>Days 1 to 5</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab<sup>[2]</sup>. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Doxorubicin and vincristine are vesicants; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> The risk of febrile neutropenia with this regimen is 10 to 20 percent<sup>[1]</sup>; primary prophylaxis with hematopoietic growth factors should be considered on an individual basis, particularly for high-risk patients such as those with preexisting neutropenia, advanced disease, poor performance status, or patients age 65 years or older. Refer to UpToDate topic on the \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Adjustment of initial cyclophosphamide, doxorubicin, and vincristine doses may be needed for preexisting liver dysfunction<sup>[3-5]</sup>. In addition, dose adjustment of cyclophosphamide may be required for renal dysfunction. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatitis screening:</strong> Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for&nbsp;antiviral prophylaxis. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac screening:</strong> LVEF should be evaluated prior to initiation of therapy. Dose alterations should be considered for LVEF &#60;50 percent, and doxorubicin therapy is contraindicated in patients with LVEF &#60;30 percent at initiation. Infusion times and schedule may be adjusted to decrease the risk of cardiotoxicity in individuals at high risk for its development. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurotoxicity:</strong> Vincristine may cause constipation, and in severe cases, paralytic ileus. A routine prophylactic regimen against constipation is recommended in all patients receiving vincristine. Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; LVEF should be evaluated periodically based on LVEF at initiation of therapy and cumulative dose of doxorubicin. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Treatment should be delayed until ANC is greater than 1500/microL and platelet count is greater than 100,000/microL. If a patient develops grade 4 (ANC &#60;500) neutropenia or febrile neutropenia with any cycle, G-CSF support is added to the regimen for subsequent cycles. If grade 4 neutropenia or febrile neutropenia occurs despite G-CSF support, or if the patient develops grade 3 (25,000 to 50,000 platelets) or 4 (&#60;25,000 platelets) thrombocytopenia with any cycle, the doses of cyclophosphamide and doxorubicin should be decreased by 50 percent for subsequent cycles.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neuropathy:</strong> Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments.</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count; G-CSF: granulocyte colony-stimulating factor.<br />* A subcutaneous formulation (rituximab-hyaluronidase) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous rituximab<SUP>[6]</SUP>. Dosing varies by histology and clinicians should refer to the US Prescribing Information for details.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Coiffier B, et al. N Engl J Med 2002; 346:235.</LI>&#xD;&#xA;<LI>Rituximab injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012). </LI>&#xD;&#xA;<LI>Cyclophosphamide injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012). </LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012). </LI>&#xD;&#xA;<LI>Vincristine sulfate injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012). </LI>&#xD;&#xA;<LI>Rituximab and hyaluronidase human injection for subcutaneous use. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 30, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 63586 Version 27.0</div></div></div>"},"63587":{"type":"graphic_picture","displayName":"Full thickness burn PI","title":"Full-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full-thickness burn</div><div class=\"cntnt\"><img style=\"width:342px; height:303px;\" src=\"images/PI/63587_Full_thickness_burn_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Full-thickness burns are white, gray, or black, and do not turn pale when touched. The burned skin cannot feel anything, so it does not hurt when you touch it.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan, MD and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 63587 Version 3.0</div></div></div>"},"63588":{"type":"graphic_figure","displayName":"Ankle arthrocentesis","title":"Ankle arthrocentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ankle arthrocentesis</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/RHEUM/63588_Ankle_arthrocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the leg-foot angle at 90 degrees, the needle is inserted at a point just medial to the tibalis anterior tendon and just lateral to the medial malleolus (arrow). The needle is then directly posteriorly.</div><div class=\"graphic_reference\">Reproduced with permission from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 63588 Version 2.0</div></div></div>"},"63589":{"type":"graphic_diagnosticimage","displayName":"Oblique view of metacarpal shaft fracture","title":"Oblique view of metacarpal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique view of metacarpal shaft fracture</div><div class=\"cntnt\"><img style=\"width:324px; height:342px;\" src=\"images/EM/63589_Metacarpal_shaft_fx_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiograph above shows an&nbsp;oblique view&nbsp;of&nbsp;a mid-shaft fracture of the 5th metacarpal with apex dorsal angulation. The&nbsp;degree of angulation is determined&nbsp;by the&nbsp;lateral view, which is not shown here.</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 63589 Version 3.0</div></div></div>"},"63590":{"type":"graphic_picture","displayName":"Lichen planus flexures dark skin","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63590_Lichen_plan_flex_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous and hyperpigmented, polygonal papules are present on ankles and ventral wrists.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63590 Version 4.0</div></div></div>"},"63591":{"type":"graphic_diagnosticimage","displayName":"Supracristal VSD short axis 2D and color still frame","title":"Supracristal VSD short axis 2D and color still frame","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Supracristal VSD short axis 2D and color still frame</div><div class=\"cntnt\"><img style=\"width:545px; height:394px;\" src=\"images/CARD/63591_Supracristal_VSD_short_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired short axis images showing a moderately large supracristal ventricular septal defect (VSD, arrow) located just proximal to the pulmonary valve and more distant from the tricuspid valve apparatus than is seen for membranous defects. The right hand panel shows the color flow jet exiting the left ventricular outflow tract and entering the right ventricle.</div><div class=\"graphic_footnotes\">RV: right ventricle; TV: tricuspid valve; LVOT: left ventricular outflow tract; PV: pulmonary valve; RA: right atrium; LA: left atrium; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 63591 Version 4.0</div></div></div>"},"63595":{"type":"graphic_picture","displayName":"Squamous papilloma Light","title":"Squamous papilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous papilloma</div><div class=\"cntnt\"><img style=\"width:378px; height:266px;\" src=\"images/ONC/63595_Squamous_papilloma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical squamous papilloma, which is surfaced by bland and maturing squamous cells around a core of loose fibrovascular tissue. This exophytic lesion is usually solitary and often human papillomavirus (HPV)-related. Multiple lesions characterize recurrent respiratory papillomatosis (RRP) usually seen in the larynx.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 63595 Version 4.0</div></div></div>"},"63597":{"type":"graphic_table","displayName":"Neurologic deficits in spinal injury","title":"Neurologic deficits in spinal cord injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic deficits in spinal cord injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Level of Lesion</td> <td class=\"subtitle1\" colspan=\"3\">Neurologic findings</td> </tr> <tr> <td class=\"subtitle2\">Motor*</td> <td class=\"subtitle2\">Sensory level</td> <td class=\"subtitle2\">Reflex*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cervical</td> </tr> <tr> <td class=\"indent1\">C2</td> <td>Facial muscles, apneic</td> <td>Occiput</td> <td>No upper or lower extremity reflex</td> </tr> <tr> <td class=\"indent1\">C3</td> <td>Facial muscles, apneic</td> <td>Thyroid cartilage</td> <td>No upper or lower extremity reflex</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">C4</td> <td rowspan=\"2\">Spontaneous breathing</td> <td>Suprasternal notch</td> <td rowspan=\"2\">No upper or lower extremity reflex</td> </tr> <tr> <td>Posterior neck</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">C5</td> <td rowspan=\"2\">Shrugging and external rotation of shoulders</td> <td>Below clavicle</td> <td rowspan=\"2\">Biceps present, remainder absent</td> </tr> <tr> <td>Middle deltoid</td> </tr> <tr> <td class=\"indent1\">C6</td> <td>Elbow flexion Wrist extension</td> <td>Thumb</td> <td> <p>Biceps and brachioradialis present, </p> <p>remainder absent</p> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">C7</td> <td>Elbow extension</td> <td rowspan=\"2\">Index and middle&nbsp;fingers</td> <td rowspan=\"2\"> <p>Triceps and above present,</p> <p>remainder absent</p> </td> </tr> <tr> <td>Wrist flexion</td> </tr> <tr> <td class=\"indent1\">C8</td> <td>Finger flexion</td> <td>Small finger and ulnar side of hand</td> <td>Triceps and above&nbsp;present, <p>remainder absent</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Thoracic</td> </tr> <tr> <td class=\"indent1\">T1 - T12</td> <td>Intercostal and abdominal muscles</td> <td>&nbsp;</td> <td>Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>&nbsp;</td> <td>Nipple line</td> <td>Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">T10</td> <td>&nbsp;</td> <td>Umbilicus</td> <td>Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Lumbar</td> </tr> <tr> <td class=\"indent1\">L1</td> <td>Intercostal and abdominal muscles&nbsp;</td> <td>Femoral pulse</td> <td>&nbsp;Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">L1 - L2</td> <td>Hip flexion</td> <td>&nbsp;</td> <td>&nbsp;Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">L2 - L3</td> <td>Hip flexion</td> <td>Medial thigh</td> <td>&nbsp;Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">L3&nbsp;</td> <td>Hip adduction</td> <td>&nbsp;</td> <td>&nbsp;Upper extremity present, lower extremity absent</td> </tr> <tr> <td class=\"indent1\">L4</td> <td>Hip abduction</td> <td>Knee</td> <td>Patellar present, Achilles absent</td> </tr> <tr> <td class=\"indent1\">L5</td> <td>Foot dorsiflexion</td> <td>Lateral calf</td> <td>Patellar present, Achilles absent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Sacral</td> </tr> <tr> <td class=\"indent1\">S1</td> <td>Foot dorsiflexion&nbsp;</td> <td>Lateral foot</td> <td>Achilles and above present</td> </tr> <tr> <td class=\"indent1\">S1 - S2</td> <td>Foot plantar flexion</td> <td>&nbsp;</td> <td>Achilles and above present</td> </tr> <tr> <td class=\"indent1\">S2 - S4</td> <td>Rectal sphincter tone</td> <td>Perianal region</td> <td>Achilles and above present&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Level of injury is at or above the given location.</div><div class=\"graphic_reference\">Adapted from Rosen, P, Barkin, R, Danzl, DF, et al. Emergency Medicine: Concepts and Clinical Practice, 4th ed, Mosby-Year Book, St. Louis 1998. p.481 and Tachdjian, MO. The neck and upper limb. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton and Lange, Stamford, CT 1997. p.263.</div><div id=\"graphicVersion\">Graphic 63597 Version 3.0</div></div></div>"},"63600":{"type":"graphic_table","displayName":"Determining BMI A","title":"Determining body mass index from weight and height","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determining body mass index from weight and height</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"7\">Good weights</td> <td class=\"subtitle1\" colspan=\"5\">Overweight</td> <td class=\"subtitle1\" colspan=\"2\">Obesity</td> </tr> <tr> <td class=\"subtitle2_left\">BMI, kg/m<sup>2</sup></td> <td>19</td> <td>20</td> <td>21</td> <td>22</td> <td>23</td> <td>24</td> <td>25</td> <td>26</td> <td>27</td> <td>28</td> <td>29</td> <td>30</td> <td>35</td> <td>40</td> </tr> <tr> <td class=\"subtitle2\">Height, inches*</td> <td class=\"subtitle2\" colspan=\"14\">Weight, pounds*</td> </tr> <tr> <td>58\"</td> <td>91</td> <td>96</td> <td>100</td> <td>105</td> <td>110</td> <td>115</td> <td>119</td> <td>124</td> <td>129</td> <td>134</td> <td>138</td> <td>143</td> <td>167</td> <td>191</td> </tr> <tr> <td>59\"</td> <td>94</td> <td>99</td> <td>104</td> <td>109</td> <td>114</td> <td>119</td> <td>124</td> <td>128</td> <td>133</td> <td>138</td> <td>143</td> <td>148</td> <td>173</td> <td>198</td> </tr> <tr> <td>60\"</td> <td>97</td> <td>102</td> <td>107</td> <td>112</td> <td>118</td> <td>123</td> <td>128</td> <td>133</td> <td>138</td> <td>143</td> <td>148</td> <td>153</td> <td>179</td> <td>204</td> </tr> <tr> <td>61\"</td> <td>100</td> <td>106</td> <td>111</td> <td>116</td> <td>122</td> <td>127</td> <td>132</td> <td>137</td> <td>143</td> <td>148</td> <td>153</td> <td>158</td> <td>185</td> <td>211</td> </tr> <tr> <td>62\"</td> <td>104</td> <td>109</td> <td>115</td> <td>120</td> <td>126</td> <td>131</td> <td>136</td> <td>142</td> <td>147</td> <td>153</td> <td>158</td> <td>164</td> <td>191</td> <td>218</td> </tr> <tr> <td>63\"</td> <td>107</td> <td>113</td> <td>118</td> <td>124</td> <td>130</td> <td>135</td> <td>141</td> <td>146</td> <td>152</td> <td>158</td> <td>163</td> <td>169</td> <td>197</td> <td>225</td> </tr> <tr> <td>64\"</td> <td>110</td> <td>116</td> <td>122</td> <td>128</td> <td>134</td> <td>140</td> <td>145</td> <td>151</td> <td>157</td> <td>163</td> <td>168</td> <td>174</td> <td>204</td> <td>232</td> </tr> <tr> <td>65\"</td> <td>114</td> <td>120</td> <td>126</td> <td>132</td> <td>138</td> <td>144</td> <td>150</td> <td>156</td> <td>162</td> <td>168</td> <td>174</td> <td>180</td> <td>210</td> <td>240</td> </tr> <tr> <td>66\"</td> <td>118</td> <td>124</td> <td>130</td> <td>136</td> <td>142</td> <td>148</td> <td>155</td> <td>161</td> <td>167</td> <td>173</td> <td>179</td> <td>186</td> <td>216</td> <td>247</td> </tr> <tr> <td>67\"</td> <td>121</td> <td>127</td> <td>134</td> <td>140</td> <td>146</td> <td>153</td> <td>159</td> <td>166</td> <td>172</td> <td>178</td> <td>185</td> <td>191</td> <td>223</td> <td>255</td> </tr> <tr> <td>68\"</td> <td>125</td> <td>131</td> <td>138</td> <td>144</td> <td>151</td> <td>158</td> <td>164</td> <td>171</td> <td>177</td> <td>184</td> <td>190</td> <td>197</td> <td>230</td> <td>262</td> </tr> <tr> <td>69\"</td> <td>128</td> <td>135</td> <td>142</td> <td>149</td> <td>155</td> <td>162</td> <td>169</td> <td>176</td> <td>182</td> <td>189</td> <td>196</td> <td>203</td> <td>236</td> <td>270</td> </tr> <tr> <td>70\"</td> <td>132</td> <td>139</td> <td>146</td> <td>153</td> <td>160</td> <td>167</td> <td>174</td> <td>181</td> <td>188</td> <td>195</td> <td>202</td> <td>209</td> <td>243</td> <td>278</td> </tr> <tr> <td>71\"</td> <td>136</td> <td>143</td> <td>150</td> <td>157</td> <td>165</td> <td>172</td> <td>179</td> <td>186</td> <td>193</td> <td>200</td> <td>208</td> <td>215</td> <td>250</td> <td>286</td> </tr> <tr> <td>72\"</td> <td>140</td> <td>147</td> <td>154</td> <td>162</td> <td>169</td> <td>177</td> <td>184</td> <td>191</td> <td>199</td> <td>206</td> <td>213</td> <td>221</td> <td>258</td> <td>294</td> </tr> <tr> <td>73\"</td> <td>144</td> <td>151</td> <td>159</td> <td>166</td> <td>174</td> <td>182</td> <td>189</td> <td>197</td> <td>204</td> <td>212</td> <td>219</td> <td>227</td> <td>265</td> <td>302</td> </tr> <tr> <td>74\"</td> <td>148</td> <td>155</td> <td>163</td> <td>171</td> <td>179</td> <td>186</td> <td>194</td> <td>202</td> <td>210</td> <td>218</td> <td>225</td> <td>233</td> <td>272</td> <td>311</td> </tr> <tr> <td>75\"</td> <td>152</td> <td>160</td> <td>168</td> <td>176</td> <td>184</td> <td>192</td> <td>200</td> <td>208</td> <td>216</td> <td>224</td> <td>232</td> <td>240</td> <td>279</td> <td>319</td> </tr> <tr> <td>76\"</td> <td>156</td> <td>164</td> <td>172</td> <td>180</td> <td>189</td> <td>197</td> <td>205</td> <td>213</td> <td>221</td> <td>230</td> <td>238</td> <td>246</td> <td>287</td> <td>328</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The health risk from any level of BMI is increased if the patient has gained more than 5 kg (11 pounds) since age 25 years, or if the waist circumference is above 100 cm (40 in) due to central fatness.</div><div class=\"graphic_footnotes\">BMI: body mass index.<BR>* Divide weight by 2.2 to convert pounds into kilograms; multiply height by 2.54 to convert inches into centimeters.</div><div id=\"graphicVersion\">Graphic 63600 Version 3.0</div></div></div>"},"63601":{"type":"graphic_diagnosticimage","displayName":"Leiomyosarcoma gastric UGI","title":"Leiomyosarcoma of the stomach","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leiomyosarcoma of the stomach</div><div class=\"cntnt\"><img style=\"width:218px; height:300px;\" src=\"images/GAST/63601_Leiomyosarcoma_gastric_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast upper gastrointestinal study demonstrates a large irregular polypoid mass arising from the greater curvature of the stomach. Irregular masses arising from this site are typically malignant.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 63601 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"63602":{"type":"graphic_figure","displayName":"Time course PEG side effects","title":"The time course of side effects associated with interferon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The time course of side effects associated with interferon</div><div class=\"cntnt\"><img style=\"width:437px; height:234px;\" src=\"images/GAST/63602_Time_course_PEG_side_effect.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Nezam H Afdhal, MD and T Barry Kelleher, MD, MRCPI.</div><div id=\"graphicVersion\">Graphic 63602 Version 1.0</div></div></div>"},"63604":{"type":"graphic_table","displayName":"Patient education skills","title":"Patient education skills","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient education skills</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Objective 1: Tell a meaningful diagnosis.</td> </tr> <tr> <td colspan=\"3\">Step 1 - Ask patient his/her understanding of what the problem or situation is. Or, reflect what you've heard if patient has already stated this.</td> </tr> <tr> <td colspan=\"3\">Step 2 - Tell patient \"You have... (diagnosis)\" or \"The diagnosis is not clear, but I'm concerned about... (list issues).\"</td> </tr> <tr> <td colspan=\"3\">Step 3 - Ask patient about his/her reaction.</td> </tr> <tr> <td class=\"subtitle2\">Ask about</td> <td class=\"subtitle2\">Description</td> <td class=\"subtitle2\">Examples</td> </tr> <tr> <td>Knowledge</td> <td>Teach patient about diagnosis. Inquire about patient's understanding of your news. Regulate quantity and level of information.</td> <td>\"What do you already know about this?\" \"What questions do you have?\" \"What do you want to know more about?\"</td> </tr> <tr> <td>Feelings</td> <td>Inquire about patient's inner state in response to the news, reflect feelings you see/hear (use PEARLS).</td> <td>\"What's your reaction to this?\" \"How are you feeling about this?\" \"You look worried.\"</td> </tr> <tr> <td>Beliefs/Meaning</td> <td>Inquire about patient's beliefs about why he/she has the problem or what it means.</td> <td>\"Why do you think you have high blood pressure?\" \"What does it mean to you to hear I'm uncertain about...?\"</td> </tr> <tr> <td>Expectations</td> <td>Inquire about the patient's expectations of future outcomes.</td> <td>\"What do you see happening when you look to the future?\" \"How do you think things will go for you?\"</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Objective 2: Negotiate and implement a plan (again use Ask-Tell-Ask format)*</td> </tr> <tr> <td class=\"subtitle2\">Action</td> <td class=\"subtitle2\">Description</td> <td class=\"subtitle2\">Examples</td> </tr> <tr> <td>Ask - existing ideas</td> <td>Find out what he/she has already tried and what ideas he/she has about what the plan should be.</td> <td>\"What have you tried already?\" \"What ideas do you have about what we should do now?\"</td> </tr> <tr> <td>Tell - plan</td> <td>Describe plan, give reasons and expectations, and forecast possible problems.</td> <td>\"I recommend... because...\" \"You can expect...\" \"If... happens, then you should...\"</td> </tr> <tr> <td>Ask - understanding</td> <td>Check patient's understanding and agreement. Inquire about obstacles. Problem-solve and negotiate differences.</td> <td>\"How does this sound to you?\" \"What problems do you anticipate?\" \"Help me understand - what's holding you back?\" \"What would it take for you to be ready?\" \"Let's look together for what might work.\"</td> </tr> <tr> <td>Rehearse</td> <td>Check to be sure your and your patient's understanding of the plan are the same.</td> <td>\"Just to be sure we're clear, what would you tell your spouse (or friend) about our plan?\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEARLS: partnership, empathy, apology (compassion), respect, legitimization, support.<br />* Caution: Patient's unspoken beliefs, fears, or lack of commitment frequently appear as defensiveness, resistance, or reluctance. Remember, when defensiveness starts, learning stops. For treatment planning, your understanding of such fears and beliefs is as important as your medical expertise. If you see, hear, or feel defensiveness in your patient, go back and focus on relationship building. If you're rushed, it is better to schedule another visit than to create frustration.</div><div class=\"graphic_reference\">Adapted by permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP 1998), now the American Academy on Communication in Healthcare.</div><div id=\"graphicVersion\">Graphic 63604 Version 5.0</div></div></div>"},"63605":{"type":"graphic_picture","displayName":"Mucous membrane lesions in systemic lupus erythematosus","title":"Oral ulcers in lupus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral ulcers in lupus</div><div class=\"cntnt\"><img style=\"width:360px; height:179px;\" src=\"images/RHEUM/63605_Mucous_membrane_lesions_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosive lesions of the mucous membrane in lupus, causing oral ulcers.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 63605 Version 3.0</div></div></div>"},"63606":{"type":"graphic_figure","displayName":"Isoelectric focusing Hgb variants","title":"Isoelectric focusing for various hemoglobin mutations","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Isoelectric focusing for various hemoglobin mutations</div><div class=\"cntnt\"><img style=\"width:591px; height:724px;\" src=\"images/HEME/63606_Isoelect_focus_Hgb_variant.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the relative positions of various hemoglobin mutations when using isoelectric focusing. Major hemoglobins (H, A, F, S, and C) are shown in bold.</div><div id=\"graphicVersion\">Graphic 63606 Version 2.0</div></div></div>"},"63607":{"type":"graphic_algorithm","displayName":"Approach to premenarcheal vaginal bleeding","title":"Approach to vaginal bleeding in the premenarcheal child","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Approach to vaginal bleeding in the premenarcheal child</div><div class=\"cntnt\"><img style=\"width:530px; height:322px;\" src=\"images/EM/63607_Approachpremenbleed.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to algorithms on vaginal bleeding in the postmenarcheal adolescent.</div><div class=\"graphic_reference\">Reproduced with permission from: Zinns LE, Chuang JH, Posner JC, Paradise J. Vaginal bleeding. In: Fleisher and Ludwig's Textbook of Pediatric Emergency Medicine, 7th edition, Bachur RG, Shaw KN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2016. Copyright © 2016 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63607 Version 13.0</div></div></div>"},"63609":{"type":"graphic_figure","displayName":"Stimulated SFEMG","title":"Stimulated single fiber electromyography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stimulated single fiber electromyography</div><div class=\"cntnt\"><img style=\"width:404px; height:584px;\" src=\"images/NEURO/63609_StimulatedSFEMG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single fiber electromyography (SFEMG) with intramuscular stimulation. Stimulating and recording electrodes are shown above. Examples of typical responses to direct muscle stimulation (low jitter) and axonal stimulation (jitter &gt;4 &mu;s) are shown below.</div><div class=\"graphic_reference\">Reproduced with permission from: Stålberg E, Trontelj JV. Single fiber electromyography: Studies in healthy and diseased muscle, 2nd edition, Raven Press, New York 1994. Copyright © 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63609 Version 8.0</div></div></div>"},"63610":{"type":"graphic_diagnosticimage","displayName":"Acetaminophen toxicity CT","title":"Acute liver failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute liver failure</div><div class=\"cntnt\"><img style=\"width:360px; height:311px;\" src=\"images/GAST/63610_Acetaminophen_toxicity_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan of the liver in a 35-year-old female who took an overdose of acetaminophen demonstrates a heterogenous poorly enhancing liver with areas of lower attenuation due to acute fatty replacement. Note also the patent recanalized paraumbilical vein coursing through the ligamentum teres (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 63610 Version 2.0</div></div></div>"},"63611":{"type":"graphic_figure","displayName":"Esophageal varices PI","title":"Esophageal varices","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Esophageal varices</div><div class=\"cntnt\"><img style=\"width:498px; height:537px;\" src=\"images/PI/63611_EsophageaL_varices_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cirrhosis can cause the blood vessels around the esophagus to swell. This is called \"esophageal varices.\" In severe cases, these blood vessels can burst and cause internal bleeding.</div><div id=\"graphicVersion\">Graphic 63611 Version 6.0</div></div></div>"},"63612":{"type":"graphic_table","displayName":"Diagnostic testing hibernation","title":"Diagnostic testing for hibernating myocardium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic testing for hibernating myocardium</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Usually not needed*</td> </tr> <tr> <td class=\"indent1\">Normal left ventricular function</td> </tr> <tr> <td class=\"indent1\">Coronary arteries not suitable for revascularization</td> </tr> <tr> <td class=\"subtitle1_single\">Usually needed*</td> </tr> <tr> <td class=\"indent1\">Suspected CAD/IDCM, being considered for heart transplantation</td> </tr> <tr> <td class=\"indent1\">CAD plus severe left ventricular dysfunction (LVEF &#8804;0.35)</td> </tr> <tr> <td class=\"indent1\">CAD plus dysfunction in patients who are asymptomatic or have heart failure symptoms: mild/minimal angina</td> </tr> <tr> <td class=\"subtitle1_single\">Individualize<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Unstable angina or severe stable angina</td> </tr> <tr> <td class=\"indent1\">Acute myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Anomalous left coronary artery from pulmonary artery</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CAD: coronary artery disease; IDCM: idiopathic dilated cardiomyopathy; LVEF: left ventricular ejection fraction.<br />* Clinical judgment may be needed.<br />&para; Clinical judgment frequently needed.</div><div class=\"graphic_reference\">Adapted from: Rahimtoola SH. J Am Coll Cardiol 1997; 30:1701.</div><div id=\"graphicVersion\">Graphic 63612 Version 3.0</div></div></div>"},"63613":{"type":"graphic_diagnosticimage","displayName":"Gastroschisis","title":"Gastroschisis with herniated stomach","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gastroschisis with herniated stomach</div><div class=\"cntnt\"><img style=\"width:468px; height:314px;\" src=\"images/OBGYN/63613_Gastroschisis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fetal stomach and other abdominal organs have herniated through the abdominal wall defect.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO.</div><div id=\"graphicVersion\">Graphic 63613 Version 4.0</div></div></div>"},"63614":{"type":"graphic_diagnosticimage","displayName":"TTTS4","title":"TTTS4","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS4</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/OBGYN/63614_TTTS4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Donor twin with marked oligohydramnios at 24 2/7 weeks of gestation. Arrow denotes the membrane which can be seen extending between the lower fetal abdomen and the fetal thigh. The difficulty is finding this membrane can often lead to the erroneous diagnosis of monoamniotic twins.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 63614 Version 2.0</div></div></div>"},"63615":{"type":"graphic_table","displayName":"Gaucher resources","title":"Resources for information on Gaucher disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for information on Gaucher disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p><strong>Children's Gaucher Research Fund</strong></p> <p><a href=\"http://www.childrensgaucher.org/\" target=\"_blank\">www.childrensgaucher.org</a></p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Gaucher's Association</strong></p> <p><a href=\"http://www.gaucher.org.uk/\" target=\"_blank\">www.gaucher.org.uk/</a></p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>National Gaucher Foundation</strong></p> <p><a href=\"http://www.gaucherdisease.org/\" target=\"_blank\">www.gaucherdisease.org</a></p> </td> </tr> <tr> <td> <p><strong>International Gaucher Disease Associations</strong></p> <p><a href=\"http://www.gaucher.org.uk/links/associations_around_the_world\" target=\"_blank\">www.gaucher.org.uk/links/associations_around_the_world</a></p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63615 Version 4.0</div></div></div>"},"63616":{"type":"graphic_picture","displayName":"Angiostrongylus costaricensis biopsy","title":"<EM>Angiostrongylus costaricensis</EM> biopsy","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\"><EM>Angiostrongylus costaricensis</EM> biopsy</div><div class=\"cntnt\"><img style=\"width:547px; height:457px;\" src=\"images/ID/63616_Angiostrongy_costaricensis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Female <em>Angiostrongylus costaricensis</em> in an appendix biopsy, stained with hematoxylin and eosin (H&amp;E). Notice the thick, multinucleated intestine (IN), reproductive tubes (RT), eggs (EG) within the uterus (UT), and lateral chords (LC).<br />(C) <em>Angiostrongylus costaricensis</em> eggs in tissue, stained with H&amp;E.<br />(D) <em>Angiostrongylus costaricensis</em> larva in tissue sections stained with H&amp;E.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Angiostrongyliasis. Available at: <a href=\"http://www.cdc.gov/dpdx/angiostrongyliasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/angiostrongyliasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 63616 Version 6.0</div></div></div>"},"63617":{"type":"graphic_table","displayName":"Diff diagnosis pheo spells","title":"Differential diagnosis of pheochromocytoma-type spells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of pheochromocytoma-type spells</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">\"Hyperandrenergic spells\"</td> </tr> <tr> <td class=\"indent1\">Thyrotoxicosis</td> </tr> <tr> <td class=\"indent1\">Primary hypogonadism (menopausal syndrome)</td> </tr> <tr> <td class=\"indent1\">Medullary thyroid carcinoma</td> </tr> <tr> <td class=\"indent1\">Pancreatic tumors (eg, insulinoma)</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> </tr> <tr> <td class=\"indent1\">Carbohydrate intolerance</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Labile essential hypertension</td> </tr> <tr> <td class=\"indent1\">Cardiovascular deconditioning</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Syncope</td> </tr> <tr> <td class=\"indent1\">Orthostatic hypotension</td> </tr> <tr> <td class=\"indent1\">Paroxysmal cardiac arrhythmia</td> </tr> <tr> <td class=\"indent1\">Angina</td> </tr> <tr> <td class=\"indent1\">Renovascular disease</td> </tr> <tr> <td class=\"subtitle1_single\">Psychologic</td> </tr> <tr> <td class=\"indent1\">Anxiety and panic attacks</td> </tr> <tr> <td class=\"indent1\">Somatization disorder</td> </tr> <tr> <td class=\"indent1\">Hyperventilation</td> </tr> <tr> <td class=\"indent1\">Factitious (eg, drugs, valsalva)</td> </tr> <tr> <td class=\"subtitle1_single\">Pharmacologic</td> </tr> <tr> <td class=\"indent1\">Withdrawal of andernergic-inhibitor</td> </tr> <tr> <td class=\"indent1\">MAOI treatment plus decongestant</td> </tr> <tr> <td class=\"indent1\">Sympathomimetic ingestion</td> </tr> <tr> <td class=\"indent1\">Illegal drug ingestion (cocaine, PCP, LSD)</td> </tr> <tr> <td class=\"indent1\">Chlorpropamide-alcohol flush</td> </tr> <tr> <td class=\"indent1\">Vancomycin (\"red man syndrome\")</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">POTS</td> </tr> <tr> <td class=\"indent1\">Autonomic neuropathy</td> </tr> <tr> <td class=\"indent1\">Migraine headache</td> </tr> <tr> <td class=\"indent1\">Diencephalic epilepsy (autonomic seizures)</td> </tr> <tr> <td class=\"indent1\">Stroke</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Unexplained flushing spells</td> </tr> <tr> <td class=\"indent1\">Mast cell disease</td> </tr> <tr> <td class=\"indent1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"indent1\">Recurrent idiopathic anaphylaxis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LSD: lysergic acid diethylamide;&nbsp;MAOI: monoamine oxidase inhibitor;&nbsp;PCP: phencyclidine; POTS: postural orthostatic tachycardia syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Young WF Jr. Pheochromocytoma and primary aldosteronism. Cancer Treat Res 1997; 89:239. Copyright &copy; 1997 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 63617 Version 4.0</div></div></div>"},"63618":{"type":"graphic_diagnosticimage","displayName":"Sellar mass MRI I","title":"Sellar masses","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Sellar masses</div><div class=\"cntnt\"><img style=\"width:468px; height:199px;\" src=\"images/ENDO/63618_Sellar_mass_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The unenhanced MRI on the left shows, in sagittal view, a clinically nonfunctioning pituitary adenoma that is extending just above the sella (arrow). The unenhanced MRI on the right shows a sellar mass of similar size (arrow), which is interpreted radiologically as a pituitary adenoma, but pathologically was found to be lymphocytic hypophysitis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Peter J Snyder, MD.</div><div id=\"graphicVersion\">Graphic 63618 Version 4.0</div></div></div>"},"63622":{"type":"graphic_table","displayName":"Nonabsorbable sutures","title":"Nonabsorbable sutures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonabsorbable sutures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Suture material</td> <td class=\"subtitle1\">Knot security</td> <td class=\"subtitle1\">Wound tensile strength</td> <td class=\"subtitle1\">Tissue reactivity</td> <td class=\"subtitle1\">Workability</td> <td class=\"subtitle1\">Anatomic site</td> </tr> <tr> <td>Nylon (Ethilon)</td> <td>Good</td> <td>Good</td> <td>Minimal</td> <td>Good</td> <td>Skin closure anywhere</td> </tr> <tr> <td>Polybutester (Novafil)</td> <td>Good</td> <td>Good</td> <td>Minimal</td> <td>Good</td> <td>Skin closure anywhere</td> </tr> <tr> <td>Polypropylene (Prolene)</td> <td>Least</td> <td>Best</td> <td>Least</td> <td>Fair</td> <td>Skin closure anywhere. Blue dyed suture useful in dark-skinned individuals.</td> </tr> <tr> <td>Silk</td> <td>Best</td> <td>Least</td> <td>Most</td> <td>Best</td> <td>Rarely used</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356. Copyright &copy; 1999 The American College of Emergency Physicians.</div><div id=\"graphicVersion\">Graphic 63622 Version 4.0</div></div></div>"},"63623":{"type":"graphic_picture","displayName":"Vitiligo - hands","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63623_Vitiligo_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple depigmented macules and patches are present on the hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63623 Version 3.0</div></div></div>"},"63624":{"type":"graphic_picture","displayName":"Diabetic retinopathy view PI","title":"How diabetic retinopathy affects vision","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">How diabetic retinopathy affects vision</div><div class=\"cntnt\"><img style=\"width:514px; height:188px;\" src=\"images/PI/63624_Diabet_retinopath_view_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diabetic retinopathy can impair vision and cause dark spots in your vision.</div><div class=\"graphic_reference\">Reproduced from: the National Eye Institute. Available at: <a href=\"http://www.nei.nih.gov/health/examples/\" target=\"_blank\">http://www.nei.nih.gov/health/examples/</a>.</div><div id=\"graphicVersion\">Graphic 63624 Version 2.0</div></div></div>"},"63626":{"type":"graphic_figure","displayName":"Modified hair apposition","title":"Modified hair apposition of scalp wounds","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Modified hair apposition of scalp wounds</div><div class=\"cntnt\"><img style=\"width:483px; height:684px;\" src=\"images/EM/63626_Hair-apposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Grasp 5-15 hairs on either side of the wound with hemostats or forceps.<br> (B) Twist the hairs once until the wound edges appose.<br> (C) Place one drop of glue on the twist. Do not get glue in the wound.<br> (D) Repeat the procedure until the laceration is closed.</div><div id=\"graphicVersion\">Graphic 63626 Version 2.0</div></div></div>"},"63627":{"type":"graphic_figure","displayName":"Ecological fallacy","title":"Ecological fallacy","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Ecological fallacy</div><div class=\"cntnt\"><img style=\"width:480px; height:523px;\" src=\"images/PC/63627_Ecological_fallacy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypothetical relationships between age and treatment effect both within trials (represented by the solid lines) and between trials (represented by the circles, which indicate the study means, and the dashed lines, which indicate the regression lines).<br> In the top example, individual studies demonstrate an association between age and treatment effect, but the association appears to be lost when looking only at the mean values across studies. Alternatively, in the bottom example, individual studies demonstrate no association between age and treatment effect. However, possibly due to chance or confounding, an apparent association is seen across the mean values of studies.</div><div class=\"graphic_reference\">Adapted from: Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559.</div><div id=\"graphicVersion\">Graphic 63627 Version 3.0</div></div></div>"},"63628":{"type":"graphic_table","displayName":"Treatment of hypertension by underlying disease","title":"Considerations for individualizing antihypertensive therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Considerations for individualizing antihypertensive therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Antihypertensive drugs</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Compelling indications (major improvement in outcome independent of blood pressure)</td> </tr> <tr> <td class=\"indent1\">Systolic heart failure</td> <td>ACE inhibitor or ARB, beta blocker, diuretic, aldosterone antagonist*</td> </tr> <tr> <td class=\"indent1\">Postmyocardial infarction</td> <td>ACE inhibitor, beta blocker, ARB,&nbsp;aldosterone antagonist</td> </tr> <tr> <td class=\"indent1\">Proteinuric chronic kidney disease</td> <td>ACE inhibitor or ARB</td> </tr> <tr> <td class=\"indent1\">Angina pectoris</td> <td>Beta blocker, calcium channel blocker</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation rate control </td> <td>Beta blocker, nondihydropyridine calcium channel blocker</td> </tr> <tr> <td class=\"indent1\">Atrial flutter rate control </td> <td>Beta blocker, nondihydropyridine calcium channel blocker</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Likely to have a favorable effect on symptoms in comorbid conditions</td> </tr> <tr> <td class=\"indent1\">Benign prostatic hyperplasia</td> <td>Alpha blocker</td> </tr> <tr> <td class=\"indent1\">Essential tremor</td> <td>Beta blocker (noncardioselective)</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> <td>Beta blocker</td> </tr> <tr> <td class=\"indent1\">Migraine</td> <td>Beta blocker, calcium channel blocker</td> </tr> <tr> <td class=\"indent1\">Osteoporosis</td> <td>Thiazide diuretic</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon</td> <td>Dihydropyridine calcium channel blocker</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Angioedema</td> <td>ACE inhibitor</td> </tr> <tr> <td class=\"indent1\">Bronchospastic disease</td> <td>Beta blocker</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td>Reserpine</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> <td>Methyldopa</td> </tr> <tr> <td class=\"indent1\">Pregnancy (or at risk for)</td> <td>ACE inhibitor, ARB, renin inhibitor</td> </tr> <tr> <td class=\"indent1\">Second- or third-degree heart block</td> <td>Beta blocker, nondihydropyridine calcium channel blocker</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">May have adverse effect on comorbid conditions</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td>Beta blocker, central alpha-2 agonist</td> </tr> <tr> <td class=\"indent1\">Gout</td> <td>Diuretic</td> </tr> <tr> <td class=\"indent1\">Hyperkalemia</td> <td>Aldosterone antagonist, ACE inhibitor, ARB, renin inhibitor</td> </tr> <tr> <td class=\"indent1\">Hyponatremia</td> <td>Thiazide diuretic</td> </tr> <tr> <td class=\"indent1\">Renovascular disease</td> <td>ACE inhibitor, ARB, or renin inhibitor</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ARB: angiotensin receptor&nbsp;blocker.<br />* A benefit from an aldosterone antagonist has been demonstrated in patients with NYHA class III-IV heart failure or decreased left ventricular ejection fraction after a myocardial infarction.</div><div class=\"graphic_reference\">Adapted from: The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289:2560.</div><div id=\"graphicVersion\">Graphic 63628 Version 11.0</div></div></div>"},"63630":{"type":"graphic_table","displayName":"SIDS resources PI","title":"Sudden infant death syndrome support groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sudden infant death syndrome support groups</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First Candle/SIDS Alliance </td> </tr> <tr> <td>(A national network of SIDS support groups)</td> </tr> <tr> <td>1314 Bedford Avenue</td> </tr> <tr> <td>Suite 210 Baltimore, MD 21208</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-221-7437<a href=\"#\" title=\"Call: 1-800-221-7437\"><img alt=\"\" title=\"Call: 1-800-221-7437\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-410-653-8226<a href=\"#\" title=\"Call: 1-410-653-8226\"><img alt=\"\" title=\"Call: 1-410-653-8226\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr> <td>Email: <a href=\"mailto:info&#64;firstcandle.org\"><span style=\"color: #0000ff;\">info&#64;firstcandle.org</span></a></td> </tr> <tr> <td>Website: <a href=\"http://www.firstcandle.org/\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #3966bf;\">www.firstcandle.org</span></a> </td> </tr> <tr> <td class=\"subtitle1_single\">The Lullaby Trust</td> </tr> <tr> <td>11 Belgrave Road</td> </tr> <tr> <td>London, SW1V 1RB</td> </tr> <tr> <td>020 7802 3200</td> </tr> <tr> <td>Email: <a href=\"mailto:office&#64;lullabytrust.org.uk\" spellcheck=\"true\">office&#64;lullabytrust.org.uk</a><a href=\"mailto:office&#64;lullabytrust.org.uk\" spellcheck=\"true\"></a></td> </tr> <tr> <td>Website: <a href=\"http://www.lullabytrust.org.uk/\" spellcheck=\"true\" target=\"_blank\">www.lullabytrust.org.uk</a></td> </tr> <tr> <td class=\"subtitle1_single\">Canadian Foundation for the Study of Infant Deaths (CFSID) </td> </tr> <tr> <td>586 Eglinton Avenue East</td> </tr> <tr> <td>Suite 308</td> </tr> <tr> <td>Toronto, Ontario, Canada M4P 1P2</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-363-7437<a href=\"#\" title=\"Call: 1-800-363-7437\"><img alt=\"\" title=\"Call: 1-800-363-7437\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (toll-free) or</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-416-488-3260<a href=\"#\" title=\"Call: 1-416-488-3260\"><img alt=\"\" title=\"Call: 1-416-488-3260\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-416-488-3864<a href=\"#\" title=\"Call: 1-416-488-3864\"><img alt=\"\" title=\"Call: 1-416-488-3864\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (fax)</td> </tr> <tr> <td>Email: <a href=\"mailto:sidsinfo&#64;sidscanada.org%20?subject=sidsinfo&#64;sidscanada.org%20\" spellcheck=\"true\"><span style=\"color: #3966bf;\">sidsinfo&#64;sidscanada.org</span></a></td> </tr> <tr> <td>Website: <a href=\"http://www.sidscanada.org/\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #3966bf;\">www.sidscanada.org</span></a> </td> </tr> <tr> <td class=\"subtitle1_single\">Red Nose (formerly National SIDS Council of Australia)</td> </tr> <tr> <td>17/75 Lorimer Street</td> </tr> <tr> <td>Docklands, VIC 3008, Australia</td> </tr> <tr> <td>1300 308 307&nbsp;or</td> </tr> <tr> <td>03 9818 4596 (fax)</td> </tr> <tr> <td>Email: <a href=\"mailto:support&#64;rednosec\"><span style=\"color: #3966bf;\"><a href=\"mailto:support&#64;rednose.com.au\">support&#64;rednose</a></span><a href=\"mailto:support&#64;rednose.com.au\">.com.au</a></a>.com.au</td> </tr> <tr> <td>Website: <a href=\"https://rednosegriefandloss.com.au/\">rednosegriefandloss.com.au</a><span>​</span></td> </tr> <tr> <td class=\"subtitle1_single\">SIDS Family Association Japan (SIDSFAJ) </td> </tr> <tr> <td>Email: <a href=\"mailto:englishcontact&#64;sids.gr.jp\"><span style=\"color: #3966bf;\">englishcontact&#64;sids.gr.jp</span></a> </td> </tr> <tr> <td>Website: <a href=\"http://www.sids.gr.jp/\" spellcheck=\"true\" target=\"_blank\"><span style=\"color: #3966bf;\">www.sids.gr.jp</span></a> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: National Institute of Child Health &amp; Human Development Fact Sheet: Sudden infant death syndrome. Available at: <A spellcheck=true href=\"https://www.nichd.nih.gov/sts/campaign/pages/collaborators.aspx\"target=_blank>https://www.nichd.nih.gov/sts/campaign/pages/collaborators.aspx</A> (Accessed on September 1, 2016).</div><div id=\"graphicVersion\">Graphic 63630 Version 8.0</div></div></div>"},"63631":{"type":"graphic_figure","displayName":"Corneal light reflex","title":"Corneal light reflex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal light reflex</div><div class=\"cntnt\"><img style=\"width:411px; height:410px;\" src=\"images/PEDS/63631_Corneal_light_reflection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The corneal light reflex test involves shining a light onto the child's eyes from a distance and observing the reflection of the light on the cornea with respect to the pupil. The location of the reflection from both eyes should appear symmetric and generally slightly nasal to the center of the pupil. <br />(A) Normal corneal reflex. <br />(B) Corneal light reflex in esotropia. <br />(C) Corneal light reflex in exotropia.</div><div id=\"graphicVersion\">Graphic 63631 Version 3.0</div></div></div>"},"63632":{"type":"graphic_table","displayName":"Initial labs encephalitis","title":"Suggested initial laboratory evaluation for children and adolescents with encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested initial laboratory evaluation for children and adolescents with encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">For nonimmunocompromised patients</td> </tr> <tr> <td class=\"subtitle2_single\">Blood</td> </tr> <tr> <td class=\"indent1\">Complete blood count with differential count and platelets</td> </tr> <tr> <td class=\"indent1\">Blood culture</td> </tr> <tr> <td class=\"indent1\">Serum electrolytes, glucose, ammonia, blood urea nitrogen, creatinine; blood pH</td> </tr> <tr> <td class=\"indent1\">Serum aminotransferases (alanine aminotransferase, aspartate aminotransferase)</td> </tr> <tr> <td class=\"indent1\">Coagulation studies</td> </tr> <tr> <td class=\"indent1\">Serology for EBV, HIV, and <em>Mycoplasma pneumoniae </em>(IgM and IgG)</td> </tr> <tr> <td class=\"indent1\">Anti-NMDAR and anti-VGKC antibodies if clinically indicated</td> </tr> <tr> <td class=\"indent1\">Acute serum sample (to hold for subsequent serologic testing if necessary)</td> </tr> <tr> <td class=\"subtitle2_single\">CSF</td> </tr> <tr> <td class=\"indent1\">Opening pressure (when feasible)</td> </tr> <tr> <td class=\"indent1\">Cell count, differential, protein, glucose, Gram stain, acid fast stain</td> </tr> <tr> <td class=\"indent1\">Bacterial culture; <em>M. tuberculosis</em> culture (if clinically indicated)</td> </tr> <tr> <td class=\"indent1\">PCR: HSV, enterovirus (PCR for other <em>Herpesviridae</em>, WNV, influenza, and other pathogens, as indicated by history and epidemiology)</td> </tr> <tr> <td class=\"indent1\">CSF sample (to hold for subsequent testing)</td> </tr> <tr> <td class=\"subtitle2_single\">Respiratory samples</td> </tr> <tr> <td class=\"indent1\">Respiratory panel (PCR) (influenza, adenovirus, human metapneumovirus, and respiratory syncytial virus)</td> </tr> <tr> <td class=\"indent1\">Viral culture of respiratory secretions and nasopharynx</td> </tr> <tr> <td class=\"indent1\">Throat swab for HSV, enterovirus, <em>M. pneumoniae</em></td> </tr> <tr> <td class=\"subtitle2_single\">Stool (or rectal swab)</td> </tr> <tr> <td class=\"indent1\">Viral culture of stool</td> </tr> <tr> <td class=\"indent1\">Enterovirus PCR</td> </tr> <tr> <td class=\"subtitle2_single\">Urine</td> </tr> <tr> <td class=\"indent1\">Urinalysis</td> </tr> <tr> <td class=\"indent1\">Urine toxicology screen</td> </tr> <tr> <td class=\"subtitle2_single\">Skin lesions (if present)</td> </tr> <tr> <td class=\"indent1\">Biopsy for DFA and PCR for <em>R. rickettsia</em></td> </tr> <tr> <td class=\"indent1\">Culture and/or DFA of skin lesions for HSV, VZV, and enteroviruses</td> </tr> <tr> <td class=\"subtitle1_single\">For immunocompromised patients</td> </tr> <tr> <td class=\"subtitle2_single\">Above tests, plus:</td> </tr> <tr> <td class=\"indent1\">Blood: Serum cryptococcal antigen, <em>Toxoplasma gondii</em> IgG</td> </tr> <tr> <td class=\"indent1\">CSF: Cryptococcal antigen, Histoplasma antigen; PCR for CMV, CJ, HHV6, WNV</td> </tr> <tr> <td class=\"indent1\">Urine: Histoplasma antigen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBV: Epstein-Barr virus; HIV: human immunodeficiency virus; NMDAR: N-methyl-D-aspartate receptor; VGKC: voltage-gated potassium channel; CSF: cerebrospinal fluid; PCR: polymerase chain reaction; HSV: herpes simplex virus; WNV: West Nile virus; DFA: direct fluorescent antibody; VZV: varicella zoster virus; CMV: cytomegalovirus; CJ: Creutzfeldt-Jakob disease; HHV6: human herpesvirus 6.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Willoughby RE, Long SS. Encephalitis, meningoencephalitis, acute disseminated encephalomyelitis, and acute necrotizing encephalopathy. In: Principles and Practice of Pediatric Infectious Diseases, 2nd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. p.310. </LI>&#xD;&#xA;<LI>Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. </LI>&#xD;&#xA;<LI>Bronstein DE, Shields WD, Glaser CA. Encephalitis and meningoencephalitis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.492.</LI></OL></div><div id=\"graphicVersion\">Graphic 63632 Version 6.0</div></div></div>"},"63633":{"type":"graphic_picture","displayName":"Pneumatic otoscope","title":"Pneumatic otoscope","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Pneumatic otoscope</div><div class=\"cntnt\"><img style=\"width:456px; height:212px;\" src=\"images/PEDS/63633_Pneumatic_otoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pneumatic otoscope with enlargement of the head of the otoscope delineating the magnifying lens (which is moveable) and the nipple to which the insufflator bulb is attached.</div><div id=\"graphicVersion\">Graphic 63633 Version 2.0</div></div></div>"},"63634":{"type":"graphic_table","displayName":"Efficacy of IFNa in chronic HBV","title":"Endpoints for assessing efficacy of IFNa in chronic HBV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endpoints for assessing efficacy of IFNa in chronic HBV infection</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Suppression of HBV replication</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clearance of HBV DNA from serum</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clearance of HBeAg with or without the development anti-HBe antibodies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Improvement in liver disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normalization in ALT level</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Decrease in necroinflammatory activity on liver biopsies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Eradication of HBV (which is seldom achieved)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clearance of HBsAg with or without the development of anti-HBs antibodies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Clearance of HBV DNA from serum (by PCR); rare in patients who remain HBsAg positive</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Disappearance of HBV DNA from liver</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Prevention of cirrhosis and hepatocellular carcinoma and improvement in survival</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Scanty data</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 63634 Version 2.0</div></div></div>"},"63637":{"type":"graphic_picture","displayName":"CLL marrow low","title":"Bone marrow aspirate in a patient with chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow aspirate in a patient with chronic lymphocytic leukemia</div><div class=\"cntnt\"><img style=\"width:437px; height:288px;\" src=\"images/HEME/63637_CLL_marrow_low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a bone marrow aspirate in a patient with chronic lymphocytic leukemia shows a monotonous infiltration with small round cells having only a thin rim of cytoplasm.</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and Anna J Mitus, MD.</div><div id=\"graphicVersion\">Graphic 63637 Version 2.0</div></div></div>"},"63639":{"type":"graphic_table","displayName":"Crystalloids and colloids for plasma expansion in adults","title":"Crystalloids and colloids for plasma expansion in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Crystalloids and colloids for plasma expansion in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Solution<br /> (US trade name)</td> <td class=\"subtitle1\">Sodium<br /> (mEq/L)</td> <td class=\"subtitle1\">Potassium<br /> (mEq/L)</td> <td class=\"subtitle1\">Chlorid<br /> (mEq/L)</td> <td class=\"subtitle1\">Osmolarity<br /> (mOsm/L)</td> <td class=\"subtitle1\">Mean molecular weight<br /> (Daltons)</td> <td class=\"subtitle1\">Molar substitution*</td> <td class=\"subtitle1\">Volume effect<br /> (percent of bolus remaining intravascular)</td> <td class=\"subtitle1\">Plasma volume expansion duration<br /> (hours)</td> </tr> <tr class=\"divider_bottom\"> <td>Sodium chloride 0.9 percent</td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">310</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">20</td> <td class=\"centered\">Varies</td> </tr> <tr class=\"divider_bottom\"> <td>Lactated Ringer's injection</td> <td class=\"centered\">130</td> <td class=\"centered\">4</td> <td class=\"centered\">109</td> <td class=\"centered\">275</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">20</td> <td class=\"centered\">Varies</td> </tr> <tr class=\"divider_bottom\"> <td>Albumin (human) 5 percent</td> <td class=\"centered\">150</td> <td class=\"centered\">&#8804;2</td> <td class=\"centered\">150</td> <td class=\"centered\">300</td> <td class=\"centered\">68,000</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">70</td> <td class=\"centered\">2-4</td> </tr> <tr class=\"divider_bottom\"> <td>Gelatin 4 percent<sup>&#182;</sup></td> <td class=\"centered\">145</td> <td class=\"centered\">4</td> <td class=\"centered\">145</td> <td class=\"centered\">284</td> <td class=\"centered\">30,000</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">70-80</td> <td class=\"centered\">2-3</td> </tr> <tr class=\"divider_bottom\"> <td>Tetrastarch 6 percent 130/0.4 (Voluven&#174;)<sup>&#916;</sup></td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">308</td> <td class=\"centered\">130,000</td> <td class=\"centered\">0.4</td> <td class=\"centered\">100</td> <td class=\"centered\">4-8</td> </tr> <tr class=\"divider_bottom\"> <td>Pentastarch 10 percent 200/0.5 (Pentaspan&#174; Canadian trade <span class=\"white-space:nowrap;\">&#182;<sup>&#916;</sup></span></td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">326</td> <td class=\"centered\">200,000 to 300,000</td> <td class=\"centered\">0.5</td> <td class=\"centered\">145</td> <td class=\"centered\">6-12</td> </tr> <tr class=\"divider_bottom\"> <td>Hydroxyethyl starch (hetastarch) 6 percent 450/0.6<sup>&#182;</sup></td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">308</td> <td class=\"centered\">450,000</td> <td class=\"centered\">0.6</td> <td class=\"centered\">100</td> <td class=\"centered\">24-36</td> </tr> <tr class=\"divider_bottom\"> <td>Hydroxyethyl starch (hetastarch) 6 percent 600/0.75 (Hespan&#174;)<sup>&#916;</sup></td> <td class=\"centered\">154</td> <td class=\"centered\">0</td> <td class=\"centered\">154</td> <td class=\"centered\">308</td> <td class=\"centered\">600,000</td> <td class=\"centered\">0.75</td> <td class=\"centered\">100</td> <td class=\"centered\">24-36</td> </tr> <tr> <td>Hydroxyethyl starch (hetastarch) 6 percent 600/0.75 (Hextend&#174;)<sup>&#9674;</sup></td> <td class=\"centered\">143</td> <td class=\"centered\">3</td> <td class=\"centered\">124</td> <td class=\"centered\">308</td> <td class=\"centered\">670,000</td> <td class=\"centered\">0.75</td> <td class=\"centered\">100</td> <td class=\"centered\">24-36</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Molar substitution is the average hydroxyethyl groups per one glucose unit.<br />&para; Not available in US.<br />&Delta; In sodium chloride 0.9 percent.<br /><span class=\"lozenge\">&loz;</span> In Lactated Ringer's injection.</div><div id=\"graphicVersion\">Graphic 63639 Version 10.0</div></div></div>"},"63640":{"type":"graphic_figure","displayName":"Onchocerciasis distribution in the Americas","title":"Geographic distribution of onchocerciasis in the Americas, 2014","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of onchocerciasis in the Americas, 2014</div><div class=\"cntnt\"><img style=\"width:744px; height:542px;\" src=\"images/ID/63640_Onchcrcs_dstrbt_amrc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Have requested World Health Organization (WHO) verification of elimination.<br />&para; WHO has verified elimination.</div><div class=\"graphic_reference\">Reproduced with permission from: Onchocerciasis Transmission in the Americas 2015. Copyright &copy; 2015 The Carter Center.</div><div id=\"graphicVersion\">Graphic 63640 Version 4.0</div></div></div>"},"63642":{"type":"graphic_diagnosticimage","displayName":"X-ray of dactylitis and periosteal reaction in child with psJIA","title":"Radiograph of dactylitis and periosteal reaction in child with psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Radiograph of dactylitis and periosteal reaction in child with psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:552px; height:389px;\" src=\"images/ALLRG/63642_Xray_dactilitis_perio_psJIA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hand/wrist radiographs from a child with psoriatic juvenile idiopathic arthritis (psJIA). Note dactylitic swelling of the digit (white arrowheads) and periosteal reaction of bone (black arrowheads) in comparison with the contralateral hand.</div><div class=\"graphic_reference\">Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63642 Version 3.0</div></div></div>"},"63643":{"type":"graphic_table","displayName":"Latex allergy diagnostic questionnaire","title":"Latex allergy diagnostic questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Latex allergy diagnostic questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"6\">Circle \"Yes\" or \"No\"</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Risk factor assessment:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Exposure history:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Are you a health care worker?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do you wear latex gloves regularly or are you otherwise exposed to latex regularly?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do you have a history of eczema or other rashes on your hands?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do you have a medical history of frequent surgeries or invasive medical procedures?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Did these take place when you were an infant?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do you have a history of \"hay fever\" or other common allergies?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do your fellow workers wear latex gloves regularly?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Do you take a beta-blocker medication?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Circle any foods below that cause hives, itching of the lips or throat, or more severe symptoms when you eat or handle them:</td> </tr> <tr> <td class=\"centered\">Avocado</td> <td class=\"centered\">Apple</td> <td class=\"centered\">Pear</td> <td class=\"centered\">Celery</td> <td class=\"centered\">Carrot</td> <td class=\"centered\">Hazelnut</td> </tr> <tr> <td class=\"centered\">Kiwi</td> <td class=\"centered\">Papaya</td> <td class=\"centered\">Pineapple</td> <td class=\"centered\">Peach</td> <td class=\"centered\">Cherry</td> <td class=\"centered\">Plum</td> </tr> <tr> <td class=\"centered\">Apricot</td> <td class=\"centered\">Banana</td> <td class=\"centered\">Melon</td> <td class=\"centered\">Chestnut</td> <td class=\"centered\">Nectarine</td> <td class=\"centered\">Grape</td> </tr> <tr> <td class=\"centered\">Fig</td> <td class=\"centered\">Passion fruit</td> <td class=\"centered\">Tomatoes</td> <td class=\"centered\">Potatoes</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Contact dermatitis assessment (for patients who wear latex gloves frequently):</td> </tr> <tr> <td colspan=\"4\">Do you have rash, itching, cracking, chapping, scaling, or weeping of the skin from latex glove use?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Have these symptoms recently changed or worsened?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Have you used different brands of latex gloves?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">If so, have your symptoms persisted?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Have you used nonlatex gloves?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">If so, have you had the same or similar symptoms as with latex gloves?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Do these symptoms persist when you stop wearing all gloves?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Contact urticaria (hives) assessment (for patients who wear latex gloves frequently):</td> </tr> <tr> <td colspan=\"4\">When you wear or are around others wearing latex gloves, do you get hives, red itchy swollen hands within 30 minutes, or \"water blisters\" on your hands within a day?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Aerosol reaction assessment:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">When you wear or are around others wearing latex gloves, have you noted any:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Itchy, red eyes, fits of sneezing, runny or stuffy nose, itching of the nose or palate?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Shortness of breath, wheezing, chest tightness, or difficulty breathing?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Other acute reactions, including generalized or severe swelling or shock</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">History of reactions suggestive of latex allergy: </td> </tr> <tr> <td colspan=\"4\">Do you have a history of anaphylaxis or of intraoperative shock?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Have you had itching, swelling or other symptoms following dental, rectal, or pelvic exams?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Have you experienced swelling or difficulty breathing after blowing up a balloon?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Do condoms, diaphragms, or latex sexual aids cause itching or swelling?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> <tr> <td colspan=\"4\">Do rubber handles, rubber bands or elastic bands, or clothing cause any discomfort?</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: American College of Allergy, Asthma and Immunology. Sussman G, Gold M. Guidelines for the management of latex allergies and safe latex use in health care facilities, 1996. <A style=\"FONT-STYLE: italic\" href=\"http://www.acaai.org/\" target=_blank>www.acaai.org</A>. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 63643 Version 5.0</div></div></div>"},"63644":{"type":"graphic_picture","displayName":"Urticaria 3","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:276px; height:324px;\" src=\"images/ALLRG/63644_Urticaria_3_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermal vasodilatation occurs with no epidermal change (scale).</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63644 Version 4.0</div></div></div>"},"63647":{"type":"graphic_table","displayName":"The Lawton instrumental activities of daily living scale","title":"The Lawton instrumental activities of daily living scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Lawton instrumental activities of daily living scale</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Activities </td> <td class=\"subtitle1\">Points </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ability to use telephone </td> </tr> <tr> <td class=\"indent1\">1. Operates telephone on own initiative; looks up and dials numbers </td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Dials a few well-known numbers </td> <td>1</td> </tr> <tr> <td class=\"indent1\">3. Answers telephone, but does not dial </td> <td>1</td> </tr> <tr> <td class=\"indent1\">4. Does not use telephone at all </td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Shopping </td> </tr> <tr> <td class=\"indent1\">1. Takes care of all shopping needs independently </td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Shops independently for small purchases </td> <td>0</td> </tr> <tr> <td class=\"indent1\">3. Needs to be accompanied on any shopping trip </td> <td>0</td> </tr> <tr> <td class=\"indent1\">4. Completely unable to shop </td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Food preparation </td> </tr> <tr> <td class=\"indent1\">1. Plans, prepares, and serves adequate meals independently </td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Prepares adequate meals if supplied with ingredients </td> <td>0</td> </tr> <tr> <td class=\"indent1\">3. Heats and serves prepared meals or prepares meals, but does not maintain adequate diet </td> <td>0</td> </tr> <tr> <td class=\"indent1\">4. Needs to have meals prepared and served </td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Housekeeping </td> </tr> <tr> <td class=\"indent1\">1. Maintains house alone with occasion assistance (heavy work) </td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Performs light daily tasks such as dishwashing, bed making </td> <td>1</td> </tr> <tr> <td class=\"indent1\">3. Performs light daily tasks, but cannot maintain acceptable level of cleanliness </td> <td>1</td> </tr> <tr> <td class=\"indent1\">4. Needs help with all home maintenance tasks </td> <td>1</td> </tr> <tr> <td class=\"indent1\">5. Does not participate in any housekeeping tasks </td> <td>0</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Activities </td> <td class=\"subtitle1\">Points </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Laundry </td> </tr> <tr> <td class=\"indent1\">1. Does personal laundry completely </td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Launders small items, rinses socks, stockings, etc</td> <td>1</td> </tr> <tr> <td class=\"indent1\">3. All laundry must be done by others </td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mode of transportation </td> </tr> <tr> <td class=\"indent1\">1. Travels independently on public transportation or drives own car</td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Arranges own travel via taxi, but does not otherwise use public transportation</td> <td>1</td> </tr> <tr> <td class=\"indent1\">3. Travels on public transportation when assisted or accompanied by another</td> <td>1</td> </tr> <tr> <td class=\"indent1\">4. Travel limited to taxi or automobile with assistance of another</td> <td>0</td> </tr> <tr> <td class=\"indent1\">5. Does not travel at all</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Responsibility for own medications </td> </tr> <tr> <td class=\"indent1\">1. Is responsible for taking medication in correct doses at correct time</td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Takes responsibility if medication is prepared in advance in separate doses </td> <td>0</td> </tr> <tr> <td class=\"indent1\">3. Is not capable of dispensing own medication</td> <td>0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ability to handle finances </td> </tr> <tr> <td class=\"indent1\">1. Manages financial matters independently (budgets, writes checks, pays rent and bills, goes to bank); collects and keeps track of income</td> <td>1</td> </tr> <tr> <td class=\"indent1\">2. Manages day-to-day purchases, but needs help with banking, major purchases, etc</td> <td>1</td> </tr> <tr> <td class=\"indent1\">3. Incapable of handling money</td> <td>0</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Scoring:</strong> For each category, circle the item description that most closely resembles the client's highest functional level (either 0 or 1).<br> A summary score ranges from 0 (dependent, requires significant assistance to live in the community) to 8 (independent, no assistance required to maintain self in community).</div><div class=\"graphic_reference\">Reproduced with permission from: Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179. Copyright © 1969 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 63647 Version 8.0</div></div></div>"},"63649":{"type":"graphic_table","displayName":"Sx neuropsychiatric lupus","title":"Neuropsychiatric manifestations of systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuropsychiatric manifestations of systemic lupus erythematosus</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Primary neurological manifestations</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\t\t\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">CVA</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Vasculitis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Vasculopathy (atherosclerosis)</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Emboli</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist2\">Libman-Sacks</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Antiphospholipid antibodies</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Seizures</td>\n\t\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Generalized</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Partial complex</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Migraine</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Transeverse myelitis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Optic neuritis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Meningitis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Organic brain syndrome</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Psychosis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Cognitivie defects</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Dementia</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Neuropathies</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Coma</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Primary psychiatric manifestations</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Psychosis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cognitive disorder</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pseudo dementia</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Functional</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Anxiety</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Depression</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Headache</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Conversion reaction</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Secondary complications, systemic disease, chronic disease, and/or its treatment</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Neurologic</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">CVA</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Seizures</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist2\">Uremia</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist2\">Medications</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Meningitis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist2\">Medications</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Infections</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1_start\">Psychiatric</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Psychosis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Depression</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Hypomania</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Coma</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Anxiety</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Affective disorder</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Mood swing</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"sublist1\">Adjustment disorder</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63649 Version 1.0</div></div></div>"},"63651":{"type":"graphic_figure","displayName":"Gonococcal membrane components","title":"Components of gonococcal membrane","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Components of gonococcal membrane</div><div class=\"cntnt\"><img style=\"width:503px; height:184px;\" src=\"images/ID/63651_Gonococcal_membrane_compone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RMP: reduction modifiable protein; OPA: opacity-associated proteins; LOS: lipo-oligosaccharide&nbsp;</div><div id=\"graphicVersion\">Graphic 63651 Version 2.0</div></div></div>"},"63652":{"type":"graphic_table","displayName":"Noninfectious pneumonia","title":"Noninfectious etiologies of nonresolving pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious etiologies of nonresolving pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neoplastic disorders</td> </tr> <tr> <td>Bronchogenic carcinoma</td> </tr> <tr> <td>Bronchoalveolar cell carcinoma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Immunologic disorders</td> </tr> <tr> <td class=\"sublist1_start\">Vasculitis:</td> </tr> <tr> <td class=\"sublist1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"sublist1\">Diffuse alveolar hemorrhage</td> </tr> <tr> <td>Bronchiolitis obliterans-organizing pneumonia (BOOP)</td> </tr> <tr> <td class=\"sublist1_start\">Eosinophilic pneumonia syndromes</td> </tr> <tr> <td class=\"sublist1\">Acute eosinophilic pneumonia</td> </tr> <tr> <td class=\"sublist1\">Chronic eosinophilic pneumonia</td> </tr> <tr> <td>Acute interstitial pneumonia</td> </tr> <tr> <td>Pulmonary alveolar proteinosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td class=\"subtitle1_single\">Drug toxicity</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary vascular abnormalities</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td>Pulmonary embolism</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63652 Version 3.0</div></div></div>"},"63653":{"type":"graphic_figure","displayName":"Estimation of LV mass","title":"Estimation of left ventricular mass by 2D echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimation of left ventricular mass by 2D echocardiogram</div><div class=\"cntnt\"><img style=\"width:444px; height:511px;\" src=\"images/CARD/63653_Calculation_LV_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean wall thickness (t) can be obtained by planimetry of the epicardium and endocardium in the short axis&nbsp;echocardiographic view&nbsp;(panel A). This approach circumvents the problems associated with estimating wall thickness at only one or two spots. Knowledge of the inner area also allows simple back calculation of the minor axis radius b. Using the two-chamber or four-chamber view (whichever is longer) the semimajor axis a and the truncated semiminor axis d are measured (panel B). The formula for LV mass derived from the method of discs and based on a model of the LV as a truncated ellipsoid is shown in panel C. Basically, the formula calculates volume from the inner and outer shells of the LV (epicardium and endocardium). The differnce of these two values is the volume of the myocardium or, when multiplied by muscle density (1.05), it is mass.</div><div id=\"graphicVersion\">Graphic 63653 Version 3.0</div></div></div>"},"63654":{"type":"graphic_figure","displayName":"Creation congenic strain","title":"Creation of a congenic strain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Creation of a congenic strain</div><div class=\"cntnt\"><img style=\"width:280px; height:377px;\" src=\"images/ALLRG/63654_Creation_congenic_strain.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A highly schematic representation of the relative contributions of donor and recipient alleles at sequential generations of backcrossing. The donor contribution is indicated in white and the recipient contribution is indicated in black with the checkerboard pattern indicative of heterozygous loci. By the tenth generation of backcrossing, the differential segment around the selected locus will represent the major contribution from the donor genome.</div><div class=\"graphic_reference\">Reproduced with permission from Professor Lee M. Silver, Princeton University, for use of this illustration, which appeared originally in &quot;Mouse Genetics,&quot; published in hardcopy by Oxford University Press, and online by the Jackson Laboratory (http://www.jax.org).</div><div id=\"graphicVersion\">Graphic 63654 Version 1.0</div></div></div>"},"63655":{"type":"graphic_table","displayName":"Surgery hilar cholangioCA","title":"Outcomes of surgical resection in two cohorts of patients treated for hilar cholangiocarcinoma during a similar time period","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of surgical resection in two cohorts of patients treated for hilar cholangiocarcinoma during a similar time period</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">American cohort</td> <td class=\"subtitle1\">Japanese cohort</td> </tr> <tr> <td>Number of patients undergoing resection</td> <td>25</td> <td>122</td> </tr> <tr> <td class=\"sublist1_start\">Resectability rate</td> <td class=\"sublist_other_start\">25 percent</td> <td class=\"sublist_other_start\">79 percent</td> </tr> <tr> <td class=\"sublist1\">Bile duct resection alone</td> <td class=\"sublist_other\">21 </td> <td class=\"sublist_other\">13 </td> </tr> <tr> <td class=\"sublist2_start sublist1\">Liver plus bile duct resection</td> <td class=\"sublist_other_start sublist_other\">4 </td> <td class=\"sublist_other_start sublist_other\">109</td> </tr> <tr> <td class=\"indent2 sublist2\">With caudate lobe resection</td> <td class=\"sublist_other\">2 </td> <td class=\"sublist_other\">109</td> </tr> <tr> <td class=\"indent2 sublist2\">With portal vein resection</td> <td class=\"sublist_other\">0 </td> <td class=\"sublist_other\">39</td> </tr> <tr> <td class=\"indent2 sublist2\">With pancreaticoduodenectomy</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">18</td> </tr> <tr> <td>5-year survival overall</td> <td>7 percent</td> <td>16 percent</td> </tr> <tr> <td>10-year survival overall</td> <td>0 percent</td> <td>12 percent</td> </tr> <tr> <td>5-year survival in completely resected patients</td> <td>43 percent</td> <td>25 percent</td> </tr> <tr> <td>10-year survival in completely resected patients</td> <td>0 percent</td> <td>18 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Tsao JI, et al. Ann Surg 2000; 232:166.</div><div id=\"graphicVersion\">Graphic 63655 Version 3.0</div></div></div>"},"63656":{"type":"graphic_table","displayName":"Time zone shift PI","title":"Recommendations for time zone shifts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for time zone shifts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Try to choose daytime flights to minimize sleep loss.</td> </tr> <tr> <td>2. If traveling at night or for long distance, try to travel in business or first class to allow sleep during the flight.</td> </tr> <tr> <td>3. Avoid large meals, caffeine, and alcohol during your normal sleep period.</td> </tr> <tr> <td>4. Drink water.</td> </tr> <tr> <td>5. If the flight is&nbsp;eight hours or more in length and occurs during your destination sleep period, consider the use of a short-acting hypnotic during the flight (this would contraindicate the use of any alcohol during the flight) and for the first few nights after arrival.</td> </tr> <tr> <td>6. Some research suggests that melatonin can help to alter circadian rhythms. Usage guidelines are available, but melatonin is sold only as a health food substance and is not approved by the US Food and Drug Administration (FDA). Typical use is 5 mg at the desired bedtime for&nbsp;four nights after arrival in a new time zone.</td> </tr> <tr> <td>7. Avoid important meetings on the day after arrival.</td> </tr> <tr> <td>8. Avoid distance driving or other sedentary behavior on the day of arrival.</td> </tr> <tr> <td>9. Bright light can either maintain or help to shift circadian rhythms depending upon the time of exposure.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Arendt J, Stone B, Skene DJ. Sleep disruption in jet lag and other circadian rhythm-related disorders. In: Principles and Practice of Sleep Medicine, 4th ed, Kryger M, Roth T, Dement WC (eds), Saunders, New York 2005.</div><div id=\"graphicVersion\">Graphic 63656 Version 2.0</div></div></div>"},"63660":{"type":"graphic_picture","displayName":"Comparison of Pap histology","title":"Comparison of normal, low grade and high grade lesions by cervical cytology findings and histology from colposcopically directed biopsies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of normal, low grade and high grade lesions by cervical cytology findings and histology from colposcopically directed biopsies</div><div class=\"cntnt\"><img style=\"width:432px; height:393px;\" src=\"images/OBGYN/63660_Comparison_of_Pap_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Normal, low-grade, and high-grade cervical cytology. B) Cervical intraepithelial neoplasia I, II, III. </div><div class=\"graphic_reference\">A) Reproduced with permission from Christopher Crum, MD. Copyright © Christopher Crum, MD.<BR>B) Reproduced with permission from: Apgar BS, Brotzman GL, Spitzer M (Eds). Colposcopy Principles and Practice, W.B. Saunders Company, Philadelphia 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 63660 Version 4.0</div></div></div>"},"63661":{"type":"graphic_diagnosticimage","displayName":"Pedunculated fibroid","title":"Pedunculated fibroid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pedunculated fibroid</div><div class=\"cntnt\"><img style=\"width:432px; height:367px;\" src=\"images/OBGYN/63661_Pedunculated_fibroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the right adnexa showing a pedunculated fibroid. A solid-appearing mass is noted in the right adnexa (long arrow). No cystic areas are identified. The mass is slightly heterogeneous and has no appreciable posterior enhancement but has some areas of shadowing (short arrow). The mass is separate from the right ovary. The arrowhead demonstrates a thick stalk&nbsp;that connects the fibroid to the uterus.</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright © Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 63661 Version 3.0</div></div></div>"},"63662":{"type":"graphic_diagnosticimage","displayName":"Cerebral abscess with PAVM","title":"Clinical image from patient with PAVM-induced cerebral abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clinical image from patient with PAVM-induced cerebral abscess</div><div class=\"cntnt\"><img style=\"width:298px; height:370px;\" src=\"images/HEME/63662_Cerebral_abscess_PAVM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced magnetic resonance image of cerebral abscess. Note enhancing vascular capsule and central area of necrosis in the temporoparietal abscess.</div><div class=\"graphic_footnotes\">PAVM: Pulmonary arteriovenous malformation.</div><div class=\"graphic_reference\">Reproduced by permission from: Macmillan Publishers Ltd: Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br J Dent 2008; 205:531. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 63662 Version 6.0</div></div></div>"},"63663":{"type":"graphic_figure","displayName":"Follic lymphoma nodal areas","title":"Follicular lymphoma lymph node locations","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Follicular lymphoma lymph node locations</div><div class=\"cntnt\"><img style=\"width:559px; height:572px;\" src=\"images/HEME/63663_Follic_lymphoma_nodal_areas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mannikin showing the eight potentially involved lymph node areas used for calculating the Follicular Lymphoma International Prognostic Index (FLIPI). The eight nodal areas include cervical, axillary, epitrochlear, mediastinal, mesenteric, paraaortic, inguinal, and popliteal areas, with the sub-areas as noted in the figure.</div><div class=\"graphic_reference\">Modified with permission from: Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258. Copyright © 2004. American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 63663 Version 2.0</div></div></div>"},"63664":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray - Dilated cardiomyopathy in 13 yo boy","title":"Chest radiograph of 13-year-old boy with dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of 13-year-old boy with dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:540px; height:448px;\" src=\"images/PEDS/63664_Chest_xray_dilat_cardiomyop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrating cardiomegaly and pulmonary interstitial edema in a 13-year-old boy with dilated cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 63664 Version 2.0</div></div></div>"},"63666":{"type":"graphic_picture","displayName":"Adult with CHH","title":"Adult with cartilage-hair hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adult with cartilage-hair hypoplasia</div><div class=\"cntnt\"><img style=\"width:234px; height:432px;\" src=\"images/ALLRG/63666_AdultwithCHH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 22-year-old woman with metaphyseal chondrodysplasia, McKusick type (cartilage-hair hypoplasia). Note disproportionately short stature, fine light hair, and genu varum.</div><div class=\"graphic_reference\">Reproduced with permission from: Sponseller PD, Ain MC. The Skeletal Dysplasias. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63666 Version 12.0</div></div></div>"},"63667":{"type":"graphic_table","displayName":"Toddler hypoallergenic formulas","title":"Formulas for children >1 year with cow's milk and soy allergy/intolerance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formulas for children &gt;1 year with cow's milk and soy allergy/intolerance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Manufacturer</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extensively hydrolyzed casein-based formula</td> </tr> <tr> <td class=\"indent1\">Enfamil Nutramigen with Enflora LGG Toddler</td> <td>Mead Johnson Nutrition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Amino acid-based formulas</td> </tr> <tr> <td class=\"indent1\">Alfamino Junior</td> <td>Nestle&nbsp;</td> </tr> <tr> <td class=\"indent1\">Elecare Junior - Unflavored, vanilla</td> <td>Abbot Nutrition&nbsp;</td> </tr> <tr> <td class=\"indent1\">EO28 Splash - Orange pineapple, grape, tropical fruit*</td> <td>Nutricia&nbsp;</td> </tr> <tr> <td class=\"indent1\">Neocate Junior - Unflavored, chocolate, and tropical</td> <td>Nutricia</td> </tr> <tr> <td class=\"indent1\">Neocate Junior Prebiotic - Unflavored, vanilla, and strawberry</td> <td>Nutricia</td> </tr> <tr> <td class=\"indent1\">Neocate Splash</td> <td>Nutricia</td> </tr> <tr> <td class=\"indent1\">PurAmino Toddler*</td> <td>Mead Johnson Nutrition</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGG: <EM>Lactobacillus rhamnosus</EM> GG.<br />* As a supplemental formula.</div><div id=\"graphicVersion\">Graphic 63667 Version 12.0</div></div></div>"},"63668":{"type":"graphic_picture","displayName":"AIP plasma cells Light LP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/63668_AIP_plasma_cells_Light_LP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power (40X) view of a pancreas biopsy in a patient with autoimmune pancreatitis showing a large pancreatic duct surrounded by a dense lymphoplasmacytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 63668 Version 1.0</div></div></div>"},"63669":{"type":"graphic_picture","displayName":"Endoclip bleeding DU endosc","title":"Bleeding duodenal ulcer","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Bleeding duodenal ulcer</div><div class=\"cntnt\"><img style=\"width:512px; height:511px;\" src=\"images/GAST/63669_Endoclip_bleeding_DU_endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoclip hemostasis of a bleeding duodenal ulcer after epinephrine injection. This patient began to bleed while an inpatient and required six units of packed RBC transfusion for resuscitation. After the combination hemostasis (epinephrine and hemoclips) he was treated with 72 hours with high dose proton pump inhibitor (PPI) (pantoprazole 80 mg IV bolus and 8 mg/hr IV drip, followed by twice daily oral PPI. He did not rebleed.</div><div class=\"graphic_reference\">Courtesy of Dennis M. Jensen, MD.</div><div id=\"graphicVersion\">Graphic 63669 Version 1.0</div></div></div>"},"63670":{"type":"graphic_figure","displayName":"Posterior leg splint","title":"Posterior leg splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior leg splint</div><div class=\"cntnt\"><img style=\"width:319px; height:392px;\" src=\"images/PEDS/63670_Posterior_leg_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior leg (or ankle) splint is used for distal leg, ankle, tarsal, and metatarsal fractures.</div><div id=\"graphicVersion\">Graphic 63670 Version 1.0</div></div></div>"},"63674":{"type":"graphic_table","displayName":"Granulomatous diseases nose and sinuses","title":"Granulomatous diseases of nose and paranasal sinuses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Granulomatous diseases of nose and paranasal sinuses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Granulomatous diseases</td> <td class=\"subtitle1\">Diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infections</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>Mycobacterial</em></td> </tr> <tr> <td class=\"indent2\">Tuberculosis (M. tuberculosis)</td> <td>PPD, CXR, QFT-G, AFB smear and culture</td> </tr> <tr> <td class=\"indent2\">Leprosy (M. leprae)</td> <td>Skin smear or biopsy, PCR</td> </tr> <tr> <td class=\"indent2\">Atypical mycobacterial (eg, M. chelonei)</td> <td>AFB smear and culture</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>Treponemal</em></td> </tr> <tr> <td class=\"indent2\">Syphilis</td> <td>RPR, FTA-ABS</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>Bacterial</em></td> </tr> <tr> <td class=\"indent2\">Rhinoscleroma (Klebsiella rhinoscleromatis)</td> <td>Culture</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>Fungal</em></td> </tr> <tr> <td class=\"indent2\">Histoplasmosis (Histoplasma capsulatum)</td> <td>Special stains, culture, serology</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\"><em>Protozoan</em></td> </tr> <tr> <td class=\"indent2\">Leishmaniasis (Leishmania braziliensis)</td> <td>Skin smear or aspirate, PCR, biopsy showing intra and extracellular Leishman bodies</td> </tr> <tr> <td class=\"indent2\">Rhinosporidiosis (Rhinosporidium seeberi)</td> <td>Biopsy showing granulomas and typical sporangia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vasculitides</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> <td>ANCA, biopsy</td> </tr> <tr> <td class=\"indent1\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> <td>Peripheral eosinophilia, ANCA, biopsy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lethal midline granulomatosis (extranodal NK/T cell lymphoma)</td> <td>Biopsy showing polymorphous lymphoid infiltrate; immunophenotype positive for CD2, surface CD3, CD56; clonal EBV genomes present</td> </tr> <tr> <td class=\"indent1\">Nonkeratinizing nasopharyngeal carcinoma</td> <td>Biopsy shows an epithelial neoplasm with a dense lymphoplasmacytic infiltrate (predominantly T cells); associated with EBV infection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Biopsy showing noncaseating granulomas, CXR</td> </tr> <tr> <td class=\"indent1\">Cocaine-induced midline destructive lesion</td> <td>History of cocaine use</td> </tr> <tr> <td class=\"indent1\">Granulomatous rosacea</td> <td>Granulomatous perifolliculitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPD: purified protein derivative skin test; CXR: chest radiograph; QFT-G: Quantiferon-Gold; AFB: acid fast bacilli; PCR: polymerase chain reaction; RPR: rapid plasma reagin; FTA-ABS: fluorescent treponemal antibody absorption; ANCA: antineutrophil cytoplasmic antibody; EBV: Epstein Barr virus.</div><div class=\"graphic_reference\">Data from: Zargari O, Elpern DJ. Granulomatous diseases of the nose. Int J Dermatol 2009; 48:1275.</div><div id=\"graphicVersion\">Graphic 63674 Version 5.0</div></div></div>"},"63675":{"type":"graphic_figure","displayName":"AF mechanisms","title":"AF mechanisms","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">AF mechanisms</div><div class=\"cntnt\"><img style=\"width:588px; height:470px;\" src=\"images/CARD/63675_AF_mechanisms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overview of mechanisms of AF. Four different positive-feedback loops are proposed as the main driving forces for the atrial remodeling process. Enhanced Ca<SUP>2</SUP>+ loading during AF is believed to underlie most of the cellular proarrhythmic mechanisms (trigger loop). The main process in the electrical loop is an altered contribution of ion channels to the action potential configuration that protects atrial myocytes against excessive Ca<SUP>2</SUP>+ loading. Abbreviation of the action potential facilitates re-entry and thereby promotes AF. In the structural loop, chronic atrial stretch activates numerous signaling cascades that produce alterations of the extracellular matrix and conduction disturbances, also facilitating re-entrant mechanisms. The main changes of the contractile properties of the heart are loss of atrial contractility which increases atrial compliance and the development of a ventricular tachycardiomyopathy, both of which increase stretch in the atrial wall. The circular positive-feedback enhancement of these pathophysiological changes explains the general tendency of AF to become more stable with time. It should be noted that the different loops are interconnected by mechanisms that are part of more than one loop. For example, increased Ca<SUP>2</SUP>+ loading enhances trigger activity (trigger loop) and also results in a change in the ion channel population and activity (electrical loop). Re-entrant mechanisms are promoted by both shortening of refractoriness (electrical loop) as well as by conduction disturbances resulting from tissue fibrosis (structural loop). Like in a system of meshing gear wheels, one loop will drive the other, leading to progression of the arrhythmia. However, the proposed system of gear wheels does not start to move spontaneously. Structural heart diseases, arrhythmias, aging, or inherited diseases are required to initiate movement of one or more of these wheels. When the pathophysiological alterations eventually reach a certain threshold, AF will ensue.</div><div class=\"graphic_reference\">Ulrich Schotten, Sander Verheule, Paulus Kirchhof, and Andreas Goette. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiol Rev January 2011 91:265-325 [PRV1/2011]. Reproduced with permission. Copyright © 2011 The American Physiological Society.</div><div id=\"graphicVersion\">Graphic 63675 Version 5.0</div></div></div>"},"63684":{"type":"graphic_picture","displayName":"Plasma cell","title":"Plasma cell","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plasma cell</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/HEME/63684_Plasma_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smear of the peripheral blood demonstrates a circulating plasma cell that is oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing. The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson SC, PhD. Anderson's Atlas of Hematology. Copyright 2003, Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63684 Version 3.0</div></div></div>"},"63685":{"type":"graphic_diagnosticimage","displayName":"Sequestration CXR II","title":"Intralobar sequestration left lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intralobar sequestration left lower lobe</div><div class=\"cntnt\"><img style=\"width:360px; height:370px;\" src=\"images/PULM/63685_Sequestration_CXR_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph several months later reveals that the multicystic structure is now gas-filled due to decreased drainage of secretions with subsequent infection.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63685 Version 2.0</div></div></div>"},"63686":{"type":"graphic_diagnosticimage","displayName":"DISH CT cervical spine","title":"Ossification of posterior longitudinal spinal ligament","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ossification of posterior longitudinal spinal ligament</div><div class=\"cntnt\"><img style=\"width:324px; height:521px;\" src=\"images/RHEUM/63686_DISHCTcervicalspine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This reformatted multislice CT scan shows ossification of the posterior longitudinal spinal ligament in a patient with DISH.</div><div class=\"graphic_footnotes\">CT: computed tomography; DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of Neal Roberts, MD and Curtis Hayes, MD.</div><div id=\"graphicVersion\">Graphic 63686 Version 4.0</div></div></div>"},"63687":{"type":"graphic_figure","displayName":"Arthroscopic surgery PI","title":"Arthroscopic surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arthroscopic surgery</div><div class=\"cntnt\"><img style=\"width:408px; height:404px;\" src=\"images/PI/63687_ArthroscopicsurgeryPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows arthroscopic&nbsp;surgery on a knee. This type of surgery can also&nbsp;be used to repair or replace joints in the shoulder or hip.</div><div id=\"graphicVersion\">Graphic 63687 Version 3.0</div></div></div>"},"63688":{"type":"graphic_picture","displayName":"Umbilical cord cyst","title":"Umbilical cord cyst","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Umbilical cord cyst</div><div class=\"cntnt\"><img style=\"width:540px; height:322px;\" src=\"images/OBGYN/63688_US_umbilical_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Yves Jacquemyn, MD.</div><div id=\"graphicVersion\">Graphic 63688 Version 1.0</div></div></div>"},"63689":{"type":"graphic_figure","displayName":"TIMI flow time to therapy","title":"Patency rate with streptokinase, but not with tPA, is related to earlier treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patency rate with streptokinase, but not with tPA, is related to earlier treatment</div><div class=\"cntnt\"><img style=\"width:358px; height:315px;\" src=\"images/CARD/63689_TIMI_flow_time_to_therapy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rate of a patent artery, defined as TIMI flow grade 3, with streptokinase (SK) therapy is greater when the drug is administered within three hours, compared to longer than three hours, after symptom onset (p = 0.001). The frequency of TIMI grade 3 flow after tissue-type plasminogen activator (tPA) does not display this time dependence.</div><div class=\"graphic_reference\">Data from Steg PG, LaPerche T, Golmard J-L, et al, for the PERM Study Group. J Am Coll Cardiol 1998; 31:776.</div><div id=\"graphicVersion\">Graphic 63689 Version 2.0</div></div></div>"},"63696":{"type":"graphic_table","displayName":"Diagnostic criteria NF1","title":"NIH diagnostic criteria for neurofibromatosis type 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NIH diagnostic criteria for neurofibromatosis type 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Two or more of the following clinical features must be present:</td> </tr> <tr> <td class=\"indent1\">Six or more caf&#233;-au-lait macules of more than 5 mm in greatest diameter in prepubertal individuals, and more than 15 mm in greatest diameter in postpubertal individuals</td> </tr> <tr> <td class=\"indent1\">Two or more neurofibromas of any type or one plexiform neurofibroma</td> </tr> <tr> <td class=\"indent1\">Freckling in the axillary or inguinal regions</td> </tr> <tr> <td class=\"indent1\">Optic glioma</td> </tr> <tr> <td class=\"indent1\">Two or more iris hamartoma (Lisch nodules)</td> </tr> <tr> <td class=\"indent1\">Distinctive bony lesion, such as <span style=\"color: black;\">sphenoid dysplasia, or&nbsp;medullary narrowing and cortical thickening&nbsp;of the long bone cortex with or without pseudoarthrosi</span>s</td> </tr> <tr> <td class=\"indent1\">A first-degree relative (parent, sibling, or offspring) with NF1 based on the above criteria</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NIH: National Institutes of Health; NF1: neurofibromatosis type 1.</div><div id=\"graphicVersion\">Graphic 63696 Version 5.0</div></div></div>"},"63697":{"type":"graphic_figure","displayName":"Parotid gland PI","title":"Parotid gland","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parotid gland</div><div class=\"cntnt\"><img style=\"width:443px; height:446px;\" src=\"images/PI/63697_Parotid-gland-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parotid gland makes saliva, which flows into the mouth through a thin tube called the parotid duct.</div><div id=\"graphicVersion\">Graphic 63697 Version 1.0</div></div></div>"},"63698":{"type":"graphic_table","displayName":"Differential diagnosis of shock in trauma","title":"Differential diagnosis of shock in trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of shock in trauma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">I. Low CVP</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>A. Hypovolemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2_start\">1. Hemorrhage</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">a. External (compressible)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">i. Lacerations</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">ii. Contusions</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">iii. Fractures (partly compressible)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">b. Internal (noncompressible)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">i. Intrathoracic</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">ii. Intraperitoneal</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist3\">iii. Retroperitoneal (partly compressible)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">c. Fractures (partly compressible)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">2. Third spacing (eg, burns)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>B. Neurogenic (high cervical cord injury)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">II. High CVP</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>A. Pericardial tamponade</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>B. Tension pneumothorax</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>C. Myocardial contusion</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">III. Other diagnoses to consider</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>A. Pharmacologic or toxicologic agents</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>B. Myocardial infarction (severe)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>C. Diaphragmatic rupture with herniation</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>D. Fat or air embolism</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13094&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Shock_trauma_ddx.htm</title></head></div><div class=\"graphic_footnotes\">CVP: central venous pressure.</div><div id=\"graphicVersion\">Graphic 63698 Version 3.0</div></div></div>"},"63701":{"type":"graphic_table","displayName":"Senstivities of diagnostic tests for dementia","title":"Sensitivity and specificity of diagnostic tests for dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of diagnostic tests for dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic test</td> <td class=\"subtitle1\">Sensitivity (percent)</td> <td class=\"subtitle1\">Specificity (percent)</td> </tr> <tr> <td>Mini-Mental State Exam*</td> <td class=\"centered\">87</td> <td class=\"centered\">82</td> </tr> <tr> <td>Montreal Cognitive Assessment&nbsp;</td> <td class=\"centered\">&#8805;94&nbsp;</td> <td class=\"centered\">&#8804;60&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Short Portable Mental Status Questionnaire*</td> </tr> <tr> <td class=\"sublist1\">Any dementia</td> <td class=\"sublist_other_centered\">82</td> <td class=\"sublist_other_centered\">92</td> </tr> <tr> <td class=\"sublist1\">Mild dementia</td> <td class=\"sublist_other_centered\">55</td> <td class=\"sublist_other_centered\">96</td> </tr> <tr> <td>NINCDS criteria<sup>&#182;</sup></td> <td class=\"centered\">92</td> <td class=\"centered\">65</td> </tr> <tr> <td>DSM-IV criteria<sup>&#182;</sup></td> <td class=\"centered\">76</td> <td class=\"centered\">80</td> </tr> <tr> <td>Clinical judgment<sup>&#182;</sup></td> <td class=\"centered\">85</td> <td class=\"centered\">82</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NINCDS: National Institute of Neurological and Communicative Diseases; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4<SUP innerHtml>th </SUP>ed.<br /><br />* Diagnosis of dementia.<br />¶ Diagnosis of Alzheimer disease.</div><div id=\"graphicVersion\">Graphic 63701 Version 5.0</div></div></div>"},"63702":{"type":"graphic_picture","displayName":"Hamman Rich Low","title":"Acute interstitial pneumonia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:284px; height:186px;\" src=\"images/PULM/63702_Hamman_Rich_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows dramatic interstitial thickening in a patient with acute interstitial pneumonia (Hamman-Rich disease). The prominent air spaces represent alveolar ducts while the intervening lung shows collapsed alveolar septa distorted by proliferating fibroblasts and myofibroblasts.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 63702 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"63703":{"type":"graphic_picture","displayName":"Tectonic scleral graft","title":"Tectonic scleral graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tectonic scleral graft</div><div class=\"cntnt\"><img style=\"width:215px; height:142px;\" src=\"images/RHEUM/63703_Tectonic_scleral_graft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patch scleral graft was required in this patient with necrotizing disease to cover an area of severe scleral thinning with a threat of perforation.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 63703 Version 2.0</div></div></div>"},"63704":{"type":"graphic_figure","displayName":"Location of anorectal abscesses","title":"Location of anorectal abscesses","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Location of anorectal abscesses</div><div class=\"cntnt\"><img style=\"width:477px; height:404px;\" src=\"images/SURG/63704_Anorectal_abscesses.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63704 Version 5.0</div></div></div>"},"63705":{"type":"graphic_figure","displayName":"Early ST segment shifts after thrombolysis predict outcome","title":"Early ST segment shifts after thrombolysis predict outcome after MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early ST segment shifts after thrombolysis predict outcome after MI</div><div class=\"cntnt\"><img style=\"width:355px; height:458px;\" src=\"images/CARD/63705_ST_segment_shifts_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 734 patients in GUSTO-I, 243 patients had a new ST segment shift 6 to 24 hours after thrombolytic therapy; these patients had a higher 30-day and one-year mortality compared to patients without ST segment changes (upper panel). The duration of the ST segment shift (bottom panel) was also related to the one-year mortality.</div><div class=\"graphic_reference\">Data from Langer, A, Krucoff, MW, Klootwijk, P, et al, for the GUSTO-1 ECG Monitoring Substudy Group, J Am Coll Cardiol 1998; 31:783.</div><div id=\"graphicVersion\">Graphic 63705 Version 3.0</div></div></div>"},"63706":{"type":"graphic_figure","displayName":"Age-specific odds ratios for suicidal ideation and behavior","title":"Age-specific odds ratios for suicidal ideation and behavior","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Age-specific odds ratios for suicidal ideation and behavior</div><div class=\"cntnt\"><img style=\"width:494px; height:472px;\" src=\"images/PSYCH/63706_Age_spec_odds_rat_suic_idea.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Odds ratios &gt;1.0 indicate that the risk of suicidality while receiving antidepressants is elevated relative to placebo; odds ratios &lt;1.0 indicate a protective effect of antidepressants.</div><div class=\"graphic_reference\">Reprinted with permission from: the American Journal of Psychiatry (Copyright © 2007). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 63706 Version 6.0</div></div></div>"},"63709":{"type":"graphic_table","displayName":"Signs of autism","title":"Signs of autism spectrum disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs of autism spectrum disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A child with an ASD might:</td> </tr> <tr> <td class=\"indent1\">Not point at objects to show interest (point at an airplane flying over)</td> </tr> <tr> <td class=\"indent1\">Not look at objects when another person points at them</td> </tr> <tr> <td class=\"indent1\">Have trouble relating to others or not have an interest in other people at all</td> </tr> <tr> <td class=\"indent1\">Avoid eye contact and want to be alone</td> </tr> <tr> <td class=\"indent1\">Have trouble understanding other people's feelings or talking about their feelings</td> </tr> <tr> <td class=\"indent1\">Prefer not to be held or cuddled or might cuddle only when they want to</td> </tr> <tr> <td class=\"indent1\">Appear to be unaware when other people talk to them but respond to other sounds</td> </tr> <tr> <td class=\"indent1\">Be very interested in people, but not know how to talk to, play with, or relate to them</td> </tr> <tr> <td class=\"indent1\">Repeat or echo words or phrases said to them, or repeat words or phrases in place of normal language (echolalia)</td> </tr> <tr> <td class=\"indent1\">Have trouble expressing their needs using typical words or motions</td> </tr> <tr> <td class=\"indent1\">Not play \"pretend\" games (pretend to feed a doll)</td> </tr> <tr> <td class=\"indent1\">Repeat actions over and over again</td> </tr> <tr> <td class=\"indent1\">Have trouble adapting when a routine changes</td> </tr> <tr> <td class=\"indent1\">Have unusual reactions to the way things smell, taste, look, feel, or sound</td> </tr> <tr> <td class=\"indent1\">Lose skills they once had (for instance, stop saying words they were once using)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Autism spectrum disorder (ASD). Facts about ASD. Available at: <a href=\"http://www.cdc.gov/ncbddd/autism/facts.html\" target=\"_blank\">www.cdc.gov/ncbddd/autism/facts.html</a>.</div><div id=\"graphicVersion\">Graphic 63709 Version 5.0</div></div></div>"},"63710":{"type":"graphic_diagnosticimage","displayName":"Diffuse alveolar hemorrhage PA","title":"Diffuse alveolar hemorrhage","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar hemorrhage</div><div class=\"cntnt\"><img style=\"width:333px; height:302px;\" src=\"images/PULM/63710_Diffuse_alveolar_hemorrhage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread alveolar filling representing diffuse alveolar hemorrhage following bone marrow transplantation.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63710 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"63712":{"type":"graphic_figure","displayName":"Mechanisms of platelet activation with vascular injury","title":"Mechanisms of platelet activation with vascular injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanisms of platelet activation with vascular injury</div><div class=\"cntnt\"><img style=\"width:421px; height:461px;\" src=\"images/CARD/63712_Platelet_activat_vessel_inj.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endothelial cells normally release inhibitors of platelet aggregation, including nitric oxide and prostacyclin (PGI2) (Panel A). Disruption of the intact endothelium exposes the subendothelium and leads to the adherence of platelets. Once activated (Panel B), platelets degranulate, thereby releasing platelet aggregation agonists such as ADP and thromboxane A2. Degranulation also promotes surface thrombin generation and the recruitment of additional platelets, leading to thrombus formation.</div><div class=\"graphic_footnotes\">vWF: von Willebrand factor; GP: glycoprotein receptor.</div><div id=\"graphicVersion\">Graphic 63712 Version 2.0</div></div></div>"},"63713":{"type":"graphic_figure","displayName":"Medial retraction thyroid","title":"Medial retraction thyroid","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Medial retraction thyroid</div><div class=\"cntnt\"><img style=\"width:479px; height:420px;\" src=\"images/SURG/63713_Medialretractionthyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medial retraction of thyroid with index finger covered with surgical sponge, and peanut for blunt lateral dissection.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63713 Version 10.0</div></div></div>"},"63714":{"type":"graphic_picture","displayName":"Split-thickness skin graft meshing process","title":"Split-thickness skin graft meshing process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Split-thickness skin graft meshing process</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/SURG/63714_Spl_thick_skin_graft_proc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The split-thickness skin graft is processed through the skin mesher. Note the apertures for graft expansion as the skin exits the mesher.</div><div class=\"graphic_reference\">Courtesy of Jorge Leon-Villapalos, MD, FRCS.</div><div id=\"graphicVersion\">Graphic 63714 Version 2.0</div></div></div>"},"63715":{"type":"graphic_picture","displayName":"Heparin necrosis ulcers","title":"Heparin necrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Heparin necrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63715_Heparin_necrosis_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic ulcers are present in this patient with heparin necrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63715 Version 3.0</div></div></div>"},"63717":{"type":"graphic_picture","displayName":"Lichen scrofulosorum","title":"Lichen scrofulosorum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen scrofulosorum</div><div class=\"cntnt\"><img style=\"width:333px; height:288px;\" src=\"images/DERM/63717_Lichen_scrofulos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular lichenoid papules are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 63717 Version 1.0</div></div></div>"},"63722":{"type":"graphic_figure","displayName":"Urine protein creat ratio","title":"Protein-creatinine ratio to estimate protein excretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protein-creatinine ratio to estimate protein excretion</div><div class=\"cntnt\"><img style=\"width:428px; height:284px;\" src=\"images/NEPH/63722_Urine_protein_creat_ratio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph illustrates the relation between total 24-hour urinary protein excretion and the total protein-to-creatinine ratio (mg/mg) determined on a random urine specimen. Athough there appears to be a close correlation, there can be wide variability in 24-hour protein excretion at a given total protein-to-creatinine ratio. At a ratio of 4, for example, 24-hour protein excretion varied from 2 to almost 8 g/day/1.73 m<SUP>2</SUP>.</div><div class=\"graphic_reference\">Data from: Ginsberg JM, Chang BS, Matarese RA, Garella S. N Engl J Med 1983; 309:1543.</div><div id=\"graphicVersion\">Graphic 63722 Version 4.0</div></div></div>"},"63723":{"type":"graphic_diagnosticimage","displayName":"IVUS coronary artery plaque","title":"Intracoronary ultrasound image of coronary artery disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracoronary ultrasound image of coronary artery disease</div><div class=\"cntnt\"><img style=\"width:133px; height:458px;\" src=\"images/CARD/63723_IVUS_coronary_artery_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracoronary ultrasound is useful to establishing the presence and severity of coronary artery disease. The image in panel A and B show minimal plaque in the coronary artery while C and D demonstrate a moderate size plaque.</div><div class=\"graphic_reference\">Reproduced with permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.</div><div id=\"graphicVersion\">Graphic 63723 Version 3.0</div></div></div>"},"63724":{"type":"graphic_algorithm","displayName":"Algorithm for risk assessment TLS","title":"Algorithmic approach to risk assessment of tumor lysis syndrome","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to risk assessment of tumor lysis syndrome</div><div class=\"cntnt\"><img style=\"width:506px; height:582px;\" src=\"images/ONC/63724_Algorithm-for-risk-assessment-TLS.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TLS: tumor lysis syndrome; ULN: Upper limit of normal.</div><div class=\"graphic_reference\">Modified from Howard SC, Jones DP, Pui CH. The Tumor Lysis Syndrome. N Engl J Med 2011; 364:1844.</div><div id=\"graphicVersion\">Graphic 63724 Version 4.0</div></div></div>"},"63725":{"type":"graphic_diagnosticimage","displayName":"Comminuted intertrochanteric hip fracture","title":"Comminuted intertrochanteric hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comminuted intertrochanteric hip fracture</div><div class=\"cntnt\"><img style=\"width:279px; height:432px;\" src=\"images/EM/63725_Hip_fx_intertroch3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;anteroposterior radiograph&nbsp;shows a&nbsp;comminuted intertrochanteric fracture with displacement of the lesser trochanter.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, MD and Zuckerman, JD, MD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63725 Version 2.0</div></div></div>"},"63726":{"type":"graphic_picture","displayName":"Open fx forearm","title":"Open forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open forearm fracture</div><div class=\"cntnt\"><img style=\"width:350px; height:453px;\" src=\"images/EM/63726_Openfxforearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open fracture. This 8-year-old boy fell on his hand and was referred to the emergency department with a deformed forearm (Panel A) due to a distal radial/ulnar fracture. After removal from his splint a small ecchymosis and laceration were noted over the ventral aspect of his forearm (Panel B).</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63726 Version 12.0</div></div></div>"},"63727":{"type":"graphic_picture","displayName":"Colonic adenoma pseudoinvasion","title":"Colonic adenoma with pseudoinvasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic adenoma with pseudoinvasion</div><div class=\"cntnt\"><img style=\"width:237px; height:344px;\" src=\"images/GAST/63727_Colonic_adenoma_pseudoinvas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a benign colonic adenoma containing a central focus of &quot;misplaced&quot; pseudoinvasive crypts in the polyp stalk (arrow).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 63727 Version 1.0</div></div></div>"},"63728":{"type":"graphic_picture","displayName":"Endoscopic view of the papilla of Vater","title":"Endoscopic view of the papilla of Vater","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of the papilla of Vater</div><div class=\"cntnt\"><img style=\"width:347px; height:360px;\" src=\"images/GAST/63728_Endosc_ampulla_of_Vater.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The papilla of Vater, also known as the ampulla, is a small nipple-like structure located in the duodenum (first part of the intestine). Bile is coming out through the orifice.</div><div class=\"graphic_reference\">Courtesy of Silvano Loperfido, MD.</div><div id=\"graphicVersion\">Graphic 63728 Version 2.0</div></div></div>"},"63729":{"type":"graphic_table","displayName":"Amine alkaloid sympath herbs B","title":"Herbal ingredients with amines, alkaloids or sympathomimetic action: part B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Herbal ingredients with amines, alkaloids or sympathomimetic action: part B</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr><tr>\n<td>Golden seal</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Gravel root</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Hawthorn</td>\n<td>Tyramine</td>\n</tr><tr>\n<td>Horehound, white</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Hydrocotyle</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Ispaghula</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Jamaica dogwood</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Liferoot</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Lobelia</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Mat&eacute;</td>\n<td>Alkaloids, amines</td>\n</tr><tr>\n<td>Mistletoe</td>\n<td>Histamine release</td>\n</tr><tr>\n<td>Motherwort</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Nettle</td>\n<td>Choline</td>\n</tr><tr>\n<td>Parsley</td>\n<td>Myristicin, sympathomimetic</td>\n</tr><tr>\n<td>Passionflower</td>\n<td>Alkaloids, MAOI activity</td>\n</tr><tr>\n<td>Plantain</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Pleurisy root</td>\n<td>Sympathomimetic</td>\n</tr><tr>\n<td>Pokeroot</td>\n<td>Betalains</td>\n</tr><tr>\n<td>Prickly ash, northern and southern</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Quassia</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Sassafras</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Shepherd's purse</td>\n<td>Choline, tyramine</td>\n</tr><tr>\n<td>Skunk cabbage</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>St. John's Wort</td>\n<td>MAOI activity, in vitro</td>\n</tr><tr>\n<td>Stone root</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Valerian</td>\n<td>Alkaloids</td>\n</tr><tr>\n<td>Vervain</td>\n<td>Sympathomimetic</td>\n</tr><tr>\n<td>Yarrow</td>\n<td>Betonicine, stachydrine, betaine</td>\n</tr></tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996. p.284.</div><div id=\"graphicVersion\">Graphic 63729 Version 2.0</div></div></div>"},"63730":{"type":"graphic_picture","displayName":"Acute rejection vascular I","title":"Vascular pattern of acute lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vascular pattern of acute lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/63730_Acute_rejection_vascular_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of acute vascular rejection demonstrating a perivascular lymphocytic infiltrate within the alveolar wall.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 63730 Version 1.0</div></div></div>"},"63732":{"type":"graphic_figure","displayName":"Molecular basis of LQTS","title":"Molecular basis for the long QT syndrome","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Molecular basis for the long QT syndrome</div><div class=\"cntnt\"><img style=\"width:550px; height:327px;\" src=\"images/CARD/63732_Molecular_basis_LQTS_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ion channels contributing to the cardiac action potential and the impact of genetic mutations.</div><div class=\"graphic_footnotes\">+: gain-of-function mutation; &#8722;: dominant negative or loss-of-function mutation; LQT: long-QT syndrome; Ito: transient outward current; INa: inward sodium current; ICa: inward calcium current; IKr: rapid component of delayed rectifier current; IKs: slow component of delayed rectifier current; IK1: inward rectifier current; SQT: short-QT syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Topol EJ, Califf RM, et al. Textbook of Cardiovascular Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63732 Version 7.0</div></div></div>"},"63734":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis PA","title":"Right middle lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:382px; height:376px;\" src=\"images/PULM/63734_RML_atelectasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior (PA) view of right middle lobe atelectasis in which the right cardiac border is obscured. Other findings include a faint increase in opacity in the right lower lung and a slight reduction in the overall right lung volume when compared with the left lung and oligemia of the right upper lobe when compared with the left lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63734 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"63738":{"type":"graphic_figure","displayName":"Brandt Daroff maneuver","title":"Brandt-Daroff maneuver","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Brandt-Daroff maneuver</div><div class=\"cntnt\"><img style=\"width:537px; height:300px;\" src=\"images/NEURO/63738_Brandt_Daroff_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Brandt-Daroff maneuver is performed in the same manner for right and left-sided posterior canalithiasis. The seated patient begins by rapidly lying on one side (1), and then waits until any provoked vertigo subsides. The patient then sits up again (2), and waits once more for vertigo to subside. The next move is to rapidly lie on the other side (3), wait for any vertigo to subside, and then sit up again (4). The sequence is repeated 10 to 20 times, up to three times a day, until the patient is asymptomatic. The symmetry of this maneuver makes it appropriate for either left or right-sided pathology, and it also makes this maneuver useful when one is uncertain as to the side of the canalithiasis.</div><div class=\"graphic_reference\">Modified from Troost BT, Patton JM. Exercise therapy for positional vertigo. Neurology 1992; 42:1441.</div><div id=\"graphicVersion\">Graphic 63738 Version 2.0</div></div></div>"},"63739":{"type":"graphic_figure","displayName":"Ventral cord syndrome","title":"Location of lesion in ventral cord syndrome","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Location of lesion in ventral cord syndrome</div><div class=\"cntnt\"><img style=\"width:542px; height:353px;\" src=\"images/NEURO/63739_Ventral_cord_syndrome.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63739 Version 2.0</div></div></div>"},"63740":{"type":"graphic_picture","displayName":"Hollenhorst plaque retinal artery","title":"Hollenhorst plaque retinal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hollenhorst plaque retinal artery</div><div class=\"cntnt\"><img style=\"width:430px; height:477px;\" src=\"images/CARD/63740_Hollenhorst_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Digital Reference of Opthalmology, Edward S. Harkness Eye Institute, Columbia University, NY.</div><div id=\"graphicVersion\">Graphic 63740 Version 2.0</div></div></div>"},"63741":{"type":"graphic_picture","displayName":"Paragonimiasis egg","title":"Paragonimiasis egg","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Paragonimiasis egg</div><div class=\"cntnt\"><img style=\"width:559px; height:308px;\" src=\"images/ID/63741_Paragonimiasis_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Eggs of <em>P. westermani</em> in unstained wet mounts.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Paragonimiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/paragonimiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/paragonimiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 63741 Version 5.0</div></div></div>"},"63742":{"type":"graphic_figure","displayName":"Effects vitamin D and calcium supplementation on total fracture","title":"Meta-analysis of randomized trials comparing the effects of combined vitamin D and calcium supplementation with placebo on total fracture","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Meta-analysis of randomized trials comparing the effects of combined vitamin D and calcium supplementation with placebo on total fracture</div><div class=\"cntnt\"><img style=\"width:690px; height:426px;\" src=\"images/ENDO/63742_EffvitDcalsuptotaledt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NV: nonvertebral.<br />* Equally allocated groups.<br />¶ Unequally allocated groups; two women were randomly assigned to the control group for every&nbsp;one woman randomly assigned to the treatment group.</div><div class=\"graphic_reference\">This graphic has been updated based on a correction published in Ann Intern Med 2014; 161:615. Reproduced with permission from: Chung M, Lee J, Terasawa T, et al. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827. Copyright &copy; 2014 American College of Physicians. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63742 Version 11.0</div></div></div>"},"63744":{"type":"graphic_table","displayName":"Examination of the ill appearing infant","title":"Linking physical examination and diagnosis in the ill-appearing infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Linking physical examination and diagnosis in the ill-appearing infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physical finding</td> <td class=\"subtitle1\">Potential diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Fever </li> </ul> </td> <td> <ul> <li>Bacterial or viral infection with sepsis </li> <li>Child abuse with intracranial hemorrhage </li> <li>Bowel perforation caused by a surgical condition* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Hypothermia (T &#60;36.5&#176;C [97.7&#176;F]) </li> </ul> </td> <td> <ul> <li>Bacterial or viral infection with sepsis </li> <li>Hypoglycemia (poor intake, infection, and/or inborn error of metabolism) </li> <li>Environmental exposure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Tachycardia with heart rate &#62;220 beats per minute and no beat to beat variability </li> </ul> </td> <td> <ul> <li>Supraventricular tachycardia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Bulging fontanel and/or increased head circumference (&#62;85<sup>th</sup> percentile for age) </li> </ul> </td> <td> <ul> <li>Meningitis (febrile patients) </li> <li>Child abuse with intracranial hemorrhage and/or hydrocephalus (afebrile or febrile patients) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Rales and/or wheezing </li> </ul> </td> <td> <ul> <li>Lung disease (pneumonia or bronchiolitis) </li> <li>Congenital heart disease with heart failure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Blood pressure gradient (UE &#62; LE) </li> <li>Brachial pulse &#62; femoral pulses </li> <li>Cyanosis not improved with 100% oxygen </li> <li>Single second heart sound </li> <li>Pathologic heart murmur<sup>&#182;</sup> </li> <li>Gallop rhythm </li> </ul> </td> <td> <ul> <li>Congenital heart disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Abdominal distension or tenderness </li> </ul> </td> <td> <ul> <li>Bowel obstruction from a surgical condition* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Hepatomegaly </li> </ul> </td> <td> <ul> <li>Congenital heart disease (right-sided heart failure) </li> <li>Inborn errors of metabolism </li> <li>Hepatitis (eg, herpes simplex virus infection) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Irreducible scrotal or labial mass </li> </ul> </td> <td> <ul> <li>Incarcerated hernia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Ambiguous genitalia or clitoromegaly </li> </ul> </td> <td> <ul> <li>Congenital adrenal hyperplasia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Explosive release of gas or stool on rectal examination </li> </ul> </td> <td> <ul> <li>Congenital aganglionic megacolon (Hirschsprung disease) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Immobile extremity with pain on passive motion </li> </ul> </td> <td> <ul> <li>Fracture due to child abuse </li> <li>Osteomyelitis (febrile patients) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Swollen, red, and warm joint </li> </ul> </td> <td> <ul> <li>Septic arthritis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Seizures or status epilepticus </li> </ul> </td> <td> <ul> <li>Hypoglycemia and/or inborn error of metabolism </li> <li>Hyponatremia/hypernatremia </li> <li>Child abuse with intracranial hemorrhage </li> <li>Meningitis or encephalitis </li> <li>Drug exposure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Jitteriness with increase myoclonus during loud noises </li> </ul> </td> <td> <ul> <li>Hypocalcemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Weak cry, hypotonia, hyporeflexia, poor or absent gag reflex, ptosis, and weak suck in a previously well child </li> </ul> </td> <td> <ul> <li>Infant botulism </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Jaundice (unconjugated hyperbilirubinemia) with opisthotonus and high-pitched cry </li> </ul> </td> <td> <ul> <li>Acute bilirubin encephalopathy (kernicterus) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Jaundice (conjugated hyperbilirubinemia) </li> </ul> </td> <td> <ul> <li>Sepsis<sup>&#916;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Central cyanosis despite 100% supplemental oxygen </li> </ul> </td> <td> <ul> <li>Congenital heart disease (abnormal cardiovascular examination as above) </li> <li>Methemoglobinemia (normal cardiovascular examination) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Bruising </li> </ul> </td> <td> <ul> <li>Child abuse </li> </ul> </td> </tr> <tr> <td> <ul> <li>Mucocutaneous vesicles </li> </ul> </td> <td> <ul> <li>Herpes simplex virus infection </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T: temperature; UE: upper extremity; LE: lower extremity.<br />* Surgical conditions in ill-appearing young infants that may cause bowel perforation included intestinal malrotation with volvulus, congenital aganglionic megacolon (Hirschsprung disease), incarcerated hernia, necrotizing enterocolitis, and neonatal appendicitis. Refer to UpToDate topics on approach to the ill-appearing infant (younger than 90 days of age).<br />¶ The absence of a murmur does <STRONG>not</STRONG> exclude the diagnosis of congenital heart disease.<br />Δ Jaundice with urosepsis is classically associated with galactosemia.</div><div id=\"graphicVersion\">Graphic 63744 Version 4.0</div></div></div>"},"63745":{"type":"graphic_table","displayName":"Percutaneous transtracheal ventilation summary","title":"Needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV): Procedure summary and clinical tips","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV): Procedure summary and clinical tips</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Procedure summary table:</td> </tr> <tr> <td class=\"indent1\">1. Locate the cricothyroid membrane, bound by cricoid cartilage inferiorly and thyroid cartilage superiorly.</td> </tr> <tr> <td class=\"indent1\">2. Use universal precautions and sterile technique. Cleanse the puncture site with povidone-iodine solution.</td> </tr> <tr> <td class=\"indent1\">3. Attach a 3- to 10-mL syringe with a few mL of saline to a 13 to 18 gauge IV catheter. (AVOID needleless catheters that will not attach to a syringe.)</td> </tr> <tr> <td class=\"indent1\">4. Hold the trachea in place and provide skin tension with the thumb and middle finger of the non-dominant hand on either side of the trachea while palpating the cricothyroid membrane with the index finger.</td> </tr> <tr> <td class=\"indent1\">5. Enter the cricothyroid membrane in its inferior-central part, directing the needle caudally (toward the feet) at an angle of 30 to 45 degrees.</td> </tr> <tr> <td class=\"indent1\">6. Puncture the skin and subcutaneous tissue. Advance the needle while continuously applying negative pressure on the syringe, until air bubbles are seen, confirming intratracheal placement.</td> </tr> <tr> <td class=\"indent1\">7. Advance the catheter forward off the needle until its hub rests at the skin surface. Remove the syringe and the needle.</td> </tr> <tr> <td class=\"indent1\">8. Reattach the syringe to the catheter and again aspirate for air to confirm that the catheter remains in the trachea.</td> </tr> <tr> <td class=\"indent1\">9. Hold the catheter firmly in place at all times or delegate an assistant to do so.</td> </tr> <tr> <td class=\"indent1\">10. Connect the high pressure tubing (connected to a valve and a source of 100 percent oxygen) to the catheter.</td> </tr> <tr> <td class=\"indent1\">11. Give a few ventilations by delivering short bursts of gas to reconfirm placement and ensure that the equipment is functioning properly.</td> </tr> <tr> <td class=\"indent1\">12. Secure the transtracheal catheter with suture or a tracheostomy tie while ventilation continues.</td> </tr> <tr> <td class=\"indent1\">13. Begin regular ventilation with I:E ratio 1:4 and respiratory rate 10 to 12 breaths/min in the patient without complete upper airway obstruction; adjust in patients with complete airway obstruction: I:E ratio 1:8 to 1:10 respiratory rate 5 to 6 breaths/min).</td> </tr> <tr> <td class=\"indent1\">14. Monitor the patient carefully.</td> </tr> <tr> <td class=\"indent1\">15. Initiate establishment of a more definitive airway (endotracheal tube or tracheostomy) which may require consultation with anesthesiology and/or otolaryngology.</td> </tr> <tr> <td class=\"subtitle1_single\">Procedure tips table:</td> </tr> <tr> <td class=\"indent1\">1. In older children, feel the laryngeal cartilage and then go caudad to identify cricothyroid membrane.</td> </tr> <tr> <td class=\"indent1\">2. In infants and younger children, follow the tracheal rings superiorly to locate the prominence of the cricoid cartilage. The cricothyroid membrane, even if not felt clearly, is just superior to the cricoid cartilage.</td> </tr> <tr> <td class=\"indent1\">3. If the cricothyroid membrane cannot be located with certainty in an infant or a young child, the catheter can be introduced between tracheal cartilages.</td> </tr> <tr> <td class=\"indent1\">4. The cricothyroid membrane should be punctured below its central part to avoid blood vessels.</td> </tr> <tr> <td class=\"indent1\">5. One person should be assigned to hold the hub of the IV catheter in place over the neck at all times.</td> </tr> <tr> <td class=\"indent1\">6. A pre-assembled system including all the necessary components for needle cricothyrotomy and PTV should be readily available in all resuscitation areas.</td> </tr> <tr> <td class=\"indent1\">7. The system should be used in regular mock codes to improve familiarity of the medical, nursing, and respiratory therapy staff.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12848&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 63745 Version 6.0</div></div></div>"},"63746":{"type":"graphic_figure","displayName":"Aminophylline B agonist asthma","title":"Lack of efficacy of aminophylline in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lack of efficacy of aminophylline in asthma</div><div class=\"cntnt\"><img style=\"width:418px; height:300px;\" src=\"images/PULM/63746_Aminophylline_B_agonist_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in FEV<sub>1</sub> in 20 patients treated with both intravenous aminophylline and inhaled metaproterenol (blue squares) and in 20 patients treated with inhaled metaproterenol alone (red triangles). There was no added benefit from aminophylline.</div><div class=\"graphic_reference\">Data from: Siegel D, Sheppard D, Gelb A, Weinberg PF. Am Rev Respir Dis 1985; 132:283.</div><div id=\"graphicVersion\">Graphic 63746 Version 2.0</div></div></div>"},"63747":{"type":"graphic_diagnosticimage","displayName":"Congenital tracheal stenosis","title":"Congenital tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:450px; height:344px;\" src=\"images/PULM/63747_Congenital_tracheal_stenosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast tracheobronchogram from a seven-year-old boy with congenital tracheal stenosis. The lower trachea and both mainstem bronchi are narrow. A tracheal bronchus connecting the trachea directly with the right upper lobe is present.</div><div id=\"graphicVersion\">Graphic 63747 Version 2.0</div></div></div>"},"63748":{"type":"graphic_figure","displayName":"NYHA class and survival HF","title":"New York Heart Association (NYHA) class predicts survival in heart failure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">New York Heart Association (NYHA) class predicts survival in heart failure</div><div class=\"cntnt\"><img style=\"width:372px; height:240px;\" src=\"images/CARD/63748_NYHA_class_and_survival_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient survival according to functional class in heart failure. Survival varies markedly with functional class, from as high as 81 percent at four years in asymptomatic patients (NYHA class I) to as low as 36 percent at one year in patients with NYHA class IV.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>The SOLVD Investigators, N Engl J Med 1992; 327:685.</li>&#xD;&#xA;    <li>The SOLVD Investigators, N Engl J Med 1991; 325:293.</li>&#xD;&#xA;    <li>The CONSENSUS Trial Study Group 1987; 316:1429.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 63748 Version 3.0</div></div></div>"},"63749":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CT IV","title":"Patient with Weber-Osler-Rendu syndrome presents with bilateral AVMs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with Weber-Osler-Rendu syndrome presents with bilateral AVMs</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/PULM/63749_Pulm_AVM_CT_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan demonstrates a small left lower lobe AVM.</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63749 Version 3.0</div></div></div>"},"63750":{"type":"graphic_diagnosticimage","displayName":"Traumatic stenosis CXR","title":"Tracheal stenosis after bullet injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal stenosis after bullet injury</div><div class=\"cntnt\"><img style=\"width:304px; height:338px;\" src=\"images/PULM/63750_Traumatic_stenosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal view shows irregular stenosis (red arrows) adjacent to bullet fragments.</div><div id=\"graphicVersion\">Graphic 63750 Version 2.0</div></div></div>"},"63751":{"type":"graphic_diagnosticimage","displayName":"Coronoid fracture","title":"Coronoid fracture","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Coronoid fracture</div><div class=\"cntnt\"><img style=\"width:514px; height:240px;\" src=\"images/EM/63751_Coronoidfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 12-year-old boy with a swollen elbow was thought to have a radial neck fracture based on this lateral view.<br> (B) An oblique view shows that the bony fragment (arrow) comes from the coronoid process.</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63751 Version 9.0</div></div></div>"},"63752":{"type":"graphic_picture","displayName":"Cryptococcus neoformans India ink","title":"<EM>Cryptococcus neoformans</EM> in an India ink preparation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Cryptococcus neoformans</EM> in an India ink preparation</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/63752_Cneoformansindiaink.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">India ink preparation of cerebrospinal fluid (x400) shows a prominent clear zone around individual yeasts, consistent with the capsule of <EM>Cryptococcus neoformans</EM>. The yeast in the center of the slide is budding.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 63752 Version 3.0</div></div></div>"},"63754":{"type":"graphic_picture","displayName":"Diabetic nephropathy Light II","title":"Advanced diabetic glomerulosclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced diabetic glomerulosclerosis</div><div class=\"cntnt\"><img style=\"width:378px; height:256px;\" src=\"images/NEPH/63754_Diabetic_nephropathy_Ligh1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in advanced diabetic nephropathy shows diffuse and nodular mesangial expansion and characteristic hyaline thickening of the arteriole at the glomerular hilum (arrow). Although not shown, diabetes typically affects both afferent and efferent arterioles; in comparison, only the afferent arteriole is usually involved with hypertensive injury.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63754 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"63756":{"type":"graphic_figure","displayName":"RNS incremental response","title":"Repetitive nerve stimulation showing incremental response","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation showing incremental response</div><div class=\"cntnt\"><img style=\"width:403px; height:183px;\" src=\"images/NEURO/63756_RNS_incremental_response.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superimposed median nerve compound muscle action potentials at 50 Hz stimulation, showing continued incremental response in a patient with a presynaptic neuromuscular junction defect.</div><div id=\"graphicVersion\">Graphic 63756 Version 2.0</div></div></div>"},"63759":{"type":"graphic_diagnosticimage","displayName":"Ampullary carcinoma CT","title":"Ampullary carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ampullary carcinoma</div><div class=\"cntnt\"><img style=\"width:384px; height:268px;\" src=\"images/GAST/63759_Ampullary_carcinoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiral abdominal CT scan showing a small ampullary mass (arrow) in a 74-year-old woman with occult gastrointestinal blood loss. Note that the pancreatic head appears uninvolved.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of A James Moser, MD.</div><div id=\"graphicVersion\">Graphic 63759 Version 3.0</div></div></div>"},"63760":{"type":"graphic_figure","displayName":"G protein structure","title":"Structure of a G protein-coupled receptor","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Structure of a G protein-coupled receptor</div><div class=\"cntnt\"><img style=\"width:470px; height:370px;\" src=\"images/GAST/63760_G_protein_structure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The molecular structure of a G protein-coupled receptor includes seven membrane-spanning domains, a carboxy end (COOH), and an amino end (NH2). The amino end, which is glycosylated, resides on the outside of the cell and for most peptide hormones, participates in binding. The carboxy end is located inside the cell and contains many sites of phosphorylation (open circles). These regions are phosphorylated by regulatory proteins and often assist in receptor desensitization.</div><div class=\"graphic_footnotes\">COOH: carboxylic acid; NH2: amidogen.</div><div class=\"graphic_reference\">Courtesy of Michael A Shetzline, MD, PhD and Rodger A Liddle, MD.</div><div id=\"graphicVersion\">Graphic 63760 Version 4.0</div></div></div>"},"63761":{"type":"graphic_table","displayName":"Causes of vulvovaginal pruritus","title":"Causes of vulvovaginal pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vulvovaginal pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Vaginitis (infectious or atrophic)</td>\n</tr>\n<tr>\n<td>Atopic, contact, or seborrheic dermatitis</td>\n</tr>\n<tr>\n<td>Psoriasis</td>\n</tr>\n<tr>\n<td>Lichen sclerosus, planus, or simplex chronicus</td>\n</tr>\n<tr>\n<td>Vulvar intraepithelial neoplasia</td>\n</tr>\n<tr>\n<td>Vulvar cancer</td>\n</tr>\n<tr>\n<td>Paget's disease</td>\n</tr>\n<tr>\n<td>Vulvar infection (bacterial, fungal, viral)</td>\n</tr>\n<tr>\n<td>Hidradenitis suppurativa</td>\n</tr>\n<tr>\n<td>Scabies</td>\n</tr>\n<tr>\n<td>Pediculosis pubis</td>\n</tr>\n<tr>\n<td>Systemic diseases with vulvar involvement</td>\n</tr>\n<tr>\n<td>Vulvodynia</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63761 Version 1.0</div></div></div>"},"63762":{"type":"graphic_picture","displayName":"Scleritis","title":"Scleritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleritis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/63762_Scleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angry, erythematous eye secondary to scleritis in the setting of rheumatoid vasculitis.</div><div class=\"graphic_reference\">Courtesy of John Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 63762 Version 2.0</div></div></div>"},"63763":{"type":"graphic_waveform","displayName":"RVH tutorial","title":"Right ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Right ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:527px; height:219px;\" src=\"images/CARD/63763_RVHtutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right ventricular forces become predominant in patients with right ventricular hypertrophy (RVH), producing tall R waves in the right precordial leads (V1 and V2), and deep S waves in the left precordial leads (V5 and V6); an R:S ratio &gt;1 in V1 and V2 is suggestive of RVH. Other features in this case include right axis deviation and RV1 &gt;7 mm.</div><div id=\"graphicVersion\">Graphic 63763 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"63765":{"type":"graphic_figure","displayName":"Rapid cricothyrotomy step three","title":"Rapid four-step cricothyrotomy technique: Step 3","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Rapid four-step cricothyrotomy technique: Step 3</div><div class=\"cntnt\"><img style=\"width:461px; height:444px;\" src=\"images/EM/63765_Cric_rapid_step_three.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stabilize the larynx by placing the tracheal hook under the cricoid cartilage.</div><div id=\"graphicVersion\">Graphic 63765 Version 3.0</div></div></div>"},"63766":{"type":"graphic_picture","displayName":"Air-Q intubating laryngeal airway","title":"Air-Q intubating laryngeal airway","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Air-Q intubating laryngeal airway</div><div class=\"cntnt\"><img style=\"width:516px; height:229px;\" src=\"images/EM/63766_StandardLMA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Mercury Medical.</div><div id=\"graphicVersion\">Graphic 63766 Version 5.0</div></div></div>"},"63767":{"type":"graphic_figure","displayName":"Alendronate dose osteoporosis","title":"Alendronate dose response in osteoporosis","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Alendronate dose response in osteoporosis</div><div class=\"cntnt\"><img style=\"width:550px; height:267px;\" src=\"images/ENDO/63767_Alendronate_dose_osteoporos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean changes in BMD (measured by DXA) in the lumbar spine and femoral neck in postmenopausal women with osteoporosis treated with placebo or different doses of alendronate for three years. Alendronate caused an increase in bone density, an effect that was most pronounced at a dose of 10 mg/day (red squares). Bone density fell in the placebo group.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; DXA: dual-energy x-ray absorptiometry.</div><div class=\"graphic_reference\">Data from: Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437.</div><div id=\"graphicVersion\">Graphic 63767 Version 3.0</div></div></div>"},"63769":{"type":"graphic_picture","displayName":"Resisted wrist extension for assessment of lateral epicondylitis","title":"Resisted wrist extension for assessment of lateral epicondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisted wrist extension for assessment of lateral epicondylitis</div><div class=\"cntnt\"><img style=\"width:429px; height:315px;\" src=\"images/EM/63769_Resisted_wrist_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed at 90 degrees, the forearm is firmly grasped. The patient is asked to make a &quot;light&quot; fist and then to extend the wrist against the resistance of the examiner's second hand. As this maneuver is performed, the examiner should emphasize the relationship of the wrist motion to the aggravation of elbow pain. The diagnosis of lateral epicondylitis is highly suggested by lateral epicondylar tenderness to palpation plus elbow pain aggravated by resisted wrist extension.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 63769 Version 4.0</div></div></div>"},"63771":{"type":"graphic_figure","displayName":"Mediastinal LN approach","title":"Approaches to lymph nodes in the mediastinum","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Approaches to lymph nodes in the mediastinum</div><div class=\"cntnt\"><img style=\"width:542px; height:575px;\" src=\"images/PULM/63771_Mediastinal_LN_approach.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63771 Version 2.0</div></div></div>"},"63772":{"type":"graphic_diagnosticimage","displayName":"TB pleural effusion CT","title":"Tuberculous pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculous pleural effusion</div><div class=\"cntnt\"><img style=\"width:360px; height:292px;\" src=\"images/PULM/63772_TB_pleural_effusion_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed&nbsp;tomography (CT)&nbsp;scan showing a parenchymal focus of tuberculosis close to the pleura and an ipsilateral pleural effusion.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63772 Version 3.0</div></div></div>"},"63773":{"type":"graphic_table","displayName":"Physical effects of altitude","title":"Physical effects of change in altitude","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical effects of change in altitude</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Altitude, feet</td> <td class=\"subtitle1\">Barometric pressure, mmHG</td> <td class=\"subtitle1\">Atmospheric P02, mmHG</td> <td class=\"subtitle1\">PI02, mmHG</td> <td class=\"subtitle1\">PA02, mmHG</td> <td class=\"subtitle1\">Pa02, mmHG</td> </tr> <tr> <td>0</td> <td>760</td> <td>159</td> <td>149</td> <td>103</td> <td>98</td> </tr> <tr> <td>2000</td> <td>707</td> <td>148</td> <td>138</td> <td>94</td> <td>90</td> </tr> <tr> <td>4000</td> <td>656</td> <td>137</td> <td>128</td> <td>85</td> <td>80</td> </tr> <tr> <td>5000</td> <td>632</td> <td>132</td> <td>122</td> <td>81</td> <td>66</td> </tr> <tr> <td>6000</td> <td>609</td> <td>127</td> <td>117</td> <td>77</td> <td>64</td> </tr> <tr> <td>8000</td> <td>564</td> <td>118</td> <td>108</td> <td>69</td> <td>60</td> </tr> <tr> <td>10000</td> <td>523</td> <td>109</td> <td>100</td> <td>61</td> <td>53</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PI02: partial pressure of inspired oxygen; PA02: partial pressure of alveolar oxygen; Pa02: partial pressure of oxygen in arterial blood 8000 feet represents the maximum allowable altitude in commercial aircraft.</div><div class=\"graphic_reference\">Adapted from Gong, H. Exposure to moderate altitude and cardiorespiratory diseases. Cardiologica 1995; 40:477.</div><div id=\"graphicVersion\">Graphic 63773 Version 2.0</div></div></div>"},"63774":{"type":"graphic_figure","displayName":"Bisoprolol in HF CIBIS II","title":"Bisoprolol reduces mortality in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bisoprolol reduces mortality in HF</div><div class=\"cntnt\"><img style=\"width:429px; height:286px;\" src=\"images/CARD/63774_Bisoprolol_in_HF_CIBIS_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CIBIS-II enrolled 2647 patients with class III and IV heart failure (HF) who were receiving therapy with angiotensin converting enzyme inhibitors and diuretics. Compared to placebo, bisoprolol significantly reduced all-cause mortality (11.8 versus 17.3 percent, p</div><div class=\"graphic_reference\">Data from: CIBIS-II Investigators and Committees. Lancet 1999; 353:9.</div><div id=\"graphicVersion\">Graphic 63774 Version 1.0</div></div></div>"},"63775":{"type":"graphic_picture","displayName":"Lomentospora prolificans microsopy","title":"<EM>Lomentospora prolificans </EM>microsopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Lomentospora prolificans </EM>microsopy</div><div class=\"cntnt\"><img style=\"width:396px; height:290px;\" src=\"images/ID/63775_Sprolificansmicrosopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic appearance of <EM>L. prolificans </EM>illustrating the flask-shaped, inflated conidiogenous cell (arrow) with conidium attached.</div><div class=\"graphic_reference\">Courtesy of Barbara D. Alexander, MD, MHS and Sylvia F. Costa, MD.</div><div id=\"graphicVersion\">Graphic 63775 Version 4.0</div></div></div>"},"63776":{"type":"graphic_figure","displayName":"Reverse osmosis for water purification","title":"Reverse osmosis for water purification for hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Reverse osmosis for water purification for hemodialysis</div><div class=\"cntnt\"><img style=\"width:570px; height:394px;\" src=\"images/NEPH/63776_Apparatus_for_reverse_osmos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of reverse osmosis in which feed water, which is pumped, flows parallel to the membrane. High pressure on the feed side of the membrane forces water across the membrane to form the product water. Ions and other contaminants, which are rejected by the membrane, accumulate in the remaining feed water and leave the membrane module as reject water. Locations of gauges and meters for the on-line measurement of pressure, flow rate, conductivity and temperature, and sampling points for off-line measurements of contaminants are shown. The data obtained with these gauges and meters are used to monitor the performance of the reverse osmosis system.</div><div id=\"graphicVersion\">Graphic 63776 Version 3.0</div></div></div>"},"63780":{"type":"graphic_picture","displayName":"Infected and ischemic diabetic foot ulcer","title":"Infected and ischemic diabetic foot ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected and ischemic diabetic foot ulcer</div><div class=\"cntnt\"><img style=\"width:378px; height:241px;\" src=\"images/SURG/63780_Wagner_3_foot_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foot from a diabetic patient with an ulcer that extends to the deep layers with signs of local infection, cellulitis, and necrosis. This lesion healed completely after a hospital stay involving excision of necrotic tissue but no amputation.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 63780 Version 5.0</div></div></div>"},"63783":{"type":"graphic_waveform","displayName":"ECG Wolff-Parkinson-White syndrome","title":"Wolff-Parkinson-White pattern","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wolff-Parkinson-White pattern</div><div class=\"cntnt\"><img style=\"width:352px; height:295px;\" src=\"images/CARD/63783_WPW_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Precordial leads in a patient with preexcitation due to the WPW syndrome. The three characteristic findings are the short PR interval (0.09 sec in this case), the wide QRS, and the delta wave (slurring of the QRS upstroke) that is best seen in leads V5 and V6 (arrows).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 63783 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"63785":{"type":"graphic_figure","displayName":"Medial condyle fracture anatomy","title":"Anatomy of a medial condyle elbow fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of a medial condyle elbow fracture</div><div class=\"cntnt\"><img style=\"width:388px; height:532px;\" src=\"images/EM/63785_Medcondylefxanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior radiograph of a nine-year-old boy demonstrating the location of the ossification centers. A common physeal line (arrow) separates the medial and lateral condylar physes. <br />(B) Relationship of the ossification centers to the articular surface. The common physis terminates in the trochlear notch (arrow). <br />(C) Location of the usual fracture line involving the medial condylar physis (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Glotzbecker MP, Kasser JR. Distal Humeral Physeal, Medial Condyle, Lateral Epicondylar, and Other Uncommon Elbow Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed,&nbsp;Flynn JM, Skaggs DL, Waters PM&nbsp;(Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63785 Version 15.0</div></div></div>"},"63786":{"type":"graphic_picture","displayName":"Passive extension of wrist","title":"Passive extension of the wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passive extension of the wrist</div><div class=\"cntnt\"><img style=\"width:396px; height:287px;\" src=\"images/EM/63786_Wrist_passive_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain with passive terminal wrist extension with the elbow in full extension is consistent with medial epicondylitis.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 63786 Version 2.0</div></div></div>"},"63788":{"type":"graphic_diagnosticimage","displayName":"Carotid artery angiogram","title":"Normal internal carotid artery angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal internal carotid artery angiogram</div><div class=\"cntnt\"><img style=\"width:394px; height:278px;\" src=\"images/RHEUM/63788_Carotid_artery_angiogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angiogram showing the normal radiographic appearance of the internal carotid artery and its branches. The internal carotid enters the skull at the carotid foramen, passes anteromedially, and then rises vertically (C6) to pass forward opposite the sella turcica (C4). The artery then passes upward within the dura (C3) and emerges below and medial to the anterior clinoid (C2), giving rise to the ophthalmic artery. The carotid then bifurcates (C1) to form the anterior and middle cerebral arteries. The anterior cerebral artery is directed anteromedially (A1)&nbsp;until it reaches the midline, where it turns upward (A2) to be joined by the anterior communicating artery. The middle cerebral artery extends laterally (M1).</div><div class=\"graphic_reference\">Courtesy of Leonard H Sigal, MD.</div><div id=\"graphicVersion\">Graphic 63788 Version 3.0</div></div></div>"},"63789":{"type":"graphic_picture","displayName":"Padded foot splint","title":"Resting padded foot splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resting padded foot splint</div><div class=\"cntnt\"><img style=\"width:241px; height:359px;\" src=\"images/RHEUM/63789_Padded_foot_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A splint such as the one pictured here may be helpful for symptoms of plantar fasciitis or plantar fascia rupture.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 63789 Version 1.0</div></div></div>"},"63790":{"type":"graphic_figure","displayName":"Sciatic nerve block","title":"Sciatic nerve block: Posterior approach","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Sciatic nerve block: Posterior approach</div><div class=\"cntnt\"><img style=\"width:542px; height:415px;\" src=\"images/SURG/63790_Sciaticnerveblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the posterior approach of Labat, the patient is placed in the lateral decubitus position with the extremity flexed at the hip and knee (Sims' position). Anatomic landmarks include the PSIS, greater trochanter, and sacral hiatus. A line is drawn between the PSIS and greater trochanter and bisected with a line measuring 3 to 5 cm drawn toward the buttock.&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li><strong>Nerve stimulator-guided block</strong> &ndash; The needle is inserted at the intersection of the bisected line and a line drawn from the greater trochanter to the sacral hiatus, perpendicular to the skin. Local anesthetic is injected after observing the appropriate muscular response to stimulation.</li>&#xD;&#xA;    <li><strong>Ultrasound-guided block</strong> &ndash; The ultrasound probe is positioned transverse to the nerve, lateral to the ischial tuberosity. The nerve is found deep to the gluteus maximus muscle. The needle is inserted in plane; after negative aspiration, approximately 20 mL of local anesthetic is injected in 5-mL increments, with aspiration between injections.</li>&#xD;&#xA;</ul>&#xD;&#xA;Refer to topic on lower extremity nerve block techniques for details on posterior approach sciatic nerve block.</div><div class=\"graphic_footnotes\">PSIS: posterior superior iliac spine.</div><div id=\"graphicVersion\">Graphic 63790 Version 5.0</div></div></div>"},"63791":{"type":"graphic_figure","displayName":"Cesarean delivery PI","title":"Cesarean delivery","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Cesarean delivery</div><div class=\"cntnt\"><img style=\"width:512px; height:429px;\" src=\"images/PI/63791_C-section-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a c-section, the doctor makes an incision in the belly and then the uterus. The baby comes out through that incision, rather than through the vagina.</div><div id=\"graphicVersion\">Graphic 63791 Version 4.0</div></div></div>"},"63793":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of ileal atresia","title":"Prenatal ultrasound image of ileal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of ileal atresia</div><div class=\"cntnt\"><img style=\"width:360px; height:366px;\" src=\"images/OBGYN/63793_Ileal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial ultrasound at 27 weeks of gestation demonstrates several dilated loops of fluid-filled bowel. Postnatally, isolated ileal atresia was identified at surgery.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 63793 Version 4.0</div></div></div>"},"63794":{"type":"graphic_figure","displayName":"LV filling pattern mortality MI","title":"The effect of LV filling patterns on survival","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The effect of LV filling patterns on survival</div><div class=\"cntnt\"><img style=\"width:386px; height:306px;\" src=\"images/CARD/63794_LV_filling_pattern_mortalit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among patients with a first myocardial infarction, mortality was significantly higher in patients with impaired relaxation (p = 0.02), pseudonormal filling (p &lt;0.00005) or restrictive filling (p &lt;0.00005) than in patients with a normal filling pattern. With a Cox analysis, a pseudonormal and restrictive filling pattern were independent predictors of mortality.</div><div class=\"graphic_reference\">Data from Moller JE, Sondergaard E, Poulsen SH, Egstrup K. J Am Coll Cardiol 2000; 36:1841.</div><div id=\"graphicVersion\">Graphic 63794 Version 2.0</div></div></div>"},"63795":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis Lateral","title":"Bronchiectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiectasis</div><div class=\"cntnt\"><img style=\"width:330px; height:360px;\" src=\"images/PULM/63795_Bronchiectasis_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral chest radiograph demonstrating ring shadows of cystic bronchiectasis (arrow).</div><div id=\"graphicVersion\">Graphic 63795 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"63800":{"type":"graphic_diagnosticimage","displayName":"Migratory periictal MRI changes","title":"Migratory periictal MRI changes in a patient with multifocal seizures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Migratory periictal MRI changes in a patient with multifocal seizures</div><div class=\"cntnt\"><img style=\"width:412px; height:499px;\" src=\"images/NEURO/63800_MRI_acute_multifocal_sz.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FLAIR images obtained at multiple levels at time of presentation (top row), on day 14 (second row), on day 28 (third row) and on day 35 (fourth row) from a 28-year-old woman with recurrent partial seizures associated with a mitochondrial disease.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery. </div><div class=\"graphic_reference\">Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright &copy;2004 Blackwell Science.</div><div id=\"graphicVersion\">Graphic 63800 Version 4.0</div></div></div>"},"63801":{"type":"graphic_figure","displayName":"Coyne spoon","title":"Coyne spoon","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Coyne spoon</div><div class=\"cntnt\"><img style=\"width:505px; height:156px;\" src=\"images/OBGYN/63801_Coyne_spoon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63801 Version 4.0</div></div></div>"},"63804":{"type":"graphic_table","displayName":"Instruments spiritual history","title":"Instruments for obtaining a spiritual history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instruments for obtaining a spiritual history</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tool</td> <td class=\"subtitle1\">Domains</td> <td class=\"subtitle1\">Examples of content</td> </tr> <tr> <td rowspan=\"4\">HOPE*</td> <td>H: Sources of hope</td> <td>H: What gives you hope (or strength or comfort or peace) in the time of illness?</td> </tr> <tr> <td>O: Organized religion</td> <td>O: Are you a part/member of religious or spiritual community? Does it help you? How?</td> </tr> <tr> <td>P: Personal spirituality and practices</td> <td>P: What aspects of your spiritual beliefs do you find most helpful and meaningful personally?</td> </tr> <tr> <td>E: Effect on medical care and end-of-life issues</td> <td>E: How do your beliefs affect the kind of medical care you would like me to provide over the next few days/weeks/months?</td> </tr> <tr> <td rowspan=\"4\">FICA: spiritual history<sup>&#182;</sup></td> <td>F: Faith</td> <td>F: What is your faith?</td> </tr> <tr> <td>I: Importance/influence</td> <td>I: How important is it?</td> </tr> <tr> <td>C: Community</td> <td>C: Are you a part of a religious community?</td> </tr> <tr> <td>A: Address/apply</td> <td>A: How would you like me as your provider to address these issues in your care?</td> </tr> <tr> <td rowspan=\"6\">SPIRIT<sup>&#916;</sup></td> <td>S: Spiritual belief system</td> <td>S: Do you have a formal religious affiliation? Do you have a spiritual life that is important to you?</td> </tr> <tr> <td>P: Personal spirituality</td> <td>P: In what ways is your spirituality important to you?</td> </tr> <tr> <td>I: Integration with a spiritual community</td> <td>I: Do you belong to any religious or spiritual groups or communities?</td> </tr> <tr> <td>R: Ritualized practices and restriction</td> <td>R: What specific practices do you carry out as part of religious or spiritual life?</td> </tr> <tr> <td>I: Implications for medical care</td> <td>I: Would you like to discuss religious or spiritual implications of health care?</td> </tr> <tr> <td>T: Terminal events </td> <td>T: Are there particular aspects of medical care that you wish to forgo or have withheld because of your religion/spirituality?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Anadaraja G, Hight E, Spirituality and medical practice: using the HOPE questions as a practical tool for spiritual assessment. Am Fam Physician 2001; 63:81-89.<br />¶ Puchalski CM, Romer AL. Taking a spiritual history allows clinicians to understand patients more fully. J Palliat Med 2000; 3:129-137.<br />Δ Maugans TA. The SPIRITual history. Arch Fam Med 1996; 5:11-16. (Reprinted with permission from: J Palliat Med 8:402, 2005).</div><div class=\"graphic_reference\">Reproduced with permission from: Okron T. Spiritual, religious, and existential aspects of palliative care. J Palliat Med 2005; 8:392.</div><div id=\"graphicVersion\">Graphic 63804 Version 3.0</div></div></div>"},"63807":{"type":"graphic_table","displayName":"Causes of T wave inversion","title":"Selected causes of prominent T wave inversions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected causes of prominent T wave inversions</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Primary T wave inversions\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Normal variant\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Juvenile T wave pattern\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   \"Early repolarization\" variant (sometimes associated with T wave inversions)\n   </td>\n   </tr>\n   <tr>\n   <td>Myocardial ischemia or infarction (including takotsubo syndrome)</td>\n   </tr>\n   <tr>\n   <td>Left or right ventricular overload syndromes (formerly called \"strain\" patterns)</td>\n   </tr>\n   <tr>\n   <td>Cerebrovascular injury (T waves may be massively inverted)</td>\n   </tr>\n   <tr>\n   <td>\"Memory T waves\" (eg, with intermittent left bundle branch block, intermittent ventricular pacing, or intermittent Wolff-Parkinson-White pre-excitation)</td>\n   </tr>\n   <tr>\n   <td>Post-tachycardia T wave pattern</td>\n   </tr>\n   <tr>\n   <td>Apical hypertrophic cardiomyopathy (Yamaguchi's syndrome)</td>\n   </tr>\n   <tr>\n   <td>Other myocardial/pericardial diseases - dilated and restrictive cardiomyopathies, arrhythmogenic right ventricular cardiomyopathy (dysplasia), pericarditis, myocardial tumor, etc.</td>\n   </tr>\n   <tr>\n   <td>Idiopathic global T wave inversions</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Secondary T wave inversions\n   </td>\n   </tr>\n   <tr>\n   <td>Left bundle branch block</td>\n   </tr>\n   <tr>\n   <td>Right bundle branch block</td>\n   </tr>\n   <tr>\n   <td>Wolff-Parkinson-White patterns and variants</td>\n   </tr>\n   <tr>\n   <td>Ventricular beats (paced, premature or escape)</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 63807 Version 1.0</div></div></div>"},"63810":{"type":"graphic_picture","displayName":"Ober test","title":"The Ober test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Ober test</div><div class=\"cntnt\"><img style=\"width:213px; height:239px;\" src=\"images/EM/63810_Obertest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Ober test assesses the tightness of the iliotibial band (ITB). It is performed with the patient lying on the unaffected side. The examiner slightly abducts and extends the affected hip and flexes the knee. The patient is then asked to allow the affected leg to fall to the table passively, without actively adducting the hip (just letting it fall with gravity), while the examiner supports the patient's lower leg. Patients with ITB syndrome are more likely to have limited adduction of the leg with this maneuver (positive Ober test).</div><div class=\"graphic_reference\">Reproduced with permission from: Swenson EJ. Knee injuries. In: ACSM's Primary Care Sports Medicine, 2<SUP>nd</SUP> ed, McKeag DB, Moeller JL (Eds), Lippincott Williams &amp; Wilkins, New York. 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63810 Version 10.0</div></div></div>"},"63812":{"type":"graphic_picture","displayName":"Lentigo maligna melanoma dermoscopy 1","title":"Dermoscopy of lentigo maligna melanoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of lentigo maligna melanoma</div><div class=\"cntnt\"><img style=\"width:504px; height:370px;\" src=\"images/DERM/63812_Dermoscopy_of_lentigo_maligna_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 69-year-old woman was evaluated for an enlarging pigmented lesion of her right cheek. Two biopsies were performed with the help of dermoscopy to outline the borders of the lesion. Pathology revealed a lentigo maligna melanoma. On this dermoscopic image (x50), one can see slate-gray dots and globules leading to annular-granular pattern which is typical of lentigo maligna melanoma.</div><div class=\"graphic_reference\">Copyright © Eric Ehrsam, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 63812 Version 3.0</div></div></div>"},"63813":{"type":"graphic_table","displayName":"Muscles of the posterior compartment of the forearm","title":"Muscles of the posterior compartment of the forearm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscles of the posterior compartment of the forearm</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Superficial layer</td> </tr> <tr> <td class=\"indent1\">Brachioradialis</td> <td>Proximal two thirds of supraepicondylar ridge of humerus</td> <td>Lateral surface of distal end of radius proximal to styloid process</td> <td>Radial nerve (C5, <strong>C6</strong>, C7)</td> <td>Relatively week flexion of forearm, maximal when forearm is in midpronated position</td> </tr> <tr> <td class=\"indent1\">Extensor carpi radialis longus (ECRL)</td> <td>Lateral supraepicondylar ridge of humerus</td> <td>Dorsal aspect of base of second metacarpal</td> <td>Radial nerve (C6, C7)</td> <td rowspan=\"2\">Extend and abduct hand at the wrist joint; ECRL active during fist clenching</td> </tr> <tr> <td class=\"indent1\">Extensor carpi radialis brevis (ECRB)</td> <td rowspan=\"3\">Lateral epicondyle of humerus (common extensor origin)</td> <td>Doral aspect of base of third metacarpal</td> <td>Deep branch of radial nerve (<strong>C7</strong>, C8)</td> </tr> <tr> <td class=\"indent1\">Extensor digitorum</td> <td>Extensor expansions of medial four fingers</td> <td rowspan=\"3\">Posterior interosseous nerve (<strong>C7</strong>, C8), continuation of deep branch of radial nerve</td> <td>Extends medial four fingers primarily at metacarpophalangeal joints, secondarily at interphalangeal joints</td> </tr> <tr> <td class=\"indent1\">Extensor digiti minimi (EDM)</td> <td>Extensor expansion of fifth finger</td> <td>Extends fifth finger primarily at metacarpophalangeal joint, secondarily at interphalangeal joint</td> </tr> <tr> <td class=\"indent1\">Extensor carpi ulnaris (ECU)</td> <td>Lateral epicondyle of humerus; posterior border of ulna via a shared aponeurosis</td> <td>Dorsal aspect of base of fifth metacarpal</td> <td>Extends and adducts hand at wrist joint (also active during fist clenching)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Deep layer</td> </tr> <tr> <td class=\"indent1\">Supinator</td> <td>Lateral epicondyle of humerus; radial collateral and anular ligaments; supinator fossa; crest of ulna</td> <td>Lateral posterior, and anterior surfaces of proximal third of radius</td> <td>Deep branch of radial nerve (C7, <strong>C8</strong>)</td> <td>Supinates forearm; rotates radius to turn palm anteriorly or superiorly (if elbow is flexed)</td> </tr> <tr> <td class=\"indent1\">Extensor indicis</td> <td>Posterior surface of distal third of ulna and interosseous membrane</td> <td>Extensor expansion of second finger</td> <td>Posterior interosseous nerve (C7, <strong>C8</strong>), continuation of deep branch of radial nerve</td> <td>Extends second finger (enabling its independent extension); helps extend hand at wrist</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Outcropping muscles of deep layer</td> </tr> <tr> <td class=\"indent1\">Abductor pollicis longus (APL)</td> <td>Posterior surface of proximal halves of ulna, radius, and interosseous membrane</td> <td>Base of first metacarpal</td> <td rowspan=\"3\">Posterior interosseous nerve (C7, <strong>C8</strong>), continuation of deep branch of radial nerve</td> <td>Abducts thumb and extends it at carpometacarpal joint</td> </tr> <tr> <td class=\"indent1\">Extensor pollicis longus (EPL)</td> <td>Posterior surface of middle third of ulna and interosseous membrane</td> <td>Dorsal aspect of base of distal phalanx of thumb</td> <td>Extends distal phalanx of thumb at interphalangeal joint; extends metacarpophalangeal and carpometacarpal joints</td> </tr> <tr> <td class=\"indent1\">Extensor pollicis brevis (EPB)</td> <td>Posterior surface of distal third of radius and interosseous membrane</td> <td>Dorsal aspect of base of proximal phalanx of thumb</td> <td>Extends proximal phalanx of thumb at metacarpophalangeal joint; extends carpometacarpal joint</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, &quot;<strong>C7</strong>, C8&quot; means that the nerves supplying the extensor carpi radialis brevis are derived from the seventh and eighth cervical segments of the spinal cord). Numbers in boldface (<strong>C7</strong>) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63813 Version 13.0</div></div></div>"},"63814":{"type":"graphic_figure","displayName":"Ca PTH curve","title":"Schematic illustration of impact of changes in Ca<sup>2+</sup>-sensitivity on set-point","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Schematic illustration of impact of changes in Ca<sup>2+</sup>-sensitivity on set-point</div><div class=\"cntnt\"><img style=\"width:468px; height:433px;\" src=\"images/ENDO/63814_CaPTHcurve.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Ca<SUP>2+</SUP>: calcium ion; CaSR: calcium-sensing receptor; PTH: parathyroid hormone.</div><div id=\"graphicVersion\">Graphic 63814 Version 2.0</div></div></div>"},"63815":{"type":"graphic_figure","displayName":"Closure rectovaginal fistula2","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:410px; height:434px;\" src=\"images/OBGYN/63815_Closure_rectovaginal_fist1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Second layer of the closure, which inverts the first layer.</div><div id=\"graphicVersion\">Graphic 63815 Version 1.0</div></div></div>"},"63816":{"type":"graphic_picture","displayName":"AML FAB M5B","title":"Acute monocytic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute monocytic leukemia</div><div class=\"cntnt\"><img style=\"width:390px; height:288px;\" src=\"images/HEME/63816_AML_FAB_M5B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear from a patient with acute monocytic leukemia, differentiated (FAB AML M5B). The predominant promonocytes have abundant cytoplasm with scattered myeloperoxidase-negative azurophilic granules. The nuclei have delicate folds and creases. Nucleoli are&nbsp;inconspicuous (Wright-Giemsa stain).</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 63816 Version 2.0</div></div></div>"},"63817":{"type":"graphic_figure","displayName":"Effect of diet on CO2","title":"Effect of diet on carbon dioxide production in mechanically ventilated patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of diet on carbon dioxide production in mechanically ventilated patients</div><div class=\"cntnt\"><img style=\"width:262px; height:394px;\" src=\"images/PULM/63817_Effect_of_diet_on_CO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients receiving an energy intake of 1.3 times resting energy expenditure (top graph), variations in the fat:carbohydrate ratio did not affect CO2 production (VCO2). In patients receiving a constant ratio (60:20) of carbohydrate to fat calories (bottom graph), there was statistically significant increase in VCO2 with increasing total calorie intake.</div><div class=\"graphic_reference\">Redrawn from Talpers, S, Romberger, D, Bunce, S, et al, Chest 1992; 102:551.</div><div id=\"graphicVersion\">Graphic 63817 Version 1.0</div></div></div>"},"63819":{"type":"graphic_diagnosticimage","displayName":"Osteosarcoma knee CT","title":"Osteosarcoma of the distal femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteosarcoma of the distal femur</div><div class=\"cntnt\"><img style=\"width:215px; height:432px;\" src=\"images/RHEUM/63819_Osteosarcoma_knee_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal CT image of the knee demonstrates a large mass involving the distal femoral metaphysis, with lobulated soft tissue component and bony destruction, consistent with osteosarcoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 63819 Version 4.0</div></div></div>"},"63820":{"type":"graphic_table","displayName":"Nutrition assessment in children","title":"Assessment of nutritional factors related to childhood obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of nutritional factors related to childhood obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutritional factor</td> <td class=\"subtitle1\">Contribution to weight gain</td> <td class=\"subtitle1\">Examples of questions for clinical assessment</td> </tr> <tr> <td rowspan=\"2\"><strong>Restaurants and fast food</strong></td> <td rowspan=\"2\">Meals eaten away from home increase portion size and total energy intake, and are of poorer nutrient quality<sup>[1-6]</sup>. Increased frequency of eating meals away from home is associated with increased BMI<sup>[7,8]</sup>.</td> <td>\"How many times a week does your family get takeout food?\"</td> </tr> <tr> <td>\"How many meals a week does your family eat at a restaurant or eat fast food?\"</td> </tr> <tr class=\"divider_top\"> <td><strong>Sweetened beverages</strong></td> <td>High&nbsp;intake of sugar-sweetened beverages is&nbsp;linked to increased prevalence of obesity in children<sup>[9-11]</sup>, but causality has not been established<sup>[12]</sup>. Fruit juice also should be considered a sweetened beverage.</td> <td>\"How many times a day, or how many ounces, does your child drink the following: juice, soda, flavored milk, sports drinks, or sweetened tea?\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Portion sizes</strong></td> <td rowspan=\"3\">Larger portions lead to increased energy intake<sup>[13-15]</sup>.</td> <td>\"Are seconds or large portions a challenge for your child?\"</td> </tr> <tr> <td>\"How many baseball-size servings of pasta, rice, or cereal does your child eat at a meal?\"</td> </tr> <tr> <td>\"How many decks of cards of meat or protein does your child eat at a meal?\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Energy-dense foods</strong></td> <td rowspan=\"3\">An association between energy dense foods and obesity has been established in adults, but not yet in children <sup>[15]</sup>.</td> <td>\"How often does your child eat fried foods?\"</td> </tr> <tr> <td>\"What does your child typically eat for snacks?\"</td> </tr> <tr> <td>\"What type of milk, cheese, cereal, and protein do you have at home?\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Fruits and vegetables</strong></td> <td rowspan=\"3\">Eating fruits and vegetables may displace more energy dense foods and increase satiety. There is some evidence that low consumption of these foods is associated with&nbsp; obesity <sup>[16-18]</sup>.</td> <td>\"What fruits and vegetables do you currently have in your home?\"</td> </tr> <tr> <td>\"How often does your child eat vegetables at lunch or dinner?\"</td> </tr> <tr> <td>\"At which meals or snacks does your child eat fruit?\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Breakfast</strong></td> <td rowspan=\"3\">Skipping breakfast associated with increasing obesity in children despite perceived decrease in daily caloric intake<sup>[19-23]</sup>, and has adverse effects on school performance<sup>[24-26]</sup>.</td> <td>\"When is the first time your child typically has&nbsp;something to eat or drink after waking up?\"</td> </tr> <tr> <td>\"Does your child eat breakfast at home or at school?\"</td> </tr> <tr> <td>\"How often does your child skip breakfast?\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Meal frequency and snacking</strong></td> <td rowspan=\"4\">Snacking tends to result in increased energy intake and poorer diet quality; a direct association between snacking and obesity in children has not been established.</td> <td>\"When does your child eat meals and snacks at home?\"</td> </tr> <tr> <td>\"Where does your child eat their snacks?\"</td> </tr> <tr> <td>\"How long after a meal does your child eat a snack?\"</td> </tr> <tr> <td>\"How many snacks does your child eat on the weekends?\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Whitlock EP, O'Connor EA, Williams SB, Beil TL, Lutz KW. Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF. Pediatrics 2010. </li> <li>Paeratakul S, Ferdinand DP, Champagne CM, Ryan DH, Bray GA. Fast-food consumption among US adults and children: dietary and nutrient intake profile. J Am Diet Assoc 2003; 103:1332-8. </li> <li>Diliberti N, Bordi PL, Conklin MT, Roe LS, Rolls BJ. Increased portion size leads to increased energy intake in a restaurant meal. Obes Res 2004; 12:562-8. </li> <li>Bowman SA, Gortmaker SL, Ebbeling CB, Pereira MA, Ludwig DS. Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. Pediatrics 2004; 113:112-8. </li> <li>French SA, Story M, Neumark-Sztainer D, Fulkerson JA, Hannan P. Fast food restaurant use among adolescents: associations with nutrient intake, food choices and behavioral and psychosocial variables. Int J Obes Relat Metab Disord 2001; 25:1823-33. </li> <li>Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in food locations and sources among adolescents and young adults. Prev Med 2002; 35:107-13. </li> <li>Schmidt M, Affenito SG, Striegel-Moore R, Khoury PR, Barton B, Crawford P, Kronsberg S, Schreiber G, Obarzanek E, Daniels S. Fast-food intake and diet quality in black and white girls: the National Heart, Lung, and Blood Institute Growth and Health Study. Arch Pediatr Adolesc Med 2005; 159:626-31. </li> <li>Thompson OM, Ballew C, Resnicow K, Must A, Bandini LG, Cyr H, Dietz WH. Food purchased away from home as a predictor of change in BMI z-score among girls. Int J Obes Relat Metab Disord 2004; 28:282-9. </li> <li>Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, Ludwig DS. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005; 365:36-42. </li> <li>Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001; 357:505-8. </li> <li>Harnack L, Stang J, Story M. Soft drink consumption among US children and adolescents: nutritional consequences. J Am Diet Assoc 1999; 99:436-41. </li> <li>Tordoff MG, Alleva AM. Effect of drinking soda sweetened with aspartame or high-fructose corn syrup on food intake and body weight. Am J Clin Nutr 1990; 51:963-9. </li> <li>Lewis CJ, Park YK, Dexter PB, Yetley EA. Nutrient intakes and body weights of persons consuming high and moderate levels of added sugars. J Am Diet Assoc 1992; 92:708-13. Rolls BJ, Engell D, Birch LL. Serving portion size influences 5-year-old but not 3-year-old children's food intakes. J Am Diet Assoc 2000; 100:232-4. </li> <li>Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193-228. </li> <li>Orlet Fisher J, Rolls BJ, Birch LL. Children's bite size and intake of an entree are greater with large portions than with age-appropriate or self-selected portions. Am J Clin Nutr 2003; 77:1164-70. </li> <li>McCrory MA, Fuss PJ, Hays NP, Vinken AG, Greenberg AS, Roberts SB. Overeating in America: association between restaurant food consumption and body fatness in healthy adult men and women ages 19 to 80. Obes Res 1999; 7:564-71. </li> <li>Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, Whelton PK. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 2002; 76:93-9. </li> <li>Maskarinec G, Novotny R, Tasaki K. Dietary patterns are associated with body mass index in multiethnic women. J Nutr 2000; 130:3068-72. </li> <li>Wolfe WS, Campbell CC, Frongillo EA Jr, Haas JD, Melnik TA. Overweight schoolchildren in New York State: prevalence and characteristics. Am J Public Health 1994; 84:807-13. </li> <li>Gibson SA, O'Sullivan KR. Breakfast cereal consumption patterns and nutrient intakes of British schoolchildren. J R Soc Health 1995; 115:366-70. </li> <li>Ortega RM, Requejo AM, Lopez-Sobaler AM, Quintas ME, Andres P, Redondo MR, Navia B, Lopez-Bonilla MD, Rivas T. Difference in the breakfast habits of overweight/obese and normal weight schoolchildren. Int J Vitam Nutr Res 1998; 68:125-32. </li> <li>Pastore DR, Fisher M, Friedman SB. Abnormalities in weight status, eating attitudes, and eating behaviors among urban high school students: correlations with self-esteem and anxiety. J Adolesc Health 1996; 18:312-9. </li> <li>Summerbell CD, Moody RC, Shanks J, Stock MJ, Geissler C. Relationship between feeding pattern and body mass index in 220 free-living people in four age groups. Eur J Clin Nutr 1996; 50:513-9. </li> <li>Wyatt HR, Grunwald GK, Mosca CL, Klem ML, Wing RR, Hill JO. Long-term weight loss and breakfast in subjects in the National Weight Control Registry. Obes Res 2002; 10:78-82. </li> <li>Murphy JM, Pagano ME, Nachmani J, Sperling P, Kane S, Kleinman RE. The relationship of school breakfast to psychosocial and academic functioning: cross-sectional and longitudinal observations in an inner-city school sample. Arch Pediatr Adolesc Med 1998; 152:899-907. </li> <li>Ross MM, Kolbash S, Cohen GM, Skelton JA. Multidisciplinary treatment of pediatric obesity: nutrition evaluation and management. Nutr Clin Pract 2010; 25:327-34. </li> </ol> <br> Data from:<br> Krebs NF, et al. Pediatrics 2007; 120:S193.<br> Ross MM, et al. Nutr Clin Pract 2010; 25:327.</div><div id=\"graphicVersion\">Graphic 63820 Version 8.0</div></div></div>"},"63821":{"type":"graphic_figure","displayName":"Umbilical vein to umbilical artery ratio with SUA","title":"Umbilical vein to umbilical artery ratio with single umbilical artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical vein to umbilical artery ratio with single umbilical artery</div><div class=\"cntnt\"><img style=\"width:431px; height:335px;\" src=\"images/OBGYN/63821_Umbil_vein_umbil_art_ratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing shows the compensatory increase in size of the single umbilical artery. In the normal three-vessel umbilical cord the circulation is theoretically distributed equally in two arteries (left), resulting in an umbilical vein to umbilical artery ratio (UV/UA) greater than 2. In fetuses with single umbilical artery (SUA) the size increase of the artery results in a UV/UA ratio lower than 2.</div><div id=\"graphicVersion\">Graphic 63821 Version 3.0</div></div></div>"},"63825":{"type":"graphic_diagnosticimage","displayName":"Sonogram of placenta previa and placenta previa accreta","title":"Sonogram of placenta previa and placenta previa accreta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of placenta previa and placenta previa accreta</div><div class=\"cntnt\"><img style=\"width:283px; height:529px;\" src=\"images/OBGYN/63825_Sonogram_placenta_accreta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Placenta previa. Sagittal transabdominal scan shows the placenta (P) centered over the cervix (C). There is a normal hypoechoic area between the placenta and the bladder. Panel B) Placenta previa accreta in a different patient from Panel A. Oblique sagittal transvaginal scan shows the placenta (P) centered over the cervix (C). Note how the placenta invades the myometrium, with loss of the hypoechoic layer of myometrium (arrow), which can be seen in the above panel where the previa is not complicated by accreta.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 63825 Version 4.0</div></div></div>"},"63826":{"type":"graphic_picture","displayName":"Periareolar abscess male","title":"Male breast abscess","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Male breast abscess</div><div class=\"cntnt\"><img style=\"width:504px; height:264px;\" src=\"images/PC/63826_Male_breast_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before and after treatment of a male breast abscess with incision and drainage.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 63826 Version 2.0</div></div></div>"},"63827":{"type":"graphic_table","displayName":"Clinical symptoms of selected vitamin deficiencies","title":"Clinical symptoms of selected vitamin deficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical symptoms of selected vitamin deficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vitamin</td> <td class=\"subtitle1\">Deficiency syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Water-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">Vitamin B1<br /> (thiamine)</td> <td>Beriberi <span style=\"font-size: 13px;\">&ndash;</span> Congestive heart failure (wet beriberi), aphonia, peripheral neuropathy, Wernicke encephalopathy (nystagmus, ophthalmoplegia, ataxia), confusion, or coma</td> </tr> <tr> <td class=\"indent1\">Vitamin B2<br /> (riboflavin)</td> <td>Nonspecific symptoms including edema of mucous membranes, angular stomatitis, glossitis, and seborrheic dermatitis (eg, nose, scrotum)</td> </tr> <tr> <td class=\"indent1\">Niacin<br /> (nicotinic acid)</td> <td>Pellagra&nbsp;<span style=\"font-size: 13px;\">&ndash;</span> Dermatitis on areas exposed to sunlight; diarrhea with vomiting, dysphagia, mouth inflammation (glossitis, angular stomatitis, cheilitis); headache, dementia, peripheral neuropathy, loss of memory, psychosis, delirium, catatonia</td> </tr> <tr> <td class=\"indent1\">Vitamin B6<br /> (pyridoxine, pyridoxal)</td> <td>Anemia, weakness, insomnia, difficulty walking, nasolabial seborrheic dermatitis, cheilosis, stomatitis</td> </tr> <tr> <td class=\"indent1\">Vitamin B12<br /> (cobalamin)</td> <td>Megaloblastic anemia (pernicious anemia), peripheral neuropathy with impaired proprioception and slowed mentation</td> </tr> <tr> <td class=\"indent1\">Folate</td> <td>Megaloblastic anemia</td> </tr> <tr> <td class=\"indent1\">Biotin</td> <td>Nonspecific symptoms including altered mental status, myalgia, dysesthesias, anorexia, maculosquamous dermatitis</td> </tr> <tr> <td class=\"indent1\">Pantothenate</td> <td>Nonspecific symptoms including paresthesias, dysesthesias (\"burning feet\"), anemia, gastrointestinal symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin C<br /> (ascorbate)</td> <td>Scurvy <span style=\"font-size: 13px;\">&ndash;</span> fatigue, petechiae, ecchymoses, bleeding gums, depression, dry skin, impaired wound healing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fat-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">Vitamin A<br /> (retinol, retinal, retinoic acid)</td> <td>Night blindness, xerophthalmia, keratomalacia,&nbsp;Bitot spot, follicular hyperkeratosis</td> </tr> <tr> <td class=\"indent1\">Vitamin D<br /> (cholecalciferol, ergocalciferol)</td> <td>Rickets, osteomalacia, craniotabes, rachitic rosary</td> </tr> <tr> <td class=\"indent1\">Vitamin E<br /> (tocopherols)</td> <td>Sensory and motor neuropathy, ataxia, retinal degeneration, hemolytic anemia</td> </tr> <tr> <td class=\"indent1\">Vitamin K<br /> (phylloquinone, menaquinone, menadione)</td> <td>Hemorrhagic disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63827 Version 11.0</div></div></div>"},"63828":{"type":"graphic_table","displayName":"Education at 1st follow up","title":"Delivery of asthma education by clinicians during patient care visits: recommendations for first followup visit (two to four weeks or sooner as needed)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Delivery of asthma education by clinicians during patient care visits: recommendations for first followup visit (two to four weeks or sooner as needed)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Assessment questions</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Focus on:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Concerns</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Quality of life</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Expectations</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Goals of treatment</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Ask relevant questions from previous visit and also ask:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\" colspan=\"1\" rowspan=\"1\">\"What medications are you taking?\"</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">\"How and when are you taking them?\"</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">\"What problems have you had using your medications?\"</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">\"Please show me how you use your inhaled medications?\"</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Information</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Teach or review in simple language:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Use two types of medications. Remind patient to bring all medications and the peak flow meter to every appointment for review.</td>\n\t\t\t\t\t\t</tr><tr><td class=\"indent1\">\n\t\t\t\t\t\t\tSelf-evaluation of progress in asthma control using symptoms and peak flow as a guide.</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Skills</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Teach or review and demonstrate:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Use of a daily self-management plan. Review and adjust as needed.</td></tr><tr><td class=\"indent1\">\n\t\t\t\t\t\t\tUse of an action plan. Review and adjust as needed.</td></tr><tr><td class=\"indent1\">\n\t\t\t\t\t\t\tPeak flow monitoring and daily diary recording.</td></tr><tr><td class=\"indent1\">\n\t\t\t\t\t\t\tCorrect inhaler and spacer/holding chamber technique.</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 63828 Version 1.0</div></div></div>"},"63830":{"type":"graphic_table","displayName":"Chronic pelvic pain","title":"Characteristics of women with chronic pelvic pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of women with chronic pelvic pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Not given a specific diagnosis</td>\n<td>65 percent</td>\n</tr>\n<tr>\n<td>Given a gynecological diagnosis (eg, endometriosis, chronic pelvic inflammatory disease)</td>\n<td>31 percent</td>\n</tr>\n<tr>\n<td>Given a nongynecologic diagnosis (eg, hernia, irritable bowel)</td>\n<td>4 percent</td>\n</tr>\n<tr>\n<td>Actively seeking medical treatment</td>\n<td>30 percent</td>\n</tr>\n<tr>\n<td>Average number of visits to the gynecologist per year</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Average number of visits to the internist or family practitioner per year</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td>Average number of visits to a mental health specialist per year</td>\n<td>0.14</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from data in Mathias, SD, Kuppermann, M, Liberman, RF, et al. Obstet Gynecol 1996; 87:321.</div><div id=\"graphicVersion\">Graphic 63830 Version 1.0</div></div></div>"},"63831":{"type":"graphic_table","displayName":"Acute versus chronic DIC","title":"Coagulation parameters in acute and chronic disseminated intravascular coagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coagulation parameters in acute and chronic disseminated intravascular coagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Acute (decompensated) DIC</td> <td class=\"subtitle1\">Chronic (compensated) DIC</td> </tr> <tr> <td>Platelet count</td> <td>Reduced</td> <td>Variable</td> </tr> <tr> <td>Prothrombin time (PT)</td> <td>Prolonged</td> <td>Normal</td> </tr> <tr> <td>Activated partial thromboplastin time (aPTT)</td> <td>Prolonged</td> <td>Normal</td> </tr> <tr> <td>Thrombin time</td> <td>Prolonged</td> <td>Normal to slightly prolonged</td> </tr> <tr> <td>Plasma fibrinogen</td> <td>Reduced</td> <td>Normal to elevated</td> </tr> <tr> <td>Plasma factor V</td> <td>Reduced</td> <td>Normal</td> </tr> <tr> <td>Plasma factor VIII</td> <td>Reduced</td> <td>Normal</td> </tr> <tr> <td>Fibrin degradation products</td> <td>Elevated</td> <td>Elevated</td> </tr> <tr> <td>D-dimer</td> <td>Elevated</td> <td>Elevated</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In chronic DIC, the thrombin time is more sensitive than&nbsp;PT or aPTT&nbsp;to the effects of increased D-dimer and fibrin degradation products.</div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation.</div><div id=\"graphicVersion\">Graphic 63831 Version 2.0</div></div></div>"},"63833":{"type":"graphic_table","displayName":"Gelatin content of United States available vaccines","title":"Gelatin content of United States available vaccines (subject to change - refer to local prescribing information)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gelatin content of United States available vaccines (subject to change - refer to local prescribing information)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine (United States brand name and manufacturer)</td> <td class=\"subtitle1\">Gelatin content in micrograms per dose</td> </tr> <tr> <td>Influenza (Flumist Quadrivalent 2017-2018, Medimmune vaccines)*</td> <td>2000 micrograms per 0.2 mL dose</td> </tr> <tr> <td>Measles, mumps, rubella (M-M-R-II, Merck)</td> <td>14,500 micrograms per 0.5 mL dose</td> </tr> <tr> <td>Measles, mumps, rubella, varicella (ProQuad, Merck)</td> <td>11,000 micrograms per 0.5 mL dose</td> </tr> <tr> <td>Rabies (RabAvert, Novartis)</td> <td>&#8804;12,000 micrograms per 1 mL dose</td> </tr> <tr> <td>Varicella (Varivax, Merck)</td> <td>12,500 micrograms per 0.5 mL dose</td> </tr> <tr> <td>Yellow fever (YF-Vax, Sanofi Pasteur)</td> <td>6250 micrograms per 0.5 mL dose<sup>&#182;</sup></td> </tr> <tr> <td>Zoster (Zostavax, Merck)</td> <td>15,580 micrograms per 0.65 mL dose</td> </tr> <tr> <td>Typhoid oral Ty21a&nbsp;(Vivotif, Crucell Vaccines)</td> <td>Capsule</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not recommended for use in the United States for the 2017-2018 season.<br />¶ Gelatin content provided by Sanofi Pasteur United States vaccine medical information telephone <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">1-800-822-2463</FONT>.</div><div class=\"graphic_reference\">US Food&nbsp;and Drug Administration, Vaccines Licensed for Use in the United States; approved product information (package insert) available at <A spellcheck=true href=\"https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm\" target=_blank>https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm</A> (accessed on September 6, 2017).</div><div id=\"graphicVersion\">Graphic 63833 Version 9.0</div></div></div>"},"63834":{"type":"graphic_algorithm","displayName":"Morphea treatment algorithm","title":"Treatment algorithm for morphea","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for morphea</div><div class=\"cntnt\"><img style=\"width:588px; height:750px;\" src=\"images/DERM/63834_Morphea_trtmnt_algo_edit3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Therapeutic algorithm for morphea based on existing evidence. Superficial involvement is defined by histologic evidence of papillary dermal involvement. Deep involvement is defined as sclerosis or inflammation of the deep dermis, subcutis, fascia, or muscle. Histologic examination and/or magnetic resonance imaging (MRI) are used to evaluate lesions for depth of involvement and, likewise, determine appropriate treatment as well as evaluation of therapeutic efficacy.</div><div class=\"graphic_footnotes\">NB UVB: narrowband ultraviolet B; BB UVB: broadband ultraviolet B; UVA1: ultraviolet A1; PT: physical therapy; OT: occupational therapy.<br />* There is very little evidence for any therapy addressing disease damage in morphea. The risk of disease reactivation is also unknown but possible with the use of invasive procedures. Therefore, surgery and the like should only be undertaken after prolonged inactivity of disease.</div><div class=\"graphic_reference\">Original figure modified for this publication. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011; 65:925. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63834 Version 5.0</div></div></div>"},"63835":{"type":"graphic_algorithm","displayName":"Crotalinae snakebite referral maintenance and follow up","title":"Management of pit viper* snakebite: Indications for referral, maintenance therapy, follow up, and treatments to avoid","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Management of pit viper* snakebite: Indications for referral, maintenance therapy, follow up, and treatments to avoid</div><div class=\"cntnt\"><img style=\"width:626px; height:557px;\" src=\"images/EM/63835_Crotalinae_snakebite_refer2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTES:&#xD;&#xA;<ul>&#xD;&#xA;    <li><strong>All treatment recommendations in this worksheet refer to Crotalinae polyvalent immune Fab (ovine) (CroFab&reg;).</strong></li>&#xD;&#xA;    <li>This worksheet represents general advice from a panel of US snakebite experts convened in May, 2010. No guideline can anticipate all clinical situations. Other valid approaches exist, and deviations from this worksheet based on individual patient needs, local resources, local treatment guidelines, and patient preferences are expected. <strong>This document is not intended to represent a standard of care.</strong> For more information, please see the accompanying manuscript, available at: <a href=\"http://www.biomedcentral.com/1471-227X/11/2\" target=\"_blank\">http://www.biomedcentral.com/1471-227X/11/2</a>.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Includes rattlesnakes, copperheads, and cottonmouths (water moccasins).</div><div class=\"graphic_reference\">Reproduced with permission from: Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 63835 Version 7.0</div></div></div>"},"63838":{"type":"graphic_table","displayName":"Dx of alcoholic liver disease","title":"ACG guideline for the diagnosis of alcoholic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACG guideline for the diagnosis of alcoholic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>All patients should\nbe screened for alcoholic liver disease. A thorough history of alcohol\nuse should be obtained. The CAGE questionnaire is a useful screening\nmethod for alcohol abuse or dependency.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A detailed physical examination should be done, searching for signs of chronic liver disease and staging its severity.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A liver chemistry\nprofile (including serum albumin, bilirubin and transaminases\n[AST/ALT]). A complete blood count and prothrombin time or INR should\nbe obtained to support a clinical suspicion of alcoholic liver disease\nand to assess its severity. However, both laboratory abnormalities and\nphysical findings may be minimal or absent even in patients with\nestablished alcoholic liver disease.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>When evaluating a\npatient for alcoholic liver disease, the clinician must remember that\nthe toxic daily threshold dose of 80 g of alcohol is not absolute.\nElevations in serum ALT may develop at much lower doses, especially in\nwomen and patients with hepatitis C infection.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>It may be necessary\nto perform a liver biopsy in patients with suspected alcoholic liver\ndisease when the diagnosis is unclear because of atypical features or\npossible concomitant disease.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">From the American College of Gastroenterology with permission. Recommendations for the diagnosis of alcoholic liver disease. Am J Gastroenterol 1998; 93:2022.</div><div id=\"graphicVersion\">Graphic 63838 Version 1.0</div></div></div>"},"63839":{"type":"graphic_table","displayName":"Dosing of ticarcillin and piperacillin","title":"Dosing of ticarcillin and piperacillin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing of ticarcillin and piperacillin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Normal unit dose*</td> <td class=\"subtitle1\">Normal dose interval</td> <td class=\"subtitle1\">Dosing changes in severe renal failure</td> </tr> <tr> <td>Ticarcillin</td> <td>3</td> <td>Q4h</td> <td>Yes</td> </tr> <tr> <td>Piperacillin</td> <td>3-4</td> <td>Q4-6h<sup>&#182;</sup></td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Dose given at each normal dose interval, ie, 3g Q4h for ticarcillin.<br />&para; These drugs have dose-dependent pharmacokinetics and can be given as 4 g Q6h.</div><div id=\"graphicVersion\">Graphic 63839 Version 3.0</div></div></div>"},"63840":{"type":"graphic_picture","displayName":"Amyloid light","title":"Light micrograph showing glomerular amyloidosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing glomerular amyloidosis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/63840_AmyloidLight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of glomerular amyloidosis shows nodular amorphous material (arrows) extending from the mesangium into the capillary loops and narrowing or closing the capillary lumens.&nbsp;Amyloid deposits are pale when H&amp;E stain is applied and do not stain with PAS or with methenamine silver stain.&nbsp;They are usually more amorphous than those of diabetic nephropathy, which are positive on PAS and silver stain. The diagnosis of renal amyloidosis relies upon the demonstration of amyloid fibrils by electron microscopy or green birefringence with Congo red staining.</div><div class=\"graphic_footnotes\">PAS: periodic acid-Schiff.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 63840 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"63843":{"type":"graphic_picture","displayName":"Diabetic papillopathy","title":"Diabetic papillopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diabetic papillopathy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/NEURO/63843_Diabetic_papillopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 63843 Version 1.0</div></div></div>"},"63844":{"type":"graphic_picture","displayName":"Fastrach or intubating LMA","title":"Fastrach™ or intubating LMA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fastrach™ or intubating LMA</div><div class=\"cntnt\"><img style=\"width:396px; height:369px;\" src=\"images/EM/63844_Fastrach.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission from: LMA North America, Inc. Copyright © 2008 LMA North America, Inc.</div><div id=\"graphicVersion\">Graphic 63844 Version 5.0</div></div></div>"},"63845":{"type":"graphic_figure","displayName":"Beta globin bands Hb H disease","title":"Beta globin attached to the red cell cytoskeleton in hemoglobin H disease","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Beta globin attached to the red cell cytoskeleton in hemoglobin H disease</div><div class=\"cntnt\"><img style=\"width:459px; height:359px;\" src=\"images/HEME/63845_Beta_globin_bands_Hb_H_dise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red blood cell ghosts and cytoskeletons from patients with hemoglobin H (Hb H) disease analyzed by Triton acid urea gel electrophoresis are shown here; the reference standard is normal (Hb A) hemolysate (lane 4). Alpha and beta globin bands are not found on normal red cell ghosts (lane 1) or their cytoskeletons (lane 5). Although both beta and alpha globin bands are attached to the Hb H ghosts (lanes 2 and 3), only beta globin bands are attached to the cytoskeleton (lanes 6 and 7).</div><div class=\"graphic_reference\">Reproduced with permission from Advani, S, Sorenson, E, Shinar, W, et al. Characterization and comparison of the red blood cell membrane damage in severe human alpha and beta-thalassemia. Blood 1992; 79:1058. Copyright &#169; 1992 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 63845 Version 2.0</div></div></div>"},"63847":{"type":"graphic_table","displayName":"T cell cytokine secretion profiles","title":"T cell cytokine secretion profiles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">T cell cytokine secretion profiles</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Th1</td> </tr> <tr> <td class=\"indent1\">IL-2</td> </tr> <tr> <td class=\"indent1\">IL-3</td> </tr> <tr> <td class=\"indent1\">IFN-gamma</td> </tr> <tr> <td class=\"indent1\">TNF</td> </tr> <tr> <td class=\"subtitle1_single\">Th2</td> </tr> <tr> <td class=\"indent1\">IL-4</td> </tr> <tr> <td class=\"indent1\">IL-5</td> </tr> <tr> <td class=\"indent1\">IL-6</td> </tr> <tr> <td class=\"indent1\">IL-9</td> </tr> <tr> <td class=\"indent1\">IL-10</td> </tr> <tr> <td class=\"indent1\">IL-13</td> </tr> <tr> <td class=\"subtitle1_single\">Th17</td> </tr> <tr> <td class=\"indent1\">IL-17</td> </tr> <tr> <td class=\"subtitle1_single\">Treg</td> </tr> <tr> <td class=\"indent1\">TGF-beta</td> </tr> <tr> <td class=\"indent1\">IL-10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Th: T helper cell (types 1, 2, and 17); IL: interleukin; IFN: interferon; TNF: tumor necrosis factor; Treg: regulatory T cell; TGF: transforming-growth factor.</div><div id=\"graphicVersion\">Graphic 63847 Version 6.0</div></div></div>"},"63848":{"type":"graphic_table","displayName":"Neurodevelopmental outcome of extremely premature survivors","title":"Rates of neurodevelopmental outcomes among survivors in selected studies for infants 22 to 25 weeks gestation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of neurodevelopmental outcomes among survivors in selected studies for infants 22 to 25 weeks gestation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"8%\"></colgroup><colgroup width=\"36%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study</td> <td class=\"subtitle1\" rowspan=\"2\">Study year</td> <td class=\"subtitle1\" rowspan=\"2\">Outcome</td> <td class=\"subtitle1\" colspan=\"5\">Rate (%) by gestational week</td> <td class=\"subtitle1\" rowspan=\"2\">Comment</td> </tr> <tr> <td class=\"subtitle2\">22</td> <td class=\"subtitle2\">23</td> <td class=\"subtitle2\">24</td> <td class=\"subtitle2\">25</td> <td class=\"subtitle2\">Total</td> </tr> <tr> <td class=\"divider_bottom\" style=\"white-space: nowrap;\" rowspan=\"2\">EPICure<sup>[1]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">1995</td> <td>CP</td> <td class=\"centered\">N/A</td> <td class=\"centered\">13</td> <td class=\"centered\">21</td> <td class=\"centered\">20</td> <td class=\"centered\">20</td> <td>As defined by European Surveillance of CP Network at two years</td> </tr> <tr class=\"divider_bottom\"> <td>Cognitive score &#60;70</td> <td class=\"centered\">N/A</td> <td class=\"centered\">11</td> <td class=\"centered\">14</td> <td class=\"centered\">7</td> <td class=\"centered\">10</td> <td>K-ABC test at five to six years in 64% of children without severe disability</td> </tr> <tr> <td class=\"divider_bottom\" style=\"white-space: nowrap;\" rowspan=\"2\">Epipage<sup>[2]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">1997</td> <td>CP</td> <td class=\"centered\">N/A</td> <td class=\"centered\">33</td> <td class=\"centered\">13</td> <td class=\"centered\">16.3</td> <td class=\"centered\">16</td> <td>As defined by European Surveillance of CP Network at two years</td> </tr> <tr class=\"divider_bottom\"> <td>Cognitive score &#60;70</td> <td class=\"centered\">N/A</td> <td class=\"centered\">0</td> <td class=\"centered\">23</td> <td class=\"centered\">12</td> <td class=\"centered\">14</td> <td>K-ABC test at five to six years in 57% of children without severe disability</td> </tr> <tr> <td class=\"divider_bottom\" style=\"white-space: nowrap;\" rowspan=\"2\">Tyson<sup>[3]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">1998 to 2003</td> <td>Impairment</td> <td class=\"centered\">80</td> <td class=\"centered\">65</td> <td class=\"centered\">50</td> <td class=\"centered\">36</td> <td class=\"centered\">47</td> <td>MDI or PDI &#60;70, moderate or severe CP, blindness, or bilateral hearing loss requiring amplification at 18 to 22 months corrected age</td> </tr> <tr class=\"divider_bottom\"> <td>Profound impairment</td> <td class=\"centered\">60</td> <td class=\"centered\">38</td> <td class=\"centered\">23</td> <td class=\"centered\">17</td> <td class=\"centered\">24</td> <td>MDI or PDI &#60;50 or severe gross motor deficit requiring adult assistance to move at 18 to 22 months corrected age</td> </tr> <tr> <td class=\"divider_bottom sublist1_start\" style=\"white-space: nowrap;\" rowspan=\"6\">Carlo<sup>[4]</sup></td> <td class=\"divider_bottom sublist1_start\" rowspan=\"6\">1993 to 2009</td> <td class=\"sublist1_start\" colspan=\"6\">Impairment</td> <td rowspan=\"3\">MDI or PDI &#8804;70, moderate or severe CP, blindness, or bilateral hearing loss requiring amplification at 18 to 22 months corrected age</td> </tr> <tr> <td class=\"indent1\">ANS</td> <td class=\"centered\">59</td> <td class=\"centered\">55</td> <td class=\"centered\">42</td> <td class=\"centered\">34</td> <td class=\"centered\">39</td> </tr> <tr> <td class=\"indent1\">No ANS</td> <td class=\"centered\">56</td> <td class=\"centered\">56</td> <td class=\"centered\">52</td> <td class=\"centered\">44</td> <td class=\"centered\">49</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\">CP</td> <td class=\"divider_bottom\" rowspan=\"3\">Moderate or severe CP</td> </tr> <tr> <td class=\"indent1\">ANS</td> <td class=\"centered\">14</td> <td class=\"centered\">11</td> <td class=\"centered\">10</td> <td class=\"centered\">7</td> <td class=\"centered\">9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">No ANS</td> <td class=\"centered\">16</td> <td class=\"centered\">19</td> <td class=\"centered\">12</td> <td class=\"centered\">9</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"divider_bottom\" style=\"white-space: nowrap;\" rowspan=\"2\">Ishii<sup>[5]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">2003 to 2005</td> <td>Impairment</td> <td class=\"centered\">52</td> <td class=\"centered\">57</td> <td class=\"centered\">37</td> <td class=\"centered\">37</td> <td class=\"centered\">42</td> <td>Moderate to severe CP, hearing impairment requiring amplification, blindness in one or both eyes, or a score of &#60;70 at 36 to 42 months corrected age on the Kyoto Scale of Psychological Development (KSPD)</td> </tr> <tr class=\"divider_bottom\"> <td>Profound impairment</td> <td class=\"centered\">30</td> <td class=\"centered\">40</td> <td class=\"centered\">16</td> <td class=\"centered\">17</td> <td class=\"centered\">23</td> <td>Severe CP or a score &#60;50 at 36 to 42 months corrected age on KSPD</td> </tr> <tr> <td style=\"white-space: nowrap;\" rowspan=\"3\">Serenius<sup>[6]</sup></td> <td rowspan=\"3\">2004 to 2007</td> <td>Mild</td> <td class=\"centered\">40</td> <td class=\"centered\">19</td> <td class=\"centered\">33</td> <td class=\"centered\">29</td> <td class=\"centered\">29</td> <td>Mild disability: scores on any Bayley-III scales between 1 and 2 SD below the mean or mild CP at 2.5 years corrected age</td> </tr> <tr> <td>Moderate</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">21</td> <td class=\"centered\">17</td> <td class=\"centered\">20</td> <td>Moderate disability: scores on any Bayley-III scales between 2 and 3 SD below the mean, moderate CP, or moderate visual or hearing impairment at 2.5 years corrected age</td> </tr> <tr> <td>Severe</td> <td class=\"centered\">40</td> <td class=\"centered\">21</td> <td class=\"centered\">13</td> <td class=\"centered\">10</td> <td class=\"centered\">13</td> <td>Severe disability: score &#62;3 SD below the mean for any of the Bayley-III scales, severe CP, or bilateral blindness or deafness at 2.5 years corrected age</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CP: cerebral palsy; N/A: not available; K-ABC test: Mental Processing Composite of the Kaufman Assessment Battery for Children; MDI: Mental Developmental Index of the Bayley Scales of Infant Development-II; PDI: Psychomotor Developmental Index of the Bayley Scales of Infant Development-II; ANS: antenatal steroid therapy; SD: standard deviation.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659. </li>&#xD;&#xA;    <li>Larroque B, Br&eacute;art G, Kaminski M, et al. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89:F139. </li>&#xD;&#xA;    <li>Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672. </li>&#xD;&#xA;    <li>Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.</li>&#xD;&#xA;    <li>Ishii N, Kono Y, Yonemoto N, et al. Outcomes of infants born at 22 and 23 weeks' gestation. Pediatrics 2013; 132:62.</li>&#xD;&#xA;    <li>Serenius F, K&auml;ll&eacute;n K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA 2013; 309:1810.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 63848 Version 13.0</div></div></div>"},"63852":{"type":"graphic_table","displayName":"Allografts","title":"Allografts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Allografts</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tissue source</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Preservation</td> <td class=\"subtitle1\">Crosslinking</td> <td class=\"subtitle1\">Sterilization</td> </tr> <tr> <td class=\"divider_bottom\">Fascia lata</td> <td>Coloplast</td> <td>Suspend<sup>&#916;</sup>, Tutoplast<sup>&#916;</sup></td> <td>Solvent dehydrated</td> <td>No</td> <td>Irradiation</td> </tr> <tr> <td rowspan=\"3\">Dermis</td> <td>LifeCell</td> <td>AlloDerm<sup>&#9674;</sup></td> <td>Freeze dried</td> <td>No</td> <td>Irradiation</td> </tr> <tr> <td>Boston Scientific</td> <td>Repliform<sup>&#9674;</sup></td> <td>Lyophilized</td> <td>No</td> <td>Ethylene Oxide</td> </tr> <tr> <td>Coloplast</td> <td>Axis</td> <td>Solvent dehydrated</td> <td>No</td> <td>Irradiation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Freeze-dried under vacuum.<br />¶ Gamma radiation.<br />Δ Tutoplast refers to a sterilization process used by RTI Surgical to process various allografts.&nbsp;Although the literature refers to a Tutoplast and Suspend allograft, these are the same fascia lata material. <br /><FONT class=lozenge>◊</FONT> AlloDerm and Repliform are the same material.</div><div id=\"graphicVersion\">Graphic 63852 Version 4.0</div></div></div>"},"63854":{"type":"graphic_figure","displayName":"Lymphatic system PI","title":"Lymphatic system","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Lymphatic system</div><div class=\"cntnt\"><img style=\"width:485px; height:707px;\" src=\"images/PI/63854_Lymph_node_regions_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the organs of the lymphatic system, which include the bone marrow, thymus, spleen, and lymph nodes. These organs are connected by lymph vessels.</div><div id=\"graphicVersion\">Graphic 63854 Version 4.0</div></div></div>"},"63855":{"type":"graphic_table","displayName":"DT DTaP contraindications","title":"Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children aged 0 through 6 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children aged 0 through 6 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vaccine </td> <td class=\"subtitle1\">Contraindications </td> <td class=\"subtitle1\">Precautions* </td> <td class=\"subtitle1\">Neither contraindications nor precautions </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">DTaP </td> </tr> <tr> <td rowspan=\"7\">&nbsp;</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> <td>Mild acute illness with or without fever</td> </tr> <tr> <td>Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of DTwP/DTaP</td> <td>Temperature &#8805;105&#176;F (40.5&#176;C) for 48 hours after vaccination with a previous dose of DTwP/DTaP</td> <td>Family history of seizure, sudden infant death syndrome, or adverse event after DTwP/DTaP</td> </tr> <tr> <td>Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy: defer DTaP until neurologic status clarified and stabilized</td> <td>Collapse or shock-like state (ie, hypotonic hyporesponsive episode) within 48 hours after DTwP/DTaP</td> <td>Stable or resolved neurologic condition (eg, controlled idiopathic epilepsy, cerebral palsy, developmental delay)</td> </tr> <tr> <td>&nbsp;</td> <td>Seizure within 3 days after DTwP/DTaP<sup>&#182;</sup></td> <td>Immunosuppression</td> </tr> <tr> <td>&nbsp;</td> <td>Persistent inconsolable crying lasting &#8805;3 hours within 48 hours after DTwP/DTaP</td> <td>Extensive local reaction to fourth DTaP</td> </tr> <tr> <td>&nbsp;</td> <td>Guillain-Barr&#233; syndrome within 6 weeks of tetanus toxoid-containing vaccine </td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>History of Arthus-type hypersensitivity reaction following diphtheria- or tetanus toxoid-containing vaccine (including MCV4)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">DT </td> </tr> <tr> <td rowspan=\"3\">&nbsp;</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> <td>(As for DTaP)</td> </tr> <tr> <td>&nbsp;</td> <td>Guillain-Barr&#233; syndrome within 6 weeks after tetanus toxoid-containing vaccine</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>History of Arthus-type hypersensitivity reaction following diphtheria- or tetanus toxoid-containing vaccine (including MCV4)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; DTwP: diphtheria tetanus, whole-cell pertussis vaccine; DT: diphtheria toxoid, tetanus toxoid (pediatric DT); MCV4: quadrivalent meningococcal conjugate vaccine.<br />* Precautions should be reviewed carefully. Benefits and risks of administering specific vaccines to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. Whether and when to administer DTaP to children with proven or suspected underlying disorders should be decided on a case-by-case basis.<br />¶&nbsp;Acetaminophen or other appropriate antipyretic can be administered to infants and children with a history of seizures at the time of DTaP vaccination and at appropriate intervals for 24 hours thereafter to reduce the possibility of postvaccination fever.</div><div class=\"graphic_reference\">Adapted from:<br />1. Immunization Action Coalition. Guide to contraindications and precautions to commonly used vaccines. Available at: <A spellcheck=true href=\"http://www.immunize.org/catg.d/p3072A.pdf\" target=_blank>www.immunize.org/catg.d/p3072A.pdf</A>. Accessed on April 28, 2017.<br />2. Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>. Accessed on April 28, 2017.<br />3. American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.609. <br />4. American Academy of Pediatrics. Vaccine contraindications and precautions In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.52. <br /><br /></div><div id=\"graphicVersion\">Graphic 63855 Version 5.0</div></div></div>"},"63856":{"type":"graphic_table","displayName":"Normal BP boys","title":"Blood pressure levels for boys by age and height percentile","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood pressure levels for boys by age and height percentile</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"14\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">BP<br /> (percentile)</td> <td class=\"subtitle1\" colspan=\"7\">Systolic BP (mmHg)</td> <td class=\"subtitle1\" colspan=\"7\">Diastolic BP (mmHg)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"7\">Height percentile or measured height</td> <td class=\"subtitle2\" colspan=\"7\">Height percentile or measured height</td> </tr> <tr> <td class=\"subtitle3\">5%</td> <td class=\"subtitle3\">10%</td> <td class=\"subtitle3\">25%</td> <td class=\"subtitle3\">50%</td> <td class=\"subtitle3\">75%</td> <td class=\"subtitle3\">90%</td> <td class=\"subtitle3\">95%</td> <td class=\"subtitle3\">5%</td> <td class=\"subtitle3\">10%</td> <td class=\"subtitle3\">25%</td> <td class=\"subtitle3\">50%</td> <td class=\"subtitle3\">75%</td> <td class=\"subtitle3\">90%</td> <td class=\"subtitle3\">95%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">1 year</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">30.4</td> <td class=\"centered\">30.8</td> <td class=\"centered\">31.6</td> <td class=\"centered\">32.4</td> <td class=\"centered\">33.3</td> <td class=\"centered\">34.1</td> <td class=\"centered\">34.6</td> <td class=\"centered\">30.4</td> <td class=\"centered\">30.8</td> <td class=\"centered\">31.6</td> <td class=\"centered\">32.4</td> <td class=\"centered\">33.3</td> <td class=\"centered\">34.1</td> <td class=\"centered\">34.6</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">77.2</td> <td class=\"centered\">78.3</td> <td class=\"centered\">80.2</td> <td class=\"centered\">82.4</td> <td class=\"centered\">84.6</td> <td class=\"centered\">86.7</td> <td class=\"centered\">87.9</td> <td class=\"centered\">77.2</td> <td class=\"centered\">78.3</td> <td class=\"centered\">80.2</td> <td class=\"centered\">82.4</td> <td class=\"centered\">84.6</td> <td class=\"centered\">86.7</td> <td class=\"centered\">87.9</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">85</td> <td class=\"centered\">85</td> <td class=\"centered\">86</td> <td class=\"centered\">86</td> <td class=\"centered\">87</td> <td class=\"centered\">88</td> <td class=\"centered\">88</td> <td class=\"centered\">40</td> <td class=\"centered\">40</td> <td class=\"centered\">40</td> <td class=\"centered\">41</td> <td class=\"centered\">41</td> <td class=\"centered\">42</td> <td class=\"centered\">42</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">99</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">101</td> <td class=\"centered\">101</td> <td class=\"centered\">52</td> <td class=\"centered\">52</td> <td class=\"centered\">53</td> <td class=\"centered\">53</td> <td class=\"centered\">54</td> <td class=\"centered\">54</td> <td class=\"centered\">54</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">102</td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> <td class=\"centered\">54</td> <td class=\"centered\">54</td> <td class=\"centered\">55</td> <td class=\"centered\">55</td> <td class=\"centered\">56</td> <td class=\"centered\">57</td> <td class=\"centered\">57</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">114</td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">117</td> <td class=\"centered\">66</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">69</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">2 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">33.9</td> <td class=\"centered\">34.4</td> <td class=\"centered\">35.3</td> <td class=\"centered\">36.3</td> <td class=\"centered\">37.3</td> <td class=\"centered\">38.2</td> <td class=\"centered\">38.8</td> <td class=\"centered\">33.9</td> <td class=\"centered\">34.4</td> <td class=\"centered\">35.3</td> <td class=\"centered\">36.3</td> <td class=\"centered\">37.3</td> <td class=\"centered\">38.2</td> <td class=\"centered\">38.8</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">86.1</td> <td class=\"centered\">87.4</td> <td class=\"centered\">89.6</td> <td class=\"centered\">92.1</td> <td class=\"centered\">94.7</td> <td class=\"centered\">97.1</td> <td class=\"centered\">98.5</td> <td class=\"centered\">86.1</td> <td class=\"centered\">87.4</td> <td class=\"centered\">89.6</td> <td class=\"centered\">92.1</td> <td class=\"centered\">94.7</td> <td class=\"centered\">97.1</td> <td class=\"centered\">98.5</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">87</td> <td class=\"centered\">87</td> <td class=\"centered\">88</td> <td class=\"centered\">89</td> <td class=\"centered\">89</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">43</td> <td class=\"centered\">43</td> <td class=\"centered\">44</td> <td class=\"centered\">44</td> <td class=\"centered\">45</td> <td class=\"centered\">46</td> <td class=\"centered\">46</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">101</td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">55</td> <td class=\"centered\">55</td> <td class=\"centered\">56</td> <td class=\"centered\">56</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> <td class=\"centered\">58</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> <td class=\"centered\">58</td> <td class=\"centered\">59</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">61</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">117</td> <td class=\"centered\">118</td> <td class=\"centered\">119</td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">73</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">3 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">36.4</td> <td class=\"centered\">37.0</td> <td class=\"centered\">37.9</td> <td class=\"centered\">39.0</td> <td class=\"centered\">40.1</td> <td class=\"centered\">41.1</td> <td class=\"centered\">41.7</td> <td class=\"centered\">36.4</td> <td class=\"centered\">37.0</td> <td class=\"centered\">37.9</td> <td class=\"centered\">39.0</td> <td class=\"centered\">40.1</td> <td class=\"centered\">41.1</td> <td class=\"centered\">41.7</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">92.5</td> <td class=\"centered\">93.9</td> <td class=\"centered\">96.3</td> <td class=\"centered\">99.0</td> <td class=\"centered\">101.8</td> <td class=\"centered\">104.3</td> <td class=\"centered\">105.8</td> <td class=\"centered\">92.5</td> <td class=\"centered\">93.9</td> <td class=\"centered\">96.3</td> <td class=\"centered\">99.0</td> <td class=\"centered\">101.8</td> <td class=\"centered\">104.3</td> <td class=\"centered\">105.8</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">88</td> <td class=\"centered\">89</td> <td class=\"centered\">89</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">92</td> <td class=\"centered\">92</td> <td class=\"centered\">45</td> <td class=\"centered\">46</td> <td class=\"centered\">46</td> <td class=\"centered\">47</td> <td class=\"centered\">48</td> <td class=\"centered\">49</td> <td class=\"centered\">49</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">101</td> <td class=\"centered\">102</td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> <td class=\"centered\">58</td> <td class=\"centered\">58</td> <td class=\"centered\">59</td> <td class=\"centered\">59</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">61</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">106</td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">109</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">64</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">118</td> <td class=\"centered\">118</td> <td class=\"centered\">119</td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">121</td> <td class=\"centered\">121</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">73</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">76</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">4 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">38.8</td> <td class=\"centered\">39.4</td> <td class=\"centered\">40.5</td> <td class=\"centered\">41.7</td> <td class=\"centered\">42.9</td> <td class=\"centered\">43.9</td> <td class=\"centered\">44.5</td> <td class=\"centered\">38.8</td> <td class=\"centered\">39.4</td> <td class=\"centered\">40.5</td> <td class=\"centered\">41.7</td> <td class=\"centered\">42.9</td> <td class=\"centered\">43.9</td> <td class=\"centered\">44.5</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">98.5</td> <td class=\"centered\">100.2</td> <td class=\"centered\">102.9</td> <td class=\"centered\">105.9</td> <td class=\"centered\">108.9</td> <td class=\"centered\">111.5</td> <td class=\"centered\">113.2</td> <td class=\"centered\">98.5</td> <td class=\"centered\">100.2</td> <td class=\"centered\">102.9</td> <td class=\"centered\">105.9</td> <td class=\"centered\">108.9</td> <td class=\"centered\">111.5</td> <td class=\"centered\">113.2</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">92</td> <td class=\"centered\">93</td> <td class=\"centered\">94</td> <td class=\"centered\">94</td> <td class=\"centered\">48</td> <td class=\"centered\">49</td> <td class=\"centered\">49</td> <td class=\"centered\">50</td> <td class=\"centered\">51</td> <td class=\"centered\">52</td> <td class=\"centered\">52</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">64</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">107</td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">110</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">119</td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">120</td> <td class=\"centered\">121</td> <td class=\"centered\">122</td> <td class=\"centered\">122</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">5 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">41.1</td> <td class=\"centered\">41.8</td> <td class=\"centered\">43.0</td> <td class=\"centered\">44.3</td> <td class=\"centered\">45.5</td> <td class=\"centered\">46.7</td> <td class=\"centered\">47.4</td> <td class=\"centered\">41.1</td> <td class=\"centered\">41.8</td> <td class=\"centered\">43.0</td> <td class=\"centered\">44.3</td> <td class=\"centered\">45.5</td> <td class=\"centered\">46.7</td> <td class=\"centered\">47.4</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">104.4</td> <td class=\"centered\">106.2</td> <td class=\"centered\">109.1</td> <td class=\"centered\">112.4</td> <td class=\"centered\">115.7</td> <td class=\"centered\">118.6</td> <td class=\"centered\">120.3</td> <td class=\"centered\">104.4</td> <td class=\"centered\">106.2</td> <td class=\"centered\">109.1</td> <td class=\"centered\">112.4</td> <td class=\"centered\">115.7</td> <td class=\"centered\">118.6</td> <td class=\"centered\">120.3</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">91</td> <td class=\"centered\">92</td> <td class=\"centered\">93</td> <td class=\"centered\">94</td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> <td class=\"centered\">96</td> <td class=\"centered\">51</td> <td class=\"centered\">51</td> <td class=\"centered\">52</td> <td class=\"centered\">53</td> <td class=\"centered\">54</td> <td class=\"centered\">55</td> <td class=\"centered\">55</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">108</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">65</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">67</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">121</td> <td class=\"centered\">121</td> <td class=\"centered\">122</td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">82</td> <td class=\"centered\">83</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">6 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">43.4</td> <td class=\"centered\">44.2</td> <td class=\"centered\">45.4</td> <td class=\"centered\">46.8</td> <td class=\"centered\">48.2</td> <td class=\"centered\">49.4</td> <td class=\"centered\">50.2</td> <td class=\"centered\">43.4</td> <td class=\"centered\">44.2</td> <td class=\"centered\">45.4</td> <td class=\"centered\">46.8</td> <td class=\"centered\">48.2</td> <td class=\"centered\">49.4</td> <td class=\"centered\">50.2</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">110.3</td> <td class=\"centered\">112.2</td> <td class=\"centered\">115.3</td> <td class=\"centered\">118.9</td> <td class=\"centered\">122.4</td> <td class=\"centered\">125.6</td> <td class=\"centered\">127.5</td> <td class=\"centered\">110.3</td> <td class=\"centered\">112.2</td> <td class=\"centered\">115.3</td> <td class=\"centered\">118.9</td> <td class=\"centered\">122.4</td> <td class=\"centered\">125.6</td> <td class=\"centered\">127.5</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">93</td> <td class=\"centered\">93</td> <td class=\"centered\">94</td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">54</td> <td class=\"centered\">54</td> <td class=\"centered\">55</td> <td class=\"centered\">56</td> <td class=\"centered\">57</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">105</td> <td class=\"centered\">105</td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">110</td> <td class=\"centered\">66</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">69</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">114</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> <td class=\"centered\">72</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">120</td> <td class=\"centered\">121</td> <td class=\"centered\">122</td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">125</td> <td class=\"centered\">126</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">82</td> <td class=\"centered\">83</td> <td class=\"centered\">84</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">7 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">45.7</td> <td class=\"centered\">46.5</td> <td class=\"centered\">47.8</td> <td class=\"centered\">49.3</td> <td class=\"centered\">50.8</td> <td class=\"centered\">52.1</td> <td class=\"centered\">52.9</td> <td class=\"centered\">45.7</td> <td class=\"centered\">46.5</td> <td class=\"centered\">47.8</td> <td class=\"centered\">49.3</td> <td class=\"centered\">50.8</td> <td class=\"centered\">52.1</td> <td class=\"centered\">52.9</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">116.1</td> <td class=\"centered\">118.0</td> <td class=\"centered\">121.4</td> <td class=\"centered\">125.1</td> <td class=\"centered\">128.9</td> <td class=\"centered\">132.4</td> <td class=\"centered\">134.5</td> <td class=\"centered\">116.1</td> <td class=\"centered\">118.0</td> <td class=\"centered\">121.4</td> <td class=\"centered\">125.1</td> <td class=\"centered\">128.9</td> <td class=\"centered\">132.4</td> <td class=\"centered\">134.5</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">94</td> <td class=\"centered\">94</td> <td class=\"centered\">95</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">56</td> <td class=\"centered\">56</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> <td class=\"centered\">58</td> <td class=\"centered\">59</td> <td class=\"centered\">59</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">106</td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">111</td> <td class=\"centered\">68</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> <td class=\"centered\">71</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">110</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">71</td> <td class=\"centered\">71</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">73</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">122</td> <td class=\"centered\">122</td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">126</td> <td class=\"centered\">127</td> <td class=\"centered\">128</td> <td class=\"centered\">83</td> <td class=\"centered\">83</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">85</td> <td class=\"centered\">86</td> <td class=\"centered\">86</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">8 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">47.8</td> <td class=\"centered\">48.6</td> <td class=\"centered\">50.0</td> <td class=\"centered\">51.6</td> <td class=\"centered\">53.2</td> <td class=\"centered\">54.6</td> <td class=\"centered\">55.5</td> <td class=\"centered\">47.8</td> <td class=\"centered\">48.6</td> <td class=\"centered\">50.0</td> <td class=\"centered\">51.6</td> <td class=\"centered\">53.2</td> <td class=\"centered\">54.6</td> <td class=\"centered\">55.5</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">121.4</td> <td class=\"centered\">123.5</td> <td class=\"centered\">127.0</td> <td class=\"centered\">131.0</td> <td class=\"centered\">135.1</td> <td class=\"centered\">138.8</td> <td class=\"centered\">141.0</td> <td class=\"centered\">121.4</td> <td class=\"centered\">123.5</td> <td class=\"centered\">127.0</td> <td class=\"centered\">131.0</td> <td class=\"centered\">135.1</td> <td class=\"centered\">138.8</td> <td class=\"centered\">141.0</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">99</td> <td class=\"centered\">100</td> <td class=\"centered\">57</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> <td class=\"centered\">59</td> <td class=\"centered\">59</td> <td class=\"centered\">60</td> <td class=\"centered\">60</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">112</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> <td class=\"centered\">72</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">112</td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">73</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">124</td> <td class=\"centered\">126</td> <td class=\"centered\">127</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">85</td> <td class=\"centered\">86</td> <td class=\"centered\">87</td> <td class=\"centered\">87</td> <td class=\"centered\">87</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">9 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">49.6</td> <td class=\"centered\">50.5</td> <td class=\"centered\">52.0</td> <td class=\"centered\">53.7</td> <td class=\"centered\">55.4</td> <td class=\"centered\">56.9</td> <td class=\"centered\">57.9</td> <td class=\"centered\">49.6</td> <td class=\"centered\">50.5</td> <td class=\"centered\">52.0</td> <td class=\"centered\">53.7</td> <td class=\"centered\">55.4</td> <td class=\"centered\">56.9</td> <td class=\"centered\">57.9</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">126.0</td> <td class=\"centered\">128.3</td> <td class=\"centered\">132.1</td> <td class=\"centered\">136.3</td> <td class=\"centered\">140.7</td> <td class=\"centered\">144.7</td> <td class=\"centered\">147.1</td> <td class=\"centered\">126.0</td> <td class=\"centered\">128.3</td> <td class=\"centered\">132.1</td> <td class=\"centered\">136.3</td> <td class=\"centered\">140.7</td> <td class=\"centered\">144.7</td> <td class=\"centered\">147.1</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">100</td> <td class=\"centered\">101</td> <td class=\"centered\">101</td> <td class=\"centered\">57</td> <td class=\"centered\">58</td> <td class=\"centered\">59</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">107</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">110</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">114</td> <td class=\"centered\">70</td> <td class=\"centered\">71</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">112</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">118</td> <td class=\"centered\">119</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">76</td> <td class=\"centered\">77</td> <td class=\"centered\">77</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">124</td> <td class=\"centered\">124</td> <td class=\"centered\">125</td> <td class=\"centered\">127</td> <td class=\"centered\">128</td> <td class=\"centered\">130</td> <td class=\"centered\">131</td> <td class=\"centered\">86</td> <td class=\"centered\">86</td> <td class=\"centered\">87</td> <td class=\"centered\">88</td> <td class=\"centered\">88</td> <td class=\"centered\">89</td> <td class=\"centered\">89</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">10 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">51.3</td> <td class=\"centered\">52.2</td> <td class=\"centered\">53.8</td> <td class=\"centered\">55.6</td> <td class=\"centered\">57.4</td> <td class=\"centered\">59.1</td> <td class=\"centered\">60.1</td> <td class=\"centered\">51.3</td> <td class=\"centered\">52.2</td> <td class=\"centered\">53.8</td> <td class=\"centered\">55.6</td> <td class=\"centered\">57.4</td> <td class=\"centered\">59.1</td> <td class=\"centered\">60.1</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">130.2</td> <td class=\"centered\">132.7</td> <td class=\"centered\">136.7</td> <td class=\"centered\">141.3</td> <td class=\"centered\">145.9</td> <td class=\"centered\">150.1</td> <td class=\"centered\">152.7</td> <td class=\"centered\">130.2</td> <td class=\"centered\">132.7</td> <td class=\"centered\">136.7</td> <td class=\"centered\">141.3</td> <td class=\"centered\">145.9</td> <td class=\"centered\">150.1</td> <td class=\"centered\">152.7</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> <td class=\"centered\">100</td> <td class=\"centered\">101</td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">59</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">72</td> <td class=\"centered\">73</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">114</td> <td class=\"centered\">116</td> <td class=\"centered\">118</td> <td class=\"centered\">120</td> <td class=\"centered\">121</td> <td class=\"centered\">76</td> <td class=\"centered\">76</td> <td class=\"centered\">77</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">124</td> <td class=\"centered\">125</td> <td class=\"centered\">126</td> <td class=\"centered\">128</td> <td class=\"centered\">130</td> <td class=\"centered\">132</td> <td class=\"centered\">133</td> <td class=\"centered\">88</td> <td class=\"centered\">88</td> <td class=\"centered\">89</td> <td class=\"centered\">89</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">11 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">53.0</td> <td class=\"centered\">54.0</td> <td class=\"centered\">55.7</td> <td class=\"centered\">57.6</td> <td class=\"centered\">59.6</td> <td class=\"centered\">61.3</td> <td class=\"centered\">62.4</td> <td class=\"centered\">53.0</td> <td class=\"centered\">54.0</td> <td class=\"centered\">55.7</td> <td class=\"centered\">57.6</td> <td class=\"centered\">59.6</td> <td class=\"centered\">61.3</td> <td class=\"centered\">62.4</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">134.7</td> <td class=\"centered\">137.3</td> <td class=\"centered\">141.5</td> <td class=\"centered\">146.4</td> <td class=\"centered\">151.3</td> <td class=\"centered\">155.8</td> <td class=\"centered\">158.6</td> <td class=\"centered\">134.7</td> <td class=\"centered\">137.3</td> <td class=\"centered\">141.5</td> <td class=\"centered\">146.4</td> <td class=\"centered\">151.3</td> <td class=\"centered\">155.8</td> <td class=\"centered\">158.6</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">99</td> <td class=\"centered\">99</td> <td class=\"centered\">101</td> <td class=\"centered\">102</td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">106</td> <td class=\"centered\">61</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">63</td> <td class=\"centered\">63</td> <td class=\"centered\">63</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">114</td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">118</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">76</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">114</td> <td class=\"centered\">114</td> <td class=\"centered\">116</td> <td class=\"centered\">118</td> <td class=\"centered\">120</td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">126</td> <td class=\"centered\">126</td> <td class=\"centered\">128</td> <td class=\"centered\">130</td> <td class=\"centered\">132</td> <td class=\"centered\">135</td> <td class=\"centered\">136</td> <td class=\"centered\">89</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">12 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">55.2</td> <td class=\"centered\">56.3</td> <td class=\"centered\">58.1</td> <td class=\"centered\">60.1</td> <td class=\"centered\">62.2</td> <td class=\"centered\">64.0</td> <td class=\"centered\">65.2</td> <td class=\"centered\">55.2</td> <td class=\"centered\">56.3</td> <td class=\"centered\">58.1</td> <td class=\"centered\">60.1</td> <td class=\"centered\">62.2</td> <td class=\"centered\">64.0</td> <td class=\"centered\">65.2</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">140.3</td> <td class=\"centered\">143.0</td> <td class=\"centered\">147.5</td> <td class=\"centered\">152.7</td> <td class=\"centered\">157.9</td> <td class=\"centered\">162.6</td> <td class=\"centered\">165.5</td> <td class=\"centered\">140.3</td> <td class=\"centered\">143.0</td> <td class=\"centered\">147.5</td> <td class=\"centered\">152.7</td> <td class=\"centered\">157.9</td> <td class=\"centered\">162.6</td> <td class=\"centered\">165.5</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">101</td> <td class=\"centered\">101</td> <td class=\"centered\">102</td> <td class=\"centered\">104</td> <td class=\"centered\">106</td> <td class=\"centered\">108</td> <td class=\"centered\">109</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">63</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">113</td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">117</td> <td class=\"centered\">119</td> <td class=\"centered\">121</td> <td class=\"centered\">122</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">76</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">118</td> <td class=\"centered\">121</td> <td class=\"centered\">124</td> <td class=\"centered\">126</td> <td class=\"centered\">128</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">79</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">130</td> <td class=\"centered\">133</td> <td class=\"centered\">136</td> <td class=\"centered\">138</td> <td class=\"centered\">140</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">91</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">13 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">57.9</td> <td class=\"centered\">59.1</td> <td class=\"centered\">61.0</td> <td class=\"centered\">63.1</td> <td class=\"centered\">65.2</td> <td class=\"centered\">67.1</td> <td class=\"centered\">68.3</td> <td class=\"centered\">57.9</td> <td class=\"centered\">59.1</td> <td class=\"centered\">61.0</td> <td class=\"centered\">63.1</td> <td class=\"centered\">65.2</td> <td class=\"centered\">67.1</td> <td class=\"centered\">68.3</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">147.0</td> <td class=\"centered\">150.0</td> <td class=\"centered\">154.9</td> <td class=\"centered\">160.3</td> <td class=\"centered\">165.7</td> <td class=\"centered\">170.5</td> <td class=\"centered\">173.4</td> <td class=\"centered\">147.0</td> <td class=\"centered\">150.0</td> <td class=\"centered\">154.9</td> <td class=\"centered\">160.3</td> <td class=\"centered\">165.7</td> <td class=\"centered\">170.5</td> <td class=\"centered\">173.4</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">103</td> <td class=\"centered\">104</td> <td class=\"centered\">105</td> <td class=\"centered\">108</td> <td class=\"centered\">110</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">61</td> <td class=\"centered\">60</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">65</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">118</td> <td class=\"centered\">121</td> <td class=\"centered\">124</td> <td class=\"centered\">126</td> <td class=\"centered\">126</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">77</td> <td class=\"centered\">77</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">122</td> <td class=\"centered\">125</td> <td class=\"centered\">128</td> <td class=\"centered\">130</td> <td class=\"centered\">131</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">78</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">81</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">131</td> <td class=\"centered\">132</td> <td class=\"centered\">134</td> <td class=\"centered\">137</td> <td class=\"centered\">140</td> <td class=\"centered\">142</td> <td class=\"centered\">143</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">90</td> <td class=\"centered\">92</td> <td class=\"centered\">93</td> <td class=\"centered\">93</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">14 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">60.6</td> <td class=\"centered\">61.8</td> <td class=\"centered\">63.8</td> <td class=\"centered\">65.9</td> <td class=\"centered\">68.0</td> <td class=\"centered\">69.8</td> <td class=\"centered\">70.9</td> <td class=\"centered\">60.6</td> <td class=\"centered\">61.8</td> <td class=\"centered\">63.8</td> <td class=\"centered\">65.9</td> <td class=\"centered\">68.0</td> <td class=\"centered\">69.8</td> <td class=\"centered\">70.9</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">153.8</td> <td class=\"centered\">156.9</td> <td class=\"centered\">162.0</td> <td class=\"centered\">167.5</td> <td class=\"centered\">172.7</td> <td class=\"centered\">177.4</td> <td class=\"centered\">180.1</td> <td class=\"centered\">153.8</td> <td class=\"centered\">156.9</td> <td class=\"centered\">162.0</td> <td class=\"centered\">167.5</td> <td class=\"centered\">172.7</td> <td class=\"centered\">177.4</td> <td class=\"centered\">180.1</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">105</td> <td class=\"centered\">106</td> <td class=\"centered\">109</td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">113</td> <td class=\"centered\">60</td> <td class=\"centered\">60</td> <td class=\"centered\">62</td> <td class=\"centered\">64</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">119</td> <td class=\"centered\">120</td> <td class=\"centered\">123</td> <td class=\"centered\">126</td> <td class=\"centered\">127</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">74</td> <td class=\"centered\">74</td> <td class=\"centered\">75</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">123</td> <td class=\"centered\">125</td> <td class=\"centered\">127</td> <td class=\"centered\">130</td> <td class=\"centered\">132</td> <td class=\"centered\">133</td> <td class=\"centered\">134</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">83</td> <td class=\"centered\">84</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">135</td> <td class=\"centered\">137</td> <td class=\"centered\">139</td> <td class=\"centered\">142</td> <td class=\"centered\">144</td> <td class=\"centered\">145</td> <td class=\"centered\">146</td> <td class=\"centered\">89</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">93</td> <td class=\"centered\">94</td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">15 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">62.6</td> <td class=\"centered\">63.8</td> <td class=\"centered\">65.7</td> <td class=\"centered\">67.8</td> <td class=\"centered\">69.8</td> <td class=\"centered\">71.5</td> <td class=\"centered\">72.5</td> <td class=\"centered\">62.6</td> <td class=\"centered\">63.8</td> <td class=\"centered\">65.7</td> <td class=\"centered\">67.8</td> <td class=\"centered\">69.8</td> <td class=\"centered\">71.5</td> <td class=\"centered\">72.5</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">159.0</td> <td class=\"centered\">162.0</td> <td class=\"centered\">166.9</td> <td class=\"centered\">172.2</td> <td class=\"centered\">177.2</td> <td class=\"centered\">181.6</td> <td class=\"centered\">184.2</td> <td class=\"centered\">159.0</td> <td class=\"centered\">162.0</td> <td class=\"centered\">166.9</td> <td class=\"centered\">172.2</td> <td class=\"centered\">177.2</td> <td class=\"centered\">181.6</td> <td class=\"centered\">184.2</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">108</td> <td class=\"centered\">110</td> <td class=\"centered\">112</td> <td class=\"centered\">113</td> <td class=\"centered\">114</td> <td class=\"centered\">114</td> <td class=\"centered\">114</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">64</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">123</td> <td class=\"centered\">124</td> <td class=\"centered\">126</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">130</td> <td class=\"centered\">130</td> <td class=\"centered\">75</td> <td class=\"centered\">76</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">81</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">127</td> <td class=\"centered\">129</td> <td class=\"centered\">131</td> <td class=\"centered\">132</td> <td class=\"centered\">134</td> <td class=\"centered\">135</td> <td class=\"centered\">135</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">81</td> <td class=\"centered\">83</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">85</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">139</td> <td class=\"centered\">141</td> <td class=\"centered\">143</td> <td class=\"centered\">144</td> <td class=\"centered\">146</td> <td class=\"centered\">147</td> <td class=\"centered\">147</td> <td class=\"centered\">90</td> <td class=\"centered\">91</td> <td class=\"centered\">93</td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">97</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">16 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">63.8</td> <td class=\"centered\">64.9</td> <td class=\"centered\">66.8</td> <td class=\"centered\">68.8</td> <td class=\"centered\">70.7</td> <td class=\"centered\">72.4</td> <td class=\"centered\">73.4</td> <td class=\"centered\">63.8</td> <td class=\"centered\">64.9</td> <td class=\"centered\">66.8</td> <td class=\"centered\">68.8</td> <td class=\"centered\">70.7</td> <td class=\"centered\">72.4</td> <td class=\"centered\">73.4</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">162.1</td> <td class=\"centered\">165.0</td> <td class=\"centered\">169.6</td> <td class=\"centered\">174.6</td> <td class=\"centered\">179.5</td> <td class=\"centered\">183.8</td> <td class=\"centered\">186.4</td> <td class=\"centered\">162.1</td> <td class=\"centered\">165.0</td> <td class=\"centered\">169.6</td> <td class=\"centered\">174.6</td> <td class=\"centered\">179.5</td> <td class=\"centered\">183.8</td> <td class=\"centered\">186.4</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">111</td> <td class=\"centered\">112</td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">116</td> <td class=\"centered\">63</td> <td class=\"centered\">64</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">69</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">126</td> <td class=\"centered\">127</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">131</td> <td class=\"centered\">131</td> <td class=\"centered\">132</td> <td class=\"centered\">77</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">82</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">130</td> <td class=\"centered\">131</td> <td class=\"centered\">133</td> <td class=\"centered\">134</td> <td class=\"centered\">135</td> <td class=\"centered\">136</td> <td class=\"centered\">137</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">83</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">86</td> <td class=\"centered\">86</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">142</td> <td class=\"centered\">143</td> <td class=\"centered\">145</td> <td class=\"centered\">146</td> <td class=\"centered\">147</td> <td class=\"centered\">148</td> <td class=\"centered\">149</td> <td class=\"centered\">92</td> <td class=\"centered\">93</td> <td class=\"centered\">95</td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">98</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"15\">17 years</td> </tr> <tr> <td class=\"indent1\">Height (in)</td> <td class=\"centered\">64.5</td> <td class=\"centered\">65.5</td> <td class=\"centered\">67.3</td> <td class=\"centered\">69.2</td> <td class=\"centered\">71.1</td> <td class=\"centered\">72.8</td> <td class=\"centered\">73.8</td> <td class=\"centered\">64.5</td> <td class=\"centered\">65.5</td> <td class=\"centered\">67.3</td> <td class=\"centered\">69.2</td> <td class=\"centered\">71.1</td> <td class=\"centered\">72.8</td> <td class=\"centered\">73.8</td> </tr> <tr> <td class=\"indent1\">Height (cm)</td> <td class=\"centered\">163.8</td> <td class=\"centered\">166.5</td> <td class=\"centered\">170.9</td> <td class=\"centered\">175.8</td> <td class=\"centered\">180.7</td> <td class=\"centered\">184.9</td> <td class=\"centered\">187.5</td> <td class=\"centered\">163.8</td> <td class=\"centered\">166.5</td> <td class=\"centered\">170.9</td> <td class=\"centered\">175.8</td> <td class=\"centered\">180.7</td> <td class=\"centered\">184.9</td> <td class=\"centered\">187.5</td> </tr> <tr> <td class=\"indent1\">50<sup>th</sup></td> <td class=\"centered\">114</td> <td class=\"centered\">115</td> <td class=\"centered\">116</td> <td class=\"centered\">117</td> <td class=\"centered\">117</td> <td class=\"centered\">118</td> <td class=\"centered\">118</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">67</td> <td class=\"centered\">68</td> <td class=\"centered\">69</td> <td class=\"centered\">70</td> <td class=\"centered\">70</td> </tr> <tr> <td class=\"indent1\">90<sup>th</sup></td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> <td class=\"centered\">130</td> <td class=\"centered\">131</td> <td class=\"centered\">132</td> <td class=\"centered\">133</td> <td class=\"centered\">134</td> <td class=\"centered\">78</td> <td class=\"centered\">79</td> <td class=\"centered\">80</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">82</td> <td class=\"centered\">83</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup></td> <td class=\"centered\">132</td> <td class=\"centered\">133</td> <td class=\"centered\">134</td> <td class=\"centered\">135</td> <td class=\"centered\">137</td> <td class=\"centered\">138</td> <td class=\"centered\">138</td> <td class=\"centered\">81</td> <td class=\"centered\">82</td> <td class=\"centered\">84</td> <td class=\"centered\">85</td> <td class=\"centered\">86</td> <td class=\"centered\">86</td> <td class=\"centered\">87</td> </tr> <tr> <td class=\"indent1\">95<sup>th</sup> + 12 mmHg</td> <td class=\"centered\">144</td> <td class=\"centered\">145</td> <td class=\"centered\">146</td> <td class=\"centered\">147</td> <td class=\"centered\">149</td> <td class=\"centered\">150</td> <td class=\"centered\">150</td> <td class=\"centered\">93</td> <td class=\"centered\">94</td> <td class=\"centered\">96</td> <td class=\"centered\">97</td> <td class=\"centered\">98</td> <td class=\"centered\">98</td> <td class=\"centered\">99</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The 50<SUP>th</SUP>, 90<SUP>th</SUP>, and 95<SUP>th</SUP> percentiles were derived by using quantile regression on the basis of normal-weight children (BMI &lt;85<SUP>th</SUP> percentile). BP stages are defined as elevated BP ≥90<SUP>th</SUP> percentile but &lt;95<SUP>th</SUP> percentile; stage 1 HTN: ≥95<SUP>th</SUP> percentile or 130/80 to 139/89 mmHg; and stage 2 HTN: ≥95<SUP>th</SUP> percentile + 12 mmHg or &gt;140/90 mmHg.</div><div class=\"graphic_footnotes\">BP: blood pressure; BMI:&nbsp;body mass index;&nbsp;HTN: hypertension</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatrics, Vol. 140, doi: 10.1542/peds.2017-1904. Copyright © 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 63856 Version 10.0</div></div></div>"},"63857":{"type":"graphic_figure","displayName":"LDL phenotypes and HDL","title":"LDL phenotypes and HDL-cholesterol","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">LDL phenotypes and HDL-cholesterol</div><div class=\"cntnt\"><img style=\"width:462px; height:255px;\" src=\"images/CARD/63857_LDL_phenotypes_and_HDL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percent cumulative frequency of HDL-cholesterol levels according to LDL phenotypes A and B. Phenotype B (solid line) is associated with lower HDL levels and a higher risk of coronary heart disease.</div><div class=\"graphic_reference\">Data from Austin MA, King MC, Vranizan KM, Krauss RM. Circulation 1990; 82:495.</div><div id=\"graphicVersion\">Graphic 63857 Version 2.0</div></div></div>"},"63858":{"type":"graphic_table","displayName":"Diagnosis autoimmune hepatitis","title":"Differential diagnosis of autoimmune hepatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of autoimmune hepatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Other autoimmune liver diseases</td> </tr> <tr> <td>Primary biliary cholangitis</td> </tr> <tr> <td>Primary sclerosing cholangitis</td> </tr> <tr> <td>Autoimmune hepatitis/primary biliary cholangitis overlap syndrome</td> </tr> <tr> <td>Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome</td> </tr> <tr> <td>Autoimmune cholangiopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic viral hepatitis</td> </tr> <tr> <td>Chronic hepatitis B</td> </tr> <tr> <td>Chronic hepatitis C</td> </tr> <tr> <td>Chronic hepatitis delta</td> </tr> <tr> <td>Chronic hepatitis due to other viruses</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Chronic drug-induced hepatitis</td> </tr> <tr> <td>Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Cholangiopathy related to AIDS</td> </tr> <tr> <td class=\"sublist1_start\">Steatohepatitis</td> </tr> <tr> <td class=\"sublist1\">Nonalcoholic</td> </tr> <tr> <td class=\"sublist1\">Alcoholic</td> </tr> <tr> <td>Granulomatous hepatitis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td>Cryptogenic chronic hepatitis or cirrhosis</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Iron overload/hemochromatosis</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63858 Version 4.0</div></div></div>"},"63859":{"type":"graphic_table","displayName":"Factors in SCD in dialysis patients","title":"Factors that contribute to sudden cardiac death (SCD) in dialysis patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that contribute to sudden cardiac death (SCD) in dialysis patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Coronary artery disease/myocardial infarction</td> </tr> <tr> <td>Significant left ventricular hypertrophy</td> </tr> <tr> <td>Anemia/calcium/phosphorus/parathyroid hormone</td> </tr> <tr> <td>Uremia</td> </tr> <tr> <td>Chronic fluid overload</td> </tr> <tr> <td>Inflammation</td> </tr> <tr> <td>Electrolyte abnormalities</td> </tr> <tr> <td>Autonomic imbalance</td> </tr> <tr> <td>Heart failure/decreased left ventricular function</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63859 Version 3.0</div></div></div>"},"63862":{"type":"graphic_figure","displayName":"Dorsal cord syndrome","title":"Location of lesion in dorsal cord syndrome","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Location of lesion in dorsal cord syndrome</div><div class=\"cntnt\"><img style=\"width:542px; height:353px;\" src=\"images/NEURO/63862_Dorsal_cord_syndrome.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63862 Version 2.0</div></div></div>"},"63863":{"type":"graphic_diagnosticimage","displayName":"Amniotic band sequence with abdominal wall defect","title":"Amniotic band sequence with abdominal wall defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniotic band sequence with abdominal wall defect</div><div class=\"cntnt\"><img style=\"width:428px; height:318px;\" src=\"images/OBGYN/63863_ABS_abd_wall_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal image through the fetal body shows disruption of the anterior abdominal wall with the abdominal contents (arrows) extruding out.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 63863 Version 2.0</div></div></div>"},"63864":{"type":"graphic_picture","displayName":"Perioral dermatitis in child","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:367px;\" src=\"images/DERM/63864_Perioral_dermatitis_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules are present around the oral cavity in this child. Note the relative sparing of skin around the border of the lip.</div><div class=\"graphic_reference\">Reprinted by permission of Edizioni Minerva Medica from G Ital Dermatol Venereol 2010; 145:433. Copyright &#169; 2010. All rights reserved.</div><div id=\"graphicVersion\">Graphic 63864 Version 1.0</div></div></div>"},"63865":{"type":"graphic_diagnosticimage","displayName":"Fracture dislocation of metacarpal joint of the middle finger","title":"Fracture dislocation of the metacarpal joint of the middle finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture dislocation of the metacarpal joint of the middle finger</div><div class=\"cntnt\"><img style=\"width:444px; height:320px;\" src=\"images/EM/63865_Fingerfxdislocationchild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 9-year-old girl sustained this radial fracture-dislocation of the middle finger. <br />(B) Closed reduction restored joint and fracture alignment.</div><div class=\"graphic_reference\">Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63865 Version 12.0</div></div></div>"},"63867":{"type":"graphic_picture","displayName":"Aplastic anemia bone marrow","title":"Bone marrow biopsy in aplastic anemia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow biopsy in aplastic anemia</div><div class=\"cntnt\"><img style=\"width:436px; height:288px;\" src=\"images/HEME/63867_Aplastic_anemia_bone_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy in aplastic anemia. There are virtually no hematopoietic cells, and the marrow space consists of fat and stroma.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 63867 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal bone marrow biopsy at low power</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/68384_Normal_bone_marrow_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 68384 Version 2.0</div></div></div>"},"63868":{"type":"graphic_picture","displayName":"BDCA1 immunoreactive mixed with other inflammatory cells in IBM","title":"BDCA1 immunoreactive mixed with other inflammatory cells in IBM","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">BDCA1 immunoreactive mixed with other inflammatory cells in IBM</div><div class=\"cntnt\"><img style=\"width:490px; height:369px;\" src=\"images/RHEUM/63868_BDCA1_mixed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myeloid dendritic cells (BDCA1 immunoreactive) mixed with other inflammatory cells in inclusion body myositis muscle.</div><div class=\"graphic_reference\">Courtesy of Steven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 63868 Version 1.0</div></div></div>"},"63869":{"type":"graphic_figure","displayName":"Anatomy of the liver - posterior view","title":"Anatomy of the liver - posterior view","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anatomy of the liver - posterior view</div><div class=\"cntnt\"><img style=\"width:538px; height:383px;\" src=\"images/SURG/63869_Anatliverposteriorview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is the posterior view of the liver. The left triangular ligament is a fold of peritoneal tissue that attaches the liver to the diaphragm. Division of the peritoneal attachment allows for access to the esophageal hiatus and intra-abdominal esophagus.</div><div id=\"graphicVersion\">Graphic 63869 Version 4.0</div></div></div>"},"63870":{"type":"graphic_figure","displayName":"Dermoscopic structures 2","title":"Dermoscopic structures most commonly seen in melanocytic neoplasms and their histopathologic correlation<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures most commonly seen in melanocytic neoplasms and their histopathologic correlation<sup>[1-3]</sup></div><div class=\"cntnt\"><img style=\"width:596px; height:971px;\" src=\"images/DERM/63870_Dermoscopicstruct2edt4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a continuation of figure \"Criteria for melanocytic neoplasms and their histopathologic correlation.\"</div><div class=\"graphic_footnotes\">DEJ: dermo-epidermal junction. <br />* Shiny, white structures can also be seen in nonmelanocytic lesions. Crystalline structures are most common in melanoma. Both crystalline structures and shiny, white areas are common in dermatofibromas and basal cell carcinomas. Rosettes are more common in actinic keratoses and squamous cell carcinomas.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.</li>&#xD;&#xA;    <li>Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571.</li>&#xD;&#xA;    <li>Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759.</li>&#xD;&#xA;    <li>Braun RP, Gaide O, Oliviero M, et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007; 157:907.</li>&#xD;&#xA;    <li>Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2012; 67:194.e1.</li>&#xD;&#xA;    <li>Cuellar F, Vilalta A, Puig S, et al. New dermoscopic pattern in actinic keratosis and related conditions. Arch Dermatol 2009; 145:732.</li>&#xD;&#xA;    <li>Navarrete-Dechent C, Bajaj S, Marchetti MA, et al. Association of shiny white blotches and strands with nonpigmented basal cell carcinoma: Evaluation of an additional dermoscopic diagnostic criterion. JAMA Dermatol 2016; 152:546.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 63870 Version 10.0</div></div></div>"},"63871":{"type":"graphic_figure","displayName":"Side view of neck bones and muscles","title":"Side view of neck bones and muscles","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Side view of neck bones and muscles</div><div class=\"cntnt\"><img style=\"width:457px; height:531px;\" src=\"images/PC/63871_Side-view-of-neck-edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63871 Version 1.0</div></div></div>"},"63874":{"type":"graphic_table","displayName":"Indic for karyotype","title":"Decision tree – Indications for sending tissue for cytogenetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Decision tree&nbsp;– Indications for sending tissue for cytogenetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Clinician request</td> </tr> <tr> <td>Third loss, does not need to be consecutive</td> </tr> <tr> <td>Nonimmune hydrops fetalis</td> </tr> <tr> <td>Severe growth restriction (&#60;3<sup>rd</sup> percentile by best estimate of gestational age)</td> </tr> <tr> <td>One anomaly in first-trimester loss</td> </tr> <tr> <td>Two anomalies for all other losses</td> </tr> <tr> <td>Single, \"specific\" anomaly (eg, <span style=\"color: black;\">complete common&nbsp;atrioventricular </span>canal defect)</td> </tr> <tr> <td>Known maternal or paternal balanced translocation</td> </tr> <tr> <td>Verification of abnormal amniotic fluid-based karyotype</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63874 Version 3.0</div></div></div>"},"63875":{"type":"graphic_diagnosticimage","displayName":"Dysostosis metacarpal","title":"Dysostosis metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dysostosis metacarpal</div><div class=\"cntnt\"><img style=\"width:260px; height:393px;\" src=\"images/PEDS/63875_Dysostosis_metacarpal_ed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysostosis multiplex manifested as proximal pointing of metacarpals.</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 63875 Version 3.0</div></div></div>"},"63877":{"type":"graphic_figure","displayName":"WHO weight for age girls 0 to 24 months","title":"Weight-for-age percentiles, girls 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Weight-for-age percentiles, girls 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:573px; height:532px;\" src=\"images/PEDS/63877_WHO_wt_age_girls_0to2yrs_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 63877 Version 5.0</div></div></div>"},"63878":{"type":"graphic_figure","displayName":"Patterns of airflow","title":"Patterns of airflow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patterns of airflow</div><div class=\"cntnt\"><img style=\"width:310px; height:467px;\" src=\"images/PULM/63878_Patterns_of_airflow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Laminar flow.<br />(B) Turbulent flow.<br />(C)&nbsp;Transition flow at a bifurcation. EL is the entrance length, the distance required to re-establish laminar flow.</div><div id=\"graphicVersion\">Graphic 63878 Version 2.0</div></div></div>"},"63880":{"type":"graphic_figure","displayName":"AV nodal conduction in EAVNC","title":"Patterns of AV nodal conduction in EAVNC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patterns of AV nodal conduction in EAVNC</div><div class=\"cntnt\"><img style=\"width:386px; height:280px;\" src=\"images/CARD/63880_AV_nodal_conduction_in_EAVN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrial to His (A-H) interval, which represents atrioventricular (AV) nodal conduction time, is plotted against the pacing cycle length or A1-A2 interval. The normal response is a progressive lengthening of the AH interval with a shorter pacing cycle length (ie, faster heart rate), a phenomenon known as decremental conduction. In patients with enhanced AV nodal conduction (EAVNC), four patterns of response are seen. Type I represents reduced AH interval prolongation in response to atrial pacing; type II shows an initial increase in the AH interval followed by a plateau and then a further increase in the AH interval with faster pacing rates; type III reveals no change in AH interval in response to increasing atrial pacing rates; type IV represents no change in AH interval until the pacing cycle lengths are very short, thereby resulting in marked AH prolongation.</div><div id=\"graphicVersion\">Graphic 63880 Version 1.0</div></div></div>"},"63881":{"type":"graphic_table","displayName":"Susceptibility of pneumococci","title":"Interpretive breakpoints for <em>Streptococcus pneumoniae</em> for selected antibiotics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretive breakpoints for <em>Streptococcus pneumoniae</em> for selected antibiotics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antibiotic </td> <td class=\"subtitle1\">Susceptible </td> <td class=\"subtitle1\">Intermediate </td> <td class=\"subtitle1\">Resistant </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Penicillin G (parenteral) </td> </tr> <tr> <td class=\"sublist1\">Meningitis </td> <td class=\"sublist_other\">&#8804;0.06 mcg/mL </td> <td class=\"sublist_other\">&ndash;&nbsp;</td> <td class=\"sublist_other\">&#8805;0.12 mcg/mL </td> </tr> <tr> <td class=\"sublist1\">Non-meningitis* </td> <td class=\"sublist_other\">&#8804;2 mcg/mL </td> <td class=\"sublist_other\">4 mcg/mL </td> <td class=\"sublist_other\">&#8805;8 mcg/mL </td> </tr> <tr> <td>Penicillin V (oral)*</td> <td>&#8804;0.06 mcg/mL</td> <td>0.12 to 1 mcg/mL</td> <td>&#8805;2 mcg/mL</td> </tr> <tr> <td>Amoxicillin (non-meningitis)</td> <td>&#8804;2 mcg/mL</td> <td>4 mcg/mL</td> <td>&#8805;8 mcg/mL</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Cefuroxime </td> </tr> <tr> <td class=\"sublist1\">Parenteral </td> <td class=\"sublist_other\">&#8804;0.5 mcg/mL </td> <td class=\"sublist_other\">1 mcg/mL </td> <td class=\"sublist_other\">&#8805;2 mcg/mL </td> </tr> <tr> <td class=\"sublist1\">Oral </td> <td class=\"sublist_other\">&#8804;1 mcg/mL </td> <td class=\"sublist_other\">2 mcg/mL </td> <td class=\"sublist_other\">&#8805;4 mcg/mL </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Cefotaxime, Ceftriaxone </td> </tr> <tr> <td class=\"sublist1\">Meningitis </td> <td class=\"sublist_other\">&#8804;0.5 mcg/mL </td> <td class=\"sublist_other\">1 mcg/mL </td> <td class=\"sublist_other\">&#8805;2 mcg/mL </td> </tr> <tr> <td class=\"sublist1\">Non-meningitis </td> <td class=\"sublist_other\">&#8804;1 mcg/mL </td> <td class=\"sublist_other\">2 mcg/mL </td> <td class=\"sublist_other\">&#8805;4 mcg/mL </td> </tr> <tr> <td>Cefpodoxime</td> <td>&#8804;0.5 mcg/mL</td> <td>1 mcg/mL</td> <td>&#8805;2 mcg/mL</td> </tr> <tr> <td>Cefdinir</td> <td>&#8804;0.5 mcg/mL</td> <td>1 mcg/mL</td> <td>&#8805;2 mcg/mL</td> </tr> <tr> <td>Clindamycin</td> <td>&#8804;0.25 mcg/mL</td> <td>0.5 mcg/mL</td> <td>&#8805;1 mcg/mL</td> </tr> <tr> <td>Rifampin</td> <td>&#8804;1 mcg/mL</td> <td>2 mcg/mL</td> <td>&#8805;4 mcg/mL</td> </tr> <tr> <td>Azithromycin</td> <td>&#8804;0.5 mcg/mL</td> <td>1 mcg/mL</td> <td>&#8805;2 mcg/mL</td> </tr> <tr> <td>Clarithromycin</td> <td>&#8804;0.25 mcg/mL</td> <td>0.5 mcg/mL</td> <td>&#8805;2 mcg/mL</td> </tr> <tr> <td>Gemifloxacin</td> <td>&#8804;0.12 mcg/mL</td> <td>0.25 mcg/mL</td> <td>&#8805;0.5 mcg/mL</td> </tr> <tr> <td>Levofloxacin</td> <td>&#8804;2 mcg/mL</td> <td>4 mcg/mL</td> <td>&#8805;8 mcg/mL</td> </tr> <tr> <td>Moxifloxacin</td> <td>&#8804;1 mcg/mL</td> <td>2 mcg/mL</td> <td>&#8805;4 mcg/mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">When the E-test is used to determine minimum inhibitory concentrations (MICs), exact results are reported rather than the twofold dilutions that were used when the cut-offs were defined. An MIC value that falls between standard twofold dilutions must therefore be rounded up to the next dilution in order to be categorized. As an example, an <EM>S. pneumoniae</EM> isolate from a patient with meningitis with a cefotaxime/ceftriaxone MIC of 1.5 mcg/mL would be rounded up to 2 mcg/mL and would be considered resistant.</div><div class=\"graphic_footnotes\">* For non-meningitis isolates, the penicillin MIC can predict susceptibility to other beta-lactams as follows:<br /><UL>&#xD;&#xA;<LI>Penicillin MICs ≤0.06 mcg/mL indicate susceptibility to ampicillin (oral or parenteral), ampicillin-sulbactam, cefaclor, cefdinir, cefditoren, cefpodoxime, cefprozil, ceftizoxime, cefuroxime, imipenem, loracarbef, and meropenem.</LI>&#xD;&#xA;<LI>Penicillin MICs ≤2 mcg/mL indicate susceptibility to amoxicillin, amoxicillin-clavulanate, cefepime, cefotaxime, ceftriaxone, and ertapenem.</LI></UL></div><div class=\"graphic_reference\">Data from: Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA, 2009.</div><div id=\"graphicVersion\">Graphic 63881 Version 6.0</div></div></div>"},"63883":{"type":"graphic_picture","displayName":"Intraluminal calcified meconium","title":"Intraluminal calcified meconium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraluminal calcified meconium</div><div class=\"cntnt\"><img style=\"width:393px; height:260px;\" src=\"images/OBGYN/63883_Intraluminal_cal_meconium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraluminal calcified meconium present in an autolyzed 16 week fetus. This finding is seen often in Trisomy 21 but can also be seen in cases of intestinal atresias or in congenital cystic fibrosis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 63883 Version 2.0</div></div></div>"},"63884":{"type":"graphic_picture","displayName":"Henoch Schonlein PI","title":"Rash in a person with Henoch-Schönlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Rash in a person with Henoch-Schönlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/63884_Henoch_Schonlein_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Susan Kim, MD.</div><div id=\"graphicVersion\">Graphic 63884 Version 2.0</div></div></div>"},"63885":{"type":"graphic_diagnosticimage","displayName":"CPAM prenatal ultrasound_width x height","title":"Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/PEDS/63885_CCAM_prenat_USG_WH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After measuring the longest dimension of the lesion (L), the probe is turned 90 degrees and the \"width\" (W) and \"height\" (H) of the lesion are measured. The L x W x H x 0.52 = volume of CPAM. The CPAM volume ratio (CVR) is then calculated by dividing the CPAM volume by the head circumference.</div><div class=\"graphic_footnotes\">* CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).</div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, MD and Andrew P Schuller, RDMS.</div><div id=\"graphicVersion\">Graphic 63885 Version 6.0</div></div></div>"},"63886":{"type":"graphic_diagnosticimage","displayName":"Abnormal lateral elbow","title":"Abnormal lateral elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormal lateral elbow</div><div class=\"cntnt\"><img style=\"width:360px; height:354px;\" src=\"images/EM/63886_Abnormallateralelbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the elbow of a 2-year-old girl. Both the anterior and posterior fat pads are elevated (small arrows). In addition, the anterior humeral line passes along the anterior edge of the capitellum rather than through its center. Mild buckling of the posterior cortex of the distal humerus can be seen (large arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Bachman D, Santora S. Musculoskeletal trauma. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63886 Version 14.0</div></div></div>"},"63887":{"type":"graphic_picture","displayName":"Pseudopapill neoplasm gross","title":"Gross image of pseudopapillary neoplasm of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross image of pseudopapillary neoplasm of the pancreas</div><div class=\"cntnt\"><img style=\"width:450px; height:338px;\" src=\"images/GAST/63887_Pseudopapill_neoplasm_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corresponding gross image of the solid pseudopapillary neoplasm depicted in Radiograph 5.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.</div><div id=\"graphicVersion\">Graphic 63887 Version 2.0</div></div></div>"},"63888":{"type":"graphic_picture","displayName":"Mycosis fungoides poikiloderma","title":"Mycosis fungoides - poikiloderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - poikiloderma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/HEME/63888_Mycosis_fungoides_poikilo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A poikilodermatous patch exhibiting red-brown mottled pigmentation, telangiectasias, and subtle atrophy is present on the chest of this patient with mycosis fungoides.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63888 Version 6.0</div></div></div>"},"63889":{"type":"graphic_picture","displayName":"Sclerocornea","title":"Sclerocornea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sclerocornea</div><div class=\"cntnt\"><img style=\"width:432px; height:230px;\" src=\"images/PEDS/63889_Sclerocornea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-month-old with sclerocornea. Both corneas appear opaque with an undetectable limbus.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63889 Version 1.0</div></div></div>"},"63890":{"type":"graphic_table","displayName":"Pressure Ulcer Scale for Healing","title":"Pressure Ulcer Scale for Healing (PUSH)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pressure Ulcer Scale for Healing (PUSH)*</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Assessments</td>\n\t\t\t\t\t<td class=\"subtitle1\">Instructions</td>\n\t\t\t\t\t<td class=\"subtitle1\">Assign a subscore (cm<sup>2</sup>)</td>\n\t\t\t\t\t<td class=\"subtitle1\">Total the subscores</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"11\">Size (length x width)</td>\n\t\t\t\t\t<td rowspan=\"11\">Measure the greatest length and width using a centimeter ruler. Multiply the two measurements to obtain an estimate of surface area.</td>\n\t\t\t\t\t<td>0 - 0</td>\n\t\t\t\t\t<td class=\"subtitle2_left\">Subscore</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1 - &#60;0.3</td>\n\t\t\t\t    <td rowspan=\"10\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2 - 0.3-0.6</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3 - 0.7-1.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4 - 1.1-2.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5 - 2.1-3.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>6 - 3.1-4.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>7 - 4.1-8.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>8 - 8.1-12</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>9 - 12.1-24.0</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>10 - &#62;24</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"4\">Exudate</td>\n\t\t\t\t\t<td rowspan=\"4\">Estimate the amount of drainage after removal of the dressing.</td>\n\t\t\t\t\t<td>0 - None</td>\n\t\t\t\t\t<td class=\"subtitle2_left\">Subscore</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1 - Light</td>\n\t\t\t\t    <td rowspan=\"3\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2 - Moderate</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3 - Heavy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"5\">Tissue type</td>\n\t\t\t\t\t<td rowspan=\"5\">Assess the presence of sloughing or necrosis</td>\n\t\t\t\t\t<td>0 - Closed</td>\n\t\t\t\t\t<td class=\"subtitle2_left\">Subscore</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>1 - Epithelial tissue</td>\n\t\t\t\t    <td rowspan=\"4\">&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2 - Granulation tissue</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3 - Slough</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4 - Necrotic tissue</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"3\">Add together all subscores = </td>\n\t\t\t\t\t<td class=\"subtitle2_left\">Total score</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Changes in the score over time provide an indication of the healing process. The score goes down with improvement and increases with wound deterioration.</div><div class=\"graphic_footnotes\">* Version 3.0 National Pressure Ulcer Advisory Panel (www.npuap.org).</div><div class=\"graphic_reference\">Adapted with permission from: National Pressure Ulcer Advisory Panel. Version 3.0 Pressure Ulcer Scale for Healing (PUSH). Copyright &copy;1998 National Pressure Ulcer Advisory Panel.</div><div id=\"graphicVersion\">Graphic 63890 Version 3.0</div></div></div>"},"63891":{"type":"graphic_diagnosticimage","displayName":"Kerleys A lines PA","title":"Transfusion reaction due to leukoagglutinins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transfusion reaction due to leukoagglutinins</div><div class=\"cntnt\"><img style=\"width:364px; height:352px;\" src=\"images/PULM/63891_Kerleys_A_lines_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows so-called Kerley's A lines radiating from the hilar regions into the periphery of the lung on a background of pulmonary edema. The Kerley A lines are 2 to 4 cm in length and represent thickening of the axial interstitium.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 63891 Version 3.0</div></div></div>"},"63892":{"type":"graphic_table","displayName":"FDA pregnancy categories","title":"Food and Drug Administration pregnancy categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food and Drug Administration pregnancy categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Animal studies</td> <td class=\"subtitle1\">Human data</td> <td class=\"subtitle1\">Benefit may outweigh risk</td> </tr> <tr> <td>A</td> <td>Negative*</td> <td>Studies<sup>&#182;</sup> negative</td> <td>Yes</td> </tr> <tr> <td>B</td> <td>Negative</td> <td>Studies not done</td> <td>Yes</td> </tr> <tr> <td>B</td> <td>Positive<sup>&#916;</sup></td> <td>Studies negative</td> <td>Yes</td> </tr> <tr> <td>C</td> <td>Positive</td> <td>Studies not done</td> <td>Yes</td> </tr> <tr> <td>C</td> <td>Not done</td> <td>Studies not done</td> <td>Yes</td> </tr> <tr> <td>D</td> <td>Positive or negative</td> <td>Studies or reports positive</td> <td>Yes</td> </tr> <tr> <td>X<sup>&#9674;</sup></td> <td>Positive</td> <td>Studies or reports positive</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In 2015, the US Food &amp; Drug Administration (FDA) began overseeing the phase-out of pregnancy risk categories (A, B, C, D, and X) from prescription drug labeling and began requiring information from available human and animal studies of (1) known or potential maternal or fetal adverse reactions, and (2) dose adjustments needed during pregnancy and the postpartum period. Additional information is available at the FDA website: <A spellcheck=true href=\"http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm\">Pregnancy and Lactation Labeling Final Rule</A>.</div><div class=\"graphic_footnotes\">* No teratogenicity demonstrated<br />¶&nbsp;Adequate and well-controlled studies in pregnant women (Fed Reg 1979; 44:37461)<br />Δ Teratogenicity demonstrated<br />◊ Drug is contraindicated in pregnancy</div><div class=\"graphic_reference\">Reproduced with permission from: Schatz M, Hoffman CP, Zeiger RS, et al. The course and management of asthma and allergic diseases during pregnancy. In: Allergy: Principles and Practice, Middleton E, Reed CE, Ellis EF, et al (Eds), St. Louis, Mosby, 1998. Copyright © 1998 Mosby.</div><div id=\"graphicVersion\">Graphic 63892 Version 3.0</div></div></div>"},"63893":{"type":"graphic_table","displayName":"Hints early Dx FM","title":"Hints for early and cost-effective diagnosis of fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hints for early and cost-effective diagnosis of fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Chronic widespread musculoskeletal pain for &#8805;three months</td> </tr> <tr> <td>Absence of other systemic condition accounting for pain</td> </tr> <tr> <td>Excess tenderness in soft-tissues</td> </tr> <tr> <td class=\"sublist1_start\">Characteristic symptoms:</td> </tr> <tr> <td class=\"sublist1\">&#8226; \"I hurt all over\"</td> </tr> <tr> <td class=\"sublist1\">&#8226; \"It feels like I always have the flu\"</td> </tr> <tr> <td class=\"sublist1\">&#8226; Fatigue, sleep and mood disturbances</td> </tr> <tr> <td class=\"sublist1\">&#8226; IBS, irritable bladder, multiple other somatic complaints</td> </tr> <tr> <td class=\"sublist1_start\">Exclusion of structural or systemic disease</td> </tr> <tr> <td class=\"sublist1\">&#8226; Not a \"fishing\" expedition</td> </tr> <tr> <td class=\"sublist1\">&#8226; Avoid \"screening\" rheumatology tests</td> </tr> <tr> <td class=\"sublist1\">&#8226; Most efficient with early subspecialty referral</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBS: irritable bowel syndrome.</div><div class=\"graphic_reference\">Courtesy of Don L Goldenberg, MD.</div><div id=\"graphicVersion\">Graphic 63893 Version 3.0</div></div></div>"},"63894":{"type":"graphic_picture","displayName":"Acral lentiginous melanoma 3","title":"Acral lentiginous melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acral lentiginous melanoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/63894_Acral_lentig_melanoma_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerated melanoma of the plantar surface.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63894 Version 3.0</div></div></div>"},"63895":{"type":"graphic_waveform","displayName":"Basic case 2","title":"Basic case 2","html":"<div class=\"graphic normal\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Basic case 2</div><div class=\"cntnt\"><img style=\"width:478px; height:293px;\" src=\"images/CARD/63895_Basic_case_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63895 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"63897":{"type":"graphic_picture","displayName":"Purpura in pneumococcal sepsis","title":"Purpuric rash of pneumococcal sepsis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpuric rash of pneumococcal sepsis</div><div class=\"cntnt\"><img style=\"width:356px; height:227px;\" src=\"images/ID/63897_Purpura_in_pneumococcal_sep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpura with a reticular pattern on the abdomen and flank in an HIV-infected patient with pneumococcal pneumonia. Courtesy of Charles V Sanders, MD.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 63897 Version 5.0</div></div></div>"},"63898":{"type":"graphic_picture","displayName":"Strongyloides in stool","title":"<EM>Strongyloides stercoralis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Strongyloides stercoralis</EM></div><div class=\"cntnt\"><img style=\"width:359px; height:240px;\" src=\"images/ID/63898_Strongyloides_in_stool.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wet mount of stool (x100) shows the diagnostic larval form of <EM>Strongyloides stercoralis</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 63898 Version 2.0</div></div></div>"},"63899":{"type":"graphic_diagnosticimage","displayName":"Electroanatomic mapping normal","title":"Electroanatomic voltage map from a normal subject","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electroanatomic voltage map from a normal subject</div><div class=\"cntnt\"><img style=\"width:396px; height:403px;\" src=\"images/CARD/63899_Electroanatomicmappingnor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right ventricular (RV) voltage map in the right anterior oblique projection from a normal subject is obtained using electroanatomic mapping. The colors represent the amplitude of the local unipolar electrogram and blue and purple indicated normal unipolar voltage values (≥ 5 mV) throughout the RV.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium.</div><div class=\"graphic_reference\">Reproduced with permission from: Boulos M, Lashevsky I, Reisner S, Gepstein L. J Am Coll Cardiol 2001; 38:2020. Copyright © 2001 American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 63899 Version 4.0</div></div></div>"},"63900":{"type":"graphic_picture","displayName":"Insect sting reaction PI","title":"Insect sting","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insect sting</div><div class=\"cntnt\"><img style=\"width:396px; height:344px;\" src=\"images/PI/63900_InsectstingreactionPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a normal reaction to a bee or wasp sting. There is usually some redness and mild, painful swelling around the spot where the stinger went in. These symptoms usually go away within a few hours.</div><div class=\"graphic_reference\">Courtesy of Theodore Freeman, MD.</div><div id=\"graphicVersion\">Graphic 63900 Version 3.0</div></div></div>"},"63903":{"type":"graphic_table","displayName":"Neutropenia and infectious risk","title":"Relation of non-chemotherapy-related neutropenia and infection risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relation of non-chemotherapy-related neutropenia and infection risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Absolute neutrophil count</td> <td class=\"subtitle1\">Risk management</td> </tr> <tr> <td>&#62;1500/microL (&#62;1.5 x 10<sup>9</sup>/liter)</td> <td>None</td> </tr> <tr> <td>1000 to 1500/microL</td> <td>No significant risk of infection; fever can be managed on an outpatient basis</td> </tr> <tr> <td>500 to 999/microL</td> <td>Some risk of infection; fever can occasionally be managed on an outpatient basis</td> </tr> <tr> <td>200 to 499/microL</td> <td>Significant risk of infection; fever should always be managed on an inpatient basis with parenteral antibiotics; few clinical signs of infection</td> </tr> <tr> <td>&#60;200/microL</td> <td>Very significant risk of infection; fever should always be managed on an inpatient basis with parenteral antibiotics; few or no clinical signs of infection</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The correlation between absolute neutrophil count and infectious risk only applies to conditions in which the bone marrow neutrophil reserve is diminished. Refer to UpToDate topics on neutropenia for further discussions of the causes of neutropenia and the estimation of infectious risk.</div><div id=\"graphicVersion\">Graphic 63903 Version 10.0</div></div></div>"},"63904":{"type":"graphic_table","displayName":"Causes persistent tearing in children","title":"Causes of persistent tearing with or without eye redness or discharge in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of persistent tearing with or without eye redness or discharge in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Characteristic clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nasolacrimal duct obstruction</td> </tr> <tr> <td class=\"indent1\">Simple</td> <td>Increased tear meniscus; reflux of tears/mucoid discharge through puncta with palpation of lacrimal sac</td> </tr> <tr> <td class=\"indent1\">Dacryocystocele</td> <td>Bluish swelling overlying the lacrimal sac; superior displacement of medial canthal tendon</td> </tr> <tr> <td class=\"subtitle2_left\">Glaucoma</td> <td>Photophobia; corneal clouding; increased corneal diameter; increased intraocular pressure</td> </tr> <tr> <td class=\"subtitle2_left\">Uveitis</td> <td>Photophobia, pain, ciliary injection; may occur after trauma or with various systemic conditions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Viral</td> <td>Watery, stringy discharge; respiratory symptoms</td> </tr> <tr> <td class=\"indent1\">Bacterial</td> <td>Purulent discharge</td> </tr> <tr> <td class=\"indent1\">Allergic</td> <td>Pruritus; allergic stigmata</td> </tr> <tr> <td class=\"indent1\">Mechanical</td> <td>History of trauma</td> </tr> <tr> <td class=\"indent1\">Toxic</td> <td>History of ocular exposure</td> </tr> <tr> <td class=\"subtitle2_left\">Ophthalmia neonatorum</td> <td>Infants younger than one month; usually associated with systemic illness (eg, gonorrhea, chlamydia)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Corneal abnormalities</td> </tr> <tr> <td class=\"indent1\">Corneal abrasion</td> <td>Photophobia, erythema, history of trauma; positive fluorescein examination</td> </tr> <tr> <td class=\"indent1\">Corneal foreign body</td> <td>Photophobia, erythema, history of trauma; foreign body may be viewed directly or with slit lamp</td> </tr> <tr> <td class=\"subtitle2_left\">Conjunctival foreign body</td> <td>Photophobia, erythema, history of trauma; foreign body may be viewed directly or with slit lamp</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lid abnormalities</td> </tr> <tr> <td class=\"indent1\">Entropion</td> <td>In-turning of the eyelid</td> </tr> <tr> <td class=\"indent1\">Epiblepharon</td> <td>Extra fold of skin along the lower lid margin extending over the medial canthal tendon</td> </tr> <tr> <td class=\"indent1\">Trichiasis</td> <td>Ingrown eyelashes</td> </tr> <tr> <td class=\"indent1\">Blepharitis</td> <td>Inflammation/infection of the eyelids; debris on eyelashes; itching; burning; redness</td> </tr> <tr> <td class=\"indent1\">Posttraumatic lid and orbit abnormalities</td> <td>History of trauma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63904 Version 2.0</div></div></div>"},"63905":{"type":"graphic_diagnosticimage","displayName":"Left hemidiaph paralysis","title":"Left hemidiaphragm paralysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left hemidiaphragm paralysis</div><div class=\"cntnt\"><img style=\"width:396px; height:373px;\" src=\"images/PULM/63905_Left_hemidiaph_paralysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Bartolome Celli, MD.</div><div id=\"graphicVersion\">Graphic 63905 Version 2.0</div></div></div>"},"63906":{"type":"graphic_table","displayName":"IHC interpretation for mismatch repair genes","title":"Interpretation of immunohistochemistry results for mismatch repair genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of immunohistochemistry results for mismatch repair genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Result</td> <td class=\"subtitle1\">Possible interpretation</td> <td class=\"subtitle1\">Explanation/comments</td> <td class=\"subtitle1\">Next steps to consider</td> </tr> <tr> <td rowspan=\"2\">Absence of MLH1 only (rare occurrence)</td> <td>1. MLH1 germline mutation</td> <td rowspan=\"2\">Epigenetic silencing of the MLH1 gene occurs through hypermethylation of the MLH1 promoter</td> <td>MLH1 germline genetic testing or MLH1 methylation +/- BRAF V600E studies</td> </tr> <tr> <td>2. Hypermethylation of MLH1 promoter</td> <td>Genetic testing for constitutional MLH1 hypermethylation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Absence of both MLH1 and PMS2</td> <td>1. MLH1 germline mutation</td> <td>MLH1 and PMS2 proteins form a heterodimer. Therefore, PMS2 staining is often absent as a result of a MLH1 mutation.</td> <td>MLH1 germline genetic testing or MLH1 methylation +/- BRAF V600E studies</td> </tr> <tr> <td>2. Hypermethylation of MLH1 promoter</td> <td>PMS2 germline mutations when tumors show loss of both MLH1 and PMS2 proteins are rare<sup>[1,2]</sup></td> <td>Genetic testing for constitutional MLH1 hypermethylation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Absence of PMS2 only</td> <td>1. PMS2 germline mutation</td> <td>MLH1 protein has dimer partners other than PMS2; therefore, germline mutations in PMS2 may not necessarily cause loss of staining for MLH1</td> <td>PMS2 germline genetic testing</td> </tr> <tr> <td>2. MLH1 germline mutation</td> <td>MLH1 germline mutations have been identified when tumors show loss of staining for PMS2 only<sup>[3,4]</sup></td> <td>MLH1 germline genetic testing if PMS2 testing does not identify a germline mutation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Absence of MSH2 only (rare occurrence)</td> <td>1. MSH2 germline mutation</td> <td>Strong likelihood of a MSH2 or EPCAM mutation</td> <td>MSH2 germline genetic testing</td> </tr> <tr> <td>2. EPCAM germline mutation</td> <td>Other epigenetic events that result in silencing of MSH2 are undetermined</td> <td>EPCAM deletion studies if MSH2 testing does not identify a germline mutation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Absence of both MSH2 and MSH6</td> <td>1. MSH2 germline mutation</td> <td rowspan=\"3\">MSH2 and MSH6 proteins form a heterodimer; therefore, MSH6 staining is often absent as a result of MSH2 mutation.</td> <td>MSH2 germline genetic testing</td> </tr> <tr> <td>2.&nbsp;EPCAM germline mutation</td> <td rowspan=\"2\">EPCAM +/- MSH6 germline genetic testing if MSH2 testing does not identify a germline mutation</td> </tr> <tr> <td>3. MSH6 mutation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Absence of MSH6 only</td> <td>1. MSH6 germline mutation</td> <td rowspan=\"2\">MSH2 protein has dimer partners other than MSH6; therefore, germline mutations in MSH6 tend to cause loss of staining for MSH6 only</td> <td>MSH6 germline genetic testing</td> </tr> <tr> <td>2. MSH2 germline mutation</td> <td>MSH2 germline genetic testing if MSH6 testing does not identify a germline mutation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">All proteins exhibit normal staining</td> <td>1. No Lynch syndrome</td> <td rowspan=\"2\">Normal IHC results do not exclude Lynch syndrome; missense mutation could result in intact, but nonfunctional MMR protein</td> <td rowspan=\"2\">Refer to MSI results +/- family history to guide further evaluation</td> </tr> <tr> <td>2. Possible missense germline mutation in MLH1, MSH2, MSH6 or PMS2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IHC: immunohistochemistry; MSI: microsatellite instability.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Niessen RC, Kleibeuker JH, Westers H, Jager PO, Rozeveld D, Bos KK, et al. (2009). PMS2 involvement in patients suspected of Lynch syndrome. Genes, Chromosomes and Cancer, 48(4), 322-329. </li> <li>Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419-428. </li> <li>De Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MG, et al. (2004b). Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clinical Cancer Research, 10(3), 972-980. </li> <li>Zighelboim I, Powell M, Babb S, Whelan A, Schmidt A, Clendenning M, et al. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 8 (4), 501-504. </li> </ol> Reproduced from: Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for lynch syndrome-a review. J Genet Couns 2011; 20:5, with kind permission from Springer Science + Business Media B.V. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 63906 Version 11.0</div></div></div>"},"63911":{"type":"graphic_table","displayName":"Findings in RP fibrosis","title":"Associated diagnoses among 491 patients with retroperitoneal fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Associated diagnoses among 491 patients with retroperitoneal fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Findings</td> <td class=\"subtitle1\">Percent of patients</td> </tr> <tr> <td>Idiopathic</td> <td class=\"centered\">67.8</td> </tr> <tr> <td>Methysergide exposure</td> <td class=\"centered\">12.4</td> </tr> <tr> <td>All malignancies</td> <td class=\"centered\">7.9</td> </tr> <tr> <td>Mediastinal fibrosis</td> <td class=\"centered\">3.3</td> </tr> <tr> <td>Periaortic inflammation-arteritis</td> <td class=\"centered\">2.4</td> </tr> <tr> <td>Mesenteric fibrosis</td> <td class=\"centered\">2.0</td> </tr> <tr> <td>Sclerosing cholangitis</td> <td class=\"centered\">1.6</td> </tr> <tr> <td>Abdominal aortic aneurysm</td> <td class=\"centered\">1.8</td> </tr> <tr> <td>Crohn disease</td> <td class=\"centered\">1.2</td> </tr> <tr> <td>Thrombophlebitis</td> <td class=\"centered\">1.0</td> </tr> <tr> <td>Reidel's thyroiditis</td> <td class=\"centered\">0.8</td> </tr> <tr> <td>Other</td> <td class=\"centered\">5.3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Koep L, Zuidemia GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977; 81:250.</div><div id=\"graphicVersion\">Graphic 63911 Version 4.0</div></div></div>"},"63912":{"type":"graphic_figure","displayName":"Effects combined statin resin","title":"The combination of a statin and a bile acid binding resin is more effective than either alone","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">The combination of a statin and a bile acid binding resin is more effective than either alone</div><div class=\"cntnt\"><img style=\"width:522px; height:452px;\" src=\"images/PC/63912_Effectscombinedstatinres.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reduction in LDL cholesterol concentration and the increase in HDL concentration is greater with the combination of a statin and a bile acid binding resin, given as cholestyramine, when compared with therapy with either drug alone. The effects of both drugs decline exponentially with increasing doses.</div><div class=\"graphic_footnotes\">HDL: high-density lipoprotein; LDL: low-density lipoprotein.</div><div class=\"graphic_reference\">Data from The Prevastatin Multicenter Study Group II, Arch Intern Med 1993; 153:1321.</div><div id=\"graphicVersion\">Graphic 63912 Version 2.0</div></div></div>"},"63913":{"type":"graphic_table","displayName":"Causes neonatal acute kidney injury","title":"Causes of acute kidney injury in newborns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute kidney injury in newborns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Prerenal</td> </tr> <tr> <td class=\"indent1\">Hypovolemia</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> </tr> <tr> <td class=\"indent1\">Hypoxemia</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> </tr> <tr> <td class=\"indent1\">Septicemia</td> </tr> <tr> <td class=\"indent1\">Hypoalbuminemia</td> </tr> <tr> <td class=\"indent1\">Perinatal asphyxia/respiratory distress syndrome</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease/cardiac surgery</td> </tr> <tr> <td class=\"indent1\">Polycythemia</td> </tr> <tr> <td class=\"indent1\">Pharmacologic agents*</td> </tr> <tr> <td class=\"subtitle1_single\">Postrenal</td> </tr> <tr> <td class=\"indent1\">Posterior urethral valves</td> </tr> <tr> <td class=\"indent1\">Bilateral obstructive uropathy</td> </tr> <tr> <td class=\"indent1\">Neurogenic bladder</td> </tr> <tr> <td class=\"subtitle1_single\">Intrinsic renal</td> </tr> <tr> <td class=\"indent1\">Acute tubular necrosis</td> </tr> <tr> <td class=\"indent1\">Corticomedullary necrosis</td> </tr> <tr> <td class=\"indent1\">Renal venous/arterial thrombosis</td> </tr> <tr> <td class=\"indent1\">Acute pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Hemoglobin/myoglobin</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"indent1\">Isoimmune hemolytic disease with massive hemoglobinuira</td> </tr> <tr> <td class=\"indent1\">Congenital renal anomalies (renal agenesis, cystic disease/dysplasia, polycystic kidney disease, congenital nephrotic syndrome)</td> </tr> <tr> <td class=\"indent1\">Infections (eg, pyelonephritis)</td> </tr> <tr> <td class=\"indent1\">Intrauterine infections (eg, candidiasis, toxoplasmosis)</td> </tr> <tr> <td class=\"indent1\">Toxic nephropathy due to pharmacologic agents</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes agents such as prostaglandin inhibitors (indomethacin), angiotensin-converting enzyme inhibitors (captopril), and vasodilators. Drugs, such as aminoglycosides, amphotericin, and radiocontrast agents, cause prerenal as well as intrinsic renal failure.</div><div id=\"graphicVersion\">Graphic 63913 Version 5.0</div></div></div>"},"63916":{"type":"graphic_picture","displayName":"H pylori on crypt cells Light","title":"Helicobacter pylori adherence on gastric surface cells","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Helicobacter pylori adherence on gastric surface cells</div><div class=\"cntnt\"><img style=\"width:454px; height:288px;\" src=\"images/GAST/63916_H_pylori_on_crypt_cells_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of surface and foveolar epithelium shows numerous <EM>Helicobacter pylori</EM> organisms lining the surface of the cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 63916 Version 2.0</div></div></div>"},"63919":{"type":"graphic_algorithm","displayName":"Adult bradycardia algorithm","title":"Adult bradycardia algorithm","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Adult bradycardia algorithm</div><div class=\"cntnt\"><img style=\"width:537px; height:572px;\" src=\"images/EM/63919_Adult_bradycardia_algo_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The algorithm presented above has been modified to make it more consistent with the 2015 update to the ACLS Guidelines while we await permission from the AHA to reproduce the latest version.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IV: intravenous; mcg: microgram.</div><div class=\"graphic_reference\">Reprinted with permission. Adult Advanced Cardiovascular Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. © 2010 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 63919 Version 14.0</div></div></div>"},"63920":{"type":"graphic_figure","displayName":"Difference in the angle of the eustachian tube","title":"Difference in the angle of the eustachian tube in the infant and the adult","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Difference in the angle of the eustachian tube in the infant and the adult</div><div class=\"cntnt\"><img style=\"width:510px; height:617px;\" src=\"images/PC/63920_Diff_ang_eustach_tube_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infants and young children have shorter, more horizontal tubes, immature floppy elastic cartilage, and larger adenoids compared to adults, which place them at a higher risk for eustachian tube obstruction and reflux.</div><div id=\"graphicVersion\">Graphic 63920 Version 2.0</div></div></div>"},"63922":{"type":"graphic_figure","displayName":"Echinostomiasis life cycle","title":"Echinostomiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Echinostomiasis life cycle</div><div class=\"cntnt\"><img style=\"width:608px; height:493px;\" src=\"images/ID/63922_Echinostomiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Many animals may serve as definitive hosts for various echinostome species, including aquatic birds, carnivores, rodents, and humans. Unembryonated eggs are passed in feces <STRONG>(1)</STRONG> and develop in the water <STRONG>(2)</STRONG>. The miracidium takes on average 10 days to mature before hatching <STRONG>(3)</STRONG> and penetrating the first intermediate host, a snail <STRONG>(4)</STRONG>. Several genera of snails may serve as the first intermediate host. The intramolluscan stages include a sporocyst <STRONG>(4a)</STRONG>, one or two generations of rediae <STRONG>(4b)</STRONG>, and cercariae <STRONG>(4c)</STRONG>. The cercariae may encyst as metacercariae within the same first intermediate host or leave the host and penetrate a new second intermediate host <STRONG>(5)</STRONG>. Depending on the species, several animals may serve as the second intermediate host, including other snails, bivalves, fish, and tadpoles. The definitive host becomes infected after eating infected second intermediate hosts <STRONG>(6)</STRONG>. Metacercariae excyst in the duodenum <STRONG>(7)</STRONG>, and adults reside in the small intestine <STRONG>(8)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Echinostomiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/echinostomiasis/index.html\">http://www.cdc.gov/dpdx/echinostomiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 63922 Version 5.0</div></div></div>"},"63924":{"type":"graphic_picture","displayName":"Condyloma lata syphilis","title":"Condyloma lata in the perineal region of a woman with secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condyloma lata in the perineal region of a woman with secondary syphilis</div><div class=\"cntnt\"><img style=\"width:281px; height:364px;\" src=\"images/ID/63924_Condyloma_lata_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous organisms are generally present in these lesions, which makes them highly infectious.</div><div class=\"graphic_reference\">Courtesy of Charles Hicks, MD.</div><div id=\"graphicVersion\">Graphic 63924 Version 1.0</div></div></div>"},"63925":{"type":"graphic_figure","displayName":"History of C trachomatis","title":"Natural history of <EM>Chlamydia trachomatis </EM>infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natural history of&nbsp;<EM>Chlamydia trachomatis </EM>infection</div><div class=\"cntnt\"><img style=\"width:421px; height:327px;\" src=\"images/ID/63925_History_of_C_trachomatis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repeated episodes of infection cause recurrent conjunctival inflammation, leading to eyelid scarring, trichiasis (ingrown eyelashes), corneal opacification, and subsequent blindness.</div><div id=\"graphicVersion\">Graphic 63925 Version 2.0</div></div></div>"},"63926":{"type":"graphic_figure","displayName":"Plastibell procedure","title":"Technique for performing circumcision using a Plastibell","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technique for performing circumcision using a Plastibell</div><div class=\"cntnt\"><img style=\"width:228px; height:470px;\" src=\"images/OBGYN/63926_Plastibell_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An incision is made in the top of the foreskin. <BR>(B) The Plastibell is placed over the head of the penis, and the foreskin is pulled over the Plastibell. <BR>(C) A suture is tied around the foreskin over the tying groove in the Plastibell. Excess skin beyond the suture is trimmed away. The Plastibell falls off in three to seven&nbsp;days.</div><div class=\"graphic_reference\">Reproduced with permission from: Mabis Healthcare. The Plastibell Circumcision Device&#174; is a Registered Trademark of Mabis Healthcare.</div><div id=\"graphicVersion\">Graphic 63926 Version 2.0</div></div></div>"},"63928":{"type":"graphic_picture","displayName":"Lymphedema stageIII ABC","title":"Lymphedema stage III","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Lymphedema stage III</div><div class=\"cntnt\"><img style=\"width:479px; height:586px;\" src=\"images/ONC/63928_Lymphedema_stageIII_ABC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage III lymphedema. A) Left lower extremity. B) Right upper extremity. C) Right upper extremity.</div><div class=\"graphic_reference\">Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.</div><div id=\"graphicVersion\">Graphic 63928 Version 2.0</div></div></div>"},"63929":{"type":"graphic_figure","displayName":"Mechanism of TSH action","title":"Schematic representation of the steps involved in TSH action","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of the steps involved in TSH action</div><div class=\"cntnt\"><img style=\"width:272px; height:374px;\" src=\"images/ENDO/63929_Mechanism_of_TSH_action.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mode of action of thyroid stimulating hormone (TSH). The biologically active TSH consisting of two subunits, alpha and beta, binds to the extracellular domain of the TSH receptor (TSHr), to activate the G proteins. This results in the production of cyclic AMP. The latter mediates most action of TSH.</div><div class=\"graphic_reference\">From Refetoff S, Sunthornthepvarakul T, Gottschalk ME, Hayashi Y, Recent Prog Horm Res 1996; 51:97.</div><div id=\"graphicVersion\">Graphic 63929 Version 2.0</div></div></div>"},"63932":{"type":"graphic_figure","displayName":"Hemoglobin absorption spectra","title":"Hemoglobin absorption spectra","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Hemoglobin absorption spectra</div><div class=\"cntnt\"><img style=\"width:489px; height:405px;\" src=\"images/SURG/63932_Hemoglobin_absorption_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oxyhemoglobin (Hb02) contained within red blood cells has three major absorption peaks at 418, 542, and 577 nm, with an additional infrared absorption around 1000 nm.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott Prahl. Available at: <a href=\"http://omlc.ogi.edu/spectra/hemoglobin/\">http://omlc.ogi.edu/spectra/hemoglobin/</a>. Copyright &#169; 1999.</div><div id=\"graphicVersion\">Graphic 63932 Version 2.0</div></div></div>"},"63933":{"type":"graphic_table","displayName":"Ultrasound assessment of suspected skeletal dysplasia","title":"Prenatal ultrasound assessment of suspected skeletal dysplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prenatal ultrasound assessment of suspected skeletal dysplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Obtain the following</td> <td class=\"subtitle1\">General comment</td> <td class=\"subtitle1\">Specific comments</td> </tr> <tr> <td>Accurate gestational age</td> <td>LMP or early dating ultrasound</td> <td>If unable to obtain accurate dating consider BPD:FL ratios</td> </tr> <tr class=\"divider_top\"> <td>Measure all long bones</td> <td> <p>Are any bones missing?</p> <p>Determine the pattern and degree of limb shortening</p> </td> <td> <p>Rhizomelia, Mesomelia, Acromelia, Micromelia (mild, severe, severe/bowed)</p> </td> </tr> <tr class=\"divider_top\"> <td>Measure foot length</td> <td>Calculate femur:foot length ratio</td> <td>&#60;0.9 abnormal</td> </tr> <tr class=\"divider_top\"> <td>Assess the shape and contour of long bones</td> <td>Bowing, angulations, fractures</td> <td>If fractures, query occasional or numerous</td> </tr> <tr class=\"divider_top\"> <td>Determine if decreased mineralization</td> <td>Determine if diffuse or focal</td> <td>If focal specifically determine if the calvarium or spine or specific bones appear \"absent\"</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Determine if this may be a lethal condition</td> <td>Obtain axial, coronal, sagittal images of the thorax</td> <td> <p>Look for narrow AP diameter on sagittal</p> Look for bell-shape thorax on coronal</td> </tr> <tr> <td>Obtain chest circumference</td> <td>Chest circumference &#60;5<sup>th</sup> percentile suspicious</td> </tr> <tr> <td>Determine if ribs appear short</td> <td>Ribs should encircle &#62;70 percent thoracic circumference</td> </tr> <tr> <td>Obtain chest: abdomen circumference ratio</td> <td>Chest: abdomen ratio &#60; 0.6 concern for lethality</td> </tr> <tr> <td>Obtain femur length:abdominal circumference ratio</td> <td>&#60;0.16 concern for lethality</td> </tr> <tr> <td>Consider obtaining lung volume</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Skull</td> <td>Shape, size, mineralization</td> <td>Assess for cloverleaf deformity, macrocranium, compressibility</td> </tr> <tr class=\"divider_top\"> <td>Facial profile</td> <td>&nbsp;</td> <td>Look for frontal bossing, micrognathia, flat nasal bridge, cleft lip/palate</td> </tr> <tr class=\"divider_top\"> <td>Vertebrae/spine</td> <td>Degree and pattern of demineralization, shape, alignment</td> <td>Is there platyspondyly?</td> </tr> <tr class=\"divider_top\"> <td>Abnormal posturing of joints</td> <td>&nbsp;</td> <td>Query kyphoscoliosis, fixed contractures</td> </tr> <tr class=\"divider_top\"> <td>Hands and feet</td> <td>Postural deformitites, abnormal number of digits</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Scapulae size and shape</td> <td>Hypoplastic or dysplastic</td> <td>Think campomelic dysplasia</td> </tr> <tr class=\"divider_top\"> <td>Growth parameters</td> <td>Placental and well-being parameters</td> <td>Is there intrauterine growth restriction?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMP: last menstrual period; BPD: biparietal diameter; FL: femur length; AP: anterior-posterior.</div><div id=\"graphicVersion\">Graphic 63933 Version 5.0</div></div></div>"},"63934":{"type":"graphic_picture","displayName":"Pseudofolliculitis barbae - close view","title":"Pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63934_Pseudofollic_barbae_CV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous and hyperpigmented papules are present on the beard area in this patient with pseudofolliculitis barbae.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63934 Version 3.0</div></div></div>"},"63935":{"type":"graphic_diagnosticimage","displayName":"CT bilateral adrenal hemorrhage","title":"Adrenal insufficiency with bilateral adrenal hemorrhage on CT","html":"<div class=\"graphic\"><div style=\"width: 959px\" class=\"figure\"><div class=\"ttl\">Adrenal insufficiency with bilateral adrenal hemorrhage on CT</div><div class=\"cntnt\"><img style=\"width:939px; height:368px;\" src=\"images/RADIOL/63935_CT_bilateral_adrenal_hmrrhg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient had a history of sepsis (Legionella pneumonia). He subsequently developed signs and symptoms of adrenal insufficiency.<br />(A) An axial CT scan through the adrenals initially showed normal adrenals (arrows).<br />(B) An axial CT scan performed one week later to follow up on the pneumonia shows bilateral subacute adrenal hemorrhage (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 63935 Version 4.0</div></div></div>"},"63939":{"type":"graphic_figure","displayName":"Schematic figure demonstrating hd access in parallel with circ","title":"Schematic figure demonstrating hemodialysis access in parallel with circulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic figure demonstrating hemodialysis access in parallel with circulation</div><div class=\"cntnt\"><img style=\"width:424px; height:251px;\" src=\"images/NEPH/63939_Hemodialysis_in_parallel.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of standard hemodialysis in which flow through the access is in parallel with the systemic circulation. If flow through the access is relatively low, then urea removal is limited because most of the blood is not entering the dialyzer.</div><div class=\"graphic_footnotes\">Qb: Blood flow rate.</div><div id=\"graphicVersion\">Graphic 63939 Version 5.0</div></div></div>"},"63940":{"type":"graphic_table","displayName":"Suggestive and atypical features of MS","title":"Suggestive and atypical features of multiple sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggestive and atypical features of multiple sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Features suggestive of multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Relapses and remissions</td> </tr> <tr> <td class=\"indent1\">Onset between ages 15 and 50 years</td> </tr> <tr> <td class=\"indent1\">Optic neuritis</td> </tr> <tr> <td class=\"indent1\">Lhermitte sign</td> </tr> <tr> <td class=\"indent1\">Internuclear ophthalmoplegia</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> </tr> <tr> <td class=\"indent1\">Heat sensitivity (Uhthoff phenomenon)</td> </tr> <tr> <td class=\"subtitle1_single\">Features atypical for multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Steady progression</td> </tr> <tr> <td class=\"indent1\">Onset before age 10 or after age 50 years</td> </tr> <tr> <td class=\"indent1\">Cortical deficits such as aphasia, apraxia, alexia, or neglect</td> </tr> <tr> <td class=\"indent1\">Rigidity or sustained dystonia</td> </tr> <tr> <td class=\"indent1\">Convulsions</td> </tr> <tr> <td class=\"indent1\">Early dementia</td> </tr> <tr> <td class=\"indent1\">Deficit developing within minutes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 63940 Version 6.0</div></div></div>"},"63943":{"type":"graphic_figure","displayName":"Pediatric olecranon fractures","title":"Pediatric olecranon fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediatric olecranon fractures</div><div class=\"cntnt\"><img style=\"width:278px; height:590px;\" src=\"images/EM/63943_Pediatricolecranonfractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type I: Apophysitis.<br> (B) Type II: Incomplete stress fracture.<br> (C) Type III: Complete fracture, apophyseal avulsion, apophyseal metaphyseal combination.</div><div class=\"graphic_reference\">Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 63943 Version 8.0</div></div></div>"},"63944":{"type":"graphic_figure","displayName":"Breast development and milk lines","title":"Breast development and milk lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast development and milk lines</div><div class=\"cntnt\"><img style=\"width:417px; height:580px;\" src=\"images/SURG/63944_Breast-development-and-milk-lines.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polymastia (supernumerary breasts) and polythelia (supernumerary nipples) may develop in males and females anywhere along the length of the mammary ridges (milk lines). Breast tissue may not develop (amastia) or there may be nipple development but no breast tissue (amazia).</div><div id=\"graphicVersion\">Graphic 63944 Version 1.0</div></div></div>"},"63945":{"type":"graphic_picture","displayName":"Asteatotic eczema","title":"Asteatotic eczema (eczema craquelé)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Asteatotic eczema (eczema craquelé)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63945_Asteatoticeczema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient, the asteatotic skin of the lower leg appears dry and slightly scaly, with&nbsp;a characteristic cracked appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63945 Version 6.0</div></div></div>"},"63946":{"type":"graphic_table","displayName":"Assessment for auto-HCT eligibility","title":"Assessment for autologous hematopoietic cell transplantation eligibility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment for autologous hematopoietic cell transplantation eligibility</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Detailed history and physical examination</td> </tr> <tr> <td class=\"sublist1\">Including Karnofsky performance status and dental examination</td> </tr> <tr> <td class=\"sublist1_start\">Laboratory studies</td> </tr> <tr> <td class=\"sublist1\">Complete blood count with differential; chemistries with liver and renal function and electrolytes; pregnancy test as clinically indicated; serology for HIV, hepatitis B, hepatitis C, herpes simplex and varicella, and cytomegalovirus; urine for microanalysis and macroanalysis; ABO typing</td> </tr> <tr> <td>Bone marrow aspiration and biopsy</td> </tr> <tr> <td class=\"sublist1_start\">Imaging</td> </tr> <tr> <td class=\"sublist1\">Chest radiograph, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA)</td> </tr> <tr> <td>Pulmonary function test, including DLCO</td> </tr> <tr> <td>Disease-specific restaging studies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MUGA: multiple gated cardiac blood pool imaging; DLCO: diffusing capacity of the lungs for carbon monoxide.</div><div id=\"graphicVersion\">Graphic 63946 Version 1.0</div></div></div>"},"63947":{"type":"graphic_picture","displayName":"Pemphigoid gestationis abdomen","title":"Pemphigoid gestationis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/63947_Pemphigoid_gestationis_abd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered erythematous, urticarial plaques are present on the abdomen of this patient with pemphigoid gestationis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63947 Version 5.0</div></div></div>"},"63948":{"type":"graphic_diagnosticimage","displayName":"Invasive GH secreting tumor","title":"Invasive GH-secreting macroadenoma lifting the optic chiasm and extending to parasellar regions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Invasive GH-secreting macroadenoma lifting the optic chiasm and extending to parasellar regions</div><div class=\"cntnt\"><img style=\"width:289px; height:464px;\" src=\"images/ENDO/63948_Invasive_GH_secreting_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GH: growth hormone.</div><div class=\"graphic_reference\">Courtesy of Shlomo Melmed, MD.</div><div id=\"graphicVersion\">Graphic 63948 Version 3.0</div></div></div>"},"63950":{"type":"graphic_figure","displayName":"Penile self injection PI","title":"Method of administering intrapenile injection","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Method of administering intrapenile injection</div><div class=\"cntnt\"><img style=\"width:477px; height:526px;\" src=\"images/PI/63950_PenileselfinjectionPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To be fully effective, the medications must be injected directly into one of the penile erectile bodies, the corporus cavernosum. The medication will diffuse over to the other side of the penis so that symmetrical erection is achieved. A cross-section of the penis shows the relationship of the site of injection to the corpora cavernosae. Most men use an insulin syringe with a 26- to 30-gauge,&nbsp;half-inch needle.</div><div id=\"graphicVersion\">Graphic 63950 Version 3.0</div></div></div>"},"63951":{"type":"graphic_waveform","displayName":"ECG third degree AV block","title":"Third degree AV block","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Third degree AV block</div><div class=\"cntnt\"><img style=\"width:540px; height:107px;\" src=\"images/PEDS/63951_ECG_third_degree_AV_block.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63951 Version 2.0</div></div></div>"},"63952":{"type":"graphic_diagnosticimage","displayName":"TEE longitudinal view aortic rupture","title":"Transesophageal echocardiography longitudinal view of a traumatic rupture of the aortic isthmus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography longitudinal view of a traumatic rupture of the aortic isthmus</div><div class=\"cntnt\"><img style=\"width:422px; height:288px;\" src=\"images/CARD/63952_Longitudinal_TEE_aortic_rup.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thick &quot;medial flap&quot; (arrow) was almost perpendicular to aortic walls because the injury was confined within a few centimeters.</div><div class=\"graphic_reference\">Courtesy of P Vignon, MD.</div><div id=\"graphicVersion\">Graphic 63952 Version 3.0</div></div></div>"},"63955":{"type":"graphic_table","displayName":"DDx of rash by appearance 2","title":"Differential diagnosis of fever and rash based upon appearance of the rash","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of fever and rash based upon appearance of the rash</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"3\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Macules, papules, nodules, or plaques</td> <td class=\"subtitle1\">Vesicles, bullae, or pustules</td> <td class=\"subtitle1\">Purpuric macules, purpuric papules, or purpuric vesicles</td> <td class=\"subtitle1\">Widespread erythema with or without edema followed by desquamation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fungal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p><em>Blastomyces dermatitidis</em>*</p> <p><em>Candida</em> spp</p> <p><em>Coccidioides immitis</em></p> <p><em>Cryptococcus neoformans</em></p> <p><em>Histoplasma capsulatum</em></p> Other disseminated deep fungal infections in immunocompromised patients</td> <td><em>Histoplasma capsulatum</em></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Viral</td> </tr> <tr> <td class=\"indent1\"> <p>Adenovirus</p> <p>Arbovirus</p> <p>Atypical measles*</p> <p>Chikungunya&nbsp;virus</p> <p>Colorado tick fever</p> <p>Coxsackieviruses A and B</p> <p>Cytomegalovirus, primary infection</p> <p>Dengue virus</p> <p>Epstein-Barr virus, primary infection</p> <p>Echoviruses</p> <p>Hepatitis B (urticaria)*</p> <p>Human herpesvirus 6 (exanthem subitum)*</p> <p>Human immunodeficiency virus (HIV-1)*</p> <p>Kawasaki syndrome (presumed viral)</p> <p>Molluscum contagiosum</p> <p>Orf</p> <p>Parvovirus B19 (erythema infectiosum [fifth disease])</p> <p>Rubella (German measles)*<sup>&#182;</sup></p> <p>Rubeola (measles)*</p> <p>Varicella (chickenpox)*</p> <p>Varicella-zoster (disseminated)</p> <p>Viral hemorrhagic fevers (many)</p> <p>West Nile virus</p> <p>Zika virus</p> </td> <td> <p>Colorado tick fever</p> <p>Coxsackie A5, 9, 10, 16, B2, 7</p> <p>Echoviruses</p> <p>Eczema herpeticum<sup>&#916;</sup></p> <p>Herpes simplex (disseminated)<sup>&#916;</sup></p> <p>Varicella (chickenpox)<sup>&#916;</sup></p> Varicella-zoster (disseminated)<sup>&#916;</sup></td> <td> <p>Adenovirus (rare)</p> <p>Atypical measles*</p> <p>Chikungunya&nbsp;virus</p> <p>Colorado tick fever</p> <p>Congenital cytomegalovirus</p> <p>Coxsackie A and B (rare, types A-9, B2-5)</p> <p>Dengue fever</p> <p>Epstein-Barr virus (rare)</p> <p>Echoviruses (rare, types 3, 4, 9)</p> <p>Rubella*</p> <p>Varicella-zoster virus</p> <p>West Nile virus</p> Yellow fever</td> <td>Kawasaki syndrome (presumed viral)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reportable disease.<br />&para; May have arthralgia or musculoskeletal pain.<br />&Delta; Umbilicated papule or vesicle a characteristic of these exanthems.</div><div class=\"graphic_reference\">Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.</div><div id=\"graphicVersion\">Graphic 63955 Version 6.0</div></div></div>"},"63957":{"type":"graphic_picture","displayName":"Osteitis fibrosa","title":"Micrograph showing osteitis fibrosa due to severe secondary hyperparathyroidism","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing osteitis fibrosa due to severe secondary hyperparathyroidism</div><div class=\"cntnt\"><img style=\"width:378px; height:267px;\" src=\"images/NEPH/63957_Osteitisfibrosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone biopsy from the iliac crest showing osteitis fibrosa due to severe secondary hyperparathyroidism.<br />(Left panel) Goldner Masson trichrome stain shows an increased number of multinucleate osteoclasts at the resorptive surfaces (arrow) and extensive bone marrow fibrosis (as shown by the light blue staining of the marrow) replacing normal marrow elements. The increased resorptive activity results in a thin and scalloped appearance to mineralized trabecular bone (blue).<br />(Right panel) Tetracycline labeling reveals a marked increase both in osteoid (orange-red staining) and in new bone formation (two distinct yellow-green bands below the majority of orange-red stained osteoid surfaces).</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 63957 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Micrograph showing normal bone histology</div><div class=\"cntnt\"><img style=\"width:382px; height:269px;\" src=\"images/NEPH/66330_Normalboneedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of normal bone.<br />(Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25% of bone surfaces. The cellular area between the osseous structures is the marrow space.<br />(Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 66330 Version 6.0</div></div></div>"},"63960":{"type":"graphic_picture","displayName":"Omphalitis I","title":"Omphalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omphalitis</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PEDS/63960_Omphalitis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows omphalitis, or infection of the umbilical cord stump, in an infant with leukocyte-adhesion deficiency.</div><div id=\"graphicVersion\">Graphic 63960 Version 5.0</div></div></div>"},"63961":{"type":"graphic_table","displayName":"Maternal mortality","title":"Estimated pregnancy related maternal mortality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated pregnancy related maternal mortality</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Type of pregnancy</td>\n\n      <td class=\"subtitle1\">Death rate</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Legal pregnancy termination</td>\n\n      <td>0.567 per 100,000 terminations</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Miscarriage</td>\n\n      <td>1.19 per 100,000 miscarriages</td>\n\n    </tr>\n    <tr>\n      <td>Live birth</td>\n      <td>7.06 per 100,000 live births</td>\n    </tr>\n    <tr>\n      <td>Ectopic pregnancy</td>\n      <td>31.9 per 100,000 ectopic pregnancies</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Estimates based on data from over 57 million pregnancies in the United States from 1991 to 1999.</div><div class=\"graphic_reference\">Adapted from Grimes, D. Am J Obstet Gynecol 2006; 194:92.</div><div id=\"graphicVersion\">Graphic 63961 Version 1.0</div></div></div>"},"63962":{"type":"graphic_figure","displayName":"Nociceptor sensitization following tissue injury","title":"Nociceptor sensitization following tissue injury","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Nociceptor sensitization following tissue injury</div><div class=\"cntnt\"><img style=\"width:517px; height:295px;\" src=\"images/PULM/63962_Injury_nociceptor_sensory_i.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nociceptor sensitization is partly mediated by the release of toxic substances (potassium, prostaglandin, bradykinins, and substance P) from damaged tissue. Those toxic substances excite nociceptors and increase their sensitivity to pain (hyperalgesia). Substance P, released by an axon reflex, induces vasodilation and mast-cell degranulation leading to histamine and serotonin release. These inflammatory agents sensitize damaged tissue and surrounding nociceptors even further prolonging the hypersensitivity state (secondary hyperalgesia).</div><div class=\"graphic_footnotes\">K+: potassium; PG: prostaglandin; BK: bradykinin; SP: substance P; 5HT: serotonin.</div><div class=\"graphic_reference\">Redrawn from: Sosnowski M, Lebrun P, Fodderie L. Anesth Clin North Am 1992; 10:211.</div><div id=\"graphicVersion\">Graphic 63962 Version 7.0</div></div></div>"},"63963":{"type":"graphic_diagnosticimage","displayName":"Parasternal short axis TTE I","title":"Parasternal short axis view of aortic valve","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis view of aortic valve</div><div class=\"cntnt\"><img style=\"width:523px; height:171px;\" src=\"images/CARD/63963_Parasternal_short_axis_TTE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal short axis view from a transthoracic echocardiogram shows the noncoronary (NCC), right coronary (RCC) and left coronary (LCC) leaflets of the aortic valve. Also seen are the left atrium (LA), right atrium (RA), tricuspid valve (TV), right ventricle (RV) and pulmonic valve (PV).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 63963 Version 3.0</div></div></div>"},"63965":{"type":"graphic_figure","displayName":"Galeazzi test","title":"Galeazzi test","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Galeazzi test</div><div class=\"cntnt\"><img style=\"width:453px; height:264px;\" src=\"images/EM/63965_Galeazzi_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is positioned as shown. The knee is lower on the affected side because of posterior displacement in the developmentally dysplastic hip (arrow).</div><div id=\"graphicVersion\">Graphic 63965 Version 2.0</div></div></div>"},"63967":{"type":"graphic_figure","displayName":"Polyp removal PI","title":"Removing a colon polyp","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Removing a colon polyp</div><div class=\"cntnt\"><img style=\"width:514px; height:238px;\" src=\"images/PI/63967_Polyp_removal_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One way doctors remove colon polyps is to use a noose as a tool. They loop a wire around the polyp and squeeze the loop tight. When the polyp comes off, the doctor sucks it up into the endoscope, so that it can go to the lab for tests.</div><div id=\"graphicVersion\">Graphic 63967 Version 5.0</div></div></div>"},"63968":{"type":"graphic_diagnosticimage","displayName":"CBD obstruction dilated","title":"Anastomotic stricture following balloon dilation in a liver tranplatation recipient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anastomotic stricture following balloon dilation in a liver tranplatation recipient</div><div class=\"cntnt\"><img style=\"width:292px; height:324px;\" src=\"images/GAST/63968_CBD_obstruction_dilated.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cholangiogram obtained following balloon dilation of an anastomotic stricture in a patient who underwent liver transplantation demonstrates dilated intrahepatic ducts and a residual, but wider, stricture at the anastamosis (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 63968 Version 3.0</div></div></div>"},"63969":{"type":"graphic_diagnosticimage","displayName":"Paracocci imaging","title":"Imaging of paracoccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Imaging of paracoccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:379px; height:594px;\" src=\"images/ID/63969_Paracocci_imaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images of paracoccidioidomycosis. A. Chest radiograph demonstrating a &quot;butterfly wing&quot; pattern. B. Chest radiograph with a diffuse nodular and micronodular pattern. C. Chest computed tomography (CT) scan demonstrating multiple cavities. D. Abdominal CT scan demonstrating enlarged adrenal glands bilaterally. E and F. Head CT demonstrating hypodense ring-enhancing lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Shikanai-Yasuda MA, Queiroz Telles Filho F, Mendes RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright ©2006 Sociedade Brasileira de Medicina Tropical.</div><div id=\"graphicVersion\">Graphic 63969 Version 3.0</div></div></div>"},"63970":{"type":"graphic_diagnosticimage","displayName":"Tracheal occlusion","title":"Plain radiographs comparing patients with (left) severe CDH on ECMO and (right) CDH status post tracheal occlusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plain radiographs comparing patients with (left) severe CDH on ECMO and (right) CDH status post tracheal occlusion</div><div class=\"cntnt\"><img style=\"width:504px; height:290px;\" src=\"images/OBGYN/63970_Tracheal_occlusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Holly L Hedrick, MD.</div><div id=\"graphicVersion\">Graphic 63970 Version 2.0</div></div></div>"},"63971":{"type":"graphic_table","displayName":"Neoadjuvant therapy rectal CA","title":"Preoperative therapy in patients prospectively declared to require an APR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative therapy in patients prospectively declared to require an APR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"10\" width=\"9%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">(1)</td> <td class=\"subtitle1\">(2)</td> <td class=\"subtitle1\">(3)</td> <td class=\"subtitle1\">(4)</td> <td class=\"subtitle1\">(5)</td> <td class=\"subtitle1\">(6)</td> <td class=\"subtitle1\">(7)</td> <td class=\"subtitle1\">(8)</td> <td class=\"subtitle1\">(9)</td> <td class=\"subtitle1\">(10)</td> </tr> <tr> <td>Treatment</td> <td>RT</td> <td>RT</td> <td>CMT</td> <td>CMT</td> <td>CMT</td> <td>RT</td> <td>CMT</td> <td>CMT</td> <td>CMT</td> <td>RT</td> </tr> <tr> <td>Total no. enrolled</td> <td>36</td> <td>37</td> <td>59*</td> <td>37</td> <td>83</td> <td>201</td> <td>72</td> <td>392<sup>&#182;</sup></td> <td>54</td> <td>27</td> </tr> <tr> <td>No. who underwent surgery</td> <td>35</td> <td>27</td> <td>59</td> <td>36</td> <td>81</td> <td>34</td> <td>72</td> <td>NR</td> <td>54</td> <td>27</td> </tr> <tr> <td>No. judged to need an APR</td> <td>36</td> <td>37</td> <td>40</td> <td>37</td> <td>47</td> <td>34*</td> <td>35</td> <td>105</td> <td>20</td> <td>27</td> </tr> <tr> <td>No. with T3 disease</td> <td>31 (86%)</td> <td>12 (32%)</td> <td>NR (100%)</td> <td>NR</td> <td>83 (66%)&nbsp;</td> <td>62 (44%)</td> <td>72 (100%)</td> <td>NR</td> <td>52 (96%)</td> <td>0 (all cT2)</td> </tr> <tr> <td>No. who underwent LAR and/or coloanal anastomosis</td> <td>27 (77%)</td> <td>17 (63%)</td> <td>30 (75%)</td> <td>28 (78%)</td> <td>31 (66%)</td> <td>15 (44%)</td> <td>68 (94%)</td> <td>41 (39%)</td> <td>13 (65%)</td> <td>21 (78%)</td> </tr> <tr> <td>Percent local failure</td> <td>17</td> <td>8</td> <td>NR</td> <td>11</td> <td>10</td> <td>12</td> <td>2</td> <td>7</td> <td>4</td> <td>10</td> </tr> <tr> <td>Percent survival</td> <td>64%- 5-yr</td> <td>83%- 2-yr</td> <td>NR</td> <td>87%<sup>&#916;</sup></td> <td>72%- 5-yr</td> <td>75%- 3-yr</td> <td>95%- 3-yr&nbsp;</td> <td>78%- 5-yr</td> <td>92%- 2-yr</td> <td>86%- 5-yr</td> </tr> <tr> <td>No. evaluable for sphincter function analysis</td> <td>27 (77%)</td> <td>14 (52%)</td> <td>NR</td> <td>NR</td> <td>63</td> <td>82&#167;</td> <td>21</td> <td>NR</td> <td>NR</td> <td>21</td> </tr> <tr> <td>Sphincter function</td> <td>85%- good to excellent</td> <td>75%- perfect</td> <td>NR</td> <td>NR</td> <td>6%- moderate soilage</td> <td>78%- normal</td> <td>81%- good to excellent</td> <td>NR</td> <td>NR</td> <td>77%- good to excellent at 2-3 yr</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APR: abdominoperineal resection; RT: radiation therapy; CMT: combined modality therapy; NR: data not reported; cT2: clinical (and endoscopy) stage T2.<br />* These data from an early report of NSABP R-03 that included 59 patients randomized to the preoperative arm, 40 of whom were judged to require APR, 22. Data on patients in the postoperative arm not included.<br />&para; Data from a preliminary report of the preoperative therapy arm of a randomized German study comparing preoperative and postoperative chemoradiotherapy.<br />&Delta; Disease free survival with a median follow-up of 12 months.</div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>(MSKCC) Wagman R, et al. Int J Radiat Oncol Biol Phys 1998; 42:51. </LI>&#xD;&#xA;<LI>(Montpellier) Rouanet P, et al. Dis Colon Rectum 2002; 45:305. </LI>&#xD;&#xA;<LI>(NSABP R-03) Hyams DM, et al. Dis Colon Rectum 1997; 40:131.&nbsp;</LI>&#xD;&#xA;<LI>(Ellis Fischel) Kuvshinoff B, et al. Ann Surg Oncol 2001; 8:163. </LI>&#xD;&#xA;<LI>(Cath Univ) Valentini V, et al. Int J Radiat Oncol Biol Phys 1998; 40:1067.</LI>&#xD;&#xA;<LI>(Lyon R90-01) Francois, et al. J Clin Oncol 1999; 17:23296. </LI>&#xD;&#xA;<LI>(MSKCC) Grann A, et al. Int J Radiat Oncol Biol Phys 2001; 49:987. </LI>&#xD;&#xA;<LI>(German) Sauer R, et al. Int J Radiat Oncol Biol Phys 2003; 57(2 suppl): S124.</LI>&#xD;&#xA;<LI>(Italian) Gambacorta M, et al Int J Radiat Oncol Biol Phys 2004; 60:130. </LI>&#xD;&#xA;<LI>(MSKCC) Rengan, R, et al. J Clin Oncol 2005; 23:4905. </LI></OL>Data from a preliminary report of the preoperative therapy arm of a randomized German study comparing preoperative and postoperative chemoradiotherapy.</div><div id=\"graphicVersion\">Graphic 63971 Version 3.0</div></div></div>"},"63972":{"type":"graphic_diagnosticimage","displayName":"Enchondroma vs infarct","title":"Difference between matrix and heterotopic calcification","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Difference between matrix and heterotopic calcification</div><div class=\"cntnt\"><img style=\"width:498px; height:386px;\" src=\"images/PEDS/63972_Enchondroma_vs_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Enchondroma of the distal femur demonstrates flocculent matrix resembling rings, or Cs and Os. Calcification is concentrated in the center of the lesion. <BR>B) Heterotopic calcification in a bone infarct. The calcification is mainly in the periphery of the lesion and has a wavy or serpentine appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 63972 Version 2.0</div></div></div>"},"63973":{"type":"graphic_table","displayName":"Oral antibiotics suspected MRSA SSTI children","title":"Our approach to empiric oral antibiotic therapy for children >28 days with suspected <em>Staphylococcus aureus</em> skin and soft tissue infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Our approach to empiric oral antibiotic therapy for children &gt;28 days with suspected <em>Staphylococcus aureus</em> skin and soft tissue infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Options for first-line therapy</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Options for second-line therapy (including parenteral agents)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High prevalence of CA-MRSA* or SSTI of face, hand, or perineum: Use one of the following non-beta-lactam antibiotics</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#182;</sup></td> <td> <p>30 to 40 mg/kg per day in 3 or 4 doses</p> Maximum daily dose: 1.8 g</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Oral or parenteral linezolid: <ul> <li>&#60;12 years: 30 mg/kg per day orally or IV in 3 doses </li> <li>&#8805;12 years: 600 mg twice per day&nbsp;orally or IV </li> </ul> </li> <li>Parenteral vancomycin: <ul> <li>40 mg/kg per day IV in 4 doses, or </li> <li>45 mg/kg per day IV divided in 3 doses, or </li> <li>60 mg/kg per day IV in 4 doses (if the child is seriously ill)<sup>&#167;</sup> </li> </ul> </li> </ul> Maximum daily dose 4 g, unless levels are inappropriately low</td> </tr> <tr> <td class=\"indent1\">Doxycycline<sup>&#916;</sup><sup>&#9674;</sup></td> <td> <p>2 to 4 mg/kg per day in 1 or 2 doses</p> Maximum daily dose: 200 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">TMP-SMX<sup>&#916;</sup></td> <td> <p>8 to 12 mg/kg per day of TMP, 40 to 60 mg/kg per day of SMX in 2 doses</p> Maximum daily dose: 320 mg of TMP, 1.6 g SMX</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Low prevalence of CA-MRSA* and SSTI does not involve face, hand, or perineum: Use a beta-lactam antibiotic</td> </tr> <tr> <td class=\"indent1\">Cefuroxime</td> <td> <p>Oral suspension: 30 mg/kg per day in 2 doses</p> Maximum daily dose: 1 g</td> <td rowspan=\"4\"> <ul> <li>Oral clindamycin (dose provided above) </li> <li>Oral doxycycline (dose provided above) </li> <li>Oral TMP-SMX (dose provided above) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> <td> <p>25 to 50 mg/kg per day in 2 to 4 doses</p> Maximum daily dose: 1 g</td> </tr> <tr> <td class=\"indent1\">Cloxacillin (not available in the United States)</td> <td> <p>25 to 50 mg/kg per day in 4 doses</p> Maximum daily dose: 2 g</td> </tr> <tr> <td class=\"indent1\">Dicloxacillin</td> <td> <p>25 to 50 mg/kg per day in 4 doses</p> Maximum daily dose: 2g</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CA-MRSA: community-associated methicillin-resistant <EM>S. aureus</EM>; SSTI: skin and soft tissue infection; IV: intravenously; TMP-SMX: trimethoprim-sulfamethoxazole.<br />* We define high prevalence of CA-MRSA as greater than 5 to 10 percent and low prevalence of CA-MRSA as less than 5 to 10 percent. Others may choose to provide coverage for CA-MRSA at different prevalence levels.<br />¶ If the prevalence of clindamycin resistance in the community is low (eg, &lt;10 percent). If an organism is isolated, D testing is required to evaluate for inducible resistance. Refer to UpToDate content on antibacterial susceptibility testing. To overcome unpleasant taste: Flavoring can be added to solution or capsule contents can be emptied into a small amount of chocolate syrup, applesauce, or yogurt.<br />Δ Does not have activity against <EM>Streptococcus pyogenes </EM>(group A <EM>Streptococcus</EM>). If coverage for both MRSA and <EM>S. pyogenes </EM>is desired (eg, child with cellulitis), we use clindamycin; other experts suggest adding a beta-lactam antibiotic to doxycycline or TMP-SMX.<br /><FONT class=lozenge>◊</FONT> Tetracycline antibiotics, including doxycycline, may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracyclines and in some studies, was not associated with visible teeth staining children &lt;8 years.<br />§ Serious illness is defined by toxic appearance, limb-threatening infection, or underlying medical problems that may be associated with poor response or complications (eg, primary immune deficiency, diabetes mellitus).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</li>&#xD;&#xA;    <li>Creech CB. Treatment of staphylococcal infections in children. Infectious Diseases in Children. November 2013. Available at: <a href=\"http://www.healio.com/pediatrics/mrsa/news/print/infectious-diseases-in-children/%7B42cabf10-e3a7-41b5-949b-044ecb4a8b7a%7D/treatment-of-staphylococcal-infections-in-children\" spellcheck=\"true\" target=\"_blank\">www.healio.com/pediatrics/mrsa/news/print/infectious-diseases-in-children/%7B42cabf10-e3a7-41b5-949b-044ecb4a8b7a%7D/treatment-of-staphylococcal-infections-in-children</a>. Accessed on February 24, 2016.</li>&#xD;&#xA;    <li>Liu C, Bayer A, Cosgrove SE, et, al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</li>&#xD;&#xA;    <li>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 63973 Version 8.0</div></div></div>"},"63974":{"type":"graphic_picture","displayName":"Scabies infant axilla","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:400px; height:455px;\" src=\"images/DERM/63974_Scabies_infant_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and vesicles are present in the axilla of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63974 Version 6.0</div></div></div>"},"63975":{"type":"graphic_diagnosticimage","displayName":"Post traumatic arthritis","title":"Post traumatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Post traumatic arthritis</div><div class=\"cntnt\"><img style=\"width:540px; height:464px;\" src=\"images/EM/63975_Post_traumatic_arthritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient sustained an elbow fracture in the past. Osteoarthritis is now manifest by severe narrowing of the joint space, sclerosis (arrow), and osteophytes (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 63975 Version 3.0</div></div></div>"},"63976":{"type":"graphic_figure","displayName":"Schematic for incisions","title":"Escharotomy incisions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Escharotomy incisions</div><div class=\"cntnt\"><img style=\"width:426px; height:462px;\" src=\"images/EM/63976_Schematic_for_incisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the approximate location for escharotomy incisions, should such incisions become necessary due to compromised respiratory function or inadequate distal perfusion. Escharotomy is rarely required in the emergency department and ideally is performed by experienced clinicians to avoid injury to underlying tissue.</div><div id=\"graphicVersion\">Graphic 63976 Version 2.0</div></div></div>"},"63981":{"type":"graphic_table","displayName":"Borg scale","title":"The modified Borg Scale for assessing the intensity of dyspnea or fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The modified Borg Scale for assessing the intensity of dyspnea or fatigue</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup width=\"95%\"></colgroup> <tbody> <tr> <td class=\"centered\">0</td> <td>Nothing at all</td> </tr> <tr> <td class=\"centered\">0.5</td> <td>Very, very slight (just noticeable)</td> </tr> <tr> <td class=\"centered\">1</td> <td>Very slight</td> </tr> <tr> <td class=\"centered\">2</td> <td>Slight (light)</td> </tr> <tr> <td class=\"centered\">3</td> <td>Moderate</td> </tr> <tr> <td class=\"centered\">4</td> <td>Somewhat severe</td> </tr> <tr> <td class=\"centered\">5</td> <td>Severe (heavy)</td> </tr> <tr> <td class=\"centered\">6</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">7</td> <td>Very severe</td> </tr> <tr> <td class=\"centered\">8</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">9</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">10</td> <td>Very, very severe (maximal)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This Borg scale should be printed on heavy paper (11 inches high and perhaps laminated) in 20-point type size. At the beginning of the 6-minute exercise, show the scale to the patient and ask the patient this: \"Please grade your level of shortness of breath using this scale.\" Then ask this: \"Please grade your level of fatigue using this scale.\" At the end of the exercise, remind the patient of the breathing number that they chose before the exercise and ask the patient to grade their breathing level again. Then ask the patient to grade their level of fatigue, after reminding them of their grade before the exercise.</div><div class=\"graphic_reference\">Sources:<br /><ol>&#xD;&#xA;    <li>Reproduced with permission from: Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377. Copyright &copy; 1982 Lippincott Williams &amp; Wilkins.</li>&#xD;&#xA;    <li>Reproduced with permission from: the American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 63981 Version 3.0</div></div></div>"},"63982":{"type":"graphic_picture","displayName":"LIP with lymphoid hyperplasia","title":"Lymphocytic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:400px; height:359px;\" src=\"images/PULM/63982_LIP_with_lymphoid_hyperplas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of&nbsp;lung biopsy showing lymphocytic interstitial pneumonia&nbsp;with lymphoid hyperplasia. A marked interstitial infiltrate of mononuclear cells and a germinal center are shown.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 63982 Version 2.0</div></div></div>"},"63984":{"type":"graphic_picture","displayName":"Circumscribed morphea - hyperpigmented plaque","title":"Circumscribed morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumscribed morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/63984_Circumscribed_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-defined, sclerotic plaque with central hyperpigmentation is present in this patient with circumscribed morphea.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>.&nbsp;Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63984 Version 3.0</div></div></div>"},"63985":{"type":"graphic_figure","displayName":"Inside-out integrin activation pathway","title":"Inside-out integrin activation pathway","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Inside-out integrin activation pathway</div><div class=\"cntnt\"><img style=\"width:576px; height:410px;\" src=\"images/ALLRG/63985_Inside_out_signl_integr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chemokines bind to their G protein-coupled receptors (GPCRs) on leukocytes, triggering a series of intracellular signals, which lead to the activation of Rap1 (repressor activator protein 1). Rap1 is crucial for integrin activation. In order to assure anchorage to the cytoskeleton and optimal integrin activation, talin and kindlin 3 must bind to the beta subunit of the integrin. Activated integrins have a fully extended, high-affinity structure, with an open ligand binding site.</div><div class=\"graphic_footnotes\">GPCR: G protein-coupled receptors; Rac1/RhoA: Ras-related C3 botulinum toxin substrate 1/Ras homolog gene family, member A; CalDAG GEFs: diacylglycerol guanine nucleotide exchange factors; Rap1: repressor activator protein 1; RapL: repressor activator protein lysine.</div><div id=\"graphicVersion\">Graphic 63985 Version 5.0</div></div></div>"},"63989":{"type":"graphic_table","displayName":"Neonatal morbidity by delivery type (SVD, forceps, vacuum,C/S)","title":"Frequency of birth trauma related to mode of delivery cases per 10,000 births","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of birth trauma related to mode of delivery cases per 10,000 births</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Trauma</td> <td class=\"subtitle1\">Spontaneous birth</td> <td class=\"subtitle1\">Vacuum assisted</td> <td class=\"subtitle1\">Forceps assisted</td> <td class=\"subtitle1\">Cesarean no labor</td> <td class=\"subtitle1\">Cesarean with labor</td> </tr> <tr> <td>Subdural or cerebral hemorrhage</td> <td class=\"centered\">2.9</td> <td class=\"centered\">8.0</td> <td class=\"centered\">9.8</td> <td class=\"centered\">4.1</td> <td class=\"centered\">7.4</td> </tr> <tr> <td>Intraventricular hemorrhage</td> <td class=\"centered\">1.1</td> <td class=\"centered\">1.5</td> <td class=\"centered\">2.6</td> <td class=\"centered\">0.8</td> <td class=\"centered\">2.5</td> </tr> <tr> <td>Subarachnoid hemorrhage</td> <td class=\"centered\">1.3</td> <td class=\"centered\">2.2</td> <td class=\"centered\">3.3</td> <td class=\"centered\">0.0</td> <td class=\"centered\">1.2</td> </tr> <tr> <td>Facial nerve injury</td> <td class=\"centered\">3.3</td> <td class=\"centered\">4.6</td> <td class=\"centered\">45.4</td> <td class=\"centered\">4.9</td> <td class=\"centered\">3.1</td> </tr> <tr> <td>Brachial plexus injury</td> <td class=\"centered\">7.7</td> <td class=\"centered\">17.6</td> <td class=\"centered\">25.0</td> <td class=\"centered\">4.1</td> <td class=\"centered\">1.8</td> </tr> <tr> <td>Convulsions</td> <td class=\"centered\">6.4</td> <td class=\"centered\">11.7</td> <td class=\"centered\">9.8</td> <td class=\"centered\">8.6</td> <td class=\"centered\">21.3</td> </tr> <tr> <td>CNS depression</td> <td class=\"centered\">3.1</td> <td class=\"centered\">9.2</td> <td class=\"centered\">5.2</td> <td class=\"centered\">6.7</td> <td class=\"centered\">9.6</td> </tr> <tr> <td>Feeding difficulty</td> <td class=\"centered\">68.5</td> <td class=\"centered\">72.1</td> <td class=\"centered\">74.6</td> <td class=\"centered\">106.3</td> <td class=\"centered\">117.2</td> </tr> <tr> <td>Mechanical ventilation</td> <td class=\"centered\">25.8</td> <td class=\"centered\">39.1</td> <td class=\"centered\">45.4</td> <td class=\"centered\">71.3</td> <td class=\"centered\">103.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Data from: Towner D, Castro MA, Eby-Wilkens E, et al. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709.</div><div id=\"graphicVersion\">Graphic 63989 Version 7.0</div></div></div>"},"63990":{"type":"graphic_table","displayName":"Neuroendocrine disorders associated with childhood obesity","title":"Selected neuroendocrine disorders associated with childhood obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected neuroendocrine disorders associated with childhood obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Key features</td> </tr> <tr class=\"divider_bottom\"> <td>Hypothyroidism</td> <td> <p>Decreased linear growth, mildly accelerated weight gain, mostly due to fluid retention.</p> Altered school performance, sluggishness, constipation, pubertal delay.</td> </tr> <tr class=\"divider_bottom\"> <td>Cortisol excess (corticosteroid medication, Cushing syndrome)</td> <td> <p>Decreased linear growth, mild or moderately accelerated weight gain, with central fat distribution.</p> Suprascapular fat pad, violaceous striae, acne, hirsutism, signs of insulin resistance, neuropsychological changes.</td> </tr> <tr class=\"divider_bottom\"> <td>Growth hormone deficiency</td> <td> <p>Decreased linear growth, mildly accelerated weight gain, delayed bone age.</p> Cherubic face with underdeveloped nasal bridge.</td> </tr> <tr class=\"divider_bottom\"> <td>Pseudohypoparathyroidism type 1a (Albright's hereditary osteodystrophy)</td> <td>Obesity with round facies, short stature, short fourth metacarpal bones, developmental delay, hypocalcemia, subcutaneous calcifications, and hyperparathyroid bone disease.</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Acquired hypothalamic lesions</td> </tr> <tr> <td class=\"sublist1\">After brain surgery (eg, for craniopharyngioma)</td> <td class=\"sublist_other\">Abrupt very rapid weight gain, hyperphagia. Often associated with panhypopituitarism.</td> </tr> <tr> <td class=\"sublist1\">Diencephalic tumor</td> <td class=\"sublist_other\">Variable onset; may include headache, vomiting, vision defects, and other symptoms of increased intracranial pressure.</td> </tr> <tr> <td class=\"sublist1\">Congenital central hypoventilation syndrome (early- or late-onset)</td> <td class=\"sublist_other\">Prominent central hypoventilation and autonomic dysfunction; associated with PHOX2B mutations. Obesity is not a prominent symptom, and the reported association may be due to historical misclassification of ROHHAD.</td> </tr> <tr> <td class=\"sublist1\">ROHHAD/ROHHADNET syndrome</td> <td class=\"sublist_other\">Rapid onset of obesity, central hypoventilation, and autonomic dysregulation (may include hyperthermia or hypothermia), with or without neural crest tumors. Onset typically during early childhood. Possible immune-mediated mechanism. In the past, some cases of apparent \"idiopathic\" hypothalamic obesity may have been ROHHAD without the hypoventilation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROHHAD/ROHHADNET: rapid onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation, with or without neural crest tumors.</div><div id=\"graphicVersion\">Graphic 63990 Version 7.0</div></div></div>"},"63992":{"type":"graphic_picture","displayName":"Bullous impetigo","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/OBGYN/63992_Bullous_impetigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and pustules that easily rupture and evolve to erosions and crusts are characteristic of bullous impetigo.&nbsp;</div><div id=\"graphicVersion\">Graphic 63992 Version 4.0</div></div></div>"},"63993":{"type":"graphic_figure","displayName":"Nerves of the female pelvis","title":"Nerves of the female pelvis","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Nerves of the female pelvis</div><div class=\"cntnt\"><img style=\"width:542px; height:460px;\" src=\"images/OBGYN/63993_Nerves_pelvis_female.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 63993 Version 3.0</div></div></div>"},"63995":{"type":"graphic_figure","displayName":"Paracentric inversion","title":"Paracentric inversion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paracentric inversion</div><div class=\"cntnt\"><img style=\"width:408px; height:275px;\" src=\"images/HEME/63995_Paracentric_inversion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a paracentric inversion, the inverted chromosome segment is located on one side of the centromere (ie, on one chromosome arm).&nbsp;A representation of normal chromosome 15 is shown on the left. An example of a GTG stained chromosome 15&nbsp;from a patient with a paracentric inversion of the long arm of chromosome 15 between bands q15 and q24 is shown on the right.&nbsp;A normal GTG stained chromosome 15 is shown in the center. The red arrows show the&nbsp;locations on the normal chromosome where breaks occured in the abnormal chromosome (corresponding to the boxed area).</div><div class=\"graphic_footnotes\">GTG: G-banding with trypsin and Giemsa</div><div id=\"graphicVersion\">Graphic 63995 Version 2.0</div></div></div>"},"63996":{"type":"graphic_picture","displayName":"Urticaria annular lesions 2","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/63996_Urticaria_annular_lesions_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple mildly erythematous and edematous plaques are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63996 Version 3.0</div></div></div>"},"63997":{"type":"graphic_picture","displayName":"Mucous membrane pemphigoid palate","title":"Mucous membrane pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mucous membrane pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/63997_Mucous_membrane_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucosal erosions on the gingiva and palate.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 63997 Version 4.0</div></div></div>"},"63998":{"type":"graphic_algorithm","displayName":"Acute dysphagia in children with no fever","title":"Acute dysphagia in children with no fever","html":"<div class=\"graphic\"><div style=\"width: 754px\" class=\"figure\"><div class=\"ttl\">Acute dysphagia in children with no fever</div><div class=\"cntnt\"><img style=\"width:734px; height:1096px;\" src=\"images/EM/63998_Acute_dysphagia_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Conditions include botulism, myasthenia gravis, cerebral palsy, and Miller-Fisher syndrome (variant of Guillain-Barre syndrome).</div><div id=\"graphicVersion\">Graphic 63998 Version 3.0</div></div></div>"},"63999":{"type":"graphic_table","displayName":"Physiologic effects of high altitude","title":"Physiologic effects of high altitude","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic effects of high altitude</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High altitude: 1500 to 3500 m (4921-11,483 ft) </td> </tr> <tr> <td>High-altitude illness common with abrupt ascent to above 2500 m (8202 ft)</td> </tr> <tr> <td>Decreased exercise performance and increased ventilation</td> </tr> <tr> <td>Minor impairment in SpO<sub>2</sub>, usually at least 90 percent; PaO<sub>2</sub> significantly diminished 55 to 75 mmHg</td> </tr> <tr> <td class=\"subtitle1_single\">Very high altitude: 3500 to 5500 m (11,483-18,045 ft) </td> </tr> <tr> <td>Most common range for severe high-altitude illness</td> </tr> <tr> <td>Abrupt ascent may be dangerous; requires a period of acclimatization</td> </tr> <tr> <td>SpO<sub>2</sub> 75 to 85 percent; PaO<sub>2</sub> 40 to 60 mmHg</td> </tr> <tr> <td>Extreme hypoxia may occur during sleep, exercise and high-altitude illness</td> </tr> <tr> <td class=\"subtitle1_single\">Extreme altitude: 5500 to 8850 m (18,045-29,035 ft) </td> </tr> <tr> <td>Progressive deterioration of physiologic function eventually outstrips acclimatization</td> </tr> <tr> <td>Above the highest permanent human habitation</td> </tr> <tr> <td>Abrupt ascent almost always precipitates severe high-altitude illness</td> </tr> <tr> <td>A period of acclimatization necessary to ascend to extreme altitude</td> </tr> <tr> <td>Severe hypoxia and hypocapnia; SpO<sub>2</sub> 58 to 75 percent, PaO<sub>2</sub> 28 to 40 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SaO<sub>2</sub>: arterial oxygen saturation; PaO<sub>2</sub>: arterial PO<sub>2</sub>; PO<sub>2</sub>: partial pressure of oxygen.</div><div class=\"graphic_reference\">Data from: Hackett, PH, Roach, RC. High-Altitude Medicine. In: Wilderness Medicine, 5th ed, Auerbach, PS (Ed), Mosby, Philadelphia 2007.</div><div id=\"graphicVersion\">Graphic 63999 Version 3.0</div></div></div>"}};